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ABSTRACT 
 
Dysregulated IL-1 activity has been implicated in the pathogenesis of several 
acute and chronic inflammatory as well as autoimmune diseases. Genomic 
analysis has identified additional IL-1 family members and also expanded the IL-
1 receptor family. To date, there are eleven IL-1 family members and nine IL-1 
receptor family members. Information regarding the biological activity and 
immunological role of the newer IL-1 family members is still very limited. The 
novel IL-1 cytokines, IL-1F6, IL-1F8 and IL-1F9 (recently renamed IL-Į,/-ȕ
and IL-ȖUHVSHFWLYHO\KDYHEHHQVKRZQWRVLJQDOYLD,/-1 receptor related 
protein 2 (IL-1Rrp2, recently renamed IL-36R). The main aims of this study were: 
(i) to investigate the expression of IL-1Rrp2 by human myelomonocytic and non-
myelomonocytic immune cells as well as other human cells, (ii) to determine the 
possible function of IL-1Rrp2 and (iii) to determine the effect of IL-1Rrp2 
expression on T lymphocytes. Results reported in this thesis indicate that among 
human myelomonocytic cells, constitutive IL-1Rrp2 expression is unique to 
dendritic cells (DCs). IL-1Rrp2 was expressed by monocyte- derived DCs 
(MDDCs) and plasmacytoid DCs (pDCs) but not by peripheral blood type 1 or 
type 2 myeloid DCs (mDC1 or mDC2). IL-1Rrp2 expression was regulated in 
response to both classical (IL-ȕDQGQRYHO,/-1 cytokines (IL-1F8 and IL-1F9).  
Similarly to IL-ȕDQGEDFWHULDO/36QRYHO,/-1 cytokines mediated DC 
maturation as shown by DC phenotypic changes (e.g. upregulation of HLA-DR 
 
(ii) 
expression and decreased CD1a expression following culture of DCs with IL-
1F8) and cytokine production. Among non-myelomonocytic cells, constitutive IL-
1Rrp2 expression was observed in lamina propria tissue, T lymphocytes, 
NCI/ADR-RES cells and HT 29 cells. IL-1F8-matured human DCs were fully 
functional as they induced proliferation of IFN-Ȗ-producing TH1 subsets. Results 
suggest that novel IL-1 cytokines play a role in inflammatory responses involving 
human DCs, with possible implications for inflammatory disease.  
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CHAPTER 1: GENERAL INTRODUCTION AND BACKGROUND 
 
1.1.0 The Interleukin-1 (IL-1) Cytokine Family: General Overview  
The IL-1 cytokine family is a multifunctional cytokine family with multiple and 
varied effects on biological processes.  IL-1 cytokines influence a wide array of 
physiological activities including the immune response, haematopoiesis, 
appetite, sleep and bone metabolism (Dinarello, 1996; Bagby, 1989; Smith et al., 
1992; Tatakis, 1993; Fischer et al., 1991; Okusawa et al., 1988). IL-1 cytokines 
interact with nearly every cell type and play an essential role in host immune 
defence through their effect on T and B lymphocytes.  
 
The classical IL-1 family members; IL-Į,/-ȕ,/-1Receptor antagonist (IL-
1Ra) and IL-18 have been studied for a number of years. Their importance in 
health as well as in chronic disease has been highlighted through a number of 
studies. In experimental animals, for example, pre-treatment with IL-ȕKDVEHHQ
shown to reduce mortality from bacterial and fungal infections (Van der Meer et 
al., 1988). IL-ĮDGPLQLVWUDWLRQKDVDOVREHHQIRXQGWRDFFHOHUDWHSODWHOHW
recovery following chemotherapy in humans (Smith et al., 1993). On the other 
hand, studies in human patients with advanced solid malignancies have shown 
that dose-dependent side effects such as fever, gastrointestinal disturbances, 
myalgia (muscle pain), arthralgia (joint pain) and hypotension may limit the 
therapeutic utility of IL-ĮLQSDWLHQWV6PLWKet al., 1992). Administration of IL-Į 
1 
to healthy animals induces physiological effects mimicking metabolic 
abnormalities present in human patients with catabolic diseases such as sepsis 
(Dinarello, 1996; Cooney et al., 1999a; Mitch, 2000).  
 
It is now generally accepted that IL-Į,/-ȕDQG,/-18 are highly inflammatory 
cytokines and that their excessive production results in local tissue damage 
(reviewed in Dinarello, 2009). Under normal circumstances, the production and 
activity of IL-1 cytokines is tightly regulated and contributes to host defence 
mechanisms. On the other hand, dysregulated IL-1 activity has been implicated 
in the pathogenesis of diseases such as the septic syndrome, rheumatoid 
arthritis (RA), inflammatory bowel disease (IBD), insulin-dependent diabetes 
mellitus (IDDM), atherosclerosis, psoriasis, asthma, cancer and many other 
autoimmune and/or chronic inflammatory conditions (Bistrian et al., 1992; 
Okusawa et al., 1988; Fischer et al., 1991; Fisher, 1991; Dinarello, 1996; 
Dinarello, 2002; Dinarello, 2003a; Dinarello 2003b; Arend, 2008).  
 
Diseases associated with excessive IL-1 production and/activity have a huge 
impact on the quality of life of the sufferers. They also incur a huge social and 
economic burden with regards to mortality, morbidity and long-term disability. In 
the United States of America, sepsis has a mortality rate of 20-50% and is the 
second leading cause of death in non-coronary intensive care unit (ICU) 
patients. It is also the tenth most common cause of death overall. Care of 
 
2  
patients with sepsis costs $17 billion annually (Wheeler, Bernard, 1999; Angus et 
al., 2001; Martin et al., 2003). In the United Kingdom (UK), sepsis poses a 
medical challenge. The proportion of critical care admissions with severe sepsis 
in the first 24 hours following admission rose from 23.5% in 1996 to 28.7% in 
2004 (Harrison et al., 2006). 
 
The role of IL-1 in the pathogenesis of arthritis has been confirmed by in vivo 
studies (Gracie et al., 1999). Arthritis, in its various forms, is thought to affect 1 in 
5 adults in the UK (McCormick et al., 1995). The total cost of arthritis to the 
National Health Service (NHS) and social services in the UK is believed to be in 
the region of £5.5 billion (Arthritis Care, 2002). Osteoarthritis affects over eight 
million people and is the single biggest cause of locomotor problems and the 
most common joint disease in the UK (de Verteuil et al., 2008).  
 
About 387 000 people in the UK have RA, and 12000 new cases are diagnosed 
each year (Symmons et al., 2002). Prevalence of RA in many populations is 
believed to be 0.5-1%. Higher frequencies of 5.3% and 6.8% have been 
observed in the Pima Indians and Chippewa Indians respectively and also in a 
few other populations (Silman, Pearson 2002; Del Puente et al., 1989; Harvey et 
al., 1981). RA patients have a significantly increased risk of mortality compared 
with age- and sex-matched controls without RA from the same community 
(Gabriel, 2001). RA imposes a substantial economic burden for individuals and  
 
3 
health services. Direct and indirect costs per person with RA are thought to total 
approximately US$11 542 per year on average (Cooper, 2000).  
 
IL-1 is now known to be a key mediator of inflammation and tissue destruction in 
RA (Gracie et al., 1999). Anti-cytokine therapeutic strategies are being employed 
for reducing disease severity in conditions such as RA, IBD and psoriasis. More 
than 300 000 people in the world are currently receiving medication which 
specifically blocks the biological activities of tumour necrosis factor (TNF) or IL-1. 
Reducing the biological activities of IL-1 and TNF is accomplished by several 
different, but highly specific, strategies, which involve neutralizing antibodies, 
soluble receptors, receptor antagonist, and inhibitors of proteases that convert 
inactive precursors to active, mature molecules (Dinarello, 2000; Dinarello, 
2003a; Dinarello 2003b). Blocking IL-1 action through the use of Anakinra (a 
recombinant IL-1Receptor antagonist) has been shown to be beneficial in 
patients with active RA. Anakinra is now approved for the treatment of RA and is 
commercially supplied by Amgen as Kineret (reviewed in Fleischmann, 2002, 
reviewed in Furst, 2004; reviewed in Fleischmann et al., 2004). It has also been 
found to be effective in a proportion of patients with systemic onset juvenile 
idiopathic arthritis and adult-RQVHW6WLOO¶VGLVHDVH&KHYDOLHUet al., 2005; Church 
et al., 2008).   
 
 
4 
(YLGHQFHRIDQDNLQUD¶VHIILFDF\LQGLVHDVHVRWKer than RA has not been 
consistent. Initial studies involving psoriatic arthritis models failed to demonstrate 
the efficacy of anakinra, however, recent findings suggest that it may be a 
therapeutic option in patients with active psoriatic arthritis (Jung et al., 2010). 
Use of recombinant IL-1Ra (rIL-1Ra) for treating sepsis has been extensively 
studied. Although, studies in mice, rats, rabbits and baboons with septic shock 
generally confirmed that administration of rIL-1Ra reduced mortality dramatically, 
the effects of rIL-1Ra were not uniform in all cases. Furthermore, clinical trials 
have not yet validated results obtained from animal models of sepsis or septic 
shock. Although invaluable information has been generated from studies 
involving animals, it is impossible for animal models to completely mimic the 
local and systemic picture of human sepsis (reviewed in Dinarello, 1996). 
Furthermore, the failure of rIL-1Ra and other anti-cytokine strategies to 
convincingly improve clinical outcomes in human sepsis patients suggests that 
there may be other cytokines or factors involved in the pathogenesis of sepsis.  
 
In recent years, DNA database searches for IL-1 homologues have revealed that 
IL-1 is actually a superfamily of cytokines which are related in terms of origin, 
receptor structure and signal transduction pathways employed (Arend et al., 
2008). Genomic analysis has not only revealed the existence of seven additional 
IL-1 family members but it has also identified an IL-1 receptor superfamily 
(Taylor et al., 2002, Barksby et al., 2007; Magne et al., 2006; Dunn et al., 2001; 
Smith et al., 2000; Kumar et al., 2000; Barton et al., 2000; Busfield 
5  
et al., 2000; Pan et al., 2001; Bazan et al., 1996; Lin et al., 2001; Debets et al., 
2001; Blumberg et al., 2007; Nicklin et al., 2002; Sims et al., 2001; Schmitz et 
al., 2005; Sims, 2002; Subramaniam, Stansberg, Cunningham, 2004; Dumont, 
2006).  
 
Due to the impact of classical members of the IL-1 family on inflammatory and 
autoimmune diseases, the potential role of these novel IL-1 family members is 
now being studied and may present future opportunities for the development of 
novel therapeutics.  As previously mentioned, anakinra (rIL-1Ra) is currently 
used in the treatment of RA (Furst, 2004; Cohen and Rubbert, 2003). It is, 
therefore, conceivable that scientific study of novel members of the IL-1 family 
may lead to the discovery of novel therapeutics in future.  
 
1.1.1 IL-1 cytokine family: Introduction  
Prior to its molecular identification, IL-1 had been studied for many years under 
various names including leukocyte endogenous mediator, haematopoietin 1, 
endogenous pyrogen, catabolin and osteoclast activating factor. These names 
give an idea of the variety of biological effects exerted by this interleukin (Sims 
and Smith, 2010). As already mentioned in the general background section 
(Section 1.1), research spanning the last three decades has revealed that IL-1 is 
actually a cytokine family consisting of structurally related, multifunctional  
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proteins which influence various cell types and play an important role as 
mediators of inflammatory and immune responses. Generally, IL-1 family 
members possess a highly conserved gene structure, including identical 
positioning of certain introns and a more modest preservation of key amino acid 
sequences that allow the folding of each protein into a twelve-VWUDQGHGȕ-barrel 
(Taylor et al., 2002; Sims, 2002). To date, the IL-1 cytokine family comprises 
eleven members. As previously mentioned, four of these are commonly referred 
to as the classical IL-1 members while the other seven are still considered novel.  
 
The genes for IL-Į,/-ȕDQG,/-1Ra are located in the same region on the long 
arm of human chromosome 2 (Smith et al., 2000) while the gene for human IL-
18 is located on chromosome 11q22.2-22.3 (Nolan, Greaves and Waldmann, 
1998). Despite low sequence homology, IL-18 is now widely accepted as the 
fourth member of the IL-1 family, not only because of the high structural similarity 
but also because of similarities in receptor utilisation and cytokine processing. IL-
Į,/-ȕDQG,/-18 also share parts of a common signal transducing system 
which involves IL-1 receptor-associated kinases (IRAKs), MyD88, TNF receptor-
associated factor (TRAF-6) and activation of the transcription factor NF-kB 
(Nuclear Factor-KappaB). 
 
Genes encoding the newer members of the IL-1 cytokine family were identified 
by different research groups who inevitably assigned different names to the 
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same cytokines (Dunn et al., 2001; Smith et al., 2000; Kumar et al., 2000; 
Busfield et al., 2000; Barton et al., 2000; Pan et al., 2001; Lin et al., 2001; 
Debets et al., 2001). The genes for six of these novel IL-1 cytokines are situated 
in the same cluster as those for IL-Į,/-ȕDQG,/-1Ra on human chromosome 
2 (Lander et al., 2001). A revised, standardised nomenclature was proposed by 
Sims and co-workers (2001). Under this new nomenclature, the six novel IL-1 
family members whose genes reside in the same cluster  as the IL-Į,/-ȕDQG
IL-1Ra genes were named IL-1F5, IL-1F6, IL-1F7, IL-1F8, IL-1F9 and IL-1F10. It 
was also suggested that the classical IL-1 members, IL-Į,/-ȕ,/-1Ra and IL-
18 be renamed IL-1F1, IL-1F2, IL-1F3 and IL-1F4 respectively (IL-1F stands for 
IL-1family member) (Sims et al., 2001), however, the old naming system for the 
classical IL-1 family members is still widely used and accepted.  
 
Schmitz et al. (2005) demonstrated that IL-33 (located on the short arm of 
chromosome 9 at position 24.1) has structural and functional similarities to the 
other IL-1 family members and is, therefore, an IL-1 cytokine. It has since been 
renamed IL-1F11 (Schmitz et al., 2005). Not much is known about the 
expression, biological function or regulation of expression of the novel IL-1 family 
members. In the following sections, current understanding regarding IL-1 family 
members will be discussed. The classical IL-1 family members will be discussed 
first, followed by emerging data regarding the newer IL-1 family members. The 
revised nomenclature proposed by Sims et al. (2001) for IL-1 family members 
will be used throughout this thesis when referring to the newer IL-1 family 
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members. For the classical members, IL-Į,/-ȕ,/-1Ra and IL-18, the original 
names will be adhered to as these are well established and are still commonly 
used in the literature. 
 
1.1.2 Classical IL-1 cytokines  
The synthesis of classical IL-1 cytokines is stimulated by a number of pro-
inflammatory mediators including exposure to microbial products such as 
bacterial lipopolysaccharides (LPS) and exposure to proinflammatory cytokines 
such as Tumour Necrosis Factor alpha (TNF-Į,QWHUIHURQDOSKD,)1-ĮDQG
Interferon beta (IFN-ȕUHYLHZHG in Barksby et al., 2007) Neuroactive and 
inflammatory substances, cell matrix proteins, clotting factors, lipids and other 
biological materials also induce IL-1 synthesis (Dinarello, 1991). It has also been 
observed that environmental stressors such as hypoxia, ischaemia, gamma 
radiation and thermal injury may also stimulate IL-1 synthesis (Dinarello, 1996). 
In patients with sepsis, trauma and burn injury, plasma IL-ȕOHYHOVFRUUHODWHZLWK
both the severity of inflammation and mortality (Cannon et al., 1990; Casey et 
al., 1993; Eastgate et al., 1988; Roubenoff et al., 1994), thus indicating an 
important role for this cytokine during these pathologies. 
 
IL-Į,/-ȕDQG,/-18 are secreted by various cell types including monocytes, 
macrophages, dendritic cells (DCs), epithelial cells, keratinocytes and synovial 
fibroblasts (reviewed in Dinarello, 1998). IL-ĮLVV\QWKHVLVHGDVDN'Dprotein 
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precursor (proIL-ĮZKLFKODFNVDOHDGHUVHTXHQFH3URWHRO\WLFUHPRYDORIWKH 
precursor domains by calcium-dependant calpain proteases results in the 
generation of the mature 17kDa IL-ĮSHSWLGH%RWKSUR,/-ĮDQGPDWXUH,/-Į
are biologically active (reviewed in Dinarello, 1998). 
 
IL-ȕLVDOVRWUDQVODWHGDVDQLQDFWLYHN'DOHDGHUOHVVSURF\WRNLQHSUR,/-ȕ
It remains in the cytosol prior to being cleaved intracellularly by the cysteine-
protease, IL-ȕFRQYHUWLQJHQ]\PH,&(RUFDVSDVH-1) (reviewed in Burns, 
Martinon and Tschopp J, 2003; reviewed in Dinarello, 1998). The active, mature 
17kDa IL-ȕLVVXEVHTXHQWO\ released extracellularly. It has been reported that 
two separate stimuli are required for efficient generation of active IL-ȕ7KHUHLV
an initial priming stimulus (e.g. LPS) which promotes synthesis of proIL-ȕDQG
its accumulation in the cytosol. Post-translational processing of pro-IL-ȕE\
caspase-1) and release of mature IL-ȕLVLQLWLDWHGE\DVHFRQGVWLPXOXVWKH
absence of which leads to insufficient maturation of IL-ȕUHYLHZHGLQ%XUQV
Martinon and Tschopp J, 2003; reviewed in Dinarello, 1998). IL-18 shares 
primary amino acid sequences and structural features with IL-ȕ,WLVDOVR
synthesised as a biologically inactive, 24 kDa precursor (pro-IL-18) which lacks a 
signal peptide (Dinarello, 1996; Dinarello, 1997). Caspase-1 cleaves pro-IL-18 to 
its mature, 18kDa bioactive form (Dinarello, 1996; Dinarello, 1997). There is 
evidence to suggest that IL-18 secretion occurs by a mechanism similar to the 
one observed for IL-ȕ'LQDUHOOR 
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1.1.2.1 The inflammasomes 
It is now appreciated that caspase-1 itself is present in the cytosol as an inactive 
protein, pro-caspase-1 which in turn requires activation via autoproteolytic 
FOHDYDJH7KH³VHFRQGDU\VWLPXOXV´WKDWLQGXFHVWKHSURGXFWLRQRI,/-ȕ
promotes the formation of a multi-protein molecular platform known as the 
inflammasome, which induces the oligomerization and activation of procaspase-
1 (reviewed in Burns, Martinon and Tschopp J, 2003). The inflammasome 
mediates the cleavage of inactive pro-IL-ȕDQG,/-18, as well as other proteins, 
into their active forms (reviewed in Schroder and Tschopp, 2010; reviewed in 
Barker et al., 2011). Once activated, the inflammasome in turn induces activation 
of caspase-1 which then mediates the maturation of IL-ȕ8OWLPDWHO\,/-ȕLV
excreted into the extracellular environment (Martinon et al., 2002). Extracellular 
adenosine triphosphate (ATP) has been found to be a strong inducer of mature 
IL-ȕ%XUQV.0DUWLQRQ) Tschopp J, 2003; Dinarello, 1998). A rapid lowering 
of cytoplasmic potassium ions (K+) by stimuli other than ATP (e.g. nigericin) can 
also stimulate caspase-1 activation following LPS stimulation (Kahlenberg et al., 
2005).   
 
Initially, the inflammasome complex was thought to affect infection and 
inflammation, however, recent evidence suggests that inflammasome activation 
influences many metabolic disorders, including atherosclerosis, type 2 diabetes, 
gout and obesity (reviewed in Wen et al., 2012). The inflammasome consists of  
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an intracellular pathogen recognition receptor (PRR), the precursor procaspase-
1 and the adaptor ASC (apoptosis-associated speck-like protein containing a C-
terminal caspase-recruitment domain) (reviewed in Schroder and Tschopp, 
2010; reviewed in Barker et al., 2011). To date, four inflammasomes have been 
identified; NLRP1 (Nucleotide-binding, leucine-rich repeat pyrin domain 
containing protein 1), NLRP3 (Nucleotide-binding, leucine-rich repeat pyrin 
domain containing protein 3), NLRC4 (nucleotide-binding oligomerization 
domain, leucine rich repeat and CARD domain containing protein 4) and AIM2 
(absent in melanoma 2) (reviewed in Schroder and Tschopp, 2010; reviewed in 
Barker et al., 2011; reviewed in Wen et al., 2012).  
 
NLRP1, NLRP3 and NLRC4 contain a PRR that belongs to the Nod-like receptor 
(NLR) family; a family of intracellular PRRs defined by a tripartite structure 
(reviewed in Franchi et al., 2012). NLRP3, also called NALP3 or Cryopyrin, is 
one of the best characterized NLR family members (reviewed in Chen et al., 
2011). It is encoded by the NLRP3 (NOD-like receptor family, pyrin domain 
containing 3) gene, also called cold induced autoinflammatory syndrome 1 
(CIAS1) gene (Hoffman et al., 2001; reviewed in Kubota and Koike, 2010; 
reviewed in Goldbach-Mansky, 2011). Various stimuli (including muramyl 
dipeptide, adenosine triphosphate, toxins, Staphylococcus aureus or Listeria 
monocytogenes, bacterial RNA, viral infection/viral RNA) activate the NLRP3 
inflammasome, triggering caspase-1 to process proIL-ȕSUR-IL-18 into mature 
IL-1ȕ,/-18. In addition, metabolic substrates which accumulate in target tissues  
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(such as monosodium urate in gout, oxidized low-density lipoprotein in diabetes, 
ceramide in obesity, and cholesterol crystals in atherosclerosis) can also 
stimulate the NLRP3 inflammasome to release IL-ȕ (reviewed in Kubota and 
Koike, 2010; reviewed in Goldbach-Mansky, 2011).  
 
1.1.2.2 IL-1 Receptor Antagonist (IL-1Ra) 
The third classical IL-1 family member, IL-1Ra, functions as a specific receptor 
antagonist of IL-1. It was first discovered as a 22- to 25-kDa IL-1inhibitory 
bioactivity in the supernatants of human monocytes cultured on adherent 
immunoglobulin G (IgG) and in the urine of patients with fever or 
myelomonocytic leukaemia (reviewed in Arend et al., 1998). In humans, it has 
been shown that the synthesis of IL-1Ra is inducible by IL-ȕadministration 
(Bargetzi et al., 1993).    
 
IL-1Ra is now understood to be a family of isoforms. The originally described 
isoform is now termed secreted IL-1Ra (sIL-1Ra) and is secreted as a variably 
glycosylated, 22-25 kDa protein. It exhibits approximately 26% amino acid 
sequence homology to IL-ȕDQGKRPRORJ\WR,/-Į,WLVV\QWKHVL]HGDVD
precursor protein containing a classical secretory signal sequence of 25 amino 
acids which facilitates secretion of IL-Ra via the endoplasmic reticulum/Golgi 
pathway (Eisenberg et al., 1990). The human IL-1Ra gene contains four exons 
and maps to chromosome 2q13-14.1 in the vicinity of the IL-ĮDQG,/-ȕgenes  
13 
(Lennard et al., 1992).  An 18 kDa intracellular form of IL-1Ra known as 
intracellular IL-1Ra (icIL-1Ra) has also been described. It is believed that there 
may be at least three forms of icIL-1Ra. These have been termed icIL-1Ra1, 2 
and 3. They all arise from the same extended IL-1Ra gene (IL1RN) and are 
created by the use of alternative first exons, mRNA splicing and alternative 
translation initiation (reviewed in Arend et al., 1998; Arend, 2002).  
 
Secreted IL-1Ra (sIL-1Ra) is primarily produced by monocytes and 
macrophages (reviewed in Arend et al., 1998). However, it can also be 
synthesised by any cell which produces IL-1, for example neutrophils, 
hepatocytes, microglial cells and other cells (reviewed in Arend et al., 1998). 
IcIL-1Ra1 is highly expressed in keratinocytes and other epithelial cells. It is also 
produced by stimulated monocytes and macrophages. IcIL-1Ra3 is highly 
expressed in hepatocytes and in the cytoplasm of bacterial lipopolysaccharide 
(LPS)-stimulated human neutrophils (reviewed in Arend, Palmer and Gabay, 
2008). It is also present in monocytes, macrophages and keratinocytes. Although 
cDNA for icIL-1Ra2 has been cloned from fibroblasts, keratinocytes and human 
leucocytes, the predicted 25kDa icIL-1Ra2 protein has not yet been found in 
human cells. The in vivo presence of icIL-1Ra2 remains to be established 
(Eisenberg et al., 1990; reviewed in Arend et al., 1998; Arend, 2002). There is 
speculation that it may not be translated (Banda et al., 2005). A novel IL-1Ra 
variant (CGEN-R1) with a C-terminal portion that has a unique amino acid 
sequence has also been recently reported. CGEN-R1 was detected primarily in  
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the liver but was also found to be present in several human tissues. There have 
been speculations that it might function as an IL-1 Ra since it appears to inhibit 
IL-1-stimulated IL-8 (reviewed in Dumont, 2006). 
 
As previously mentioned, IL-1 has potent, wide-ranging and potentially harmful 
effects on host physiology. To prevent host injury, the actions of IL-1 are 
normally tightly regulated, not just at the level of synthesis but also post 
synthesis. It is now known that, physiologically, IL-1Ra is an important regulator 
of IL-1 expression and of IL-1-induced responses. IL-1Ra production occurs 
immediately following IL-1 production. In vitro and in vivo, IL-1Ra is a competitive 
inhibitor of IL-1 receptor binding. It binds to the IL-1 receptor but because it 
cannot recruit the IL-1R Accessory protein (IL-1RAcP) which is crucial for signal 
transduction, IL-1Ra is unable to initiate intracellular signal transduction 
processes which normally occur after engagement of the IL-1 receptor with IL-1. 
Not only is IL-1Ra unable to induce intracellular signalling, but also, it blocks IL-
1R1 and prevents it from interacting with IL-Įȕ,/-1Ra thus functions as a 
competitive inhibitor of IL-1 and is important in the regulation of the inflammatory 
effects of IL-1 (Smith et al., 2000; Sims, 2002; Dumont, 2006). It antagonizes the 
activities of both IL-ĮDQG,/-ȕZLWKRXWH[HUWLQJDJRQLVWHIIHFWVLWVHOI+DQQXP
et al., 1990; Dipps et al., 1991; reviewed in Arend, 2002).  
 
Generally, the balance between IL-1 and IL-1Ra is thought to play an important  
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role in the normal physiology of various organs and tissues. It is even thought to 
regulate some aspects of the reproductive cycle (reviewed in Arend, 2002). The 
effect of IL-1 and IL-1Ra levels has been extensively studied in a variety of 
experimental animal models of disease including arthritis, infectious diseases, 
inflammatory bowel disease (IBD), granulomatous and fibrotic lung disorders, 
kidney diseases, diseases of the liver and pancreas, graft-versus-host disease 
(GVHD), leukaemia and different types of cancer, osteoporosis and diabetes 
(reviewed in Arend, 2002). Similar studies have also investigated central nervous 
system diseases, infectious diseases, and arterial diseases (Koch et al., 1992; 
Simón et al., 1998; Bendele et al., 1999). A consistent finding from all these 
studies was that either local overproduction of IL-1 and/or underproduction of IL-
1Ra are a prerequisite for disease development. In these studies, therapeutic 
administration of IL-1Ra was found to be efficacious in preventing tissue damage 
(Koch et al., 1992; Simón et al., 1998; Bendele et al., 1999; reviewed in Arend, 
2002). A summary of animal models of disease treated with recombinant IL-1Ra 
is given in Table 1.1. 
 
Both the secreted and intracellular isoforms of IL-1Ra are thought to contribute 
to maintenance of the balance between IL-1 and IL-1Ra. There is ample 
evidence indicating that the single biological function of sIL1Ra is to 
competitively inhibit IL-1 binding to cell-surface receptors. On the other hand, the 
intracellular isoforms of IL-1Ra are thought to carry out additional roles inside 
cells (reviewed in Arend and Guthridge, 2000). It was previously suggested that  
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these intracellular isoforms may be storage forms that are released upon cell  
death to limit inflammation caused by cell debris (Muzio et al., 1999). Others 
have suggested that the intracellular forms of IL-1Ra function as unique 
intracellular inhibitors which alter IL-1-inducible gene expression and abate IL-1 
responses at a point downstream of the initial IL-1/IL-1 receptor interaction 
(Watson et al., 1995).  
 
 
 
 
 
 
 
 
 
 
 
 
 
17 
Table 1.1 Summary of animal models of disease treated with recombinant 
IL-1Ra (adapted from Arend et al., 1998) 
 
Collagen induced arthritis in mice 
Streptococcal cell wall induced arthritis in rats 
Immune complex induced arthritis in mice 
Antigen induced arthritis in rabbits 
Osteoarthritis in dogs 
Septic shock in rabbits, baboons, rats and mice 
Bacterial meningitis in rabbits 
Ischaemic brain injury in rats 
Experimental allergic encephalomyelitis in rats 
Streptococcal cell wall induced colitis in rats 
Experimental shigellosis in rabbits 
Immune complex induced colitis in rabbits 
Acetic acid induced colitis in rats 
Lipopolysaccharide induced pleurisy in rabbits 
Monocrotaline induced pulmonary hypertension in rats 
Allergen induced late asthmatic reaction in guinea pigs 
Bleomycin or silica induced pulmonary fibrosis in mice 
Immune complex induced lung injury in rats 
Ischaemia/reperfusion lung injury in rats 
Crescentic glomerulonephritis in rats 
Anti-glomerular basement membrane antibody induced 
glomerulonephritis in rats 
Pre-term delivery in mice induced by IL1 
Osteoclast formation and bone resorption in ovariectomised mice and 
rats 
Hepatic fibrosis induced by dimethylnitrosamine in rats 
Post-cardiac transplant coronary arteriopathy in piglets 
Graft versus host disease in mice 
Streptozotocin induced diabetes in mice 
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Although the biological roles of the intracellular IL-1Ra isoforms are still not very 
clear, some of the functions are starting to be elucidated. A study which sought 
to determine the role of icIL-1Ra1 in regulation of cytokine-induced IL-6 and IL-8 
production in Caco-2 intestinal epithelial cells showed that  icIL-1Ra1 inhibited 
IL-1-induced IL-6 and IL-8 production by inhibiting p38 MAP kinase 
phosphorylation and Nuclear Factor ±kappaB (NF-ț%WUDQVORFDWLRQ*DUDWDQG
Arend, 2003). Another investigation to determine whether icIL-1Ra1mediated 
unique functions in keratinocyte cell lines (KB and A431) showed that icIL-1Ra1 
performed an anti-inflammatory role inside cells through binding to CSN3 (the 
third component of the COP9 signalosome complex)  with subsequent inhibition 
of the p38 MAPK signal transduction pathway resulting in inhibition of IL-Į-
induced IL-6 and IL-8 production (Banda et al., 2005). 
 
1.1.2.3 Deficiency of IL-1Receptor Antagonist (DIRA) 
Mutations in IL1RN, the gene encoding IL-1Ra, result in a rare autosomal 
recessive autoinflammatory disease of skin and bone known as Deficiency of IL-
1Receptor Antagonist (DIRA) (reviewed in Ferguson and El-Shanti, 2007; 
Aksentijevich et al., 2009). The main symptoms of the disease are skin 
inflammation and bone inflammation present from birth. In affected human 
subjects, the skin inflammation, which comes on spontaneously and can affect 
every part of the body, is characterized by redness, pustules and scaling. The 
bone inflammation typically involves the periosteum (the membrane covering the 
bone) and is characterized by painful bony swellings, often with the overlying  
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skin being reddened and warm. Many bones can be affected, including the limbs 
and the ribs. The nails of DIRA-patients can also become deformed 
(Aksentijevich et al., 2009). Other organs, such as the lungs may also be 
involved. There is no evidence of infection, high-titre autoantibodies, or 
autoreactive T cells (Aksentijevich et al., 2009; reviewed in Goldbach-Mansky, 
2012). Untreated, DIRA may lead to severe disability and even death 
(Aksentijevich et al., 2009).   
 
DIRA is caused by missense and non-sense mutations in the IL1RN gene 
leading to either absence of protein expression or expression of a non-functional 
IL-1Ra protein (Aksentijevich et al., 2009; reviewed in Goldbach-Mansky, 2012). 
This is in turn causes hyper-responsiveness to IL-ȕVWLPXODWLRQDQG
uncontrolled IL-Į,/-ȕsignalling which drives overproduction of 
proinflammatory cytokines and chemokines ((Aksentijevich et al., 2009; reviewed 
in Dinarello et al., 2012; reviewed in Goldbach-Mansky, 2012). Unopposed IL-1 
signalling due to IL-1Ra deficiency has been shown to induce both TH1and IL-
17-producing TH17 cells in murine models (Koenders et al., 2008). Daily injection 
with anakinra is the only therapy that has been effective in the treatment of 
DIRA. It results in rapid clearance of skin lesions and resolution of systemic 
inflammation (Aksentijevich et al., 2009; reviewed in Dinarello et al., 2012). 
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1.1.2.4 IL1RN gene polymorphism 
The second intron of the IL-1RA gene contains an 86 base pair (86bp) tandem 
repeat sequence which is repeated two to six times in different people. Allele 1 
(IL1RN*1) contains four copies, allele 2 (IL1RN*2) has two, allele 3 has three, 
allele 4 has five and allele 5 contains six copies of the 86bp tandem repeat 
sequence in intron 2 (reviewed in Witkin et al., 2002). There are differences in 
the frequency of the individual alleles based on ethnic or geographical 
differences. Generally, allele 1 (IL1RN*1) is the most common followed by allele 
2. Alleles 3, 4 and 5 occur in less than 1% of most populations. In the 
populations studied to date, the majority of people have been found to be either 
IL1RN*1 homozygotes or IL1RN*1/IL1RN*2 heterozygotes. The prevalence of 
IL1RN*2 homozygotes is typically less than 10% (reviewed in Witkin et al., 2002; 
reviewed in Arend, 2002; reviewed in Dinarello, 2011).  
 
IL-1RA genotype appears to influence the concentrations of IL-Į,/-ȕDQG,/-
1RA proteins produced (reviewed in Witkin et al., 2002; Langdahl et al., 2000; El-
Omar et al., 2000). IL1RN gene polymorphisms are associated with several 
markers of systemic inflammation (Reiner et al., 2008). IL1RN*2 homozygotes 
have a more prolonged and more severe proinflammatory immune response 
than people with other IL-1RA genotypes (reviewed in Witkin et al., 2002). In 
addition, IL1RN*2 homozygosity has been associated with inflammatory bowel 
diseases, alopecia areata, psoriasis, lichen sclerosus, lupus erythematosus, 
vulvar vestibulitis, multiple sclerosis and coronary artery disease (reviewed in 
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 Witkin et al., 2002; reviewed in Arend, 2002; reviewed in Dinarello, 2011). 
IL1RN gene polymorphism is also associated with increased risk of osteoporotic 
fractures (Langdahl et al., 2000), gastric cancer (El-Omar et al., 2000; Zhang et 
al., 2012), schizophrenia and other human diseases which are largely of 
epithelial or endothelial cell origin (reviewed in Arend, 2002; Reiner et al., 2008; 
reviewed in Dinarello, 2011). 
 
1.1.3 Classical IL-1 cytokines: Receptors and Cell Signalling 
IL-1 cytokines exert their effects through binding specific members of the IL-1 
receptor (IL-1R) family. Members of the IL-1R family have related structural 
features and are part of a superfamily characterised by the presence of a Toll/IL-
1 receptor (TIR) module in their intracellular region. They also have one to three 
copies of immunoglobulin (Ig)-like domains in their extracellular region (Sims, 
2002; Subramaniam, Stansberg and Cunningham, 2004; Li and Qin, 2005; Dunn 
DQG2¶1HLOO,/-1 family receptors which lack an intracellular TIR domain 
function as decoy receptors or soluble binding proteins (Dumont, 2006).  
 
Both IL-ĮDQG,/-ȕELQGWRWKHW\SH,,/-1R (IL-1R1) to form a complex. For 
signal transduction to occur, a homologue of IL-1R1, known as IL-1R accessory 
protein (IL-1RAcP) is recruited to this complex. Both IL-1 R1 and IL-1RAcP are 
expressed on numerous cell types including lymphocytes, endothelial cells, 
fibroblasts and other cells. Recruitment of IL-1RAcP leads to the stimulation of 
intracellular NF-ț%Dnd mitogen-activated protein kinase (MAPK) signalling 
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pathways. This results in activation of the transcription of host defence effector 
genes in target cells, including the production of numerous cytokines, 
chemokines, adhesion molecules, and enzymes such as cyclooxygenase and 
nitric oxide synthase (Barnes and Karin, 1997; Didierlaurent et al., 2006). The 
transcription factors which are activated by IL-ĮDQG,/-ȕLQFOXGHQXFOHDU
factor-ț%1)ț%DFWLYDWLQJSURWHLQ$3-1), and activating transcription factor 
(Barnes and Karin, 1997). NF-kB is a protein complex that controls the 
transcription of DNA. It is a critical transcription factor for the immune and 
inflammatory responses since a large number of genes are NF-kB regulated 
(Qian et al., 2001). 
 
Once IL-ĮRU,/-ȕKDVERXQGWRLWVUHFHSWRUFRPSOH[WKHF\WRVROLFSURWHLQV
MyD88 and Tollip, are then recruited to the receptor complex. MyD88 and Tollip 
function as adaptors and they in turn recruit IL-1 receptor-associated kinases 
(IRAKs) through a homophilic interaction of the death domains (Burns et al., 
2000; Didierlaurent et al., 2006; Brissoni et al., 2006). Following phosphorylation 
at the receptor complex, IRAKs then associate with tumor necrosis factor 
receptor-associated factor 6 (TRAF6), an ubiquitin protein ligase required for IL-
1-induced JNK and NF-ț%DFWLYDWLRQ6XEVHTXHQWO\SKRVSKRU\ODWHG,5$.VDUH
ubiquitinated and degraded probably as a means of switching off or terminating 
the signal. The interaction between phosphorylated IRAKs and TRAF6 leads to 
activation of the downstream signalling components. Transforming growth factor-
ȕ-activated kinase 1 (TAK1), which is a member of the mitogen-activated protein  
23 
kinase kinase kinase (MAPKKK) family, and two proteins that bind to it,          
transforming growth factor-ȕ-activated kinase 1 binding protein 1 (TAB1) and 
transforming growth factor-ȕ-activated kinase 1 binding protein 2 (TAB2), are 
also thought to participate in IL-1 signalling.  IRAKs are also thought to mediate 
the IL-1-induced translocation of TAB2 from the membrane to the cytosol (Qian 
et al., 2001). In untreated cells, TAB2 is membrane-bound but upon stimulation 
with IL-1, it translocates to the cytosol and functions as an adaptor, linking 
TRAF6 to TAK1 and TAB1, thereby activating TAK1 (Takaesu et al., 2000). It is 
now known that after TRAF6, has formed a complex with phosphorylated IRAKs, 
TRAF6 then dissociates and translocates to the cytosol to form a complex with 
TAK1-TAB1-TAB2. There appears to be a tight correlation between the 
translocation of TRAF6 and the activation of downstream signalling. It is thought 
that the translocation of both TAB2 and TRAF6 to the cytosol is a critical step in 
the formation of the TRAF6-TAK1-TAB1-TAB2 complex and in the activation of 
these proteins. It is still not clear how IRAKs mediate the translocation of TRAF6 
and TAB2. However, formation of the TRAF6-TAK1-TAB1-TAB2 complex leads 
to the activation of TAK1, and the phosphorylation of TAK1, TAB1, and TAB2. 
Ultimately, IL-1-induced NF-ț%DFtivation occurs. IRAK phosphorylation also 
results in the activation of other signalling cascades such as activation of p38, 
JNK, and others (Qian et al., 2001; Kaczorowski et al., 2008).  
 
In unstimulated cells, NF-ț%LVVHTXHVWHUHGLQWKHF\WRSODVPLQFRmplexes with 
WKHLQKLELWRU\,ț%,QKLELWRUVRIN%SURWHLQV)ROORZLQJVWLPXODWLRQZLWK,/-1  
24 
F\WRNLQHVRURWKHULQIODPPDWRU\F\WRNLQHVRUH[WUDFHOOXODUVWLPXOLWKH,ț% 
proteins are phosphorylated on specific serine residues, triggering their 
ubiquitination and subsequent degradation through the proteasome pathway. 
3URWHRO\VLVRI,ț%UHOHDVHV1)-ț%DQGDOORZVLWWRWUDQVORFDWHWRWKHQXFOHXV
where it binds to specific sequences of DNA called response elements (RE). The 
DNA/NF-ț%FRPSOH[WKHQUHFUXLWV other proteins such as coactivators and RNA 
polymerase, which transcribe downstream DNA into mRNA. In turn, mRNA is 
translated into protein (reviewed in Perkins, 2007). Ultimately, there is a change 
of cell function resulting from the stimulation of transcription of genes involved in 
inflammatory responses as well as an increase in the surface expression of 
costimulatory molecules on innate immune cells.  
 
In general, stimulation of transcription of specific genes following NF-kB 
activation results in specific physiological responses. These could be 
inflammatory or immune responses, cell survival responses, or cellular 
proliferation (Sims, 2002; Dumont, 2006; reviewed in Perkins, 2007). A number 
of molecules regulate IL-1 signalling pathways. As an example, MyD88 signalling 
can be inhibited by MyD88s (a shorter form of the MyD88 molecule), as MyD88s 
expression does not induce IRAK-1 phosphorylation and it hinders IRAK4 
recruitment (Burns et al., 2003a). In a similar manner, IRAK-M plays a negative 
regulatory role by preventing release of IRAK1 and IRAK4 (Kobayashi et al., 
2002). 
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IL-ȕFDQDOVRELQGZLWKDJUHDWHUDIILQLW\WKDQGRHV,/-ĮRU,/-1Ra) to another 
IL-1receptor family member known as the type II IL-1 receptor (IL-1R2) 
(McMahan et al., 1991; Novick et al., 1999). IL-1R2 is a 60-kDa protein and is 
found predominantly on lymphoid and myeloid cells such as monocytes, 
neutrophils, bone marrow cells, macrophages and B lymphocytes, 
myelomonocytic leukemia cells, and hairy cell leukemic cells (McMahan et al., 
1991; Novick et al., 1999; reviewed in Barksby et al., 2007). In vitro studies have 
shown that stimuli that induce IL-1 gene expression in keratinocytes also 
strongly induce IL-1R2 expression (Groves et al., 1995).  It has also been 
reported that IL-1-mediated inflammatory skin diseases such as psoriasis are 
characterized by strong epidermal expression of IL-1R2 (Groves et al., 1994). 
 
The binding of IL-ĮRU,/-ȕWR,/-1R2 does not result in signal transduction. 
The extracellular segment of IL-1R2 is structurally related to that of IL-1R1 in that 
both have three, characteristic immunoglobulin (Ig)-like domains McMahan et al., 
1991). Just like IL-1R1, IL-1R2 also has a transmembrane segment and a short 
cytoplasmic domain. However, while IL-5¶VF\WRSODVPLFGRPDLQFRQWDLQV
approximately 215 amino acids, IL-5¶VVKRUWF\WRSOasmic domain has only 29 
amino acids and lacks a Toll-homology domain and, as such, is unable to initiate 
signal transduction (McMahan et al., 1991). IL-ȕELQGVPRUHDYLGO\WRWKHQRQ-
signal-transducing IL-1R2 than it does to IL-1R1, thus, IL-1R2 is a decoy 
receptor for IL-ĮDQG,/-ȕ:KHQ,/-ĮRU,/-ȕELQGVWRWKHFHOOPHPEUDQHYLD
IL-1R2, no signal transduction occurs. Increased surface expression of IL-1R2  
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results in less IL-1 signalling and consequently reduces the biological response 
to IL-1 (Colotta et al., 1993; reviewed in Colotta et al., 1994).  
 
It is thought that IL-1R2 expression is induced following IL-1-mediated 
inflammation as a compensatory response to down-regulate the inflammatory 
process (Rauschmayr et al., 1997). It has been observed that cells which 
express high levels of IL-1R2 become unresponsive to IL-ȕ6LPV5Het 
al., 1996). IL-1R2 is thought to function as a decoy receptor at two levels; the 
first level is the already described binding of IL-1 to cell surface-bound IL-1R2 
thereby hindering the ability of IL-1 to form a signal-transducing complex with the 
type 1 receptor (IL-1R1) and IL-1RAcP (Colotta et al., 1993; reviewed in Colotta 
et al., 1994). The second way in which IL-1R2 is thought to function as a decoy 
receptor is by it being part of a trimeric complex consisting of the IL-1 ligand (IL-
ĮRU,/-ȕ,/-1R2 and IL-1RAcP. The effect of this complex is to prevent the 
functional IL-1 type 1 receptor from interacting with the signal-transducing IL-
1RAcP chain (Lang et al., 1998; Neumann et al., 2000). 
 
An extracellular, 47-kDa, soluble form of IL-1R2 also exists. It is released from 
the cell surface following proteolytic processing by a protease (Dower et al., 
1994). Soluble IL-1R2 binds to IL-ȕZLWKDKLJKHUDIILQLW\WKDQLWGRHVWR,/-ĮRU
IL-1Ra. The binding of IL-ȕWRsoluble IL-1R2 is almost irreversible because of a 
high dissociation rate and it neutralizes the biological effects of IL-ȕ'RZHUet  
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al., 1994). While the cell surface form of IL-1R2 can only bind mature IL-ȕ 
soluble IL-1R2 also binds the precursor form of IL-ȕSUR- IL-ȕ6\PRQVet al., 
1995). The distinct roles of membrane-bound IL-1R2 and soluble IL-1R2 in the 
control of cell activation by IL-ȕDUHQRWIXOO\XQGHUVWRRG,WLVWKRXJKWWKDWDOO
levels of regulation may occur in parallel (Neumann et al., 2000). Figure 1.1   is 
a schematic representation of ligands and receptors of the classical IL-1 family 
members. 
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Figure 1.1 Ligands and receptors of the classical IL-1 family members. The two 
agonist ligands, IL-ĮDQG,/-ȕDUHUHSUHVHQWHGE\,/-1 and the antagonist ligand 
by IL-1Ra. IL-1RI has a long cytoplasmic domain and, along with IL-1RAcP, 
activates signal transduction pathways. IL-1Ra functions as an IL-1 inhibitor by 
binding to IL-1R1 but not allowing interaction with IL-1RAcP. IL-1RII does not 
activate cells but functions as an IL-1 inhibitor both on the plasma membrane and in 
the cell microenvironment as a soluble receptor. IL-1RAcP can also inhibit IL-1 
signals by cooperating with IL-IRII in binding IL-1 either on the plasma membrane or 
as a soluble molecule (adapted from Arend et al., 2008).  
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Similar to the IL-ĮDQG,/-ȕUHFHSWRUFRPSOH[WKH,/-18 complex is a 
KHWHURGLPHUFRQWDLQLQJDQDOSKDĮFKDLQDQGDEHWDȕFKDLQ7KH,/-5Į
(also known as IL-1Rrp1) chain is responsible for extracellular binding of IL-18 
while the IL-5ȕRULJLQDOly called AcPL) chain is required for signal 
transduction (Gracie, Robertson and McInnes, 2003, Sims, 2002). The IL-18R 
complex is also expressed on a variety of cells such as macrophages, 
neutrophils, natural killer (NK) cells, endothelial and smooth muscle cells 
(Gracie, Robertson and McInnes, 2003). 
 
IL-18 also interacts with another IL-18 receptor known as IL-18 binding protein 
(IL-18BP). IL-18BP is a secreted protein which is distantly related to IL-1R2 and 
belongs to the immunoglobulin super family (Dinarello, 1996; Aizawa et al., 
1999; Novick et al., 1999). It is now known that IL-18 is down-regulated through 
its interaction with IL-18BP (reviewed in Barksby et al., 2007; Novick et al., 
1999).  IL-18BP is constitutively expressed in many cells. Its gene expression is 
enhanced by IFN-Ȗ.LPet al., 2000). Unlike the soluble IL-Į,/-ȕGHFR\
receptor, IL-18BP has little sequence similarity with IL-18 or IL-18R (Dinarello, 
1996; Aizawa et al., 1999; Novick et al., 1999). Four human (and two murine) 
isoforms of IL-18BP deriving from differential splicing of the same mRNA have 
been identified (Kim et al., 2000). IL-18BPa is the most abundant human isoform 
and has the greatest affinity for IL-18 (Kim et al., 2000; Paulukat et al., 2001; 
Moller et al., 2003). IL-18BPa binds and sequesters IL-18, thereby preventing it 
from interacting with IL-18R. Through this competitive binding, IL-18BP acts as a  
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natural IL-18 inhibitor (Novick et al., 1999). Foster et al., (2007) reported that 
infection of monocytes with LPS from Porphyromonas gingivalis induced IL-18 
and IL-18BPa secretion and that IL-18 and IL-18BPa interacted in a specific 
manner since addition of antibodies specific for IL-18BPa to the stimulated 
monocytic cell line cultures resulted in increased levels of free IL-18 (Foster et 
al., 2007). Other researchers have found that IL-18BP inhibits IL-18-induced 
IFN-ȖDQG,/-8 production and NF-kB activation in vitro (Novick et al., 1999). 
Others have observed that LPS-induced IFN-ȖSURGXFWLRQLVLQKLELWHGE\,/-18BP 
in vivo (Aizawa et al., 1999). Recently, another study showed that the inhibitory 
effect of IL-18BP on IFN-ȖSURGXFWLRQFDQEHHQKDQFHGE\,/-1F7b (Bufler et al., 
2004). 
 
IL-18 signalling was previously thought to be similar to that for IL-ĮDQG,/-ȕ
and was thought to result in similar responses (reviewed in Sims, 2002). 
Although MyD88-IRAK-TRAF6-NF-kB signalling system is the major signalling 
system for IL-18, IL-ĮDQG,/-ȕLWKDVVLQFHEHHQUHSRUWHGWKDW,/-18 primarily 
signals via the MAPKp38 pathway rather than NF-kB in human epithelial cells 
(Lee et al., 2004). Since MAPK pathways are involved in cell growth, MAPK 
signalling is important as IL-18 is thought to exert proliferative actions on T and 
Natural Killer (NK) cells (Tomura et al., 1998). It is now clear that different 
mechanisms of IL-18 gene regulation are employed, depending on the cell type. 
It has been suggested that the differences in the biological activities of IL-Įȕ 
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and IL-18 can be accounted for by differences in signalling mechanisms (Lee et 
al., 2004). Figure 1.2 below is a schematic diagram showing ligands and 
receptors for the IL-18 family. It also shows the postulated interaction between 
IL-18BP and one of the newly discovered IL-1 homologues, IL-1F7. IL-1F7 will 
be discussed in more detail in later sections. 
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Figure 1.2 Ligands and receptors for the IL-18 family. IL-18 binds to the IL-
5ĮFKDLQDQGWKLVFRPSOH[WKHQHQJDJHVWKH,/-18RȕFKDLQWRLQLWLDWH
intracellular signals. The soluble protein IL-18BP functions as an inhibitor of IL-
18 by binding this ligand in the fluid phase, preventing interaction with the IL-
5ĮFKDLQ,/-1F7 appears to enhance the inhibitory effect of IL-18BP (adapted 
from Arend et al, 2008). 
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1.1.4 Biological activity of classical IL-1 family cytokines 
 
IL-1 cytokines have been shown to play an important role with regards to how a 
host animal responds to inflammatory, infectious or other immunological 
challenges (Dumont, 2006). IL-Į,/-ȕDQG,/-18 are primarily proinflammatory 
cytokines with an ability to induce expression of genes associated with 
inflammation and autoimmune diseases. They have pleiotropic regulatory effects 
on T and B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, 
basophils, mast cells, natural killer cells, osteoblasts, fibroblasts, muscle cells, 
endothelial cells and epithelial cells. They therefore play an important role in both 
innate and adaptive immunity (Dinarello, 1984; Dinarello, 1998, Dinarello 2003c).  
 
The most prominent role of IL-1 cytokines in inflammation is the initiation of 
cyclooxygenase type 2 (COX-2), type 2 phospholipase A and inducible nitric 
oxide synthase (iNOS). Consequently, cells exposed to IL-1 (also, animals or 
humans injected with IL-1) produce large amounts of prostaglandin-E2 (PGE2), 
platelet activating factor and nitric oxide (NO) (reviewed in Dinarello 2003c). IL-1 
cytokines can also increase expression of adhesion molecules, such as 
intercellular adhesion molecule-1 (ICAM), on mesenchymal cells and vascular-
cell adhesion molecule-1 (VCAM-1) on endothelial cells. Expression of VCAM-1 
on endothelial cells causes inflammatory and immunocompetent cells to infiltrate 
the extravascular space. IL-1 cytokines also increase expression of vascular  
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endothelial growth factor (VEGF). VEGF is a signal protein which stimulates 
vasculogenesis and angiogenesis. IL-1 cytokines, therefore, play a role in 
tumour metastasis and blood vessel supply (reviewed in Dinarello 2003c). 
 
It is now widely accepted that IL-1 cytokines mediate acute phase protein (APP) 
synthesis, adhesion molecule up-regulation, vasodilation, coagulation, 
production and release of matrix metalloproteinases and production of growth 
factors (Bagby, 1989, Smith et al., 1992; reviewed in Dinarello, 1991, 1996).  IL-
1 cytokines also influence other biological responses including haematopoiesis, 
fever, appetite control, bone metabolism and sleep (reviewed in Dinarello, 1991, 
1996; Dinarello and Wolff, 1993; Bagby, 1989, Smith et al., 1992).  
 
A number of studies have shown that administration of IL-ĮWRKHDOWK\DQLPDOV
or humans causes fever, sleep and hypotension. Fischer et al. (1991) evaluated 
how responses to sublethal endotoxaemia compared with IL-ĮDGPLQLVWUDWLRQ
In their study, baboons were intravenously injected with either LPS or varying 
amounts of IL-Į7KH\REVHUYHGWKDW,/-ĮDGPLQLVWUDWLRQZDVDEOHWR
reproduce most of the effects of sublethal endotoxaemia. They also reported that 
the effect of IL-ĮGHSHQGHGRQWKHGRVH*HQHUDOO\ the most significant 
responses to IL-1 administration were observed at the highest dose (Fischer et 
al., 1991). In an earlier study, Okusawa et al. (1988) found that treating rabbits 
with IL-ȕSURGXFHGDVKRFN-like state (Okusawa et al., 1988). 
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In addition to exerting proinflammatory effects, IL-1 cytokines are also adjuvants 
during antibody production. They act on bone marrow stem cells and stimulate 
their differentiation. In one study, pre-treatment with a single low dose of 
recombinant human IL-ȕtwenty-four hours prior to administering a lethal 
bacterial challenge to granulocytopenic and normal mice was found to enhance 
nonspecific resistance and to reduce mortality (Van der Meer et al., 1988).  
 
IL-ĮLVNQRZQWRSRVVHVVDQWLSUROLIHUDWLYHLPPXQRstimulatory, anti-infection, 
myeloprotective, and myelorestorative properties that could be beneficial in 
cancer treatment (Smith et al., 1992). A study which sought to determine 
whether IL-ĮFRXOGDPHOLRUDWHGUXJ-induced thrombocytopenia found that IL-Į 
administration post-chemotherapy can accelerate platelet recovery in human 
patients with advanced neoplasms. It was concluded that administration of IL-Į
may be clinically useful in preventing or treating thrombocytopenia induced by 
chemotherapy (Smith et al., 1993). On the other hand, other studies in human 
patients with advanced solid malignancies have shown that dose-dependent side 
effects such as fever, gastrointestinal disturbances, myalgia (muscle pain), 
arthralgia (joint pain) and hypotension may limit the therapeutic utility of IL-ĮLQ
patients (Smith et al., 1992). It has been argued that although side effects such 
as chills, fever, and hypotension have been observed following administration of 
higher doses of IL-ĮWKHIDFWWKDWGUXJWROHUDQFHdevelops rapidly suggests that 
it may be possible to administer IL-ĮIRUPRUHSURORQJHGSHULRGVIRUH[DPSOHD
few days before or after chemotherapy) (Smith et al., 1993).  If doses of IL-Į 
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that can be given safely to cancer patients are adhered to, significant, potentially 
beneficial haematopoietic effects occur (Smith et al., 1992). 
 
Unlike IL-Įȕ,/-18 can stimulate both pro-inflammatory (TH1) as well as anti-
inflammatory (TH2) responses, depending on the immunological context. For 
example, IL-18 influences TH1 responses by up-regulating Fas ligand expression 
on natural killer (NK) cells thereby enhancing their cytotoxicity and by interacting 
synergistically with IL-12 to stimulate the production of IFN-ȖE\7FHOOVDQG1.
cells (reviewed in Nakanishi et al., 2001). IL-18 can also act in synergy with other 
TH2-stimulating factors (such as IL-2 or IL-4) to influence TH2 responses by 
enhancing IL-4, IL-13 and IgE production (reviewed in Dumont, 2006; Muhl and 
Pfeilschifter, 2004). 
 
Although IL-1 could potentially function as an immunoadjuvant due to its ability to 
up-regulate host defences, its inflammatory side effects can limit its beneficial 
effects (Smith et al., 1992). A study by Niki et al. (2001) showed that 
spontaneous arthritis developed in IL-ĮWUDQVJHQLFPLFH6LQFHWKHQ,/-1 has 
been implicated in other autoimmune-related inflammatory conditions such as 
colitis (Dinarello, 2002; Barksby et al., 2007). IL-ȕKDVDOVREHHQ
contraindicated in pathologies such as the septic syndrome, trauma, insulin-
dependent diabetes mellitus, atherosclerosis and other diseases (Bistrian et al., 
1992).  
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Studies examining the biological effects of IL-1 blockade have facilitated the 
understanding of the pathophysiological role that IL-1 plays in inflammatory and 
autoimmune conditions. In one such study, Palmer et al., (2003) observed that 
overexpression of IL-1Ra conferred protection against collagen induced arthritis 
(CIA) in mice, while other studies have shown that genetic deficiency in IL-Į,/-
ȕRU,/-18 also offers significant protection against CIA (Saijo et al., 2002; Wei 
et al., 2001). The clinical benefits of IL-1 blockade through the use of Anakinra 
have already been highlighted. 
 
Although IL-ĮDQG,/-ȕVLJQDOWKURXJKWKHVDPHUHFHSWRUFRPSOH[DQGKDYH
identical biological activities in solution, they differ in a number of ways. Table 
1.2 summarises some of these differences. 
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Table 1.2 Summary of differences between IL-ĮDQG,/-ȕVXPPDULVHGIURP
Kurt̻Jones et al., 1985; Maier et al., 1994; Hazuda et al, 1998; Dinarello, 1996;  
Sims, Smith, 2010) 
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IL-Į IL-ȕ 
 
Synthesized as a 33-34 kDa, 271 amino 
acid pro-cytokine which is enzymatically 
cleaved (by calpain) into a bio-active 17 
kDa, 159 amino acid mature segment 
and a 112 amino acid pro-sequence 
Synthesized as a 31-34 kDa, 269 
amino acid long precursor which is 
cleaved into a 116 amino acid pro-
segment and a 153 amino acid, 17 
kDa mature segment by IL-1 beta-
converting enzyme (ICE) 
Both precursor and mature forms show 
bioactivity. Intracellularly, pro- IL-Į
appears to act through its nuclear 
localization signal that is found between 
residues 79-85 of its pro-region. 
Shows bioactivity only when it is in its 
mature form. IL-ȕSUHFXUVor forms 
have no known biological activity. 
Generally associated with the plasma 
membrane of the producing cell and so 
acts locally 
Circulates systemically following 
secretion 
Highly expressed by several cells 
including keratinocytes and endothelial 
cells, generally more widespread 
expression than  IL-ȕ 
Mainly produced by monocytes and 
macrophages 
Important for priming T cells during 
contact hypersensitivity and for the 
induction of high levels of serum IgE 
following immunization with ovalbumin  
Can circulate to the brain and is 
important for the induction of fever 
1.1.4.1 Cryopyrin-associated Periodic Syndromes (CAPS) 
Mutations in NLRP3 (or CIAS1), the gene which encodes NLRP3 (NALP3 or 
cryopyrin) (Section 1.1.2.1) causes a group of rare, autoinflammatory diseases 
collectively known as Cryopyrin-associated periodic syndromes (CAPS) 
(Hoffman et al., 2001; reviewed in Kubota and Koike, 2010; reviewed in 
Goldbach-Mansky, 2011). Unlike autoimmune diseases, auto-inflammatory 
syndromes are characterised by a pathogenesis that does not require 
autoreactive T-lymphocytes or immunoglobulins to self-antigens. Instead, many 
auto-inflammatory syndromes are caused by abnormal regulation of cytokine 
signalling pathways, leading to persistent inflammation (reviewed in Hoffman, 
2009). Diseases included in the CAPS category are: Familial cold 
autoinflammatory syndrome (FCAS; also known as familial cold urticaria), 
Muckle-Wells syndrome (MWS) and neonatal-onset multisystem inflammatory 
disorder (NOMID; also known as chronic infantile neurological cutaneous and 
articular syndrome or CINCA) (Hoffman et al., 2001; reviewed in Kubota and 
Koike, 2010; reviewed in Goldbach-Mansky, 2011). 
 
As previously discussed (Section 1.1.2.1), NLRP3 (cryopyrin) is an intracellular  
sensor of pathogens or danger signals and is part of the multi-protein complex 
called the inflammasome which plays a key role in the generation of biologically 
active IL-ȕ and IL-18 through caspase-1 activation (Hoffman et al., 2001; 
reviewed in Hoffman, 2009; reviewed in Wen et al., 2012). CAPS have been 
associated with heterozygous gain of function mutations, either inherited in an 
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autosomal-dominant manner or developed spontaneously in the NLRP3 gene; 
however, mutations have not been detected in all patients (Hoffman, 2001). 
NLRP3 gene mutations are believed to result in a constitutively active or 
hyperactive form of the NLRP3/NALP3 inflammasome complex which, in turn, 
causes activation of caspase 1 and hypersecretion of mature IL-ȕ+RIIPDQet 
al., 2001; reviewed in Hoffman, 2009). Various NLRP3 missense mutations have 
been reported in CAPS, with each mutation causing a different degree of 
aberrant NLRP3 activation (reviewed in Kubota and Koike, 2010; reviewed in 
Goldbach-Mansky, 2011).  
 
CAPS patients usually present with several shared clinical features, including an 
urticaria-like rash that appears soon after birth. All patients possess some 
degree of systemic inflammation in the form of fever and/or chills accompanied 
by elevations in acute phase reactants which are triggered by exposure to cold in 
patients with FCAS (reviewed in Goldbach-Mansky, 2011). In most cases, there 
is some involvement of the joints and eyes (Hoffman et al., 2001; reviewed in 
Kubota and Koike, 2010; reviewed in Goldbach-Mansky, 2011). Although 
overlapping cases between FCAS and MWS or MWS and CINCA exist, there 
are critical features distinguishing FCAS, MWS and NOMID. FCAS, which is the 
mildest form of CAPS, presents with cold-induced urticarial rash, fever, and 
arthralgia. The symptoms of NOMID (or CINCA), the most severe form of CAPS, 
include neonatal-onset high fever, aseptic meningitis, mental retardation, 
sensory deafness, papilledema, arthritis with bone overgrowth, and secondary  
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amyloidosis that contributes to mortality. MWS is the intermediate phenotype 
(Hoffman et al., 2001; reviewed in Hoffman, 2009; reviewed in Kubota and 
Koike, 2010; reviewed in Goldbach-Mansky, 2011). 
 
Inhibiting IL-ȕVLJQDOOLQJKHQFHFRXQWHULQJWKHHIIHFWVRIDQRYHUDctive 
inflammasome) has proved to be highly efficacious in treating CAPS conditions, 
supporting findings which indicate the central role of IL-1 in the pathogenesis. 
The three IL-1 blocking agents currently approved for treating CAPS conditions 
are anakinra, rilonacept and canakinumab (Hoffman et al., 2008; Alten et al., 
2008; reviewed in Hoffman, 2009; reviewed in Goldbach-Mansky, 2011).  
Anakinra is a recombinant IL-1Ra that functions as a competitive inhibitor of IL-
ĮDQG,/-ȕVHFWLRQs 1.1.0 and 1.1.2.2) (reviewed in Fleischmann, 2002; 
reviewed in Furst, 2004; reviewed in Fleischmann et al., 2004), whereas 
rilonacept is a fusion protein that is made up of the receptor components 
required for IL-1 signalling (IL-1 type-1 receptor and the IL-1 receptor accessory 
protein) and the Fc portion of immunoglobulin G1 (IgG1). Rilonacept can bind to 
IL-ȕZLWKKLJKDIILQLW\WKHUHE\SUHYHQWLQJLWVLQWHUDFWLRQZLWKFHOOVXUIDFH
receptors (Hoffman et al., 2008). Canakinumab is a fully human anti-IL-ȕ
monoclonal antibody which selectively binds to IL-ȕZLWKQRFURVV-reactivity with 
other characterised IL-1 family members. By binding to IL-ȕFDQDNLQXPDE
prevents IL-ȕIURPbinding to the IL-1 receptor (Alten et al., 2008; reviewed in 
Hoffman, 2009). Anakinra, rilonacept and canakinumab have proved to not only 
be effective at countering the inflammatory symptoms of CAPS but they have 
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also shown acceptable safety profiles (reviewed in Goldbach-Mansky, 2011). 
Understanding the role of the inflammasome and cryopyrin in other inflammatory 
diseases may lead to the development of more effective medication. 
   
1.1.5 Regulation of activity: Classical IL-1 Family members 
As has already been noted, depending on tissue or plasma levels, IL-1 action 
can either be beneficial or detrimental to the host. Although the innate response 
is necessary for host survival, in the presence of an excess amount of IL-1, 
inflammatory and autoimmune diseases may develop (reviewed in Arend, 2002). 
As a result, IL-1 production is a tightly controlled event. Studies suggest that 
under normal conditions, plasma IL-1 concentrations are below the detection 
range. As already highlighted in preceding sections, in addition to regulation of 
synthesis and secretion, regulation of IL-1 bioactivity also involves the production 
of IL-1 antagonists (such as IL-1Ra), the presence of decoy IL-1 receptors (for 
example IL-1R2 and IL-18BP), regulation of IL-1 signalling pathways and IL-1 
mediated gene expression (Cooney and Shumate, 2006). The presence of such 
numerous pathways of IL-1 regulation underscores the need for tight control of 
IL-1 action. It remains to be seen whether similar regulatory mechanisms exist 
among the newer members of the IL-1 cytokine family. The following section will 
look at current understanding regarding these novel IL-1 cytokine family 
members. 
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1.2.0 Novel IL-1 family members 
1.2.1 Novel IL-1 cytokines: General overview 
As mentioned in previous sections, seven additional members have now been 
added to the IL-1 family on the basis of conservation of amino acid (aa) 
sequence, identity of gene structure, and predicted three-dimensional structure. 
It has already been noted that Sims et al. (2001) proposed a revised 
nomenclature in an effort to standardise the naming of the IL-1 family members. 
Under this revised nomenclature, it was suggested that the classical IL-1 family 
members (IL-Į,/-ȕ,/-1Ra and IL-18) be renamed IL-1F1, IL-1F2, IL-1F3 
and IL-1F4 respectively (where IL-1F stands for IL-1 Family member) while the 
novel IL-1 family members were to be named IL-1F5 to IL-1F11 (Sims et al., 
2001).  
 
The intron-exon organisation of the IL-1 genes suggests that each IL-1 family 
member arose from a common ancestral gene that later became duplicated. 
Each gene codes for a protein that contains a single structural domain formed 
from 12 beta strands connected by loop regions arranged in a beta-trefoil 
structure (Nicklin et al., 1994). Similar to IL-1ȕ and IL-1Ra, the new IL-1 family 
members differ most from each other within these loop regions (Nicklin et al., 
1994). The genes for IL-1F5-F10 map to the region of chromosome 2 between 
the IL-ȕDQG,/-1Ra loci (Dunn et al., 2001, Taylor et al., 2002, Barksby et al., 
2007; Magne et al., 2006; Smith et al., 2000; Kumar et al., 2000; Barton et al.,  
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2000; Busfield et al., 2000; Pan et al., 2001; Bazan et al., 1996; Lin et al., 2001; 
Debets et al., 2001; Blumberg et al., 2007; Nicklin et al., 2002; Lander et al., 
2001). The 11th member of the IL-1 cytokine family is located on the short arm of 
chromosome 9 at position 24.1 and was initially named IL-33. Its structural and 
functional properties have been observed to be similar to the other IL-1 family 
members. It has since been renamed IL-1F11 (Schmitz et al., 2005). 
 
More recently, Dinarello et al. (2010) proposed that as functions have now been 
elucidated for several of the novel IL-1s, an individual interleukin designation 
should now be assigned to each of these cytokines.  They argued that even 
though IL-1F6, IL-1F8 and IL-1F9 are encoded by distinct genes, they use the 
same receptor complex (IL-1Rrp2 and IL-1RAcP), they are proinflammatory and 
they also deliver almost identical signals. On this basis, the names IL-Į,/-
ȕDQG,/-ȖZHUHSURSRVHGIRU,/-1F6, IL-1F8 and IL-1F9 respectively 
(Dinarello et al., 2010).  
 
Using a similar argument, it was also proposed that natural IL-1F5 be renamed 
IL-36Ra (IL-36 receptor antagonist). This proposal was based on previous 
findings by Debets et al., (2001), Towne et al. (2004) and Blumberg et al (2007) 
which suggested that IL-1F5 binds to IL-1Rrp2 but antagonizes IL-1F6, IL-1F8 
and IL-1F9 in a manner comparable to that used by IL-1Ra to antagonize IL-Į
and IL-ȕ'LQDUHOORet al., 2010).  
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IL-37 has been proposed as the new name for IL-1F7. Under this proposal, the 
names of the IL-1F7 splice forms would be changed from IL-1F7a, IL-1F7b and 
so on to IL-37a, IL-37b and so on. It was also suggested that IL-1F10 retain its 
IL-1F designation until its properties and biological function have been clearly 
elucidated, however, IL-38 was proposed as a potential new name for it 
(Dinarello et al., 2010) and has since been adopted (van de Veerdonk et al., 
2012). Although data regarding the newer members of the IL-1 cytokine family is 
starting to emerge, their biology is still less well characterised than that of the 
classical IL-1 family members.  
 
Phylogenetic analysis suggests that IL-1F6, IL-1F8 and IL-1F9 (IL-Į,/-ȕ
and IL-Ȗ) (Dinarello et al., 2010) belong to a triplet branch of the phylogenetic 
tree (Blumberg et al., 2007). All three cytokines lack a pro-domain (Smith et al., 
2000) and were shown to trigger NF-kB and MAPK signalling via IL-1Rrp2 and 
IL-1RAcP and to induce IL-6 and IL-8 production in mammary epithelial cells 
(Towne et al., 2004). It is now known that IL-1F6, IL-1F8 and IL-1F9 (IL-Į,/-
ȕDQG,/-Ȗbind to IL-1Rrp2 (IL-36R) and IL-1RAcP, activating similar 
intracellular signals to IL-ȕZKLOH,/-1F5 (IL-36Ra) acts as an IL-1Rrp2 
antagonist (IL-36Ra) (Towne et al., 2004; Vigne et al., 2011). In separate 
studies, however, IL-1F8 and IL-1F9 failed to induce typical IL-ȕUHVSRQVHVLQ
mouse glial cells (Wang et al., 2005; Berglof et al., 2003). Whether or not IL-1F8 
and IL-1F9 have distinct activities or indeed whether they trigger alternative 
pathways to MAPK and NF-kB in the brain remains to be proven. Current 
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understanding regarding each of the newer IL-1 family members will now be 
discussed in turn. For the purposes of this thesis, the classical IL-1 family 
members will continue to be referred to by their traditional names while the 
nomenclature proposed by Sims et al. (2001) will generally be adopted for the 
novel IL-1 family members, however, where necessary, the alternative names 
will also be quoted in brackets.   
 
1.2.1.1 IL-1F5  
In humans, IL-1F5 (recently renamed IL-36 receptor antagonist or IL-36Ra) 
(Dinarello et al., 2010) is a protein encoded by the IL1F5 (also known as IL-
36RN) gene (Mulero et al., 1999; Smith et al., 2000; Sims et al., 2001). Using 
high throughput cDNA clone sequencing technology, Mulero et al. (1999) 
identified IL-1F5 for the first time and named it IL-1HY1. It was later identified as 
FIL-įE\6PLWKet al. (2000) and IL-1L1 (Barton et al., 2000). Other researchers 
named it IL-1RP3 (Busfield et al., 2000) and IL-į'HEHWVet al., 2001).  Kumar 
et al., (2000) identified a murine ortholog of this gene and named it IL-1H3. The 
predicted protein does not appear to contain a signal peptide or a propeptide 
domain at the N-terminus. Two alternatively spliced transcript variants encoding 
the same protein have been reported (Smith et al., 2000). Besides IL̻ȕ,/̻1Ra 
and IL̻18, IL̻1F5 is the only other IL-1 family member that has a published, 
experimentally determined three̻dimensional structure (Dunn et al., 2003). It is 
widely expressed in keratinocytes, psoriatic skin, placenta, uterus, brain, thymus,  
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heart, kidney, monocytes, macrophages, B cells and dendritic cells (DCs) but not 
in fibroblasts, endothelial cells or melanocytes (Smith et al., 2000; Debets et al., 
2001; Nicklin et al., 2002; Barton et al., 2000). Although IL-1F5 does not appear 
to show antagonistic activities towards the classical IL-1s (Barton et al., 2000), it 
has been found to show high (44%) sequence homology to IL-1Ra (Smith et al., 
2000; Debets et al., 2001; Nicklin et al., 2002). This fuelled speculation that IL-
1F5 may be a novel IL-1Ra. Indeed, Debets et al. (2001) found that IL-1F5 
blocked the activation of NF-kB by IL-1F9 in Jurkat cells which over-expressed 
IL-1Receptor-related Protein 2 (IL-1Rrp2). IL-1F5 was found to be a highly 
specific antagonist of the IL-1 Rrp2-mediated response to IL-1F9 (Debets et al., 
2001). As is the case with IL-1Ra, IL-1F5 mRNA was also found to be up-
regulated by treatment of human monocytic cells with phorbol esters and 
bacterial lipopolysaccharides (LPS) (Debets et al., 2001). It was postulated that 
IL-1F5 could constitute part of an independent signalling system analogous to 
the IL-1Į,/-ȕLQWHUOHXNLQ-1 receptor type I (IL-1R1) and IL-1Ra system which 
is present in epithelial barriers and takes part in local inflammatory response 
(Debets et al., 2001).  
 
In another study, Towne and co-workers used an epithelial cell line which 
expressed both IL-1Rrp2 and IL-1RAcP to demonstrate that IL-1F6, IL-1F8 and 
IL±1F9 mediated NF-kB activation via IL-1Rrp2. They were also able to show 
that IL-1RAcP was necessary for signal transduction since its absence resulted 
in no NF-kB activation even though IL-1Rrp2 and its ligands were present,  
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however, investigations to establish whether IL-1F5 was an antagonist for IL-
1F6, IL-1F8 or IL-1F9 (as suggested by Debets et al., 2001) produced equivocal 
results (Towne et al., 2004). When Magne et al. (2006) tested the ability of 
different concentrations of recombinant human IL-1F5 to inhibit the effects of IL-
1F8 on IL-6 production in human articular chondrocytes they also observed that 
antagonism of the effects of IL-1F8 by IL-1F5 was incomplete and not 
reproducible (Magne et al., 2006).  
 
Nevertheless, in a later study, Blumberg et al. (2007) demonstrated that IL-1F5 
has antagonistic activity in vivo. In their study, they generated transgenic mice 
over-expressing IL-1F6 in their basal keratinocytes. They observed that the skin 
of IL-1F6 transgenic mice over-expressing IL-1F6 in basal keratinocytes is 
characterized by acanthosis, hyperkeratosis, the presence of a mixed 
inflammatory cell infiltrate, and increased cytokine and chemokine expression. 
They also generated mice deficient in IL-1F5 and later performed a genetic cross 
between the two groups of mice. They observed that expression of the IL-1F6 
transgene in basal keratinocytes resulted in cutaneous lesions whose severity 
was worsened by co-existing IL-1F5 deficiency, suggesting that IL-1F5 plays an 
antagonistic role in vivo and that the balance between IL-1F6 agonist activity and 
IL-1F5 antagonist activity is critical in skin inflammation (Blumberg et al., 2007).  
 
In a study involving rat glial cells and whole mouse brain, Costelloe et al., (2008)  
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reported that IL-1F5, through its interaction with the novel receptor single 
immunoglobulin IL-1receptor-related (SIGIRR), antagonizes the inflammatory 
effects of IL-ȕDQG/36ERWKin vivo and in vitro through induction of IL-4. Their 
study demonstrated that IL-1F5 abrogated lipopolysaccharide (LPS)-induced 
inhibition of long-term potentiation (LTP) in the hippocampus of IL-4 gene knock-
out mice. They also found that IL-1F5 up-regulates IL-4 expression in the 
hippocampus, confirming earlier speculations that IL-1F5 may possess anti-
inflammatory effects due to its high amino acid sequence similarity to IL-1Ra, 
and also suggesting, for the first time, that IL-1F5 interacts with the SIGIRR 
receptor in the brain (Costelloe et al., 2008). Another interesting observation 
made by this study was that in contrast to its effects in brain tissue, IL-1F5 failed 
to abrogate LPS-induced changes in macrophages or dendritic cells and failed to 
up-regulate IL-4 expression in these cells (Costelloe et al., 2008), suggesting 
that IL-1F5 may have different effects on different tissues/cells. 
 
In a study which assessed expression of IL-1F5, IL-1F6, IL-1F8 and IL-1F9 in 
healthy controls, subjects with uninvolved psoriasis, and subjects with psoriasis 
plaque skin, increased expression of IL-1F5, IL-1F6, IL-1F8 and IL-1F9 was 
observed in lesional psoriatic skin compared to healthy controls (Johnston et al., 
2011). Other researchers have studied human keratinocytes derived from 
epidermal stem cells of hair follicles plucked from patients with psoriasis and 
also those from healthy individuals and observed that in the presence of IL-17, 
psoriasis-derived keratinocytes showed a significantly higher induction of the  
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proinflammatory IL-1 family members IL-1F6 and IL-1F9, but not of anti-
inflammatory members IL-1F5, IL-1F7 or IL-1Ra (IL-1F3) compared with 
keratinocytes from healthy individuals (Muhr et al., 2011). Both basal and IL-17-
induced levels of IL-Į,/-1F1) and IL-ȕ,/-1F2) were also found to be 
significantly lower in psoriasis keratinocytes (Muhr et al., 2011). These findings 
further support the potential of novel IL-1 family members as therapeutic targets 
in psoriatic conditions. 
 
To address the discrepancy between their previous IL-1F5 (IL-36Ra) in vitro 
results (Towne et al., 2004) and those of Debets et al. (2001), Towne et al. 
(2011) recently characterized several different recombinant IL-1F5 (IL-36Ra) 
preparations. They showed that IL-1F5 (IL-36Ra) binds to the IL-1Rrp2 receptor 
and is indeed an antagonist not only of IL-1F9 (IL-ȖEXWDOVRRI,/-1F6 (IL-
ĮDQG,/-1F8 (IL-ȕ; however, IL-1F5 activity requires removal of the 
amino-terminal methionine which is present in the primary translation product. 
Furthermore, the mechanism of antagonism by IL-1F5 (IL-36Ra) is comparable 
to that used by IL-1Ra to inhibit IL-1 in that a substantial molar excess is required 
for inhibition. In addition, it was also observed that as was the case with IL-1F5 
(IL-36Ra), a particular N-terminal truncation of IL-1F6 (IL-Į,/-1F8 (IL-ȕor 
IL-1F9 (IL-Ȗ resulted in a 1000-10,000-fold increase in biological activity, 
suggesting that post-translational processing is required for full activity (Towne et 
al., 2011). A later study showed that truncated IL-1F6, IL-1F8 and IL-1F9 were 
more potent than IL-ȕDWLQGXFLQJPDWXUDWLRQRIPXULQHERQHPDUURZGHULYHG 
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DCs and subsequent inflammatory cytokine production (Vigne et al., 2011). It is 
now appreciated that IL-1F5 inhibits the multiple proinflammatory effects induced 
by the agonists IL-1F6 (IL-Į,/-1F8 (IL-ȕand IL-1F9 (IL-Ȗ by 
preventing them from binding to the IL-1Rrp2 receptor (IL-36 receptor or IL-36R), 
however, the mechanism of secretion of these ligands is yet to be elucidated 
(Towne et al., 2011).  
 
1.2.1.1.1 IL-1F5 (IL-36RN) gene mutation  
 
A recent study which sought to identify genetic abnormalities responsible for 
familial generalized pustular psoriasis (GPP) provided robust genetic evidence 
for the vital role of IL-1F5 in immune regulation in the skin (Marrakchi et al., 
2011). GPP is a life-threatening, multisystemic inflammatory disease comprising 
repeated flare-ups of sudden onset, characterized by a diffuse, erythematous, 
pustular rash accompanied by a high-grade fever, general malaise, and 
extracutaneous organ involvement (Marrakchi et al., 2011). Marrakchi et al. 
(2011) performed homozygosity mapping and direct sequencing in nine Tunisian 
multiplex families with autosomal recessive GPP. The effect of mutations on 
protein expression and conformation, stability, and function was then performed. 
The study demonstrated that loss-of-function mutations in IL-1F5 (IL-36RN), the 
gene which encodes IL-1F5 (IL-36Ra), results in absence of functional IL-1F5 
(IL-36Ra) leading to unregulated secretion of inflammatory cytokines and hence  
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GPP (Marrakchi et al., 2011). The findings are consistent with previously 
mentioned mouse studies which showed that IL-1F6 (IL-ĮRYHUH[SUHVVLRQ
results in transient skin inflammation characterized by acanthosis, 
hyperkeratosis, and a mixed-cell infiltrate rich in neutrophils, features observed 
in both psoriasis vulgaris and GPP and that when crossed with IL-1F5 (IL-36Ra)-
deficient mice, the skin phenotype is strikingly enhanced and persistent with 
extensive pustule formation (Blumberg et al., 2007). These data highlight IL-1/IL-
36 signalling as a potential target for therapeutic intervention in GPP.  
 
1.2.1.2 IL-1F6 
The human IL-1F6 gene was cloned from a human genomic sequence. The 
predicted IL-1F6 (recently renamed IL-Į polypeptide is approximately 26% 
identical to IL-1Ra and its open reading frame contains neither a signal peptide 
nor a prodomain (Smith et al., 2000). One study explored the mechanism by 
which murine IL-1F6 is released from bone marrow-derived macrophages 
(BMDMs) and compared this mechanism to that used by IL-ȕ,WZDVREVHUYHG
that transduced IL-1F6 is released in parallel with endogenous mature IL-1beta 
from LPS/ATP-treated BMDMs, but that this externalization process is not 
selective for cytokines since a non-cytokine, green fluorescent protein (GFP), 
shows similar behaviour. It was concluded that IL-1F6 is probably externalized 
via a stimulus-coupled mechanism comparable to that used by IL-ȕ(Martin et 
al., 2009). 
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IL-1F6 mRNA has been detected in foetal brain, tonsils, LPS-activated 
monocytes, B cells, T cells and human skin (Smith et al., 2000; Towne et al., 
2004). Lung cancer tissue and TNF-ĮWUHDWHGVPDOODLUZD\HSLWKHOLXPDOVR 
express IL-1F6 (Dumont, 2006). Along with IL-1F8 and IL-1F9, IL-1F6 has been 
VKRZQWRDFWDVDQDJRQLVWE\DFWLYDWLQJWKHSDWKZD\LQYROYLQJ1)ț%DQG0$3.
in an IL-1Rrp2 dependent manner, suggesting that IL-1F6 signals in a similar 
fashion to IL-1ȕ and IL-18 in having a binding receptor which upon ligation 
recruits a second receptor as a signalling component, forming an active 
heterodimeric receptor complex (Towne et al., 2004; Towne et al., 2011). An 
increased expression of IL-1F6, IL-1F8, IL-1F5 and IL-1F9 was observed in 
lesional psoriatic skin compared to healthy controls (Johnston et al., 2011) and 
over-expression of the IL-1F6 transgene in basal keratinocytes has been shown 
to result in cutaneous lesions which were exacerbated by co-existing IL-1F5 
deficiency (Blumberg et al., 2007). It is becoming clear that IL-1F6 may play a 
role in the pathogenesis of psoriasis and other skin lesions.  
 
A role for IL-1F6 in obesity was suggested by a study conducted in 2010 to 
establish the effect of the IL-1 cytokine family members IL-1F6 and IL-1F8 on 
adipocyte differentiation. Adipogenic expression levels of IL-1F6 and IL-1F8 and 
their effects on adipose tissue gene expression were examined. While IL-1F6 
was found to be primarily present in adipose tissue resident macrophages and 
was also induced by inflammation, IL-1F8 was absent in both situations (van 
Asseldonk et al., 2010). Both IL-1F6 and IL-1F8 were able to induce 
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 inflammatory gene expression in mature adipocytes, however, only IL-1F6 
LQKLELWHG33$5Ȗ3HUR[LVRPHSUROLIHUDWRU-activated receptor gamma) expression 
(van Asseldonk et al., 33$5ȖLVDQXFOHDUWUDQVFULSWLRQIDFWRUZKLFK 
controls lipid metabolism in adipocytes and sensitizes these cells to insulin 
UHYLHZHGLQ.QRXIIDQG$XZHU[6LQFHLQKLELWLRQRI33$5ȖH[SUHVVLRQ
may lead to reduced adipocyte differentiation, this suggests that IL-1F6 inhibits 
adipocyte differentiation and may be involved in the inflammatory link between 
obesity and insulin resistance.  Blockade of IL-1F6 and IL-1F8 may have 
therapeutic potential in obesity or insulin resistance (van Asseldonk et al., 2010). 
 
1.2.1.3 IL-1F7 
 Until recently, very little was known about IL-1F7 (IL-37) (reviewed in Sims and 
Smith, 2010; Dinarello et al., 2010; reviewed in Tete et al., 2012). It was initially 
identified as FIL1-zeta (FIL-ȗ(Smith et al., 2000) and was subsequently 
identified as IL-1H4 (Kumar et al., 2000), IL-1RP1 (Busfield et al., 2000) and IL-
1H (Pan et al., 2001). It is the only IL̻1 family member that lacks a mouse 
orthologue (reviewed in Sims and Smith, 2010). Among the newly-discovered IL-
1 homologues, it is the only cytokine that possesses a pro-domain (pro-IL-1F7) 
(Kumar et al., 2000).  IL-1F7 is highly expressed in the testis, thymus and uterus 
but is also present in most other tissues (Smith et al., 2000; Kumar et al., 2000; 
Busfield et al., 2000; Pan et al., 2001. Mature IL-1F7 is generated following 
cleavage of pro-IL-1F7 by caspase-1. Caspase-4 is also able to cleave pro-IL-
1F7 (Kumar et al., 2002).  
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Five isoforms of IL-1F7 were identified and named IL-1F7a-7e (Smith et al., 
2000; Busfield et al., 2000; Kumar et al., 2002; Pan et al., 2001; Taylor et al., 
2002). They were recently renamed IL-37a-IL-37e (Dinarello et al., 2010). 
Published data indicates that the various isoforms are differentially expressed 
(Pan et al., 2001; Kumar et al., 2002). The best characterised of these isoforms 
is IL-1F7b. While this isoform shares sequence homology with IL-18, it also has 
a protein sequence which shows approximately 20% similarity to IL-1Ra (Kumar 
et al., 2000). Some studies have shown that IL-1F7b is unable to bind IL-1RI but 
can bind IL-5ĮZLWKRXWLQGXFLQJW\SLFDO,/-18 agonist responses such as IFN-Ȗ
production (Kumar et al., 2002; Pan et al., 2001; Bufler et al., 2002). Kumar et 
al., (2002) reported that neither pro-IL-1F7 nor mature IL-1F7 can bind IL-18BP; 
however, it has since been reported that IL-1F7b binds to IL-18BP and that this 
binding reduces IL-18 activity (Bufler et al., 2002). Figure 1.2 in section 1.1.4 
shows a schematic diagram illustrating the proposed interaction between IL-
1F7b and IL-18BP.  
 
In another study, cells transfected with IL̻1F7b showed decreased 
pro̻inflammatory cytokine production following LPS stimulation (Sharma et al., 
2008). The study also found that full̻length IL̻1F7b localizes to the nucleus, 
suggesting that IL̻1F7 primarily acts as a negative regulator inside the cell 
(Sharma et al., 2008). IL̻1F7 also interacts with the transforming growth 
factor̻ȕ7*)ȕVLJQDOOLQJSURWHLQ6P$'*ULPVE\et al., 2004) and it has been 
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suggested that this mediates the inhibitory effect of IL̻1F7 on cytokine secretion 
(Sims and Smith, 2010).   
 
In one study, the anti-tumour activity of human IL-1F7 was investigated by using 
adenovirus-mediated transfer of the IL-1F7 gene into murine tumours (Gao et al., 
2003). The same study reported that treatment of an established MCA205 
mouse fibrosarcoma by single injection of the IL-1F7 gene resulted in significant 
growth suppression (Gao et al., 2003). Further to that, complete inhibition of 
tumour growth was observed following multiple injections of the IL-1F7 gene. In 
addition, IL-1F7b was able to confer substantial anti-tumour effects in Natural 
Killer T cell (NKT)-deficient mice (Gao et al., 2003). These recent results suggest 
that IL-1F7 could prove useful in tumour immunotherapy; however, the exact 
molecular mechanism of the anti-tumour effects of IL-1F7b is still unclear. 
Previously, there were speculations that functional T and B cells may be required 
in the process as well as IL-12-dependent adaptive immunity (Gao et al., 2003). 
IL-1F7 (IL-37) is now recognised as a natural suppressor of innate inflammatory 
and immune responses. It regulates inflammatory responses, mainly by inhibiting 
the expression, production and function of proinflammatory IL-1 family cytokines 
(Tete et al., 2012). 
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1.2.1.4 IL-1F8 
The sequencing of an osteoclastoma cDNA library led to the identification of IL-
1F8 (IL-ȕ (Kumar et al., 2000; Smith et al., 2000; Dinarello et al., 2010). 
Similar to other novel IL-1homologues, IL-1F8 shows about 25% identity with IL-
1Ra, however, it contains neither a signal peptide nor a prodomain (Smith et al., 
2000). To date, IL-1F8 has been isolated from human tonsils, bone marrow, 
heart, placenta, lung, testis, monocytes and B cells (Smith et al., 2000; Dunn et 
al., 2001; Towne et al., 2004).  
 
Similarly to IL̻1F6 and IL̻1F9, IL-1F8 signals via both IL-1RAcP and IL̻1Rrp2 
(Towne et al., 2004) and, as is the case with IL-ȕDQG,/̻18, these three newer 
IL-1 cytokines also activate NF̻ț%DQG0$3.V7RZQHet al., 2004; Towne et 
al., 2011; Vigne et al., 2011). Magne et al. (2006) observed that human synovial 
fibroblasts (hSFs) and human articular chondrocytes (hACs) expressed the IL-
1Rrp2 receptor and that they also produced proinflammatory mediators in 
response to recombinant IL-1F8. They reported that human joint cells (hSFs and 
hACs) were not a major source of IL-1F8 and that joint and serum IL-1F8 levels 
did not correlate with inflammation. They were not able to explain the elevated 
IL-1F8 serum levels which they found in human samples from some healthy as 
well as rheumatoid arthritis (RA) donors (Magne et al., 2006). It is not yet clear 
whether IL-1F8 plays a part in joint inflammation associated with RA.  A recent 
study observed an increased expression of IL-1F8, IL-1F5, IL-1F6, and IL-1F9 in 
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lesional psoriatic skin compared to healthy controls (Johnston et al., 2011), 
suggesting that, together with IL-1F5, IL-1F6, and IL-1F9, IL-1F8 may play a role 
in psoriatic conditions. 
 
1.2.1.5 IL-1F9 
IL-1F9 was initially identified from an epithelial cell cDNA library and named IL-
H1 (Kumar et al., 2000). It was subsequently identified as IL-1RP2 (Busfield et 
al., 2000) and IL-İ'HEHWVet al., 2001) and was recently renamed IL-Ȗ 
(Dinarello et al., 2010). Its predicted polypeptide sequence has neither a signal 
peptide nor a prodomain. It shows about 25% similarity to IL-1Ra (Kumar et al., 
2000). IL-1F9 mRNA and IL-1F9 protein are expressed in embryonic and 
epithelial tissues such as skin, lung and stomach. IL-1F9 is constitutively 
expressed in the placenta and in the squamous epithelium of the oesophagus 
(Kumar et al., 2000; Debets et al., 2001). Similarly to the other IL̻1 family 
members, IL̻1F6, and IL̻1F8, IL-1F9 signals via both IL-1RAcP and the 
IL̻1Rrp2 receptor and activates NF̻ț%DQG0$3.V. As is the case with IL̻1F6, 
and IL̻1F8, the activity of IL-1F9 is specifically inhibited by IL-1F5 (Towne et al., 
2004; Towne et al., 2011; Vigne et al., 2011).  
 
Inflammatory cytokines such as IFN-ȖDQG71)-ĮXS-regulate IL-1F9 expression 
in human keratinocytes (Kumar et al., 2000) and murine IL-1F9 has been shown 
to be up-regulated in vivo in response to chronic contact hypersensitivity or viral 
59  
infection (Kumar et al., 2000). In other studies IL-1F9, together with IL-1F5 and 
IL-1Rrp2, was up-regulated in skin from lesional psoriatic patients compared with 
skin from healthy subjects (Debets et al., 2001). Therefore, IL-1F9 may promote 
responses to injury or infection and may also play a role in the pathophysiology 
of skin conditions.  
 
1.2.1.6 IL-1F10 
IL-1F10 was initially named IL-1HY2. Its predicted polypeptide sequence shows 
approximately 32% similarity to IL-1Ra (Lin et al., 2001). As is the case with 
most novel IL-1 homologues, IL-1F10 does not contain a signal peptide or a 
prodomain. IL-1F10 is widely expressed in the basal epithelia of human skin and 
is also expressed in the spleen and also by proliferating B cells of the tonsils (Lin 
et al., 2001). It shares 43% amino acid sequence homology with IL-1F5 (Bensen 
et al., 2001). Like IL-1F5, IL-F10 seems to also share some amino acid 
sequence homology (41%) with IL-1Ra (Taylor et al., 2002; Nicklin et al., 2002; 
Bensen et al., 2001). The genomic structure and amino acid sequence of 
IL̻1F10 point to a closer relationship to IL̻1Ra and IL̻1F5 than to the rest of 
the family. This suggests that it may have an antagonistic role. Consistent with 
this finding, it has been observed that recombinant IL-1F10 can bind to soluble 
IL-1RI with lower affinity than IL-1Ra and IL-ȕ/LQet al., 2001). A recent study 
showed that IL-10 (IL-38) binds to the IL-1Rrp2 receptor (IL-36R) and that its 
biological effects on immune cells are similar to the effects of IL-1F5 (IL-36 Ra) 
on these cells (van de Veerdonk et al., 2012).  
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1.2.1.7 IL-1F11 
IL-1F11 was originally named IL-33. It assumed the name IL-1F11 following the 
revised IL-1 family nomenclature proposed by Sims et al. (2001). IL-1F11 was 
discovered by Schmitz and co-workers through sequence database searches for 
IL-1 cytokine family members (Schmitz et al., 2005). Previous researchers had 
described it as DVS27 (a gene up-regulated in canine cerebral vasospasm) 
(Onda et al., 1999), while otKHUVKDGFDOOHGLW³QXFOHDUIDFWRUIURPKLJK
HQGRWKHOLDOYHQXOHV´1)-HEV) (Baekkevold et al., 2003). The human IL-1F11/IL-
33 gene is found on chromosome 9p24.1 while the mouse gene is located in the 
chromosome 19qC1 region. The IL-1 family member most closely related to IL-
1F11 is IL-18 (Schmitz et al., 2005). 
 
IL-1F11 is widely expressed in many tissues, but its expression appears to be 
restricted by cell type. High levels of mouse IL-1F11 can be found in the 
stomach, lung, spinal cord, brain and skin. Mouse IL-1F11 was also found in 
lymph tissue, spleen, pancreas, kidney and heart. In human tissue, IL-1F11 was 
found to be highly expressed in smooth muscle cells and in bronchial epithelial 
cells and was also present in activated DCs and macrophages. IL-1F11 gene 
expression has also been shown to be induced in primary lung or dermal 
fibroblasts and keratinocytes activated by TNF-ĮRU,/-ȕ6WLPXODWLQJTH2-
polarized naive T cell cultures with purified IL-1F11 in vitro induced the 
production of TH2-associated cytokines such as IL-5 and IL-13 and decreased 
production of IFN-ȖIURP7H1 cells. Intraperitoneal (i.p.) administration of IL-1F11 
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to wild type mice caused histological signs of inflammation in the lungs and 
gastrointestinal tract accompanied by an increase in the number of splenic 
eosinophils, mononuclear cells and plasma cells and an increase in serum levels 
of IL-5, IgE and IgA, suggesting that IL-1F11 induces TH2 type responses in vivo 
(Schmitz et al., 2005). There is speculation that IL-1F11 may be involved in TH2-
mediated immune responses, including asthma (and other inflammatory airway 
diseases) allergy, parasitic helminth infections and possibly inflammatory bowel 
disease (IBD) (reviewed in Dinarello, 2005c; reviewed in Dinarello, 2009).  
 
It is now known that IL-1F11 plays a key role in the biology of allergy̻associated 
innate immune cells and that it also augments TH2 cell responses. In addition to 
its activity on human mast cells, IL-1F11 is capable of activating human  
basophils, polarized T cells, invariant Natural killer T cells (iNKT cells) and 
Natural Killer (NK) cells (Smithgall et al., 2008).  Although IL-1F11 induces 
predominantly TH2-skewed immune responses, it can promote both TH1 and TH2 
immune reactions depending on the actual cytokine and cellular environment 
(Smithgall et al., 2008). By amplifying both TH1- and TH2-type responses through 
its activity on human basophils, allergen-reactive TH2 cells, iNKT and NK cells, 
IL-1F11 emulates the biology of the IL̻1 family member, IL̻18 (reviewed in 
Smith, 2011; Sims and Smith, 2010).   
 
There are speculations that as is the case with IL-ĮDQGKLJK-mobility group 
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protein B1 (HMGB-1), IL-1F11 may be a cytokine with dual function since studies 
have suggested that IL-1F11 may function as both a traditional cytokine and also 
as an intracellular nuclear factor with transcriptional regulatory properties 
(Carriere et al., 2007). Localization of IL-1F11 to the nucleus of endothelial cells 
is mediated by its amino terminus, which contains a nuclear localization signal 
and a homeodomain (helix-turn-helix-like motif) which can bind to 
heterochromatin (Carriere et al., 2007). The physiological role of IL-1F11 as a 
nuclear factor is not fully understood; however, it is thought to be involved in 
transcriptional repression by binding to the H2A-H2B acidic pocket of 
nucleosomes and regulating chromatin compaction by promoting nucleosome±
nucleosome interactions (Roussel et al., 2008).  
 
Initially, it was assumed that IL-1F11 was synthesized as a biologically inactive 
precursor which was subsequently activated by caspase-1 cleavage at amino 
acid 112 under pro-inflammatory conditions (Schmitz et al., 2005). More recent 
data suggests that IL-1F11 is cleaved by caspases-3 and -7 at amino acids 175 
and 178 respectively, and is not a physiological caspase-1 substrate as originally 
thought (Ali et al, 2010). It has also been shown that full length IL-1F11 is 
biologically active at the ST2 receptor indicating that proteolytic processing is not 
required to induce its cytokine activity. Available data suggest that full length 
biologically active IL-1F11 may be released during necrosis, but during apoptosis 
IL-1F11 is cleaved by caspases-3/7 leading to inactivation of its pro-inflammatory 
properties (Ali et al, 2010; reviewed in Palmer and Gabay, 2011). This has led to 
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the idea that full length IL-1F11 may function as an endogenous danger signal. 
On the other hand, inactivation of IL-1F11 during apoptosis may serve as a 
control mechanism to avoid simultaneous damage to host tissues by the pro-
inflammatory action of IL-1F11 (reviewed in Miller and Liew, 2011). 
 
IL-F11 exerts its biological effects by interacting with the receptors ST2 (also 
known as interleukin 1 receptor-like 1 (IL-1RL1)) and IL-1RAcP. This interaction 
leads to activation of intracellular molecules in the NF-ț%DQG0$3.VLJQDOOLQJ
pathways which drive production of TH2 cytokines (e.g. IL-5 and IL-13) from 
polarized TH2 cells (Smithgall et al., 2008). The severe pathological changes 
observed in mucosal organs following administration of IL-1F11 are thought to 
occur following the induction of type 2 cytokines by IL-1F11 in vivo (Schmitz et 
al., 2005; Chackerian et al., 2007). 
 
Following on from the finding that cardiac fibroblasts synthesise IL-1F11 and that 
IL-1F11 markedly antagonises angiotensin II± and phenylephrine-induced 
cardiomyocyte hypertrophy (Sanada et al., 2007), data is also starting to emerge 
about the role of the IL-1F11/ST2 pathway in the cardiovascular system (Seki et 
al., 2009). The soluble isoform of the IL-1F11 receptor, soluble ST2 (sST2), is a 
mechanically induced cardiomyocyte protein and is considered to be an 
unfavourable prognostic marker in myocardial infarction, congestive heart failure 
and trauma/sepsis shock patients (Sanada et al., 2007).  Soluble ST2 has been  
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shown to block the antihypertrophic effects of IL-1F11. This suggests that sST2 
functions in myocardium as a soluble decoy receptor (Sanada et al., 2007; Seki 
et al., 2009). On the other hand, IL-1F11 and the transmembrane ST2 isoform 
(also known as ST2L) may have a protective role in atherosclerosis, obesity and 
cardiac remodelling (Sanada et al., 2007; Seki et al., 2009; reviewed in Miller 
and Liew, 2011). 
 
1.2.2 Synthesis of novel IL-1 family members 
As already mentioned, very little is known about novel IL-1 synthesis, regulation 
of expression or biological activity. There is also very little published data 
regarding the signalling pathways involved. Although it has been observed that 
IL-1F6, IL-1F8 and IL±1F9 are all up-regulated in response to LPS in human 
monocytes; the exact signalling pathways employed in the regulation of these 
responses have not yet been elucidated (Towne et al., 2004).  It is now known 
that for some of the classical IL-1 cytokines (such as IL-ȕ51$VWDELOLW\DQG
translational control form part of the regulatory mechanism (Brook et al., 2006). It 
has already been mentioned that post-translational modification of IL-ĮPD\ be 
important for its biological activity (Kobayashi et al., 1988; Brook et al., 2006). It 
is not yet clear whether this kind of regulation occurs with novel IL-1 cytokines. 
 
It has already been noted that IL-Į,/-ȕDQG,/-18 are synthesised as pro-
cytokines from which mature forms are generated following proteolytic cleavage. 
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For IL-ȕDQG,/-18, this intracellular processing by caspase-1 is crucial because 
these cytokines are only biologically active in their mature form (Dinarello, 1998). 
Recent work by Towne et al. (2011) shows that truncation of IL-1F6, IL-1F8 and 
IL-1F9 (IL-Į,/-ȕDQG,/-Ȗ) enhances their activity, suggesting that post-
translational processing is required for full activity, however, the proteases 
responsible for cleavage of these ligands in vivo have not yet been identified.  It 
is also unclear whether a single protease is responsible for cleavage of IL-1F6, 
IL-1F8 and IL-1F9 (Towne et al., 2011). Although Kumar et al., (2002) observed 
that IL-1F7b is processed by caspase-1, no caspase-1 cleavage sites have been 
identified for IL-1F5, IL-1F6, IL-1F8, IL-1F9 or IL±1F10 (Kumar et al., 2000; 
Smith et al., 2000; Lin et al., 2001; reviewed in Miller and Liew, 2011). Further 
work is needed to clarify the mechanisms involved in the synthesis and secretion 
of these novel IL-1 cytokines. 
 
1.2.3 Receptors for the novel IL-1 family members 
IL-1 family members exert their function through binding to cell surface receptors 
on target cells (reviewed in Sims, 2002; reviewed in Subramaniam, Stansberg 
and Cunningham, 2004). IL-1 receptors are part of a structurally-related receptor 
superfamily characterised by the presence of a Toll/IL-1 receptor (TIR) module in 
the intracellular region and by the presence of one to three copies of 
immunoglobulin (Ig)-like domains in their extracellular region. To date, 11 
members of this receptor family have been identified (reviewed in Sims, 2002; 
reviewed in Subramaniam, Stansberg, Cunningham, 2004; reviewed in Dumont, 
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2006). These include T1/ST2 (Klemenz et al., 1989; Tominaga, 1989), IL-1 
receptor-related protein (IL-1Rrp)1 (Parnet et al., 1996), three immunoglobulin 
domain-containing IL1 receptor-related-1 (TIGIRR-1) (Sana et al., 2000; Born et 
al., 2000),  the IL-1 receptor accessory protein-like (IL1RAPL) molecule (Born et 
al., 2000 and Carrie et al., 1999) and  IL-1 receptor-related protein 2 (IL-1Rrp2) 
(Lovenberg et al., 1996).  
 
In accordance with conventional IL-1 receptors, all of these newly discovered 
receptors possess three extracellular immunoglobulin (Ig)-like domains and an 
intracellular Toll/IL-1 receptor-related (TIR) domain (reviewed in Subramaniam, 
Stansberg, Cunningham, 2004). To date, none of these novel receptors has 
been shown to bind IL-ȕ,/-ĮRU,/-1ra (Lovenberg et al., 1996; Berglof et al., 
2003).  
 
1.2.3.1 IL-1Rrp2  
IL-1 Receptor-related protein-2 (IL-1Rrp2) is also known as IL-1 receptor-like 2 
(IL-1RL2) (Lovenberg et al., 1996) and was recently renamed IL-36 receptor (IL-
36R). Rat and human cDNAs for IL-1Rrp2 were first identified and isolated in 
1996 (Lovenberg et al., 1996). The protein encoded by both of these cDNAs was 
found to be 561 amino acids long and to exhibit 42% and 26% overall identity 
with the IL-1 type 1 and type 2 receptors, respectively (Lovenberg et al., 1996).  
A predominant expression of IL-1Rrp2 was observed in the lung and epididymis 
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and lower levels were detected in the testis and cerebral cortex. Expression of 
IL-1Rrp2 in rat brain appeared to be non-neuronal and associated with the 
cerebral vasculature and the receptor was found to be incapable of high affinity 
binding to either recombinant human IL-ĮRUUHFRPELQDnt human IL-ȕ
(Lovenberg et al., 1996).  
 
Debets et al (2001) observed that IL-1Rrp2 binds IL-1F9 as a ligand and that this 
binding leads to the activation of transcription factor NF-kB. They also reported 
that IL-1F5 inhibited the IL-1Rrp2-mediated NF-kB response induced by IL-F9 
and proposed that IL-1F5 could be a receptor antagonist. In a later study, Towne 
et al. (2004) reported that in addition to IL-1F9, the receptor also binds IL-1F6 
and IL-1F8 and that this binding stimulates NF-kB and MAPK activation and 
induces expression of IL-6 in human cell lines. They also observed that, as is the 
case with IL-ĮDQG,/-ȕVLJQDOOLQJ,/-1F6, IL-1F8 and IL-1F9, in addition to IL-
1Rrp2, also require IL-1RAcP as an accessory subunit. The same study also 
investigated the hypothesis that IL-1F5 could be a receptor antagonist as 
proposed by Debets et al. (2001). Contrary to the findings of the earlier study, 
this later study found that inhibition of IL-1F6, IL-1F8 or IL±1F9 by IL-1F5 was 
incomplete and equivocal (Towne et al., 2004).  In a separate study, Berglof et 
al. (2003) reported that mouse astrocytes and microglial cells expressed IL-
1Rrp2 and that exposure to bacterial lipopolysaccharides (LPS) strongly reduced 
this expression. 
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Magne et al. (2006) tested the ability of different concentrations of recombinant 
human IL-1F5 to inhibit the effects of IL-1F8 on IL-6 production in human 
articular chondrocytes (hACs). They observed that antagonism by IL-1F5 was 
incomplete and not reproducible. This finding confirmed observations that had 
been made by Towne et al. (2004). It has since been shown that IL-1F5 (IL-
36Ra) is indeed an antagonist of IL-1F6, IL-1F8 and IL-1F9 (IL-Į, IL-ȕ and 
IL-36ȖEXWWKDWIXOODntagonist activity requires removal of the N-terminal 
methionine present in the primary translation product.  Furthermore, a 
substantial molar excess is required for inhibition (Towne et al., 2011). Previous 
studies had failed to show IL-1F5 antagonism (Towne et al., 2004; Magne et al., 
2006) probably because an N-terminal tag had been used to facilitate purification 
of IL-1F5 (Towne et al., 2011).   
 
Blumberg et al. (2007) reported that expression of IL-1Rrp2, IL-1F5 and IL-1F6 is 
increased in human psoriatic skin. They also showed that IL-1F5 has 
antagonistic activity in vivo since co-existing IL-1F5 deficiency exacerbated the 
skin inflammation exhibited by IL-1F6 transgenic mice (Blumberg et al., 2007). In 
a more recent study, it was proposed that IL-1Rrp2 and its ligands may 
contribute to the cytokine network in psoriasis. This study demonstrated that 
application of an irritant can rapidly induce psoriatic-like skin inflammation in 
phenotypically normal skin from 2±3-month-old mice transgenic for IL-1F6 
(Blumberg et al., 2010). Furthermore, it was shown that cytokines known to be 
involved in human psoriasis (such as IL-17, IL-22, and IL-23) are overexpressed 
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in this psoriasis model and that they can induce IL-1F6, which, in turn, can 
induce IL-17, IL-22, and IL-23, thereby establishing a self-amplifying gene-
expression loop. When psoriatic lesional human skin was transplanted onto mice 
with Severe Combined Immunodeficiency (SCID) prior to treatment with an 
antibody to IL-1Rrp2, anti-IL-1Rrp2 antibody reduced the epidermal hyperplasia 
and other skin changes associated with psoriasis (Blumberg et al., 2010). 
Observations made in this study suggest that agents which block signalling 
through IL-1Rrp2 could be useful therapeutic tools for psoriatic conditions.  
 
1.2.3.2 ST2 
The ST2 gene is found on the long arm of Chromosome 2 (2q12). It encodes two 
glycoproteins of the interleukin 1 receptor (IL-1R) family. The larger protein is a 
membrane-anchored (transmembrane) receptor (ST2 or ST2L), which is very 
similar to the type I IL-1R, and whose predominant sites of expression are mast 
cells and TH2 cells (Iwahana et al., 1999). It has 3 extracellular IgG domains, a 
single transmembrane domain, and an intracellular SIR domain homologous to 
(Toll like Receptors) TLRs and other IL-1Rs. The smaller, soluble, secreted 
isoform (sST2) corresponds to the extracellular domain of the ST2 receptor and 
is produced by fibroblasts and osteoblasts in low quantities and in much higher 
amounts after stimulation with growth factors, proinflammatory cytokines, and in 
response to oncogene expression (Iwahana et al., 1999; Weinberg et al., 2002). 
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It lacks the transmembrane and intracellular domains. Both ST2L and sST2 are 
biomechanically induced in cardiomyocytes (Iwahana et al., 1999; Weinberg et 
al., 2002; Sanada et al., 2007).  
 
For many years, ST2 (also known as Interleukin 1 receptor-like 1 or IL-1RL1, as 
previously mentioned) was an orphan receptor belonging to the interleukin-1 
receptor family (Klemenz et al., 1989; Tominaga, 1989). It was later identified by 
Schmitz et al. (2005) as being part of the receptor complex through which IL-
1F11 mediates its TH2-like biological effects. Schmitz et al. (2005) observed that 
IL-1F11 administration led to NF-kB and MAPK activation in cells which 
expressed ST2, such as mast cells and TH2 cells. They also observed that IL-
1F11-initiated- NF-kB activation resulted in the production of IL-4, IL-5 and IL-13 
(Schmitz et al., 2005). Although ST2 was shown to be part of the IL-1F11 
receptor complex, for a while, the second (signal-transducing) chain of this 
receptor complex was not identified. However, there were suggestions that the 
single immunoglobulin IL-1R-related (SIGIRR) protein or IL-1RAcP could be 
possible candidates (Schmitz et al., 2005).  
 
It has since been shown that IL-F11 exerts its biological effects by interacting 
with the receptors ST2L and IL-1 Receptor Accessory Protein (IL-1RAcP). This 
interaction leads to activation of intracellular molecules in the NF-ț%DQG0$3.
signalling pathways which drive production of type 2 cytokines (e.g. IL-5 and IL- 
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13) from polarized TH2 cells (Chackerian et al., 2007). The soluble ST2 isoform, 
sST2, acts as a decoy receptor and association of sST2 with IL-1F11 blocks 
ST2L-dependent signalling and the immunological and cardiac effects of IL-1F11 
(Sanada et al., 2007). The cardioprotective role played by the IL-1F11/ST2L 
system is beginning to be elucidated. Through ST2L-mediated signalling, IL-
1F11 appears to counteract cardiac myocyte hypertrophy which is induced by 
angiotensin II or phenylephrine (Sanada et al., 2007). 
 
The finding that IL-1F11 signals via ST2 and induces Th2-associated cytokines 
is consistent with the role that ST2 plays in Th2 development, as previously 
suggested by Townsend et al. (2000). In that study, mice with a deficiency in 
T1/ST2 expression were generated in an effort to clarify the roles of T1/ST2 in T 
helper cell type 2 (Th2) responses. The responses of T1/ST2-deficient mice to 
immunological challenges normally characterized by a Th2-like response were 
then compared with those generated by wild-type mice. It was found that in the 
absence of T1/ST2 expression, the levels of Th2 cytokine production were 
severely impaired after immunization. This study showed that ST2 plays a crucial 
role in the development of Th2-like cytokine responses (Townsend et al. (2000).  
 
1.2.4 Biological Functions of novel IL-1 family members 
Although novel IL-1 cytokines have been found to be structurally related to the 
classical IL-1 cytokines, significant research is underway to determine whether  
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novel IL-1 cytokines influence immune responses in the same way as the 
classical IL-1 family members. The severe pathophysiological effects of 
dysregulated IL-1 expression have already been highlighted. Studies suggest 
that with the classical IL-1 cytokines, very tiny amounts of IL-1 are needed to 
activate the relevant IL-1 receptor complex and to initiate IL-1-mediated effects 
(Dinarello, 1991; 1996; 2005; Smith et al., 1992). On the other hand, research 
involving novel IL-1 cytokines seems to suggest that they are only biologically 
active at much higher concentrations than those observed for classical IL-1 
family members such as IL-ȕ'HEHWVet al., 2001; Towne et al., 2004). The 
significance of this finding is not yet clear.     
 
It has also been observed that while haematopoietic cells are the main source of 
IL-ȕDQG,/-18, they do not appear to be the main source of the newer IL-1 
family members (Debets et al., 2001; Towne et al., 2004). IL-1F6, IL-1F8 and IL±
1F9 and their receptor, IL-1Rrp2 are most highly expressed in the skin and in 
gastric mucosa, suggesting a role in immune/inflammatory responses involving 
the skin and gastrointestinal tract (Debets et al., 2001; Towne et al., 2004; 
Barksby et al., 2007).Further studies are also needed to establish whether IL-
1F8 plays an inflammatory role in RA as suggested by some findings (Magne et 
al., 2006).The precise biological role of IL-1F11 and the exact mechanism by 
which it interacts with its receptor (ST2) also needs clarification.  
 
 
73 
In view of the already-mentioned role of IL-1 cytokines in health and pathological 
processes, there is clearly a case for further research in order to elucidate 
whether or not novel IL-1s and their receptors behave like typical IL-1 cytokines. 
The need to fully understand their synthesis, regulation of expression and 
bioactivity cannot be overemphasised. 
 
1.3.0 Dendritic cells (DCs)  
1.3.1 DCs: Background 
DCs are professional antigen presenting cells with a unique ability to activate 
naive T cells thereby providing a link between innate and adaptive immunity 
(reviewed in Banchereau and Steinman, 1998).  They can also capture and 
retain unprocessed antigen and can transfer this antigen to naive B cells to 
initiate a specific antibody response (Wykes et al., 1998). Maturation of dendritic 
cells (DC) is a prerequisite for induction of adaptive immunity (Fig. 1). Mature 
DCs have the capacity to both induce clonal expansion of T cells and also to 
direct differentiation of T helper (TH) effectors through secretion of cytokines 
which favour the development of different effector Th cells (Cella et al., 1996; 
reviewed in Cella et al., 1997; reviewed in Banchereau and Steinman, 1998; 
Reise e Sousa et al., 1999, reviewed in Banchereau et al., 2000). Cytokines 
such as IL-12 and IL-4 are believed to be critical for differentiation of activated TH 
cells into interferon IFN-Ȗ-producing TH1 effector cells or IL-4/IL-5/IL-10-
producing TH2 effector cells (Macatonia et al., 1993; Abbas et al., 1996; Reis et 
al., 1999). CD40 ligand (CD40L) and microbial products are known to rapidly 
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induce DCs to secrete large amounts of IL-12 which in turn leads to induction of 
TH1 responses (Cella et al., 1996; reviewed in Cella et al., 1997; Wesa and Galy, 
2002).  
 
Classical IL-1 cytokines such as IL-ȕ (IL-1F2) are also known to mediate DC 
maturation in an autocrine/paracrine fashion during bacterial infection 
(Macatonia et al., 1995; Cella et al., 1996; Koch et al., 1996; Cella et al., 1997; 
Banchereau and Steinman, 1998; Reise e Sousa et al., 1999). In addition to their 
effect on T cells, mature DCs also trigger a natural response to invading 
pathogens by activating macrophages, natural killer (NK) cells, NK-T cells and 
eosinophils (Lipscomb and Masten, 2002; Reis e Sousa, 2004). 
 
1.3.2 DC types and DC precursors 
Several different types of DCs and DC precursors have so far been described. 
These include Langerhans cells (LCs), dermal/interstitial DCs, interdigitating 
reticulum cells in lymphoid organs as well as blood DCs (reviewed in 
Banchereau et al., 2000; reviewed in Lipscomb, and Masten, 2002. It is believed 
that the different DCs differ in terms of origin, maturation state, morphology, 
localization, function and phenotype (Galy et al., 1995; reviewed in Banchereau 
et al., 2000; Lipscomb and Masten, 2002; Shortman and Liu, 2002). Human DCs 
are found as precursor populations in bone marrow and blood and as more 
mature forms in lymphoid and non-lymphoid tissues (Romani et al., 1994; 
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2¶'RKHUW\et al., 1994; Romani et al., 1996). Various combinations of growth 
factors (such as granulocyte macrophage-colony stimulating factor (GM-CSF), 
tumour necrosis factor (TNF), IL-4, transforming growth factor (TGF) and IL-3) 
favour the development of myeloid and lymphoid lineage DCs from bone marrow                       
progenitors and blood precursors (reviewed in Lipscomb, and Masten, 2002) as 
Figure 1.3 shows. Identification of subset-specific blood dendritic cell antigens 
(BDCA) in recent years has greatly facilitated DC research (Dzionek et al., 
2000). 
 
Myeloid CD34+ progenitors are thought to differentiate into monocytes (CD14+, 
CD11c+ DC precursors) which give rise to immature DCs in response to GM-
CSF and IL-4, and to macrophages in response to macrophage colony 
stimulating factor (M-CSF) (the interstitial pathway) (Caux et al., 1992; Sallusto, 
and Lanzavecchia, 1994; reviewed in Banchereau et al., 2000). Myeloid 
progenitors differentiate into CD11c+ CD14í precursors, which yield Langerhans 
cells in response to GM-CSF, IL-4 and transforming growth factor (7*)ȕDQG
macrophages in response to M-CSF. These later precursors are able to 
spontaneously differentiate into DCs in cultures (reviewed in Banchereau et al., 
2000). The CD14í CD11cí IL-5Į+ '&SUHFXUVRUDOVRFDOOHGS'&,)1Į-
producing cell, or plasmacytoid T cell; a possible equivalent to the murine 
lymphoid DCs) probably originates from the lymphoid CD34+ progenitor 
(reviewed in Banchereau et al., 2000). A blood cell population with a comparable 
phenotype has been shown to yield T cells in foetal thymic organ cultures. 
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CD11cí ,/5Į+ DC precursors differentiate into immature DCs in response to IL-
3. The immature cells differentiate to mature cells in response to cytokines 
(MCM, monocyte-conditioned medium) or pathogen products (LPS or DNA) 
(reviewed in Banchereau et al., 2000). Table 1.3 shows the main phenotypic 
features of peripheral blood dendritic cells (PBDCs) and monocytes. 
 
There is speculation that distinct types of DCs induce different types of immune 
responses (TH1 or TH2) (Pulendran et al., 1999). It is starting to become clear 
that myeloid DCs (mDCs) and pDCs show interesting differences not only in 
terms of phenotypic markers but also with regards to cytokine secretion pattern, 
chemokine receptor expression and pathogen recognition receptor (PRR) 
expression. This suggests differences in functional properties among the DC 
subsets (Sallusto and Lanzavecchia, 2002; reviewed in Banchereau et al., 
2003). The issue of which DCs regulate or influence which T cell response still 
needs clarification. Some researchers think that DC maturation stage has a big 
influence on the resulting T cell response (Lutz and Schuler, 2002) but others 
think that DC lineage is a critical parameter (Palucka and Banchereau, 2002; 
Grabbe et al., 2000). It is highly likely that a combination of factors is at play. 
There is also a possibility that DC lineages possess a unique flexibility which 
allows for lineage adaptability. Clearly, the intricacies of DC biology still need to 
be unravelled.    
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Table 1.3 Immunophenotype of PBDC subsets and monocytes (adapted 
from Robinson et al., 1999) 
 
Surface antigen  CD11c± DC           CD11c+ DC   CD 14++ 
      (Lymphoid)           (Myeloid)  Monocytes 
Progenitor 
CD34    ±    ±    ± 
DC-associated 
CD1a   ±   ±   ± 
CD83    ±    ±    ± 
Myeloid 
CD13   ±    +    ++ 
CD14    ±    ±    ++ 
CD33    ±    +    ++ 
Lymphoid 
CD2   ±    +    ± 
CD4    ++    +   ± 
CD5    ±    ±    ± 
CD8   ±    ±    ± 
CD10    ±   ±    ± 
FcR 
CD16    ±    ±    + 
CD32    ±    ++    ++ 
CD64    ±    +    ++ 
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Table 1.3 (continued) Immunophenotype of PBDC subsets and monocytes 
(adapted from Robinson et al., 1999) 
 
Surface antigen       CD11c± DC    CD11c+ DC             CD 14++ 
         (Lymphoid)                (Myeloid)  Monocytes 
Adhesion 
CD11a    +    +    ++ 
CD11b    ±    ±    ++ 
CD11c    ±    +    ++ 
CD44    +    +    + 
CD54    +    +    + 
CD62L    ++    +    ± 
E-cadherin   +    +    + 
CLA    +    ++    + 
MHC 
Class I    +    +    + 
HLA-DR    ++    +++    + 
HLA-DQ    ++    +++    + 
Co-stimulation 
CD40    ±    ±    + 
CD80    ±    ±    + 
CD86    ±    ±    + 
Activation 
CD45RA    ++    ±    + 
CD45RO    ±    +    + 
Cytokine receptors 
CD25    ±    ±    ± 
CD115    ±    ±    ++ 
CD123    ++    +    ± 
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Figure 1.3 Schematic diagram showing derivation of human dendritic cell 
(DC) subsets from CD34+ myeloid and lymphoid progenitors. Phenotypic 
and functional characteristics defining each DC subset are shown below each 
DC subset. MHC= major histocompatibility complex; IFN= interferon (adapted 
from Lipscomb and Masten, 2002). 
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1.3.3 Human Peripheral Blood Dendritic Cells (PBDCs)   
Human peripheral blood (PB) has been shown to contain a heterogeneous 
PL[WXUHRIDWOHDVWWZRPDLQGLVWLQFWW\SHVVXEVHWVRI'&SUHFXUVRUV2¶'RKHUW\
et al., 1994; Strobl et al., 1998; Robinson et al., 1999). The two main DC subsets 
have been named myeloid (m) and plasmacytoid (p)/lymphoid. Myeloid and 
lymphoid (plasmacytoid) DCs evolve from myeloid or lymphoid precursors 
respectively. Both subsets lack expression of several lineage markers for 
monocytes, lymphocytes and natural killer cells. Myeloid DCs are CD123dim and 
CD11cbright 2¶'RKHUW\et al., 1994; Strobl et al., 1998; Robinson et al., 1999). 
They are further subdivided into type 1 mDCs (mDC1) and type 2 mDCs (mDC2) 
(Dzionek et al., 2000; Grabbe et al., 2000).  
 
1.3.3.1 Type 1 myeloid dendritic cells (mDC1)  
Type 1 mDCs make up about 0.6 % of all peripheral blood mononuclear cells 
(PBMCs) and are the major subset of mDCs in human blood (Dzionek et al., 
2000; Grabbe et al., 2000). They are CD1c /BDCA-1+ and show a monocytoid 
morphology. They also express myeloid markers such as CD13 and CD33 as 
well as Fc receptors such as CD32, CD64 and FceRI. Furthermore, they were 
determined to be CD4+, Lin (CD3, CD16, CD19, CD20, CD56)±, CD2+, 
CD45RO+, CD141 (BDCA-3)low, CD303 (BDCA-2)±, and CD304 (BDCA-
4/Neuropilin-1)±.1 (Dzionek et al., 2000). A minor proportion of mDC1 expresses 
CD14 and CD11b. The CD1c (BDCA-1) marker is also found on CD1a+ dendritic 
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cells generated ex vivo from monocytes or haematopoietic precursor cells 
(Dzionek et al., 2000). In blood, apart from mDC1, a subset of B cells also 
expresses CD1c (BDCA-1) (Dzionek et al., 2000; Grabbe et al., 2000; Brigl and 
Brenner, 2004). 
 
1.3.3.2 Type 2 myeloid dendritic cells (mDC2) 
Type 2 mDCs are a minor subpopulation of mDCs constituting about 0.04 % of 
all PBMCs in human blood. They express high levels of CD141 (BDCA-3) 
(Dzionek et al., 2000). They are CD141/BDCA-3++, CD11cdim, CD123±, CD1c 
(BDCA-1)±and CD4+. They lack lineage markers such as CD3, CD14, CD16, 
CD19, CD20 and CD56 but express myeloid markers such as CD13 and CD33. 
They are also monocytoid in appearance. The CD141/BDCA-3 antigen is also 
expressed at a much lower level on mDC1 cells, plasmacytoid dendritic cells, 
monocytes, and granulocytes in blood (Dzionek et al., 2000). In contrast to 
mDC1, mDC2 cells do not express CD2 and Fc receptors such as CD32, CD64, 
and FceRI. Furthermore, mDC2 cells differ from mDC1 cells in terms of Toll-like 
receptor (TLR) expression, cytokine production, and T helper cell polarization 
(Dzionek et al., 2000; Grabbe et al., 2000; Liu, 2001a; Liu 2001b).  
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1.3.3.3 Plasmacytoid dendritic cells (pDCs) 
Plasmacytoid dendritic cells (pDCs) possess a plasmacytoid morphology, 
express CD45RA, are CD123bright, CD11c- and they depend on IL-3 for their 
survival and differentiation into mature DC (Dzionek et al., 2000; Penna et al., 
2002). They can produce high amounts of Type 1 interferon (IFN) (IFN-ĮDQG
IFN-ȕRQVWLPXODWLRQE\VHYHUDOYLUXVHV%UXQRet al., 1997; Strobl et al., 1998; 
Rissoan et al., 1999; Liu, 2005; Penna et al., 2002). This feature earned them 
WKHQDPH³LQWHUIHURQ-SURGXFLQJFHOOV´,3&EHIRUHWKHLUGHQGULWLFFHOOQDWXUHZDV
demonstrated (Bruno et al., 1997; Strobl et al., 1998; Rissoan et al., 1999; Liu, 
2005). Expression of the pre-7&HOO5HFHSWRU7&5Į-chain by pDCs is 
considered evidence that they arise from lymphoid precursors (Rissoan et al., 
1999; Dzionek et al., 2000). However, recent data from mouse studies suggests 
that pDCs can arise from both lymphoid and myeloid precursors both in vivo and 
in vitro and that the myeloid pathway is a major pathway for pDC development in 
vivo (Harman, 2006; Karsunky et al., 2005). There is clearly a need for further 
investigation into the mechanisms behind DC lineage specification and/or DC 
plasticity.  
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1.4 Justification of current study 
There is growing evidence showing that the classical IL-1 cytokines play a 
pathogenic role in diseases such as RA, periodontitis, sepsis, insulin-dependent 
diabetes mellitus, IBD, atherosclerosis and others (Bistrian et al., 1992; Graves 
and Cochran, 2003; Gracie, 1999). Based on the structural similarities between 
the novel IL-1 cytokines and the classical IL-1 cytokines, it is possible that some 
of these newly identified IL-1 cytokines may also play a role in the 
pathophysiology of conditions such as the septic syndrome. It has been 
observed that for some inflammatory disorders such as RA, inhibiting IL-1 
production, signalling and bioactivity can have beneficial effects (Braddock and 
Quinn, 2004; Dinarello, 2005; Moller and Villiger, 2006). Clinical trials have 
shown that Anakinra (a recombinant form of sIL-1Ra) has an acceptable safety 
profile and that it reduces the signs and symptoms of active disease and joint 
destruction in patients with RA (Furst, 2004; Cohen and Rubbert, 2003) and it is 
now commercially available as Kineret (Cohen and Rubbert, 2003).  
 
At the moment, there is very limited information regarding the novel IL-1 
cytokines. It is not yet clear whether or not they behave like typical IL-1 
cytokines. There is a need to fully understand their synthesis, regulation of 
expression and bioactivity. Although new members of the 11-member IL-1R 
family have been identified, their expression patterns, regulation and biological 
functions have not been well characterized (Sims, 2002; Subramaniam, 
Stansberg, Cunningham, 2004; Sims, Smith, 2010). It is not clear how some of 
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these orphan receptors interact with the novel IL-1 cytokines. A better 
understanding of the immunobiology of the novel IL-1 cytokines and their 
receptors will help shed more light into the pathogenesis of several immune and 
inflammatory diseases. Such an understanding may in turn lead to the 
development of novel therapeutic agents. 
 
1.5 Aims of current study  
x To investigate the expression of IL-1Rrp2 in human dendritic cell 
subsets, other human immune and non-immune cells 
x To establish if human dendritic cells (DCs) respond to the novel IL-1 
cytokines IL-1F8 and IL-1F9 
x To assess the effect of established mediators of DC maturation 
(bacterial LPS, recombinant IL-ȕDQGLPLTXLPRGRQ,/-1Rrp2 
expression in human DCs. (Imiquimod is a toll like receptor-7 agonist 
known to induce type I interferon in plasmacytoid DCs) (Gibson et al., 
2002) 
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The aims of this study were achieved by: 
x measuring the expression of IL-1Rrp2 mRNA in human DCs and other 
myelomonocytic cells (Chapters 3) 
x measuring IL-1Rrp2 expression in human T cells, lamina propria tissue 
and other human cells and cell lines (Chapter 4) 
x stimulating human DCs with different concentrations of IL-1F8 and IL-
1F9 and assessing effect on phenotypic profile and cytokine production 
(Chapters 3) 
x stimulating human DCs with bacterial LPS, recombinant IL-ȕDQG
imiquimod and assessing expression of IL-1Rrp2 mRNA (Chapter 3)  
x assessing the effect of IL-1F8-matured DCs on T cells in terms of T cell 
proliferation and cytokine profile (Chapter 3) 
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1.6 Challenges encountered 
The recombinant IL-1F8 and IL-1F9 reagents used in this study were kindly 
donated by Amgen Corporation, Seattle, WA, USA; however they were only 
supplied in small quantities. In addition, the ligands showed very weak biological 
activity (as they were non-truncated) and had to be used at very high 
concentrations. As a result, the range of investigations that could be pursued 
was restricted. Amgen researchers (Towne et al., 2011) and others (Vigne et al., 
2011) have since demonstrated that truncation of IL-1F6, IL-1F8 and IL-1F9 (IL-
Į,/-ȕDQG,/-ȖHQKDQFHVWKHLUDFWLYLW\ (Towne et al., 2011). 
Unfortunately, the truncated ligands were not yet available when the work 
outlined in this thesis was carried out. 
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1.0 Routine Cell culture experiments 
Cell culture experiments were performed using aseptic techniques. Appropriate 
personal protective equipment was used throughout. Work was carried out in a 
Class II Biological Safety Cabinet according to University Health and Safety 
regulations. Equipment, gloved hands, work area inside the Safety Cabinet and 
reagent bottles were decontaminated using 70% (v/v) ethanol in sterile water 
prior to cell manipulation. As much as possible, sterile, single-use consumables 
were used for cell culture experiments. Where it was necessary to use non-
disposable glassware, this was sterilised by autoclaving at 121qC for 20 minutes 
prior to use. To prevent mycoplasma contamination and to inactivate 
complement, serum used for cell culture was heat-inactivated (heated to 56°C in 
a water bath for 30 minutes with swirling every 5 to 10 minutes) prior to use. All 
solutions and cell culture media were also sterilised by passing them through a 
Thermo Scientific Nalgene 0.2µm pore size Disposable Sterile Filter Unit (Fisher 
Scientific, Loughborough, UK) prior to use. Furthermore, to minimise bacterial 
contamination, culture media was supplemented with Penicillin-Streptomycin 
solution (working concentration of 100 IU/ml penicillin, 100 µg/ml streptomycin). 
Cultures and media were examined daily for evidence of gross bacterial or 
fungal contamination. Cells were grown at 37°C in a humid 5% CO2 incubator. 
Cells that were not in use were stored at -80qC. For long term storage, cells were  
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stored in liquid nitrogen at -196qC. All equipment used was routinely cleaned, 
sanitised, maintained and serviced according to manufacturer and University 
Health and Safety specifications. Each cell culture experiment was performed in 
duplicate on at least three independent occasions.   
 
2.1.1 Routine cell counting and assessment of viability 
An Improved Neubauer Haemocytometer was used to determine cell numbers.  
This type of haemocytometer has two counting chambers, each 0.1 mm deep. 
Each chamber is engraved with a laser-etched grid containing nine large 
squares demarcated by triple white lines. The rulings of the haemocytometer grid 
cover 9 mm2 in a 3x3 square. Typically, 10µl of cell suspension were mixed with 
10µl of 0.4% Trypan Blue to make a 1:2 dilution. However, if cell concentrations 
were too high, suitable dilution factors were used to ensure that cells were 
evenly distributed (and not overlapping) on the counting grid. 10µl of the cell 
suspension/Trypan Blue mix was then gently pipetted onto the edge of the cover 
slip and allowed to run onto the chamber under the cover slip by capillary action. 
Using a fresh pipette tip, another 10µl of the cell suspension/Trypan Blue mix 
was loaded onto the second counting chamber. The haemocytometer was then 
placed on the microscope stage of a Leica DM IL inverted microscope (Leica 
Microsystems, Milton Keynes, UK) and the counting grid was brought into focus 
using the x10 objective lens. Once the grid and cells were in focus, the 
magnification needed to recognize the desired cell type was determined. Using a 
hand tally counter, cells in the large centre square of each chamber (see Figure 
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2.1) were then counted. The central square of the haemocytometer grid is ruled 
into 25 squares. Each of the 25 squares contains 16 smaller squares. The area 
of each smaller square is 0.0025 mm2 and each group is separated by triple 
lines, the middle one of which is the boundary. The area of the central square is: 
25 x 16 x 0.0025 = 1 mm2 and the volume is: 1 mm2 x 0.1 mm = 0.1mm3 or 0.1µl 
(since 1 ml = 1000 µl= 1000 mm3). 
 
To ensure accuracy of counts, the following counting pattern was adhered to: 
Cells falling on the bordering triple lines were only counted if they were on either 
the top or on the left lines of each square. Cells touching the bottom and the right 
hand side lines were excluded (see Figure 2.2). To work out the number of cells/ 
ml, the following formula was used: 
Number of cells counted per ml = number of cells counted per square mm x 
dilution factor x 104 (where 104 is the conversion factor needed to convert 10-4ml 
to 1ml). Cells in both sides (chambers) of the haemocytometer were counted and 
the average of the two counts was taken. The total number of cells was 
calculated using the following formula: 
Total cells = cells/ml x volume of original suspension 
 
Trypan blue is a vital stain used to selectively colour dead tissues or cells blue. It 
does not interact with the cell unless the cell membrane is damaged (Mishell and  
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Shiigi, 1980). To assess cell viability, cells looking faint or dark blue within the 
grid being counted were counted as dead (non-viable) while unstained cells were 
counted as viable. Cell dilutions and Trypan Blue dye addition were performed 
immediately prior to counting since viable cells may absorb Trypan blue over 
time. To calculate percentage cell viability, the following formula was used: 
% cell viability =  X 100  
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cells) unstained and stained-blue(Trypan count  cell Total
 cells) (unstainedcount  cell Live
 Figure 2.1 Diagram showing the appearance of a haemocytometer grid 
when viewed under the microscope 
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Figure 2.2 Diagram showing one of the 25 squares making up the central 
square of a haemocytometer. Each square contains 16 smaller squares as 
shown in the diagram. To ensure consistency in counting, cells that were on a 
boundary line between two squares were only counted if they were on the upper 
boundary line or the left-hand side boundary line (indicated by green tick) but not 
if they were on the lower boundary line or the right-hand side boundary line 
(indicated by a cross). 
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2.1.2 Endotoxin assays 
A chromogenic Limulus Amebocyte Lysate (LAL) assay (Kinetic-4&//RQ]D
USA) was performed on IL-1 reagents at Amgen and at the University of 
Nottingham. Assay sensitivity was between 0.005 and 50.0 EU/ml. The test is 
done on a sterile, disposable 96 well plate and is based on the principle that 
gram negative bacterial endotoxin (LPS) in a sample catalyses the activation of a 
proenzyme in the Limulus Amebocyte Lysate (LAL). The initial rate of activation 
is determined by the concentration of endotoxin present. The activated enzyme 
then catalyses the cleavage of paranitroaniline (pNA) from the colourless 
substrate Ac-Ile-Glu-Ala-Arg-pNA.  The yellow pNA released is measured 
photometrically (at 405 nm) continuously throughout the incubation period by the 
assay operating software (WinKQCLTM) on the microplate reader. Using the 
initial absorbance reading of each well as its own blank, the reader determines 
the time required for the absorbance to increase 0.200 absorbance units. This 
time is termed Reaction Time. The WinKQCLTM software automatically performs 
a log/log linear correlation of the Reaction Time of each standard with its 
corresponding endotoxin concentration. The concentration of endotoxin in a 
sample is calculated from its Reaction Time relative to the Reaction Time of 
solutions containing known amounts of endotoxin standard. The following 
equations summarise the reaction: 
Proenzyme      Endotoxin   Enzyme 
Ac-Ile-Glu-Ala-Arg-pNA substrate + water    Enzyme        Peptide + pNA 
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Results showed LPS concentrations of 0.216 for human recombinant IL-1F8 and 
0.130 for human recombinant IL-1F9, which were equivalent to <<0.01 Pg/ml in 
100 ng IL-1 protein used in cell culture. Similar results were obtained on these 
reagents by the manufacturers (Amgen Corporation, Seattle, WA, USA) prior to 
shipment. Other reagents used in the study also showed negligible endotoxin 
levels (see Table 2.1). To cause DC maturation, endotoxin (LPS) concentrations 
of 100ng/ml are required (Zhou et al., 2006). Since the concentrations of 
endotoxin in the reagents used is <<0.05 Pg/ml even at the highest 
concentration used in this study (500ng/ml), it is highly unlikely that such low 
levels would have interfered with the results obtained. Any stimulatory or other 
effect seen is very likely to have been caused by the reagents themselves.  As 
an additional test for LPS contamination, a THP-1 functional status assay was 
performed, which showed that THP-1 cells did not produce TNF-ĮLQUHVSRQVHWR
IL-1 reagents but that they did produce TNF-ĮZKHQVWLPXODWHGZLWKEDFWHULDO
lipopolysaccharide (see Appendix 1). 
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Table 2.1 Endotoxin assay results. Concentration of endotoxin, independently 
determined by Amgen Corporation (Seattle, WA, USA) and University of 
Nottingham, in IL-1F8 and IL-1F9 protein aliquots and other reagents used in all 
experiments. 
 
Reagent   EU/mg protein 
Amgen    Endotoxin-free water   0.002 
     IL-1F8     0.209 
     IL-1F9     0.092 
Nottingham University  Endotoxin-free water   <0.01 
     IL-1F8     0.216 
     IL-1F9     0.13 
     IL-ȕ    <0.005 
     IFN-Ȗ    0.005 
     IL-4    <0.005 
     GM-CSF   0.010 
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2.1.3 Human IL-1F8 and IL-1F9 reagents 
 
Human non-truncated IL-1F8 and IL-1F9 reagents were supplied by Amgen 
Corporation, Seattle, USA. They were produced using the following procedure: 
Human IL-1F8 and IL-1F9 were cloned into pGEX4T-1 (Amersham Biosciences) 
as N-terminal glutathione S-transferase fusions. A Factor Xa recognition 
sequence was placed immediately upstream of the first methionine of each IL-1F 
gene. The resulting constructs were expressed in Escherichia coli DH10B by 
induction with 100 mM isopropyl-1-thio-ȕ-D-galactopyranoside. Lysates from 
cultures were run over glutathione-Sepharose (Novagen, Madison, WI) columns 
to capture the glutathione S-transferase/IL-1F fusion proteins and then subjected 
to on-column cleavage with Factor Xa (Novagen). The cleaved IL-1F proteins 
were eluted with PBS, and the Factor Xa was removed using a specific affinity 
agarose (Novagen). The IL-1F proteins were further purified by size exclusion 
chromatography using a Superdex 75HR column. Purified proteins were then 
quantitated by amino acid analysis (Towne et al., 2004). 
 
2.2.0 Cells 
 
2.2.1 THP-1 cells: Cell culture 
Promonocytic THP-1 cells were purchased from the European Collection of Cell 
Cultures, Salisbury, UK). THP-1 cells were cultured in RPMI 1640 medium 
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supplemented with 10% v/v heat-inactivated Fetal Calf Serum (FCS), L-
glutamine (2mM), penicillin (100 U/ml), streptomycin (100µg/ml) and maintained 
in a humidified incubator at 37oC and 5% CO2. During cell culture, viability was 
assessed by the Trypan Blue Exclusion method (Mishell and Shiigi, 1980). 
Viability was >95% prior to use. Cell numbers were monitored using an improved 
Neubauer haemocytometer. Cells were fed with fresh medium twice a week. 
They were kept at a density of 400 000 cells/ml in each 75cm2 flask and medium 
was changed every 2 to 3 days. Cells were sub-cultured when numbers 
exceeded 800 000 cells/ml but were not allowed to exceed 1x106 cells/ml. Spare 
cells were suspended in freezing mixture (5% DMSO, Sigma-Aldrich, Poole, UK) 
and stored at -80 oC. For stimulation assays, THP-1 cells were used at passages 
between 5 and 10. 
 
2.2.1.1 THP-1 Functional Status test 
To confirm that THP-1 cells which were used as negative controls for IL-1Rrp2 
mRNA expression in Quantitative Real Time PCR experiments were fully 
functional, their response to LPS stimulation was investigated (Essner et al, 
1990; Agarwal et al., 1995; Asakura et al., 1996; Dedrick and Conlon, 1995; 
Jones et al., 2003; Foster et al., 2005; Lackman and Cresswell, 2006) as 
described in Appendix 1. 
 
2.2.2 NCI/ADR-RES cells (OVCAR-8 ovarian adenocarcinoma cell line) 
NCI/ADR-RES cells were a kind gift from Professor Susan Watson, University of 
Nottingham.  Cells were maintained at 37oC in a humidified atmosphere of 95% 
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air and 5% CO2 in a culture medium containing  RPMI 1640 (Fisher Scientific, 
Loughborough, UK) supplemented with heat-inactivated FCS (10%v/v), 
Penicillin-Streptomycin (1%), HEPES sodium salt (15 mM) (Fisher Scientific, 
Loughborough, UK) and L-glutamine (2mM) (Sigma-Aldrich, Poole, UK).   
For experiments, cells were harvested using trypsin (0.2%) and EDTA (0.02%) in 
PBS prior to rinsing with the appropriate medium (low-speed centrifugation). Cell 
viability was determined by haemacytometer counting after staining with Trypan 
blue as previously described (Chapter 2, Section 2.1.1). Cell viability was >95% 
prior to use. 
 
2.2.3 HT 29 cells 
The human colonic epithelial carcinoma cell line, HT-29, was a kind gift from 
Professor Susan Watson, University of Nottingham. Cells were cultured in 
Dulbecco's modified Eagle's medium supplemented with glucose (25mM),  
Sodium Bicarbonate (44mM), Transferrin (10mg/l), sodium pyruvate (1mM), L-
glutamine (2mM), 0.1 mM non-essential amino acids (NEAA) and 10% FCS. Cell 
cultures were maintained in humidified incubators at 37°C, 5% CO2. The medium 
was changed every day to prevent glucose exhaustion. 
 
2.2.4 Human ileal lamina propria cells: Analysis of IL-1Rrp2 mRNA 
expression by qRT-PCR 
After obtaining informed consent from three different patients, fresh, 
histologically normal mucosal samples surplus to clinical requirements were  
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obtained by Professor Yash Mahida (Institute of Infection, Immunity and 
,QIODPPDWLRQ4XHHQ¶V0HGLFDO&HQWUH1RWWLQJKDPIURPKXPDQWHUPLQDOLOHXP
resected for tumour. Ethical committee approval was provided by the Nottingham 
Research Ethics Committee. Mucosal samples were obtained at least 5 cm from 
the tumour. The tissue was transported to the laboratory in Hanks medium, 
gently wiped with sterile gauze to remove most of the adherent mucus and 
debris and immediately processed. Lamina propria cells were isolated from 
mucosal samples using a modification of the ethylenediamine tetra-acetic acid 
(EDTA) collagenase technique of Bull and Bookman, as previously described 
(Bull and Bookman, 1977; Gibson et al., 1985). Briefly, strips of mucosa were 
washed, dissected and incubated in 1 mmol/l dithiothreitol solution (DTT; Sigma, 
Poole, Dorset, UK) for 20 minutes at room temperature. To remove the epithelial 
cells, mucosal strips were treated three times with 5 mmol/l ethylenediamine 
tetra-acetic acid (BDH, Poole, Dorset, UK) at 37°C for half an hour.  After the 
final wash the mucosa was minced into 1 mm pieces and digested for three 
hours at 37°C in  RPMI 1640 (Fisher Scientific (Loughborough, UK) 
supplemented with 1mg/ml collagenase (from Clostridium histolyticum, Sigma, 
Poole, UK) and 10% v/v foetal calf serum (Fisher Scientific (Loughborough, UK). 
The digested tissue was passed through a sterile nylon mesh (Sigma-Aldrich, 
Dorset, UK) to obtain the lamina propria cells and exclude undigested tissue.  
Depending on down-stream applications, the isolated lamina propria cells were 
suspended in appropriate medium at a density of 1x106 cells/ml. Cell viability, 
assessed using the Trypan Blue Dye Exclusion method, varied between 90 and 
100%.  
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To stabilize RNA prior to extraction, samples for qRT-PCR analysis were 
immediately pelleted and suspended in RNAlater RNA Stabilization Reagent 
DFFRUGLQJWRWKH0DQXIDFWXUHU¶VUHFRPPHQGDWLRQV4,$*(1&UDZOH\ UK). Total 
RNA was extracted from the cells, reverse-transcribed into cDNA and amplified 
in a typical real time PCR reaction. A relative quantification analysis using 
GAPDH as the reference gene and IL-1Rrp2 as the target gene was performed 
on a LightCycler® 480 analyser. HT 29 cells and THP-1 cells were used as 
positive and negative controls respectively. Each analysis was performed in 
triplicate on samples from three different patients. 
 
2.3.0 Isolation of cells from human peripheral blood 
 
2.3.1 Human peripheral blood buffy coat preparations 
Human peripheral blood buffy coat preparations were used for the isolation of 
peripheral blood mononuclear cells (PBMCs). Preparations were purchased from 
The National Blood Service, Sheffield, and were received within 24 hours of 
blood donation. They were kept at room temperature during storage and 
transport. Peripheral blood monocytes, lymphocytes, granulocytes and dendritic 
cells were isolated from buffy coat preparations using standard techniques as 
described in the relevant sections below. Monocyte-derived dendritic cells were 
generated from isolated peripheral blood monocytes as described in the relevant 
section below. 
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2.3.2 Isolation of human peripheral blood mononuclear cells (PBMC) 
Peripheral blood buffy coat preparations obtained from the National Blood 
Service (Sheffield) were used as starting material for the isolation of peripheral 
blood mononuclear cells. Buffy coat blood is a concentrated leukocyte fraction 
derived from venipuncture donations obtained from healthy blood donors. It is 
generally enriched for white blood cells (leukocytes) but contains trace amounts 
of red cells and other blood components. If desired, it may be further purified. 
Purchased buffy coat preparations used in this study had an average volume of 
50ml.  
 
A standard Histopaque®-1077 (Sigma, UK) density gradient centrifugation 
technique was used for PBMC isolation (Boyum, 1968). Histopaque®-1077 is a 
sterile, endotoxin tested solution of polysucrose and sodium diatrizoate, adjusted 
to a density of 1.077 g/ml. It facilitates separation of blood cells according to their 
densities and enables rapid recovery of mononuclear cells from small volumes of 
whole blood. To improve isolation of pure PBMC, the purchased buffy coat 
samples were treated as whole blood. Briefly, the following method was used: 
25ml of Histopaque®-1077 was pipetted into each of 4 sterile 50 ml conical 
centrifuge tubes and allowed to reach room temperature. On a separate rack, a 
buffy coat unit was split into 2x 25ml aliquots in sterile 50 ml conical centrifuge 
tubes. 25ml of buffy coat was then diluted 1:1 with phosphate buffered saline 
(PBS) containing 2 mM ethylenediaminetetraacetic acid (EDTA) in sterile 50 ml 
conical centrifuge tubes. 25 ml of diluted buffy coat was then slowly layered on 
102  
top of each Histopaque®-1077 layer. The centrifuge tube was kept at a 45 
degree angle and the sample was allowed to run down the side of the tube until 
it was filled to the 50 ml mark. Care was taken to keep a clear separation 
between the Histopaque®-1077 medium and the blood layer prior to 
centrifugation. The sample tubes were centrifuged at 400 x g for exactly 30 
minutes at room temperature (25oC) in a swinging bucket rotor with the brake off. 
After 30 minutes, tubes were carefully removed from the centrifuge while 
ensuring that the layering was not disturbed. Figure 2.3 is a schematic diagram 
showing isolation of peripheral blood mononuclear cells (PBMCs) from human 
peripheral blood by density gradient centrifugation.  
 
As the diagram (Figure 2.3) shows, centrifugation of the blood/Histopaque®-
1077 mixture for 30 minutes at 400g resulted in rapid sedimentation of red blood 
cells to the bottom as they were aggregated by the polysucrose in Histopaque®-
1077. Granulocytes became slightly hypertonic, which increased their 
sedimentation rate, resulting in them pelleting at the bottom of the centrifuge 
tube. PBMCs formed a band at the interface between the Histopaque®-1077 and 
the plasma. The upper platelet-rich plasma layer was aspirated off to within 0.5-1 
cm from the opaque interface containing the PBMCs.  Using a sterile plastic 
pipette, the opaque PBMC or buffy coat interface was carefully transferred into a 
new 50 ml centrifuge tube, avoiding carryover of the lower clear Histopaque®-
1077 layer. PBMCs from all sample tubes were pooled into one 50 ml centrifuge 
tube. The tube was filled to 50 ml with 1X PBS (at room temperature), and gently 
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mixed by inversion prior to centrifugation at 300g for 10 minutes at room 
temperature to remove platelets and excess Histopaque®-1077. Using a 50 ml 
pipet, the supernatant was carefully removed and discarded. To remove any 
contaminating red cells, the PBMC pellet was gently loosened using a sterile 
plastic pipette and resuspended in 2ml of 1X Red Blood Cell (RBC) Lysis buffer 
(Biolegend, Cambridge, UK). Immediately after adding the lysing solution, the 
tube was gently vortexed prior to incubating at room temperature, protected from 
light, for 10 minutes. The RBC Lysis buffer was quenched by filling up the tube 
with PBS and centrifuging at 300 x g for 10 minutes.  The supernatant was 
aspirated off and discarded without disturbing the PBMC pellet. The pellet was 
resuspended in the appropriate buffer (1X PBS, supplemented RPMI 1640 
medium or staining buffer, depending on further applications). Sample 
preparation procedures were evaluated by assessing cell viability and by 
performing a cell count as previously described. PBMC yields ranged between 3 
x 108 and 8x108 per buffy coat. Average cell viability was found to be >90%. 
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 Figure 2.3 Schematic diagram showing isolation of PBMCs from human 
peripheral blood by density gradient centrifugation using Histopaque®-
1077. The diagram shows layers observed in a representative test tube 
containing peripheral blood (purchased buffy coat blood) and Histopaque®-1077 
before and after centrifugation at 400g for 30 minutes. 
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2.3.3 Isolation of Monocytes from human PBMCs by adherence 
PBMCs obtained from human peripheral blood buffy coats as described in 
previous sections were the starting material for monocyte isolation. Following 
removal of any remaining platelets by washing with PBS, PBMCs were 
resuspended at a density of 1 x 106 cells/ ml in RPMI 1640 medium 
supplemented with 2mM L-Glutamine, 10% (v/v) heat-inactivated Foetal Calf 
Serum (FCS) and 100 U/ml Penicillin-Streptomycin (made up of 100 IU/ml 
penicillin and 100 µg/ml streptomycin) (Sigma, Poole, UK). Cells were plated on 
6-well plastic culture plates in a volume of 3ml per well. Plates were incubated at 
37qC in a humidified, 5% CO2 incubator for 2 hours. After 2 hours, plates were 
visually inspected under an inverted microscope to ensure that monocytes had 
adhered to the bottom of the plastic wells. When a distinct carpet of cells was 
observed at the bottom of the wells, the supernatant, containing non-adherent 
lymphocytes was gently pipetted off and discarded. To aid removal of any 
residual non-adherent cells, the adherent monocytes in each well were gently 
washed three times with 3ml of fresh supplemented RPMI 1640 medium. 
Adherent monocytes were then removed by gently scraping with a sterile plastic 
cell scraper before being counted and resuspended in appropriate media at an 
appropriate density for each experiment. Cell morphology was confirmed by 
microscopy and purity of monocyte preparations was judged by flow cytometry.  
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2.3.4 Isolation of lymphocytes 
2.3.4.1 Isolation of lymphocytes from human PBMCs using Histopaque®-
1077 density gradient centrifugation 
PBMCs isolated from purchased human buffy coat samples as previously 
described were resuspended at a density of 1 x 106 cells/ ml in RPMI 1640 
medium supplemented with 2mM L-Glutamine, 10% (v/v) heat-inactivated Foetal 
Calf Serum (FCS) and 100 U/ml Penicillin-Streptomycin (made up of 100 IU/ml 
penicillin and 100 µg/ml streptomycin) (Sigma, Poole, UK). Cells were plated on 
6-well plastic culture plates in a volume of 3ml per well. Plates were incubated at 
37qC in a humidified, 5% CO2 incubator for 2 hours. After 2 hours, plates were 
visually inspected under an inverted microscope to ensure that monocytes had 
adhered to the bottom of the plastic wells. When a distinct carpet of cells was 
observed at the bottom of the wells, the supernatant, containing non-adherent 
lymphocytes was gently pipetted off, washed in fresh RPMI 1640 (at 300g for 10 
minutes), counted, assessed for viability and resuspended in appropriate 
medium at the right concentration for each experiment. Cell morphology was 
confirmed by microscopy.  
 
2.3.4.2 Isolation of Lymphocytes using ACCUSPIN Histopaque®-1077 
centrifuge tubes  
Total lymphocytes were isolated from PBMCs by density gradient centrifugation 
using sterile- filtered ACCUSPIN Histopaque®-1077 centrifuge tubes as per 
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PDQXIDFWXUHU¶VLQVWUXFWLRQV6LJPD-Aldrich, Poole, UK). ACCUSPIN System- 
Histopaque®-1077 centrifuge tubes have two chambers which are separated by 
a porous high-density polyethylene barrier ("frit"). Anticoagulated whole blood 
(purchased buffy coats) was added to the upper chamber without mixing with the 
Histopaque®-1077 separation medium in the lower chamber prior to 
centrifugation. On centrifugation, the blood descended through the frit and made 
contact with the Histopaque®-1077 below the frit, giving a clear separation of the 
blood components. Lymphocytes and other PBMCs remained at the plasma- 
Histopaque®-1077 interface while erythrocytes and granulocytes pelleted at the 
bottom of the ACCUSPIN tube. The isolated PBMCs were resuspended at a 
density of 1 x 106 cells/ ml in RPMI 1640 medium supplemented with 2mM L-
Glutamine, 10% (v/v) heat-inactivated Foetal Calf Serum (FCS) and 100 U/ml 
Penicillin-Streptomycin (made up of 100 IU/ml penicillin and 100 µg/ml 
streptomycin) (Sigma, Poole, UK). Cells were plated on 6-well plastic culture 
plates in a volume of 3ml per well. Plates were incubated at 37qC in a humidified, 
5% CO2 incubator for 2 hours. After 2 hours, plates were visually inspected 
under an inverted microscope to ensure that monocytes had adhered to the 
bottom of the plastic wells. When a distinct carpet of cells was observed at the 
bottom of the wells, the supernatant, containing non-adherent lymphocytes was 
gently pipetted off, washed three times (at 300g for 10 minutes) in fresh RPMI 
1640 prior to cell counting and assessment of viability using previously stated 
techniques. Cell morphology was confirmed by microscopy (Figures 2.6 and 
2.7). 
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 2.3.5 Isolation of granulocytes from human PBMCs by density gradient 
centrifugation 
Density gradient centrifugation (using Histopaque®-1077) was carried out on 
purchased buffy coat samples as already described. The polysucrose in 
Histopaque®-1077 aggregated red blood cells thereby increasing their density. 
Centrifugation of the blood/Histopaque®-1077 mixture for 30 minutes at 400g 
resulted in red blood cells sedimenting rapidly to the bottom of the centrifuge 
tube. Granulocytes became slightly hypertonic, which increased their 
sedimentation rate, resulting in them pelleting at the bottom of the centrifuge 
tube. PBMCs formed a band at the interface between the Histopaque®-1077 and 
the plasma. The plasma, PBMC and Histopaque®-1077 layers were carefully 
removed by aspiration. The remaining mixture at the bottom (containing red 
blood cells and granulocytes) was washed by topping it up to 50 ml with 1X PBS 
(at room temperature) and centrifuging at 300g for 10 minutes at room 
temperature. Using a 50 ml pipet, the supernatant was carefully removed and 
discarded.  
 
Red blood cells were removed by lysis using the RBC Lysis buffer (Biolegend, 
Cambridge, UK) as previously described. In brief the red blood cell/granulocyte 
pellet was gently loosened using a sterile plastic pipette and resuspended in 2ml 
of 1X RBC Lysis buffer. Immediately after adding the lysing solution, the tube 
was gently vortexed and then incubated at room temperature, protected from 
light, for 10 minutes. The RBC Lysis buffer was then quenched by filling up the  
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tube with PBS and centrifuging at 300 x g for 10 minutes. The supernatant was 
aspirated off and discarded without disturbing the granulocyte pellet. A cell count 
and cell viability assessment was carried out as previously described. The pellet 
was then resuspended in the appropriate buffer depending on further 
applications. Cell morphology was confirmed by phase contrast microscopy and 
purity was confirmed by flow cytometry. Neutrophils had granules in their 
cytoplasm and a conspicuous nucleus consisting of three to five lobules.   
 
,VRODWLRQRIFHOOVIURP3%0&XVLQJWKH$XWR0DFV6HSDUDWRU 
2.3.6.1 Isolation of CD14+ monoc\WHVIURP3%0&VXVLQJWKH$XWR0DFV
Separator 
In addition to isolating monocytes from purchased peripheral blood/buffy coat 
samples using density gradient centrifugation followed by adherence as already 
described, CD14+ monocytes were also isolated from buffy coat samples using 
WKH$XWR0DFV6HSDUDWRU0LOWHQ\L%LRWHF/WG6XUUH\8.7KH$XWR0DFV
Separator is a bench top automated magnetic cell sorter for the isolation of 
virtually any cell type from any species based on the MACS® Technology. Up to 
4×109 pure target cells per sample can be isolated within minutes.  MACS® 
Technology is based on MACS MicroBeads (50-nm super paramagnetic 
particles that are conjugated to highly specific antibodies against a particular 
antigen on the cell surface, MACS Separators, and MACS Columns. MACS 
MicroBeads are super-paramagnetic particles of approximately 50 nanometers in  
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diameter which are coupled to highly specific antibodies or proteins. Since they 
are composed of a biodegradable matrix, they do not need to be removed from 
cells after the separation process. MACS MicroBeads are not known to interfere 
with subsequent experiments or to alter structure, function, or activity status of 
labelled cells (Miltenyi Biotec 1999; 2006b). 
 
MACS Technology takes place within MACS Columns. When a MACS Column is 
placed in a MACS Separator, a strong permanent magnet, a high-gradient 
magnetic field is induced on the column matrix. The induced magnetic field is   
strong enough to retain cells labelled with minimal amounts of MACS 
MicroBeads. Unlabelled cells pass through and can be collected. Labelled cells 
are released after removal of the column from the magnet. MACS technology 
facilitates the isolation of highly pure labelled and unlabelled cell fractions by 
positive selection or depletion (negative selection) respectively. The isolated 
cells can immediately be used for further experiments (Miltenyi Biotec 1999; 
2006b). 
 
Anti-CD14 microbeads (Miltenyi Biotec, Surrey, UK) were used for the positive 
selection of human monocytes frRP3%0&VDFFRUGLQJWRWKHPDQXIDFWXUHU¶V
instructions. The principle of the isolation is that CD14+ cells are first 
magnetically labelled with anti-CD14 microbeads. The cell suspension is then 
loaded onto a MACS® Column which is placed in the magnetic field of an 
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$XWR0DFV6HSDUDWRU7KHPDJQHWLFDOO\ODEHOOHGFHOOVDUHUHWDLQHGZLWKLQWKH
column while the unlabelled cell fraction (depleted of CD14+ cells) runs through. 
Following removal of the column from the magnetic field, the magnetically 
labelled CD14+ cells are eluted as the positively selected cell fraction (Dzionek, 
2000; Miltenyi Biotec, 2007b). 
 
Briefly, the following protocol was used: 107 PBMCs were resuspended in 80µl of 
MACS buffer (0.5 % BSA, 2 mM EDTA in PBS).  20µl CD14 microbeads were 
then added to the suspension. The sample was mixed and incubated on a 
rotator for 15 minutes at 4qC. Following incubation, cells were washed by adding 
2ml of buffer and centrifuging at 300g for 10 minutes prior to being resuspended 
in 500 µl MACS buffer. The suspension was then loaded onto a MACS® Column 
RQDQ$XWR0DFV6HSDUDWRU7KHSRVLWLYHVHOHFWLRQSURJUDPZDVVHOHFWHGDQG
the positive fraction (CD14+ cells) was collected, washed by adding 2ml of buffer 
and centrifuging at 300g for 10 minutes. It was then resuspended in appropriate 
buffer for downstream investigations. An aliquot was also taken for FACS 
analysis to confirm purity of isolation. Cytospin preparations of monocytes 
isolated using CD14 microbeads were also made and stained with DAPI nuclear 
stain. The monocyte nucleus (Figure 2.4) was identified as being mostly kidney-
shaped, bean-shaped or horseshoe-shaped but occasionally amoeboid-shaped 
or almost segmented (William, 2005). 
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 Figure 2.4 CD14+ cells (fluorescence microscopy). Fluorescence microscopy 
image (1000x magnification) of a cytospin preparation of monocytes isolated 
using CD14 microbeads and stained with DAPI nuclear stain. The photographs 
show that the monocyte nucleus is highly variable in shape. It is mostly kidney-
shaped, bean-shaped or horseshoe-shaped but it may also be amoeboid-shaped 
or almost segmented (William, 2005). 
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2.3.6.2 Isolation of type 1 myeloid dendritic cells (mDC1s) from PBMCs 
XVLQJWKH$XWR0DFV Separator 
Human type 1 myeloid dendritic cells were isolated from PBMCs using the 
human CD1c/BDCA-1 magnetic cell separation kit (Miltenyi Biotec Ltd., Surrey, 
8.DFFRUGLQJWRWKHPDQXIDFWXUHU¶VSURWRFRO,QEULHIVHSDUDWLRQRIP'&VRQ
WKH$XWR0DFVLQYROYHGWZRPDJQHWLFVHSDUDWLRQVWHSV,QWKHILUVWVWHS
CD1c/BDCA-1-expressing B cells were magnetically labelled with anti-CD19 
microbeads and subsequently depleted by separation over a MACS® Column 
ZKLFKLVSODFHGLQWKHPDJQHWLFILHOGRIDQ$XWR0DFV6HSDUDWRU,QWKHVHFRQG
step, CD1c/BDCA+ myeloid dendritic cells in the B-cell-depleted flow-through 
fraction were indirectly magnetically labelled with biotin-conjugated CD1c 
antibodies and Anti-Biotin MicroBeads as previously described (Dzionek, 2000; 
Miltenyi Biotec, 2008). The purity of isolation was assessed by flow cytometry 
using appropriate antibodies. Cell viability was assessed using the Trypan blue 
dye exclusion test as previously described. Figure 2.11 is a schematic diagram 
showing the isolation of type 1 myeloid DCs (mDC1) from peripheral blood using 
the CD1c (BDCA-1)+ Dendritic Cell Isolation Kit.  
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 Figure 2.5 Isolation of mDC1 cells. Schematic diagram showing the isolation 
of type 1myeloid dendritic cells from peripheral blood using the CD1c (BDCA-1)+ 
Dendritic Cell Isolation Kit (adapted from Miltenyi Biotec, 2008).    
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2.3.6.3 Isolation of type 2 myeloid dendritic cells (mDC2) from PBMCs 
XVLQJWKH$XWR0DFV6HSDUDWRU 
Human type 2 myeloid dendritic cells were positively selected from PBMCs using 
the human CD141/BDCA-3+ magnetic cell separation kit (Miltenyi Biotec Ltd., 
6XUUH\8.DFFRUGLQJWRWKHPDQXIDFWXUHU¶VSURWRFRO,QEULHI&'%'&$-3+ 
cells were magnetically labelled with anti-CD141/BDCA-3 microbeads. The cell 
suspension was loaded onto a MACS® column which was then placed in the 
PDJQHWLFILHOGRIDQ$XWR0DFV6HSDUDWRU7KHPDJQHWLFDOO\ODEHOOHG
CD141/BDCA-3+ cells were retained on the column while the unlabelled 
CD141/BDCA- cells were collected in the flow-through. The column was then 
removed from the magnetic field and the CD141/BDCA-3+ cells were eluted and 
once gain separated over a new column to achieve highest purities (Dzionek, 
2000; Miltenyi Biotec, 2006c). The purity of isolation was assessed by flow 
cytometry using appropriate antibodies. Cell viability was assessed using the 
Trypan blue dye exclusion test as previously described. 
 
2.3.6.4 Isolation of Plasmacytoid Dendritic cells (pDCs) from PBMCs using 
WKH$XWR0DFV Separator 
Human plasmacytoid DCs (pDCs) were isolated from PBMCs using the Diamond 
Plasmacytoid Dendritic Cell Isolation Kit (Miltenyi Biotec Ltd., Surrey, UK) 
DFFRUGLQJWRWKHPDQXIDFWXUHU¶VSURWRFRO%ULHIO\VHSDUDWLRQRIS'&VRQWKH 
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$XWR0DFVLQYROYHGWZRPDJQHWLFVHSDUDWLRQVWHSV,QWKHILUVWVWHSDOOQRQ-
pDC cells were magnetically labelled with a cocktail of biotin-conjugated 
antibodies and anti-biotin Microbeads for depletion over a MACS Column. In the 
subsequent positive selection step, the enriched pDCs were directly magnetically 
labelled with anti-CD304 (BDCA-4/Neuropilin-1) Microbeads. The purity of 
isolation was assessed by flow cytometry using appropriate antibodies. Cell 
viability was assessed using the Trypan blue dye exclusion test as previously 
described. 
 
,VRODWLRQRI&'&'FHOOVIURP3%0&VXVLQJWKH$XWR0DFV
Separator 
The isolation of human CD209+/CD14+ cells from PBMCs was done in two steps. 
In the first step, CD14+ monocytes were isolated by negative selection using the 
human Monocyte Isolation Kit II (Miltenyi Biotec Ltd., Surrey, UK) according to 
WKHPDQXIDFWXUHU¶V instructions. Briefly, non-monocytes were indirectly 
magnetically labelled using a cocktail of biotin-conjugated antibodies and anti-
biotin Microbeads. Highly enriched unlabelled monocytes were obtained by 
depletion of the magnetically labelled cells.  In the second step, CD209+ cells 
were positively isolated from the CD14+ cell population using the CD209 (DC-
6,*10LFUR%HDG.LW0LOWHQ\L%LRWHF/WG6XUUH\8.DVSHUPDQXIDFWXUHU¶V
instructions. Briefly, CD209/DC-SIGN+ cells were first magnetically labelled with  
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anti-CD209/DC-SIGN microbeads. The cell suspension was loaded onto a 
MACS® FROXPQZKLFKZDVWKHQSODFHGLQWKHPDJQHWLFILHOGRIDQ$XWR0DFV
Separator. The magnetically labelled CD14+ CD209/DC-SIGN+ cells were 
retained within the column while the unlabelled CD14+ CD209/DC-SIGN- cells 
were collected in the flow-through.  After removing the column from the magnetic 
field, the CD14+ CD209+ cells were eluted as the positively selected cell 
fraction. Cell purity was confirmed by staining a fraction of the isolated 
CD209+CD14+ cells with appropriate fluorescent antibodies. Cell viability was 
assessed using the Trypan blue dye exclusion test as previously described. 
 
2.3.6.6 Isolation of CD3+ T cells 
Human CD3+ T cells were positively selected from PBMCs using anti-CD3 
paramagnetic beads (CD3 MicroBeads kit, Miltenyi Biotec Ltd., Surrey, UK) 
DFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV%ULHIO\&'FHOOVZHUHILUVW
magnetically labelled with anti-CD3 microbeads. The cell suspension was loaded 
onto a MACS® column which was then placed in the magnetic field of an 
$XWR0DFV6HSDUDWRU7KHPDJQHWLFDOO\ODEHOOHG&'7FHOOVZHUHUHWDLQHGRQ
the column while the cell fraction depleted of CD3+ cells was collected in the 
flow-through.  Cell purity was confirmed by staining a fraction of the isolated T 
cells with a fluorescent anti-CD3 antibody (CD3: FITC). Cell viability was 
assessed using the Trypan blue dye exclusion test as previously described. 
118 
2.4.0 Differentiation and culture of monocyte-derived dendritic cells 
(MDDCs) 
Blood products from healthy donors were obtained from the National blood 
transfusion service (Sheffield, UK) as already described. Isolation of peripheral 
blood monocytes (PBMs) was performed using differential centrifugation on 
Histopaque®-1077 as described in previous sections. PBMs were differentiated 
into MDDCs using previously reported methods (Sallusto and Lanzavecchia, 
1994). Briefly, monocytes were cultured in six well plates at a concentration of 
1x106 cells/ml in RPMI 1640 media supplemented with heat-inactivated FCS 
(10%v/v), Penicillin-Streptomycin (1%), L-glutamine (2mM) (Sigma-Aldrich, 
Poole, UK), GM-CSF (50 ng/mL) (Sigma-Aldrich, Poole, UK) and IL-4 (10 ng/mL) 
(Sigma-Aldrich, Poole, UK). To investigate the effect of IL-4 on IL-1Rp2 
expression, GM CSF (50 ng/mL) and IL-4 concentration ranges from 1, 10 and 
50 ng/mL were XVHG$OOFHOOVZHUHPDLQWDLQHGDWƕ&LQ&2IRUGD\V 
with media and cytokine change every 2 days. After 5 days the cells became 
non-adherent and were analysed for MDDC phenotype and morphology. 
 
2.5.0 Differentiation and culture of monocyte-derived macrophages (MDMs) 
PBMs were cultured for 4 days with GM-CSF (50 ng/mL) without IL-4, under the 
same experimental conditions used for MDDCs (stated above). After 5 days the 
morphological appearance of adherent macrophages were observed by phase-
contrast microscopy using a TCS SP2 UV confocal laser-scanning microscope 
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(CLSM) (Leica Microsystems, UK). IL-1Rrp2 expression was subsequently 
measured in MDMs by Fluorescent Activated cell Sorting Analysis (FACS) and 
quantitative real time PCR (qRT-PCR). In other experiments, MDMs were 
washed and stimulated for 2 days with IL-4 (10 ng/mL) prior to microscopic and 
qRT-PCR analyses. 
 
2.6.0 Immunofluorescence Assays 
2.6.1 Fluorescence Activated Cell Sorting (FACS) analyses  
FACS analyses were performed by standard methods. Briefly, cells were 
harvested and the total cell number was determined. Cells were pelleted by 
centrifuging at 300g for 10 minutes and the culture medium (supernatant) was 
discarded. 10ml FACS buffer (Phosphate buffered saline (PBS) pH 7.4; BSA 
(1% w/v); EDTA (2 mM)) was added to the cell pellet followed by centrifugation 
at 300g for 10 minutes. After discarding the supernatant, the cell suspension was 
adjusted to a concentration of 1×106 FHOOVPOZLWK)$&6EXIIHUȝORIFHOO
suspension was aliquoted into the required number of test tubes. To block Fc 
receptors on the cell surface thereby reducing non-specific antibody binding, 
cells were incubated in FACS buffer containing human serum (10% v/v) for 15 
minutes at room temperature on an orbital shaker prior to incubation with 
relevant antibodies (see Table 2.2). To detect intracellular antigens, a cell 
permeabilisation step (incubation with 0.5% Triton X for 10 minutes at room 
temperature) was done prior to staining. This step was omitted in FACS  
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analyses for the detection of cell surface antigens. 
 
For direct immunofluorescence staining (where the fluorochrome was directly 
linked to the primary antibody), blocking of Fc receptors was followed by 
incubation, in the dark, for 45 minutes with the relevant antibody at the 
appropriate concentration (determined by preliminary optimisation studies) on 
ice, on a shaker. Cells were then washed three times by adding 2ml of FACS 
buffer and centrifuging at 300g for 10 minutes each time. This was done to 
remove unbound antibody. As a negative control, isotype matched control 
samples were also included and these were incubated for 45 minutes with an 
appropriate isotype matched control antibody only but not with the primary 
antibody (Table 2.2). Isotype control antibodies have no relevant specificity and 
help to distinguish non-specific "background" staining from specific antibody 
staining.   
 
After washing cells and discarding the supernatant, cells were resuspended in 
0.2 ml of FACS buffer prior to analysis on a FACSCanto II analyser (Becton 
Dickinson, USA). Samples were acquired using the BD FACSDLYD%'
Biosciences, USA) and analysed using the WinMDI 2.8 software. Cell viability 
ZDVDVVHVVHGE\SURSLGLXPLRGLGHXSWDNHȝJP/IRUPLQYLD)$&6
analysis. 
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For indirect immunofluorescence staining (where a fluorochrome on a secondary 
antibody was used to visualize the primary antibody), sample preparation, 
including Fc receptor blocking, was done as already stated above. The primary 
antibody was then added at the appropriate concentration and the sample was 
incubated for 45 minutes in the dark under the conditions that have already been 
mentioned above. Cells were then washed with 2ml of FACS buffer and 
centrifuged at 300g for 10 minutes. After discarding the supernatant, cells were 
incubated for 45 minutes on ice, in the dark, with an appropriate secondary 
antibody (Table 2.2). Cells were washed, resuspended in 0.2 ml of FACS buffer 
and analysed as described above. To test for non-specific binding of the 
secondary antibody, secondary antibody control cells were stained as above with 
the secondary antibody only but not with the primary antibody. 
   
2.6.1.1 FACS analyses for IL-1Rrp2 expression 
Cells were resuspended in FACS buffer at a concentration of 1x106 cells/ml as 
described above (Section 2.6.1). Test cells were blocked in FACS buffer 
containing human serum (10% v/v) for 15 min prior to incubation for 45 minutes 
with 10µg/ml mouse anti-human IL-1Rrp2 antibody (M145, Amgen Corporation, 
Seattle, WA) followed by incubation for 45 minutes with the detection/secondary 
antibody (10µg/ml allophycocyanin (APC)-conjugated goat anti-mouse IgG 
(Biolegend, UK). Secondary antibody control cells were incubated for 45 minutes 
with 10µg/ml APC-conjugated goat anti-mouse IgG only and not with the primary 
antibody. Cells were then analysed using a FACSCanto II analyser (Becton 
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'LFNLQVRQ86$6DPSOHVZHUHDFTXLUHGXVLQJWKH%')$&6'LYD%'
Biosciences, USA) and analysed using the WinMDI 2.8 software. Cell viability 
was assessed as already stated and was found to be >90% in all cases. 
 
2.6.1.2 Analysis of MDDC phenotype and maturation status 
Following co-culture of PBMs with GM CSF and IL-4 for 5 days, changes in 
expression of CD1a, CD11C, CD14, HLA-DR and CD83 were measured by 
FACS analyses (as previously stated) using antibodies listed in Table 2.2. The 
phenotype of these cultured cells was CD11Chigh, CD1ahigh, HLA-DRhigh and 
CD14low, consistent with their differentiation to immature MDDCs (see Figure 
2.12). 
 
Prior to assessing the effect of mature MDDCs on T cell populations (section 
2.8.0), the surface expression of CD40 and CD80 on IL-1F8-matured MDDCs 
was measured by FACS analyses (as previously stated) to further confirm the 
ability of IL-1F8 to induce MDDC maturity.  The antibodies used are listed in 
Table 2.2.  
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Table 2.2 Concentration of antibodies used in FACS analyses. Unless 
otherwise stated, antibodies were ordered from Abd Serotec (Oxford, UK) or BD 
Biosciences (Oxford, UK).   
Antibody Concentration 
ȝg/ml) 
Mouse anti-human CD14:PE 
       5 
Mouse anti-human HLA-DR:PE        5 
Mouse anti-human CD1a:FITC        1 
Mouse anti-human CD11c:FITC        1 
Mouse anti-human CD83:FITC        5 
Mouse anti-CD80: FITC        5 
Mouse anti-human CD40: PE        5 
Mouse anti human CD40:Alexa Fluor® 
488 
        5 
Mouse IgG2a:Alexa Fluor® 488        5 
Mouse IgG2a:PE (Isotype control 
CD14/CD40) 
       5 
Mouse IgG3: PE (Isotype control 
HLA.DR) 
       5 
Mouse IgG1:FITC (Isotype control 
CD1a)/CD80 
       1 
Mouse IgG2a:FITC (Isotype control 
CD11c 
       1 
Mouse IgG2a:FITC (Isotype control 
CD83) 
       5 
Mouse anti-human IL-1Rrp2 (M145) 
(Amgen Corporation, Seattle, WA, USA) 
       10 
Goat anti-mouse IgG:APC 
(Biolegend, Cambridge UK) 
       10 
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 Figure 2.6 MDDC phenotypic characteristics. Histograms show phenotypic 
characteristics following conversion of human PBMs to immature monocyte-
derived dendritic cells (MDDCs). PBMs were co-cultured with GM CSF and IL-4 
for 5 days prior to phenotypic examination using flow cytometry. Differentiation to 
an MDDC phenotype is shown by measurement of the following parameters: (A) 
CD11Chigh; (B) CD1ahigh; (C) HLA-DRhigh and (D) CD14low. Grey shaded areas 
correspond to the control. Data are representative of at least three independent 
experiments. 
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2.6.1.3 Analysis of IL-1Rrp2 expression and maturation status following 
culture with IL-1 cytokines  
Initially, expression of IL-1Rrp2 on the cell membranes of promonocytes, PBMs, 
MDMs and MDDCs was analysed using FACS analysis as previously stated 
(Sections 2.6.1 and 2.6.1.1). To assess IL-1-dependent maturation of MDDCs, 
changes in HLA-DR and CD1a expression were assessed by FACS analysis on 
the surface of day 5 (Immature) MDDCs that had been washed three times in 
PBS prior to incubation with IL-1F8 or IL-1F9 (100 ng/ml) for 48 h. As a positive 
control, day 5 MDDCs were incubated under the same conditions for 48 h with 
IL-ȕ (100 ng/ml) or IFN-Ȗ8PO$VDQHJDWLYHFRQWUROVSRQWDQHRXV
maturation of MDDCs was also assessed. Parallel experiments were performed 
in which day 5 MDDCs were washed prior to culture in fresh RPMI 1640 media, 
which did not contain cytokines, for a further 48 h prior to measurement of CD1a 
and HLA.DR by the FACS analysis. As an additional measurement of 
maturation, the expression of CD83 by day 5 and day 7 MDDCs was compared 
with the expression of CD 83 by day 5 MDDCs which had been stimulated with 
IL-1F8 or IL-1F9 for 48 h under the same experimental conditions stated above.  
 
Cells were gated as R1 (immature) and R2 (mature) populations according to 
parameters set for immature MDDCs, which had been washed and then cultured 
for a further 48 h without cytokine stimulation (unstimulated controls). These 
parameters were then applied to all subsequent FACS data so that direct 
comparisons could be made between the numbers of cells in each R1 and R2 
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population following different treatments. Prior to co-culture of IL-1F8 matured 
MDDCs with CD3+ T lymphocytes, CD40 and CD80 expression on the surface 
of IL-1F8-stimulated MDDCs was measured by standard FACS analysis using 
antibody concentrations shown in Table 2.2. Each experiment was repeated on 
more than three separate occasions. 
 
2.6.2 Fluorescence microscopy for IL-1Rrp2 detection 
To assess IL-1Rrp2 expression in various human cells by immunofluorescence 
microscopy, harvested cells were rinsed with PBS and resuspended at a 
concentration of 1 x 105 cells/ml in PBS prior to being fixed by incubation with 
4% v/v paraformaldehyde (PFA) in PBS for 15 minutes at room temperature. 
After washing cells with PBS, 500µl of cell suspension was used to make 
cytospin preparations using a Cytospin 4 centrifuge (Thermo Scientific, UK) and 
following standard techniques. Slides were left to air dry prior to permeabilising 
cells with 0.5% Triton X for 10 minutes at room temperature. After rinsing three 
times in PBS for 3 minutes each time, slides were incubated with 50-100ul of 
human AB serum for 10 minutes at room temperature to block non-specific Fc 
Receptor binding. This was followed by incubation with 25µg/ml mouse anti-
human IL-1Rrp2 antibody (M145, Amgen Corporation, Seattle, WA) for 45 
minutes. After rinsing slides as previously stated, slides were incubated with the 
secondary/detection antibody (10µg/ml FITC-conjugated Goat anti-mouse IgG) 
for 30 minutes in the dark. Isotype control cells were incubated with secondary 
antibody only. Unstained cells were also included as controls. After rinsing slides 
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as before, a drop of ProLong Gold antifade reagent containing 4',6-diamidino-2-
phenylindole (DAPI) (Invitrogen, UK) nuclear stain was placed on the slides and 
the slides were cover-slipped and left to dry in the dark for at least 5 minutes. 
Slides were then analysed under a Leica fluorescence microscope (Leica 
Microsystems, UK). 
 
Immunofluorescence is a technique which allows the visualization of a specific 
protein or antigen in cells or tissue sections by binding a specific antibody 
chemically conjugated with a fluorescent dye such as fluorescein isothiocyanate 
(FITC). There are two main types of immunofluorescence staining methods; 
direct immunofluorescence staining (where the primary antibody is labelled with 
fluorescence dye) and indirect immunofluorescence staining (where a secondary 
antibody labelled with fluorochrome is used to recognize a primary antibody). 
Immunofluorescence staining can be performed on cells fixed on slides and on 
tissue sections. Immunofluorescence stained samples are examined under a 
fluorescence microscope or confocal microscope. 
 
2.7.0 Molecular techniques 
2.7.1 RNA Extraction 
RNA extraction was performed using the RNeasy Mini Kit (Qiagen, Crawley, UK) 
DFFRUGLQJWRWKHPDQXIDFWXUHU¶VSURWRFRO7KH51HDV\SURFHGXUHLVDZHOO-
established technology for total RNA purification. It combines the selective 
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binding properties of a silica-based membrane with the speed of microspin 
technology. A specialized high-VDOWEXIIHUV\VWHPDOORZVXSWRȝJRI51$
longer than 200 bases to bind to the RNeasy silica membrane. Biological 
samples are first lysed and homogenized in the presence of a highly denaturing 
guanidine-thiocyanate±containing buffer which immediately inactivates RNases. 
This ensures purification of intact RNA. Ethanol is added to provide appropriate 
binding conditions, and the sample is then applied to an RNeasy Mini spin 
column, where the total RNA binds to the membrane and contaminants are 
efficiently washed away. High-quality RNA is then eluted in 30±ȝOZDWHU7KH
RNeasy procedure facilitates the purification of RNA molecules longer than 200 
nucleotides. The procedure provides an enrichment for mRNA since most RNAs 
<200 nucleotides (such as 5.8S rRNA, 5S rRNA, and tRNAs, which together 
comprise 15±20% of total RNA) are selectively excluded (QIAGEN, 2006). 
 
In brief, the appropriate number of harvested cells (typically 1 x 106) was pelleted 
by centrifuging for 5 min at 30[JDQGWKHVXSHUQDWDQWVZHUHGLVFDUGHGȝO
RI5/7%XIIHUFRQWDLQLQJȝOȕ-PHUFDSWRHWKDQROȕ-ME) per ml Buffer RLT) 
was added to the cell pellet to lyse the cells. The lysate was then homogenized 
by passing it at least 5 times through a blunt 20-gauge needle (0.9 mm diameter) 
fitted to an RNase-IUHHV\ULQJH7KLVZDVIROORZHGE\WKHDGGLWLRQRIȝORI
70% ethanol to the homogenized lysate and thorough mixing (using a sterile 
pipette). The sample was then transferred to an RNeasy spin column (placed in 
a 2 ml collection tube) and centrifuged for 15 seconds at 12000 rpm. After  
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discarding the flow-through, on-column DNase digestion was done to eliminate 
genomic DNA contamination (see below). This was followed by the addition of 
ȝO%XIIHU5: to the RNeasy spin column and centrifuging for 15 seconds at 
12000 rpm to wash the spin column membrane. After discarding the flow-
WKURXJKȝORI%XIIHU53(ZDVDGGHGWRWKH51HDV\VSLQFROXPQDQGWKH
tube was centrifuged for 15 seconds at 12000 rpm to wash the spin column 
PHPEUDQH7KHIORZWKURXJKZDVGLVFDUGHGEHIRUHDGGLQJDQRWKHUȝORI
Buffer RPE was added to the RNeasy spin column and the tube was centrifuged 
for 2 minutes at 12000 rpm to wash and dry the spin column membrane, 
ensuring that no ethanol (which could interfere with downstream reactions) was 
carried over during RNA elution. The RNeasy spin column was then placed in a 
new 2 ml collection tube and centrifuged at 12000 rpm for 1 min to eliminate any 
possible carryover of Buffer RPE. This was followed by placing the RNeasy spin 
column in a new 1.5 ml RNAse-free Eppendorf tube, aGGLQJȝO51DVH-free 
water directly to the spin column membrane and centrifuging for 1 min at 12000 
rpm to elute the RNA. Purity and concentration were analysed using a Nanodrop 
(ND1000) spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) 
accorGLQJWRPDQXIDFWXUHU¶VLQVWUXFWLRQVVHHEHORZ3ULRUWRF'1$V\QWKHVLV
and other down-stream applications, RNA was stored at -80qC. 
 
2.7.2 On-column DNase Digestion using RNase-free DNase set 
The purpose of DNase digestion is to prevent genomic DNA from contaminating 
the extracted RNA. Lysis and homogenization of the sample and binding of RNA 
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 to the RNeasy membrane are performed according to the standard protocols. 
After washing with a reduced volume of Buffer RW1 (which contains a small 
amount of guanidine thiocyanate and ethanol), the RNA is treated with DNase I 
while bound to the RNeasy membrane. The DNase I is removed by a second 
wash with Buffer RW1. Washing with Buffer RPE (which contains a non-
chaotropic salt and ethanol) and elution of RNA are then performed according to 
the standard protocols (QIAGEN, 2006). 
 
Briefly, cells were harvested, lysed, homogenized and loaded onto the RNeasy 
spin column as stated in previous sections (see Section 2.8.1 above).  Prior to 
performing the first wash stepȝORI%XIIHU5:ZDVDGGHGWRWKH51HDV\
spin column and the tube was centrifuged for 15 s at 12000 rpm to wash the spin 
column membrane. After discarding the flow-WKURXJKȝORI'1DVH,LQFXEDWLRQ
PL[FRQVLVWLQJRIȝO'1DVH,VWRFNVROXWLRQDQGȝO%XIIHU5''ZDVDGGHG
directly to the RNeasy spin column membrane and the tube was placed on the 
bench top at room temperature (20±30°C) for 15 minutes. This was followed by 
WKHDGGLWLRQRIȝO%XIIHU5:WRWKH51HDV\VSLQFROXPQFHQWULIXJDWLon for 
15 seconds at 12 000 rpm and discarding of the flow-through prior to continuing 
with the first Buffer RPE wash step in the RNA extraction protocol as already 
described in Section 2.8.1.  
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2.7.3 RNA Quantification and determination of purity  
Concentration of RNA was determined by measuring the absorbance at 260 nm 
(A260) in a Nanodrop (ND1000) spectrophotometer (NanoDrop technologies, 
:LOPLQJWRQ'(86$DFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV7KHUDWLRRI
the readings at 260 nm and 280 nm (A260/A280) was used to provide an 
estimate of purity of RNA with respect to contaminants that absorb in the UV 
spectrum, such as protein. RNA with an A260/A280 ratio greater than 1.8 was 
considered to be pure (QIAGEN, 2006) and was used for reverse transcription 
and subsequently for quantitative real time PCR (qRT-PCR). 
 
2.7.4 Complementary DNA (cDNA) synthesis   
Prior to qRT-PCR analysis, RNA was first reverse-transcribed into 
complimentary DNA (cDNA) in a reverse transcription (RT) reaction using the 
Transcriptor First Strand cDNA Synthesis Kit (Roche, West Sussex, UK) as per 
VXSSOLHU¶VLQVWUXFWLRQV$UDQGRPKH[DPHUSULPHUZDVXVHGDVGHWDLOHGLQWKH
VXSSOLHU¶VPDQXDO7KHWRWDOUHDFWLRQYROXPHZDVȝOPDGHXSRI7UDQVFULSWRU
Reverse Transcriptase reDFWLRQEXIIHUȝO'HR[\QXFOHRWLGHG173PL[ȝO
UDQGRPKH[DPHUSULPHUȝOSURWHFWRU51DVHLQKLELWRUȝO7UDQVFULSWRU
5HYHUVHWUDQVFULSWDVHȝODQGDPD[LPXPRIȝOWRWDO51$XSWRȝJRI
total RNA was used). The following program was used on the thermal cycler: 10 
minutes at 25oC, 30 minutes at 55oC, 5 minutes at 85oC then hold at 4oC. All 
samples were run in duplicate. 
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2.7.5 Quantitative Real Time PCR (qRT-PCR) 
The LightCycler® 480 Probes Master Kit (Roche, West Sussex, UK) was used for 
qRT-3&5DQGWKHPDQXIDFWXUHU¶VJXLGHOLQHVIRUXVHZLWK/LJKW&\FOHU® 480 
Multiwell Plate 96 were followed. Gene-specific primers were obtained from 
Invitrogen, (Paisley, UK) through Fisher Scientific (Loughborough, UK). 5-
carboxyfluorescein (FAM)-labelled probes were obtained from Roche 
Diagnostics (West Sussex, UK). Gene-specific primers and probes were 
designed using the Roche Universal Probe Library (UPL) Assay Design Centre 
software (primer and probe sequences used are shown in Table 2.3). To allow 
differentiation of the amplified cDNA from contaminating genomic DNA, intron-
spanning primers (primers that annealed to exon sequences on both sides of an 
intron or on exon/exon boundaries) were designed (Roche Diagnostics 
Corporation, 2007). 
 
THPSODWHF'1$VȝOZHUHDPSOLILHGLQD3&5UHDFWLRQPL[ȝOWRWDOYROXPH
containing an appropriate 5-carboxyfluorescein (FAM)-labelled hydrolysis probe 
(Universal ProbeLibrary probe), FastStart Taq DNA Polymerase, reaction buffer, 
deoxynucleotide triphosphate (dNTP) mix, PCR-grade water, MgCl2 and gene-
specific primers according to the LightCycler® 480 Probes Master kit (Roche, 
:HVW6XVVH[8.7KHIROORZLQJYROXPHVZHUHXVHGȝO/LJKW&\FOHU
3UREHV0DVWHU[FRQFHQWUDWLRQȝOF'1$ȝOIRUZDUGSULPHUȝO
UHYHUVHSULPHUȝOK\GURO\VLVSUREHDQGȝO3&5-grade water. The 
ZRUNLQJFRQFHQWUDWLRQIRUDOOSULPHUVDQGSUREHVZDVȝ07KHDEVHQFHRI'1$ 
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contamination in RNA preparations was tested by including RNA samples that 
had not been reverse transcribed. A negative no template control (NTC) and a 
positive calibrator sample were also included with each run. For each target and 
control (housekeeping) gene, a standard curve was constructed from running 
serial dilutions of relevant positive standards covering six points in order to 
determine the efficiency of each gene (Figure 2.13 shows a representative 
standard curve).  All samples were analysed in triplicate. Amplifications were 
performed using a LightCycler® 480 Real-Time PCR analyser (Roche, West 
6XVVH[8.DVSHUPDQXIDFWXUHU¶VUHFRPPHQGDWLRQV7KH3&5F\FOLQJSURJUDP
used for IL-1Rrp2 and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
genes was: Pre-incubation (1 cycle; 95oC for 10 minutes), Amplification (45 
cycles; 95oC for 10 seconds, 60oC for 40 seconds and 72oC for 1 second) and 
Cooling (1 cycle; 40oC for 10 seconds).  
 
For quantification purposes, a relative quantification method based on the 
relative changes in mRNA expression of the target gene versus a reference (or 
housekeeping) gene was employed. GAPDH was used as the reference gene for 
this purpose. Relative expression of the target gene to the reference gene was 
calculated using the LC480 software program (Roche, West Sussex, UK). The 
Advanced Relative quantification efficiency corrected calculation model (E-
method) was used according to the LC 480 user manual. (Pfaffl, 2001; 2004; 
Roche Applied Sciences, 2006; Roche Applied Sciences, 2008; Roche 
Diagnostics Ltd., 2008).   
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A Relative Quantification analysis compares two ratios: the ratio of a target DNA 
sequence to a reference DNA sequence in an unknown sample, and the ratio of 
WKHVDPHWZRVHTXHQFHVLQDVWDQGDUGVDPSOHFDOOHGD³FDOLEUDWRU´7KH³7DUJHW´
is the nucleic acid of interest (specific RNA or DNA sequence); while the 
³5HIHUHQFH´LVDQXFOHLFDFLGWKDWLVIRXQGDWFRQVWDQWFRS\QXPEHULQDOO
samples and serves as endogenous control which normalizes for sample-to 
VDPSOHGLIIHUHQFHV7KH³&DOLEUDWRU´LVW\SLFDOO\DSRVLWLYHVDPSOHZLWKDVWDEOH
ratio of target to-reference and is used to normalize all samples within one run, 
but in addition provides a constant calibration point between several LightCycler 
® 480 System runs. The result is expressed as a normalized ratio. Calibrator 
Normalized ratio =  
(Concentration of target/concentration of Reference)in sample  :  (Concentration of 
target/concentration of Reference)in calibrator 
 
Relative Quantification is the best technique for determining gene expression 
and gene dosage since it allows users to easily compare the expression 
behaviour of a target gene under at least two conditions (e.g., disease-free / 
diseased or untreated / treated). By dividing the concentration of the target in 
each sample by the concentration of a reference in the same sample, this 
method corrects the sample for differences in quality and quantity caused by 
variations in initial sample amount, variations in nucleic acid recovery, possible 
RNA degradation of sample material, differences in sample and/or nucleic acid 
quality, variations in sample loading/pipetting errors and/or variations in cDNA  
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synthesis efficiency (Roche Diagnostics Ltd., 2008). 
 
A Relative Quantification analysis can be performed on an experiment that has 
an amplification program and that has the appropriate sample types. It can be 
performed on a single-colour or on a dual-colour experiment. A Relative 
Quantification analysis is based on the assumption that the concentration of 
'1$DWDVDPSOH¶VFURVVLQJSRLQWLVWKHVDPHIRUHYHU\VDPSOHFRQWDLQLQJWKH
same target DNA. This is the DNA concentration necessary for the LightCycler® 
480 instrument to detect a signal above background noise. Each sample may 
require a different number of cycles to reach the crossing point, depending on 
the initial concentration of DNA in the sample.  
 
$WWKHHQGRIWKHH[SHULPHQWHDFKVDPSOH¶V'1$FRQFHQWUDWLRQPD\YDU\
depending on how many cycles were completed by that sample after the 
FURVVLQJSRLQWZDVUHDFKHG7KHDQDO\VLVXVHVWKHVDPSOH¶VFURVVLQJSRLQW
(expressed as a cycle number), the efficiency of the reaction, the number of 
cycles completed, and other values to determine how much the DNA 
concentration must have increased for each sample by the end of the 
amplification. The analysis uses these calculations to compare the samples and 
generate the ratios. The final ratio resulting from the calibrator normalized 
Relative Quantification is only a function of PCR efficiency and of the determined 
crossing points. It does not require the knowledge of absolute copy numbers at  
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the detection threshold and thus the analysis does not determine the actual 
concentration of DNA in the samples. The calculation of the calibrator-
normalized ratio does not require a standard curve in each LightCycler® 480 run 
(Roche Diagnostics Ltd., 2008). 
 
The Efficiency Method (E-method) used by Roche Applied Sciences for 
calculation of the normalized ratio is based on true efficiency values and can 
produce more accurate relative quantification data than the previously used 
ǻǻ&T method (Livak and Schmittgen, 2001; Pfaffl, 2001; 2004) since it can 
compensate for efficiency differences between target and reference either within 
an experiment or between experiments. It uses the individual PCR efficiencies of 
target and reference gene for calculating the final normalized relative ratio. 
Efficiency is determined via linear/non-linear standard curves (Pfaffl, 2001; 2004; 
Roche Applied Sciences, 2006)     
 
The LightCycler 480® Software provides two different analysis modes for 
Relative Quantification approaches: Basic and Advanced Analysis. The Basic 
Analysis mode is based on the well-DFFHSWHGǻǻ&7-Method (Livak and 
Schmittgen, 2001) while the Advanced Analysis mode represents a manual, 
flexible mode providing sophisticated software algorithms and excellent tools for 
the most demanding research projects. The Advanced Relative Quantification 
method not only allows determination of the relative ratio, but it extends and 
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improves this concept by enabling crossing point (Cp) calling via either Fit points 
or Second Derivative Maximum methods, reference analysis via either In-Run 
references or External Reference experiments, pairing rules for multiple 
target/reference genes, the use of standards and the use of subsets. An 
Advanced Relative Quantification experiment contains target and reference 
unknowns, target and reference standards (optional), target and reference 
calibrators (optional) and target and reference negatives (optional). The 
references can be measured in the same or in a separate experiment (Roche 
Diagnostics Ltd., 2008). 
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Table 2.3 Primer and probe sequences used in the current study (*UPL No. = 
Universal Probe Library Probe Number)  
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GENE 
NAME 
Genbank 
Accesion  
Number 
Forward  
primer 
Sequence 
Reverse  
Primer 
Sequence 
*UPL   
No. 
Human  
71)Į 
BC028148 CAGCCTCTTCT
CCTTCCTGAT 
 
GCCAGAGGGC
TGATTAGAGA 
 
29 
Human 
GAPDH 
NM_002046 CTCTGCTCCTCC
TGTTCGAC      
ACGACCAAATCC
GTTGACTC 
60 
Human 
 IL-1Rrp2 
AF284434 GCTGGAGTGTCC
ACAGCATA 
GCGATAAGCCCT
CCTATCAA 
24 
  
Figure 2.7 Representative GAPDH gene RT-PCR standard curve. (Efficiency: 
2.000, Slope: 3.306, Error: 0.0219, Y-intercept: 26.82, Link: 0.00188). The 
standards used were serial five-fold dilutions of cDNA from a monocyte derived 
dendritic cell (MDDC). Standards were constructed to span five data points. The 
concentrations chosen for the standard curve reflected the expected 
concentration range of the target. All samples were analysed in duplicate using 
the LightCycler® 480 instrument. The slope of the standard curve describes the 
kinetics of the PCR amplification. The LightCycler® 480 software automatically 
calculated efficiency using the formula: E = 10 -1/slope The Error value is the mean 
squared error of the single data points fit to the regression line. It is a measure of 
the accuracy of the quantification result based on the standard curve. An 
acceptable error value should be < 0.2. 
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2.7.6 Evaluation of PCR products by agarose gel electrophoresis 
PCR products were evaluated by electrophoresis on 2% agarose gels. Briefly, 
100ml agarose solution was prepared by measuring 2g agarose into a conical 
flask and adding 100ml of 1x TAE (Tris-acetate-EDTA) buffer. The mixture was 
microwaved at medium heat for 2-3 minutes until all the agarose was dissolved 
and the solution was clear. The solution was allowed to cool to about 55-60 0C 
before adding 1-2µl of Ethidium bromide (concentration 10mg/ml) (10ug/µl). A 
10-well comb was placed in a gel tray about 1 inch from one end of the tray 
ensuring that the teeth were about 1-2mm above the surface of the tray. The gel 
solution was slowly poured into the gel tray to a depth of about 5mm. Any 
bubbles were pushed away to the side using a disposable tip. The gel was 
allowed to solidify for about 30 minutes at room temperature (when set, the gel 
changed colour from clear to opaque) before the comb was gently removed. The 
gel tray was covered with 1x TAE buffer (until wells were submerged). 2µl of 6x 
gel loading buffer was added to 10µl of DNA sample and mixed in well. 10µl of 
mixed DNA sample was loaded into appropriate wells. The first and last wells 
(first and last lanes) were loaded with 10µl of a 1kb molecular weight marker 
(DNA ladder). The gel tank was closed and the power source switched on. The 
gel was run at 100V for about 60 minutes (until bromophenol blue tracking dye 
had run ¾ of the length of the gel). When the run was complete, the gel-tank was 
switched off and unplugged and the gel was carried in a holder to the dark-room 
to view on a long wave UV transilluminator.  
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Agarose gel electrophoresis is a rapid technique used to identify, quantify and 
purify nucleic acids based on their differential separation according to their size 
and charge when an electric current is passed through them. Separation is 
based on the principle that DNA molecules are negatively charged in a neutral to 
basic solution (1X TAE buffer solution) due to dissociation of the phosphate 
backbone. During electrophoresis they migrate towards the positively charged 
electrode. The electrophoretic mobility of DNA molecules depends on the 
voltage and the composition of the electrophoresis buffer. Small DNA fragments 
migrate more rapidly in the gel matrix compared to large fragments, resulting in 
molecule separation based on size. After running the gel, the DNA fragments 
can be seen with a UV light due to the Ethidium bromide dye in the gel. Ethidium 
bromide dye adheres to the DNA in the gel and fluoresces when viewed under a 
UV light and can be photographed. Before a DNA sample is loaded onto a gel, it 
is mixed with an appropriate loading buffer or loading dye solution which 
contains Glycerol (to ensure that the sample easily sinks into the well), EDTA 
(which binds divalent metal ions that may interfere with electrophoresis and also 
stops metal-dependent enzymatic reactions such as DNA degradation by 
nucleases) and tracking dyes (such as bromophenol blue) to monitor the 
progress of electrophoresis by the migration of the dyes.  
 
The principle of agarose gel electrophoresis is that DNA fragments are 
separated according to their weight by using electricity. DNA has a sugar 
backbone that is negatively charged in a neutral to basic solution, the 
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buffer solution, which is 1X TBE. After running the gel the fragments can be seen 
with a UV light. The reason fragments can be seen with UV light is due to the 
Ethidium bromide dye that has been added to the gel. This dye will adhere to the 
DNA in the gel and when the gel is finished it can be viewed under a UV light 
and can be photographed.  
 
To help detect the presence of an expected DNA molecule/fragment and to 
estimate its size, a molecular weight marker (DNA ladder) is used as a reference 
and is added to specific wells (usually lane 1 and lane 10) in each gel 
electrophoresis run. A DNA ladder is a solution containing DNA 
molecules/fragments of different lengths. A 1kb DNA ladder was used in the 
present study. The 1 kb DNA Ladder contains discrete DNA fragments ranging 
from about 300 base pairs (bp) to 10,000 bp. 
 
2.8.0 T cell proliferation studies 
2.8.1 MDDC-induced T cell Proliferation 
Stimulated MDDCs were co-cultured with allogeneic CD3+ lymphocytes and the 
WST-1 cell proliferation assay (Roche Diagnostics Ltd., West Sussex, UK) was 
used to measure T cell proliferation. The Roche WST-1 cell proliferation reagent 
is a colorimetric assay designed to measure the relative proliferation rates of 
cells in culture. The assay principle is based on the cleavage of the stable 
tetrazolium salt WST-1 into a coloured formazan dye by mitochondrial 
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dehydrogenase enzymes which are present in viable cells. The amount of 
formazan dye formed directly correlates to the number of metabolically active 
cells in the culture. 
 
Briefly, prior to co-culturing stimulated MDDCs with CD3+ T lymphocytes, 
1.44x106 cells/well day-5-MDDC were stimulated for 48 hours in 12- well cell 
culture plates with one of the following: Complete RPMI 1640 culture medium 
only (RPMI 1640 culture medium containing 10% heat-inactivated FCS, 2mM L-
glutamine and 1% Penicillin-Streptomycin) (negative control) or complete RPMI 
1640 supplemented with one of the following: IL-1F8 100ng/ml, IL-1F8 500ng/ml, 
IL-ȕQJPO,/-ȕQJPO/36QJPORU/36QJPO
(Lipopolysaccharides from Escherichia coli 0127:B8, Sigma-Aldrich, Poole, 
Dorset, UK). Cultures were performed in duplicate. Incubation was performed at 
37oC and 5% CO2. At the end of the culture period, cells were harvested and 
checked for viability and maturity prior to further culture with CD3+ T cells. 
 
The stimulated, mature MDDCs (or unstimulated negative controls) were then 
plated at a concentration of 6x104 cells/well stimulated and co-cultured with 
6x105 cells/well CD3+ T cells (isolated from a different donor buffy coat using 
CD3+ microbeads as already described) in 1ml of complete RPMI 1640 medium 
for 96 hours in 24-well culture plates at 37oC and 5% CO2. This gave an MDDC 
(stimulator cells): CD3+ T cell (responder cells) ratio of 1:10 per well. As a  
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positive control, CD3+ T cells were also cultured with the positive control, 
Concanavalin A (Con A) (75 µg/ml) (Sigma-Aldrich, Poole, UK) in separate wells. 
Con A is a plant mitogen known for its ability to induce T cell proliferation in vitro. 
All cultures were performed in triplicate and repeated on three separate 
occasions.  After 96 hour incubation as described above, MDDC/T cell and Con 
A/T cell cultures were harvested. Supernatants were collected and frozen for 
cytokine analysis. Remaining MDDC/T cell suspensions were then treated as 
follows: 100µl cell suspension was aliquoted onto appropriate well on a 96 well 
plate, 10 µl cell proliferation reagent WST-1 was added to each well and the 
mixture was incubated in a humidified chamber at 37oC and 5% CO2 for 1½ 
hours. After the incubation period, the formazan dye formed (following cleavage 
of the stable tetrazolium salt WST-1 by mitochondrial dehydrogenase enzymes 
present in viable cells) was quantified by measuring absorbance at 450 nm on a 
Labtech LT-4000 ELISA Plate Reader. The measured absorbance (against a 
background/blank control) directly correlated to the number of viable cells in 
each well. All samples were cultured in triplicate and repeated on three separate 
occasions. The mean absorbance of each co-culture was divided by the mean 
absorbance of the unstimulated negative control and expressed as a proliferation 
ratio. 
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2.8.2 pDC-induced T cell proliferation 
To assess the effect of IL-1F8-matured pDCs on T cell proliferation, pDCs 
isolated from peripheral blood using the Diamond Plasmacytoid Dendritic Cell 
Isolation Kit as previously described were plated at a density of 1.16 x 105 
cells/well on 6 well plates and cultured for 24 hours in complete RPMI 1640 
medium supplemented with one of the following: IL-1F8 (500 ng/mL), E. coli 
0127:B8 LPS (100 ng/mL) or imiquimod (50 µg/mL). After 24 hours, cells were 
harvested and checked for viability and maturity prior to further culture with CD3 
+ T cells. To measure the effect of stimulated pDCs on T cell proliferation, the 
WST-FHOOSUROLIHUDWLRQDVVD\ZDVSHUIRUPHGDFFRUGLQJWRWKHPDQXIDFWXUHU¶V
instructions. Briefly, 4x104 cells per well stimulated, pDCs were cultured with 
4x105 cells/well CD3+ T cells (isolated from a different donor buffy coat using 
CD3+ microbeads as previously described) in 1ml of complete RPMI 1640 
medium for 48 hours in 24-well culture plates and incubated at 37oC and 5% 
CO2. The ratio of stimulator cells (pDCs) to responder cells (CD3+ T cells) was 
1:10 per well. As a positive control, CD3+ T cells were also cultured with Con A 
(75 µg/ml) in separate wells.  At the end of the culture period, 100µl of each 
pDC/T cell suspension was aliquoted into appropriate wells on a sterile 96 well 
microtitre plate. 10 µl of Cell Proliferation reagent WST-1 was added to each well 
and the plate was incubated for 1½ hours at 37oC and 5% CO2. After gently 
shaking the plate, the absorbance of the samples at 450nm was measured 
against a blank control (containing culture medium and cell proliferation reagent 
only) using a Labtech LT-4000 ELISA Plate Reader. The measured absorbance  
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directly correlated to the number of viable cells in each well. All cultures were 
performed in triplicate and repeated on three separate occasions. The mean 
absorbance of each co-culture was divided by the mean absorbance of the 
unstimulated negative control and expressed as a proliferation ratio. 
 
2.9.0 Measurement of cytokine profiles: ELISA Techniques 
To assess whether stimulating MDDCs with IL-1F8 produced functionally mature 
DCs, immature day 5 MDDCs were plated in six well culture plates at a 
concentration of 4 x 105 cells/ml and stimulated for 48 hours with IL-1F8 
(50ng/ml, 200ng/ml, 400 ng/ml, or 500ng/ml), IL-ȕQJPORUE. coli 0127:B8 
LPS (500 ng/ml). Negative control cells were cultured in cytokine-free complete 
RPMI 1640 medium for the same period. At the end of the culture period, 
supernatants were collected from the wells and IL-12 p70 and IL-18 
concentrations were measured in the supernatant of stimulated or unstimulated 
DCs by specific enzyme-linked immunosorbent assay (ELISA) methods.  
 
ELISA was also used to measure the production of IFN-ĮE\,/-1F8 or IL-ȕ-
stimulated pDCs. In this study, pDCs were stimulated with IL-1F8 or IL-ȕ
ng/mL) prior to removal of supernatants after 48 h. As a positive control, cells 
were cultured in media containing imiquimod (50 µg/ml) (3 M Healthcare, 
Loughborough, UK) and, as a negative control, immature MDDCs were washed 
and cultured in media only for a further 48 h. To determine T-cell phenotypes 
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differentiated by IL-1-matured MDDCs, analysis of IL-10 and IFN-Ȗ
concentrations were performed using standard ELISA analyses in supernatants 
obtained after 96 h co-culture of MDDCs with CD3+ lymphocytes. 
 
2.9.1 IL-12p70 ELISA 
IL-SZDVPHDVXUHGXVLQJDVROLGSKDVHVDQGZLFK(/,6$%'2SW(,$IL-
12 (p70) human ELISA kit, BD Biosciences, UK) performed according to the 
manufacturers' instructions. The sensitivity of the IL-12 p70 ELISA was < 1 
SJPO7KH%'2SW(,$IL-12 (p70) test is a solid phase sandwich ELISA 
(Enzyme-Linked Immunosorbent Assay) which utilizes a monoclonal antibody 
specific for IL-12 (p70) coated on a 96-well plate. Standards and samples are 
added to the wells, and any IL-12 (p70) present binds to the immobilized 
antibody. The wells are washed and a mixture of biotinylated anti-human IL-12 
(p70) antibody and Streptavidin-horseradish peroxidase is added, producing an 
antibody-antigen-DQWLERG\³VDQGZLFK´7KHZHOOVDUHDJDLQZDVKHGDQGD
substrate solution is added, which produces a blue colour in direct proportion to 
the amount of IL-12 (p70) present in the initial sample. The Stop Solution 
changes the colour from blue to yellow, and the wells are read at 450 nm. 
 
Briefly, lyophilized recombinant human IL-12 (p70) was reconstituted and serially 
diluted to make IL-12 (p70) standard solutions with the following concentrations: 
500 pg/ml, 250 pg/ml, 125 pg/ml, 62.5 pg/ml, 31.3 pg/ml, 15.6 pg/ml and 7.8 
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SJPOȝOVWDQGDUGRUVDPSOHZDVDGGHGWRDQDSSURSULDWHZHOORQDZHOO
plate. Each well had been pre-coated with anti-human IL-12 (p70) monoclonal 
antibody by the manufacturer. The plate was covered with plate sealer and 
incubated for 2 hours at room temperature. Contents of wells were decanted and 
ZHOOVZDVKHGE\ILOOLQJZLWKDWOHDVWȝOZHOOZDVKEXIIHUDQGWKHQGHFDQWLQJ
This washing procedure was repeated 4 times to make a total of 5 washes. After 
the last wash, the plate was blotted on absorbent paper to remove any residual 
EXIIHUEHIRUHDGGLQJȝO:RUNLQJ'HWHFWRUFRQWDLQLQJELRWLQ\ODWHGDQWL-human 
IL-12 (p70) monoclonal antibody and Streptavidin-horseradish peroxidase 
conjugate with Bovine Serum Albumin) to each well. Wells were covered with 
Plate Sealer and incubated for 1 hour at room temperature. This was followed by 
decanting contents of wells and washing as already described but with a total of 
7 WKRURXJKZDVKHVȝORI6XEVWUDWH6ROXWLRQFRQWDLQLQJK\GURJHQSHUR[LGH
in buffered solution and tetramethylbenzidine (TMB) in organic solvent) was 
added to each well and the plate was incubated without Plate Sealer for 30 
minutes at room temperature LQWKHGDUN$IWHUDGGLQJȝORI6WRS6ROXWLRQ
(containing 1M phosphoric acid) to each well the absorbance was read on a 
Labtech LT-4000 ELISA Plate Reader at 450 nm within 30 minutes of stopping 
the reaction on a Labtech LT-4000 ELISA Plate Reader (with Manta Data 
analysis software) (Labtech International Ltd, East Sussex, UK) . To eliminate 
background absorbance, the absorbance of the blank control (sample containing 
ELISA diluent only and no target antigen) was subtracted from that of the 
standards and samples. A standard curve was computer generated from the 
absorbance values of the IL-12p70 standards. A standard curve was done for 
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each assay run. Using computer-aided linear regression analysis, the 
concentration of IL-12p70 in test samples was automatically calculated and 
displayed by the Labtech LT-4000 ELISA Plate Reader. Figure 2.14 shows a 
typical standard curve for the BD OptEIA Human IL-12 (p70) ELISA. 
 
 
 
 
Figure 2.8 IL-12p70 Standard Curve (ELISA). A representative standard curve 
for the BD OptEIA Human IL-12 (p70) ELISA.  
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2.9.2 IL-18 ELISA 
IL-18 was measured using the Human IL-18 sandwich ELISA kit (R & D 
Systems, Abington, UK) according to the manufacturers' instructions. The 
sensitivity of the IL-18 ELISA was < 1 pg/ml. The Human IL-18 ELISA Kit 
measures human IL-18 by sandwich ELISA. The assay uses two monoclonal 
antibodies against two different epitopes of human IL- 18. In the wells coated 
with anti-human IL-18 monoclonal antibody, samples to be measured or 
standards are incubated. After washing, a peroxidase-conjugated anti-human IL-
18 monoclonal antibody is added into the microwell and incubated. After another 
washing, the peroxidase substrate is mixed with the chromogen and allowed to 
incubate for an additional period of time. An acid solution is then added to each 
well to terminate the enzyme reaction and to stabilize the developed colour. The 
optical density (O.D.) (absorbance) of each well is measured at 450 nm using a 
microplate reader. The concentration of human IL-18 is calibrated from a dose 
response curve based on reference standards. To eliminate background 
absorbance, the absorbance of the blank control was subtracted from that of the 
standards and samples. Using computer-aided linear regression analysis (Manta 
Data analysis software) (Labtech International Ltd, East Sussex, UK), the 
concentration of IL-18 in test samples was automatically calculated from the 
standard curve and displayed by the Labtech LT-4000 ELISA Plate Reader. 
 
2.9.3 Interferon (IFN)-Į(/,6$ 
IFN-Į concentration was measured in the supernatant of stimulated or 
unstimulated pDCs using a sandwich ELISA immunoassay (VeriKineTM Human 
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IFN-ĮELISA Kit, supplied by R & D Systems, Abington, UK) performed 
according to the manufacturers' instructions. The VeriKineTM Human IFN-Į
ELISA kit uses the sandwich immunoassay technique for the quantitative 
measurement of IFN-ĮLQPHGLD$VEHIRUHWKHFRQFHQWUDWLRQRIKXPDQIFN-ĮLQ
test samples was automatically calculated from a dose response curve 
(absorbance versus concentration) based on reference standards. To eliminate 
background absorbance, the absorbance of the blank control was subtracted 
from that of the standards and samples. The concentration of IFN-ĮLQWHVW
samples was automatically calculated and displayed by the Labtech LT-4000 
ELISA Plate Reader software. 
 
2.9.4 IFN-Ȗ(/,6$ 
IFN-Ȗ(/,6$ZDVSHUIRUPHGXVLQJWKH%'2SW(,$ Human IFN-Ȗ(/,6$.LW,,
%'%LRVFLHQFHV2[IRUG8.DVSHUPDQXIDFWXUHU¶VLQVWUXFWLRQV7KH%'
OptEIA Human IFN-Ȗ(/,6$LVDVolid phase sandwich ELISA which utilizes a 
monoclonal antibody specific for IFN-ȖFRDWHGRQD-well plate. Standards and 
samples are added to the wells, and any IFN-ȖSUHVHQWELQGVWRWKHLPPRELOL]HG
antibody. The wells are washed and Streptavidin-horseradish peroxidase 
conjugate mixed with biotinylated anti-human IFN-ȖDQWLERG\LVDGGHGSURGXFLQJ
an antibody-antigen-DQWLERG\³VDQGZLFK´7KHZHOOVDUHDJDLQZDVKHGDQG70%
substrate solution is added, which produces a blue colour whose intensity is 
directly proportional to the amount of IFN-ȖSUHVHQWLQWKHLQLWLDOVDPSOH7KH
Stop Solution changes the colour from blue to yellow, and the microwell  
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absorbances are read at 450 nm. The concentration of human IFN-Ȗin test 
samples was automatically calculated from a dose response curve (absorbance 
versus concentration) based on reference standards. To eliminate background 
absorbance, the absorbance of the blank control was subtracted from that of the 
standards and samples. The concentration of IFN-Ȗin test samples was 
automatically calculated and displayed by the Labtech LT-4000 ELISA Plate 
Reader software. 
 
2.9.5 IL-10 ELISA 
IL-10 levels in supernatants from the MDDC/CD3+ T cell co-cultures were 
PHDVXUHGXVLQJWKH%'2SW(,$+XPDQ,/-10 ELISA Kit II (BD Biosciences, 
2[IRUG8.DFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV7KH%'2SW(,$
Human IL-10 ELISA is a solid phase sandwich ELISA which utilizes a 
monoclonal antibody specific for IL-10 coated on a 96-well plate. Standards and 
samples are added to the wells, and any IL-10 present binds to the immobilized 
antibody. The wells are washed and streptavidin-horseradish peroxidase 
conjugate mixed with biotinylated anti-human IL-10 antibody is added, producing 
an antibody-antigen-DQWLERG\³VDQGZLFK´7KHZHOOs are washed again and TMB 
substrate solution is added, which produces a blue colour whose intensity is 
directly proportional to the amount of IL-10 present in the initial sample. The Stop 
Solution changes the colour from blue to yellow, and the microwell absorbances 
are read at 450 nm. As previously explained, the concentration of human IL-10 in 
test samples was automatically calculated from a dose response curve 
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(absorbance versus concentration) based on reference standards. To eliminate 
background absorbance, the absorbance of the blank control was subtracted 
from that of the standards and samples. The concentration of IL-10 in test 
samples was automatically calculated and displayed by the Labtech LT-4000 
ELISA Plate Reader software. 
 
2.10 Statistical Analysis 
The Roche LightCycler® 480 Relative Quantification Software was used to 
calculate relative and calibrator-normalized expression ratios using an 
automated mathematical computation devised by Pfaffl (Pfaffl, 2001; 2002; 
2004) and to display these as the mean of performed replicates. The Roche 
LightCycler® 480 Relative Quantification Software also calculated all means, 
standard deviation of means, medians and standard deviations of crossing 
points (CPs) and target/reference ratios. Data are expressed as mean ± 
standard deviation. Each value is the mean of at least three independent 
experiments with each analysis being performed in triplicate (or in duplicate in 
some cases). An analysis of variance (ANOVA) test with a one-way classification 
was used to calculate significant differences between test and control samples 
following cytokine ELISA analyses and the difference between the number of 
cells, within total cell populations, expressing CD1a or HLA-DR following 
stimulation with IL-1 cytokines and IFN-Ȗ$SYDOXHRI< 0.05 was considered 
VWDWLVWLFDOO\VLJQLILFDQW7XNH\¶VWHVWZDVXVHGSRVWKRFWRGHWHUPLQHVLJQLILFDQFH
between individual means. Minitab software was used for all statistical analyses. 
 
154 
CHAPTER 3: IL-1RRP2 EXPRESSION AND BIOLOGICAL 
RESPONSE IN HUMAN MYELOMONOCYTIC CELLS 
 
3.1 Introduction 
Typically, IL-ȕDVZHOODV,/-ĮH[HUWVLWVHIIHFWVRQWDUJHWFHOOVE\ELQGLQJWR
the type 1 interleukin-1 receptor (IL-1R1) to form a complex. This binding leads 
to recruitment of the signal-transducing IL-1R accessory protein (IL-1RAcP) to 
the complex which in turn results in the activation of intracellular nuclear factor 
kappa B (NF-ț%DQGPLWRJHQ-activated protein kinase (MAPK) signalling 
pathways. The end result is the transcription of host defence effector genes in 
target cells; including the production of numerous cytokines, chemokines, 
adhesion molecules, and enzymes such as cyclooxygenase and nitric oxide 
synthase (Barnes and Karin, 1997; Didierlaurent et al., 2006). The type 2 IL-1 
receptor (IL-1R2) acts as a decoy receptor for IL-ĮDQG,/-ȕDQGWKXV
suppresses IL-1 biological activities (Dinarello, 1991; Colotta et al., 1993; 
reviewed in Colotta et al., 1994; Lang et al., 1998; Neumann et al., 2000; 
reviewed in Dinarello, 2009). As previously mentioned, the activities of IL-ĮDQG
IL-ȕDUHDOVRQDWXUDOO\GRZQ-regulated by IL-1 receptor antagonist (IL-1Ra) 
(Hannum et al., 1990; Dipps et al., 1991; Smith et al., 2000; reviewed in Arend, 
2002; Sims, 2002; Dumont, 2006).   
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It has been shown that novel IL-1 cytokines do not signal via the classic IL-1R1 
receptor (Busfield et al., 2000; Debets et al., 2001; Lin et al., 2001; Pan et al., 
2001; Towne et al., 2004). IL-1F6, IL-1F8 and IL-1F9 have been shown to signal 
via a receptor complex comprising IL-1Rrp2 and IL-1RAcP (Debets et al., 2001; 
Towne et al., 2004). Thus, IL-1Rrp2 expression is central to the functioning of 
these novel IL-1 family members. 
 
Prior to the current project, there was no available data showing expression of 
IL-1Rrp2 by human myeloid immune cells. Lovenberg et al. (1996) reported that 
IL-1Rrp2 is highly expressed in rat meninges, choroid plexus and cerebral 
cortex. IL-1Rrp2 expression has also been observed in several human cell lines 
(Towne et al., 2004). The highest IL-1Rrp2 expression in humans has been 
observed in skin while lower levels were found in prostate, ovary, thyroid, uterus, 
liver, kidney, lung, and trachea. IL-1Rrp2 is either not present or is expressed at 
very low levels in human testis, heart, spleen, and small intestine (Towne et al., 
2004). Human synovial fibroblasts and human articular chondrocytes express IL-
1Rrp2 and produce inflammatory mediators in response to stimulation by IL-1F8 
(Magne et al., 2006). This suggests that IL-1Rrp2 expression may play an 
important role in some human diseases. 
 
Indeed, Blumberg et al. (2007) reported that expression of IL-1Rrp2, IL-1F5 and 
IL-1F6 is increased in human psoriatic skin. More recently, a follow-up study 
showed that treatment with anti-IL-1Rrp2 antibody reduced the epidermal 
hyperplasia and other skin changes associated with psoriasis in mice (Blumberg 
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et al., 2010), suggesting that agents which block signalling through IL-1Rrp2 
could be useful therapeutic tools for psoriatic conditions and related skin 
pathologies. 
 
Classical IL-1 family members (IL-Į,/-ȕ,/-18 and IL-1Ra) are essential for 
the complete functioning of all human myeloid immune cells. Not only are they 
mostly synthesized by myelomonocytic cells (monocytes, macrophages and 
DCs); they also regulate these and other immune cells (Dinarello, 1996; 
Dinarello, 1997). Typically, classical IL-1 cytokines (e.g. IL-ȕVWLPXODWH
maturation of DCs; a critical event in the induction of adaptive immunity. 
Immature DCs in peripheral tissue mature as they migrate to draining lymph 
nodes following stimulation by pathogens, pathogen-associated molecules or 
cytokines (reviewed in Mellman et al., 1998). Many studies have shown that IL-
ȕ,/-1F2) acts as a potent maturation signal for DCs (Banchereau and 
Steinman, 1998; Nakahara et al., 2005; Guo et al., 2003; Wesa and Galy, 2002), 
however, there is no published data on the expression of IL-1Rrp2 by human 
myelomonocytic cells or the effect of novel IL-1 cytokines, which act via this 
receptor, on the function of these cells. 
 
The specific aim of the work outlined in this chapter was to investigate IL- 
1Rrp2 expression by human myelomonocytic immune cells and to determine 
whether IL-1F8 and/or IL-1F9 function as maturation signals for these cells. 
THP-1 cells were used as a negative control in all qRT-PCR experiments 
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investigating IL-1Rrp2 mRNA expression in this study (Chapters 3 and 4). The 
decision to use THP-1 cells as a negative control for IL-1Rrp2 expression was 
based on published reports which stated absence of IL-1Rrp2 expression in 
THP-1 cells (Magne et al., 2006. Our own preliminary studies also confirmed 
these findings. However, there was a need to confirm that THP-1 cells used in 
this study were fully functional. Prior to using THP-1 cells as negative controls for 
IL-1Rrp2 expression in qRT-PCR experiments, their functional status was tested 
using an established system; measuring TNF-ĮP51$H[SUHVVLRQE\7+3-1 
cells in response to bacterial (E. coli 0127:B8 LPS) stimulation (Essner et al, 
1990; Agarwal et al., 1995; Asakura et al., 1996; Dedrick and Conlon, 1995; 
Jones et al., 2003; Foster et al., 2005; Lackman and Cresswell, 2006). Results of 
that preliminary test are shown in Appendix 1 of this thesis. 
 
3.2 Results 
 
3.2.1 Expression of IL-1Rrp2 mRNA in human myelomonocytic cells 
Quantitative Real-Time PCR (qRT-PCR) analysis was performed on human 
promonocytes (THP-1 cells), peripheral blood monocytes (PBM), monocyte-
derived macrophages (MDM), monocyte-derived dendritic cells (MDDCs) and 
peripheral blood dendritic cell subsets to assess expression of IL-1Rrp2 mRNA. 
Cells were isolated, cultured and harvested as previously stated (Chapter 2). 
RNA was extracted and quantified prior to cDNA synthesis as previously 
described. Quantitative RT-PCR for the IL-1Rrp2 gene and GAPDH gene 
(control) was then performed as stated in Chapter 2 (Sections 2.7.0-2.75). 
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Confirmation of the qRT-PCR product was made by gel electrophoresis (2% 
agarose) (Section 2.7.6) which showed presence of the expected IL-1Rrp2 RT-
PCR product (Figure 3.1). 
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Figure 3.1 Representative agarose gel electrophoresis results confirming 
IL-1Rrp2 gene expression in MDDC. Results show presence of expected IL-
1Rrp2 PCR product. 
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3.2.2 Human MDDCs express IL-1Rrp2 mRNA 
 
qRT-PCR analysis showed that IL-1Rrp2 mRNA is expressed by human 
monocyte-derived dendritic cells (MDDCs) but not by promonocytes (THP-1 
cells), peripheral blood monocytes or monocyte-derived macrophages (MDMs) 
(Figure 3.2). MDMs only express IL-1Rrp2 if IL-4 (10ng/ml) is added to the 
culture and incubated for 48 hours prior to analysis. An infinite increase in IL-
1Rrp2 mRNA expression (relative to GAPDH) was observed in MDDCs 
generated by culturing peripheral blood monocytes with GM-CSF (50ng/ml) and 
IL-4 (10ng/ml) for 5 or 7 days. Similar results were also obtained when 5-day old 
monocyte derived macrophages (MDMs) were stimulated with IL-4 (10ng/ml) for 
48 hours (Figure 3.2). The morphological appearance of a good number of the 
IL-4-stimulated MDMs resembled that of MDDCs (Figure 3.3). 
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Figure 3.2 IL-1Rrp2 mRNA expression in THP-1 cells, PBM, MDM and 
MDDCs. Graph shows IL-1Rrp2 mRNA expression (qRT-PCR) in human 
promonocytic cells (THP-1), peripheral blood monocytes (PBM), monocyte 
derived macrophages (MDM) and monocyte-derived dendritic cells (MDDC). 
IL1Rrp2 is expressed by human MDDCs but is not expressed by promonocytes, 
peripheral blood monocytes or monocyte-derived macrophages. MDMs only 
express IL-1Rrp2 following incubation with IL-4 (10ng/ml) for an extra 48 hours 
prior to analysis. Bar chart shows mean data from at least three independent 
experiments. Error bars show standard deviation (1SD) from the mean.  
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Figure 3.3 Morphology of monocyte derived macrophages following 
culture with IL-4 for 48 hours. Phase contrast microscopy image (original 
magnification x 400) showing the morphology of monocyte derived macrophages 
following culture with IL-4 for 48 hours. The majority of cells show typical 
dendritic cell morphology (presence of dendrites as shown by the red arrows). 
Scale bar represents 20 µm. 
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3.2.3 IL-4 dose-dependently increases MDDC differentiation and IL-1Rrp2 
expression 
 
When populations of peripheral blood monocytes (PBM) were cultured for 5 days 
with GM-CSF (50ng/ml) and variable concentrations of IL-4 (1, 10 or 50 ng/ml), 
lowest IL-1Rrp2 mRNA expression was measured in PBM cultures containing 
1ng/ml IL-4 while highest IL-1Rrp2 mRNA expression was obtained in cultures 
containing 50 ng/ml (Figure 3.4). These results indicate that IL-4 increases IL-
1Rrp2 expression in a dose-dependent manner. However, increase in IL-4 
concentration (and concurrent increase in IL-1Rrp2 expression) was consistent 
with increased numbers of MDDCs in these cultures, ascertained by 
morphological analysis (Figures 3.5 and 3.6).      
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Figure 3.4 IL-4 dose-dependently increases MDDC differentiation and IL-
1Rrp2 expression. qRT-PCR analysis of IL-1Rrp2 mRNA expression in HT29 
cells (calibrator), peripheral blood monocytes (PBM) and MDDCs co-cultured in 
the absence/presence of the indicated concentrations of IL-4. Results show that 
IL-4 dose-dependently increases MDDC differentiation and IL-1Rrp2 expression. 
Data shown are means of experimental data obtained on five separate 
occasions. Error bars show mean ± SD of each mean. 
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20 µm 
 
 
Figure 3.5 Peripheral blood monocytes following 5 day culture with GM-
CSF and IL-4. Phase contrast microscopy image (original magnification x400) of 
peripheral blood monocytes cultured with GM-CSF (50ng/ml) and IL-4 (1 ng/ml) 
for 5 days. Image shows presence of monocyte derived macrophages (blue 
arrows), MDDCs with visible dendrites (red arrows) and undifferentiated 
peripheral blood monocytes (black arrows). Image is representative of at least 
three independent experiments with similar results. Scale bar represents 20 µm. 
 
   
 
 
166 
  
20 µm 
 
Figure 3.6 Light microscopy MDDC morphology. MDDCs with typical 
observable dendrites (shown by red arrow) were observed using a Leica DM IL 
LED (Leica Microsystems, (UK)) inverted microscope (400x magnification) when 
peripheral blood monocytes were cultured with GM-CSF and 10 ng/ml IL-4 for 5 
days. There were more MDDCs with characteristic dendritic morphology than 
that observed when 1ng/ml IL-4 was used. Image is representative of at least 
three independent experiments with similar results. Scale bar represents 20 µm.  
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3.2.4 FACS analysis showing IL-1Rrp2 protein expression on the surface of 
MDDCs  
 
Having shown that MDDCs express IL-1Rrp2 mRNA, the presence of the IL-
1Rrp2 protein on the surface of MDDCs was confirmed by flow cytometry (FACS 
analysis) using standard methods as previously described in Chapter 2 (Section 
2.6.1.1). Briefly, 1x106 test cells per group were resuspended in FACS buffer 
(BSA (1% w/v); EDTA (2 mM)) and 100µl of the suspension was aliquoted into 
the appropriate number of tubes. Fc receptors on cells were blocked in FACS 
buffer containing human serum (10% v/v) for 15 min prior to incubation for 45 
minutes with either 10µg/ml mouse anti-human IL-1Rrp2 antibody (M145, Amgen 
Corporation, Seattle, WA) followed by incubation for 45 minutes with the 
detection/secondary antibody (10µg/ml allophycocyanin (APC)-conjugated goat 
anti-mouse IgG (Biolegend, UK)) or incubation for 45 minutes with 10µg/ml APC-
conjugated goat anti-mouse IgG only (isotype/secondary antibody control cells). 
Cells were then analysed using a FACSCanto II analyser (Becton Dickinson, 
USA). SampleVZHUHDFTXLUHGXVLQJWKH%')$&6'LYDsoftware (BD 
Biosciences, USA) and analysed using the WinMDI 2.8 software. Cell viability 
ZDVDVVHVVHGE\SURSLGLXPLRGLGHXSWDNHȝJPl in PBS for 10 minutes).  
 
Surface expression of IL-1Rrp2 was not increased above that measured for 
isotype/secondary antibody control levels on the cell membranes of 
promonocytes, peripheral blood monocytes (PBMs) or monocyte-derived 
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macrophages (MDMs) (Figure 3.7). However, a progressive increase in IL-1Rrp2 
signal (starting from day 2) above that measured for the isotype control was 
observed (Figure 3.8) when MDDCs were generated by culturing PBMs with 
GM-CSF (50ng/ml) and IL-4 (10ng/ml) for five days. 
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Figure 3.7 Promonocytes, PBM and MDM do not express IL-1Rrp2. Typical 
FACS analysis histogram obtained when promonocytic THP-1 cells, peripheral 
blood monocytes and monocyte-derived macrophages (represented by test 
sample in histogram above) were stained with either 10µg/ml mouse anti-human 
IL-1Rrp2 antibody (M145, Amgen Corporation, Seattle, WA) plus 10µg/ml 
allophycocyanin (APC)-conjugated goat anti-mouse IgG or with 10µg/ml APC-
conjugated goat anti-mouse IgG only (isotype control). The histogram shows that 
promonocytic THP-1 cells, peripheral blood monocytes or monocyte-derived 
macrophages do not express IL-1Rrp2 on the cell surface. Histogram is 
representative of at least three independent experiments with similar results. 
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 Figure 3.8 MDDCs express IL-1Rrp2 on the cell surface (FACS analysis). 
Typical FACS analysis histogram showing that monocyte derived dendritic cells 
(MDDCs) express IL-1Rrp2 on the cell surface. Cells were stained with either 
10µg/ml mouse anti-human IL-1Rrp2 antibody (M145, Amgen Corporation, 
Seattle, WA) plus 10µg/ml allophycocyanin (APC)-conjugated goat anti-mouse 
IgG or with 10µg/ml APC-conjugated goat anti-mouse IgG only (isotype control). 
Histogram is representative of at least three independent experiments with 
similar results. 
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IL-1Rrp2 fluorescence intensity: APC 
3.2.5 Expression of IL-1Rrp2 protein in MDDCs (Fluorescence microscopy) 
 
Fluorescence microscopy was used to further ascertain expression (and 
location) of the IL-1Rrp2 protein in MDDCs. MDDCs were cultured as described 
previously (Chapter 2). Cultured cells were harvested and processed for 
fluorescence microscopy as previously described (Section 2.6.2). Briefly, 
cytospin preparations were made from MDDC cell suspensions and the cells 
were stained for fluorescence microscopy using a monoclonal primary antibody 
specific for IL-1Rrp2 (M145, Amgen Corporation, Seattle, WA) followed by 
staining with a secondary detection antibody (FITC-conjugated Goat anti-mouse 
IgG). Cells were counterstained with DAPI nuclear stain prior to being analysed 
using a Leica fluorescence microscope (Leica Microsystems, UK) as described 
in Section 2.6.2. The images are shown below. Images are representative of at 
least three independent experiments.  
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MDDC sample: 
A        B      C 
           
 
Negative (secondary antibody only) control: 
D     E     F  
           
 
DAPI Nuclear stain             Mouse anti-human IL-1Rrp2       Overlay image    
 (FITC-conjugated)  
Figure 3.9 MDDCs express IL-1Rrp2 (fluorescence microscopy). Images 
show that IL-1Rrp2 is localised to the cell membrane of human MDDCs following 
incubation with an IL-1Rrp2 mAb followed by staining with a FITC-conjugated 
secondary antibody and DAPI nuclear stain (images A-C). The negative control 
sample (D-F) was incubated with secondary antibody and DAPI only but not with 
the primary IL-1Rrp2 mAb. The overlay images are shown by C and F. Images 
are representative of five independent experiments with similar results. Scale bar 
represents 20 µm.    
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Compared with the negative control (images D-F), results confirm that human 
MDDCs (images A-C) express IL-1Rrp2 protein on the cell surface (Figure 3.9). 
The blue images (A and D) show nuclear staining with DAPI while images B and 
E show immuno-cytochemical localisation of IL-1Rrp2 protein (green-staining 
due to the FITC-labelled secondary antibody binding to the IL-1Rrp2 monoclonal 
antibody which is in turn bound to IL-1Rrp2 in the cells). Image C is an overlay 
image of A and B and shows localization of IL-1Rrp2 to both the cytoplasm and 
cell membrane of MDDCs. In contrast, image F, which is an overlay of images D 
and E respectively, shows no immunoreactivity occurring when MDDCs are 
incubated with secondary antibody only.  
     
3.2.6 Both IL-1F8 and IL-1F9 can induce MDDC maturation 
 
Immature 5-day-old MDDCs were plated at a density of 4 x 105 cells/ml on 6 well 
plates and cultured for 48 hours with 100ng/ml recombinant human IL-1F8 (rhIL-
1F8), 100ng/ml recombinant human IL-1F9 (rhIL-1F9) (Amgen Corporation, 
Seattle, WA) or with positive control (100ng/ml recombinant human IL-ȕUK,/-
1F2) (R & D Systems, UK) or 100ng/ml IFN-Ȗ1HJDWLYHFRQWUROFHOOVZHUH
cultured without IL-1 cytokines. The effect of IL-1 cytokines on MDDC maturation 
was assessed by FACS analysis and compared with relative isotype controls as 
explained in Section 2.6.1.3 and cells were gated as R1 (immature) and R2 
(mature) populations according to parameters set for immature MDDCs. The 
results are shown below (Figures 3.10).   
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Figure 3.10 IL-1F8 or IL-1F9 induces maturation of human MDDCs. IL-1F8 or 
IL-1F9 induces maturation of human MDDCs. Immature MDDCs (day 5) were 
cultured in media alone (A and B); Media plus IL-1F8 (100 ng/mL) (C); Media 
plus IL-1F9 (100 ng/mL) (D); Media plus IFN-ȖQJP/(RU0HGLDSOXV,/-
1F2 (100 ng/mL) (F) for 48 h and then stained with either (A) isotype control Abs 
or (B±F) mAbs for HLA-DR and CD1a. Boxed regions indicate the CD1ahigh HLA-
DRlow (R1) and the CD1alow HLA-DRhigh (R2) populations. Both R1 and R2 gates 
are identical in all plots and were set according to data obtained from the 
unstimulated MDDC population. (G) shows FACS histograms of CD83 
expression by MDDCs matured by culture with IL-1F8 or IL-1F9, relative to 
unstimulated MDDCs and isotype controls. Data are representative of at least 
three independent experiments. 
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MDDCs that had been cultured for 7 days without IL-1 cytokines 
(unstimulated/negative controls) contained on average 15% of cells in the R2 
population (CD1alow/HLA-DRhigh) which expressed increased HLA-DR and 
decreased CD1a compared with the R1 (immature) population (CD1ahigh/HLA-
DRmed) which on average was about 77% of the total cell population (Figure 
3.10B). However, incubation with IL-1F8 clearly separated MDDCs into two 
distinct populations with R1 containing 61% and R2 (mature population) 
containing 33% of the total cell population (Figure 3.10C). When MDDCs were 
cultured with IL-1F9 there was a greater horizontal spread of cells between R1 
and R2 and although CD1a expression was clearly reduced in a large number of 
these cells (׽50%) there was a less clear effect on HLA-DR expression, 
although a clear increase in HLA-DR was measured in cells with the lowest 
expression of CD1a within the R2 population (Figure 3.10D). Positive controls 
also induced maturation with a mean 28% of cells in the R2 population following 
IFN-ȖFXOWXUH)LJXUH(DQGDPHDQRIRIFHOOVLQWKH5SRSXODWLRQ
following IL-ȕ,/-1F2) culture (Figure 3.10F). CD83 expression was also 
increased following culture of immature MDDCs with IL-1F8 or IL-1F9, when 
compared with CD83 expression by unstimulated day 5 or day 7 MDDCs (Figure 
3.10G). The numbers of cells in R2 populations were statistically analysed 
following incubation with IFN-Ȗ,/-ȕRU,/-F8 and compared with unstimulated 
controls and the results are shown in the graph below (Figure 3.11).  
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Figure 3.11 IL-1F8 stimulates a significant increase in the number of 
mature (CD1alowHLA-DRhigh) MDDCs. The number of cells in the R1(CD1ahigh 
HLA-DRlow immature) and R2 (CD1alowHLA-DRhigh mature) populations 
generated after culture of immature MDDCs (day 5) stimulated with IFN-Ȗ,/-ȕ
(IL-1F2) and IL-1F8 for 48 h as determined by flow cytometry are shown. For 
comparison, R1 and R2 populations are also shown for immature MDDCs (day 
5) cultured for a further 48 h without cytokine (unstimulated control). *p < 
0.05=statistical increase in the number of cells in the mature (R2) population 
compared with the unstimulated (control) MDDC population. Data shown are 
mean± SD of at least three independent experiments with similar results. 
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IL-1F8, IFN-ȖRU,/-ȕVLJQLILFDQWO\LQFUHDVHGSWKHVL]HRIWKH5
population above that measured in unstimulated controls (Figure 3.11). 
However, due to the spread of cells across the R1 and R2 populations following 
IL-1F9 culture, we were unable to perform the same analysis for this cytokine. 
 
3.2.7 Regulation of IL-1Rrp2 mRNA expression in MDDCs stimulated with 
IL-1F8 or IL-ȕ 
 
In separate experiments, qRT-PCR was performed to investigate whether IL-
1Rrp2 mRNA expression is upregulated in MDDCs stimulated with rhIL-1F8, 
rhIL-ȕ or E. coli 0127:B8 LPS. Immature day 5 MDDCs generated from 
peripheral blood monocytes as previously described were plated at a density of 4 
x 105 cells/ml on 6 well plates and cultured for 48 hours with IL-1F8 (100ng/ml, 
200ng/ml or 500ng/ml), IL-ȕQJPORUQJPOE. coli 0127:B8 LPS 
(50ng/ml)(positive control). Negative control cells were left unstimulated and 
were cultured for a further 48 hours in cytokine-free medium. Cells were 
harvested and processed for qRT-PCR to assess IL-1Rrp2 mRNA expression as 
previously described (Chapter 2). The qRT-PCR results obtained are shown 
below (Figure 3.12).  
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Figure 3.12 Regulation of IL-1Rrp2 mRNA expression in MDDCs stimulated 
with IL-1F8. Quantitative RT-PCR results showing that IL-1Rrp2 mRNA 
expression is significantly upregulated (*p < 0.05 relative to unstimulated 
MDDCs) in immature day 5 MDDCs stimulated with 200ng/ml IL-1F8 in a 
comparable manner to the up-regulation caused by E. coli 0127:B8 LPS or IL-ȕ
Lower or much higher concentrations of IL-1F8 (100ng/ml or 500ng/ml) still 
induce an increase in IL-1Rrp2 expression but this increase is not statistically 
significant. Results shown are means ± SD of three independent experiments 
with similar results. Each analysis was performed in triplicate. 
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 Real time PCR results (Figure 3.12) show that there is no significant fold 
increase in IL-1Rrp2 mRNA expression above unstimulated day 7 MDDCs in 
MDDCs stimulated with 100ng/ml or 500ng/ml IL-1F8. When 200ng/ml IL-1F8 is 
used as a stimulant, there is a 10-fold increase in MDDCs IL-1Rrp2 expression 
relative to the unstimulated control and this increase is comparable to the up-
regulation in IL-1Rrp2 mRNA expression caused by E. coli 0127:B8 LPS (about 
13-fold). IL-ȕQJPORUQJPOLQGXFHWKHJUHDWHVWXS-regulation in IL-
1Rrp2 mRNA expression (more than 20-fold) compared to unstimulated MDDCs.       
 
 
3.2.8 Cytokine production by IL-1F8-stimulated MDDCs 
 
Functionally mature DCs are known to produce IL-18 (IL-1F4) and IL-12p70 in 
response to relevant stimuli (reviewed in Reis e Sousa, 2006). IL-12p70 is a 
critical cytokine required for TH1 polarization (reviewed in Hunter, 2005). TH cells 
are essential regulators of adaptive immune responses and inflammatory 
diseases. They have little or no cytotoxic or phagocytic activity but are involved 
in activating and directing other immune cells (reviewed in Mosmann and 
Coffman, 1989; reviewed in Romagnani, 1994). They also play a role in the 
induction of autoimmune and allergic diseases (Sutton et al., 2006). 
 
Up until 2005, the production of specific cytokines by antigen-presenting cells 
such as mature DCs was thought to direct the differentiation of naïve T cells to 
specific TH1 or TH2 subsets and the cytokine profile within the DC-T cell  
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microenvironment was believed to be a critical factor in determining the 
phenotype of the subsequent specific response (reviewed in Mosmann and 
Coffman, 1989; reviewed in Romagnani, 1994). Although the cytokine 
environment at the time of antigen encounter is a major element influencing TH 
cell differentiation, it is now apparent that TH cell polarisation is also influenced 
by the antigen type, antigen affinity to the T-cell receptor (TCR), type of available 
costimulatory molecules and by a sophisticated network of transcription factors 
(reviewed in Zhu and Paul, 2010).  
 
After activation by (TCR)-and cytokine-mediated signalling, naive CD4+ T cells 
may differentiate into various TH cells which influence different types of immune 
responses; TH1, TH2, TH17, inducible T-regulatory (iTreg) cells, TH9, TH22 as well 
as other functional subsets including memory T cells (Harrington et al., 2005; 
Sutton et al., 2006; reviewed in Zhu and Paul, 2008; reviewed in Locksley, 2009; 
reviewed in Zhu and Paul, 2010).  
 
Differentiated TH cell subsets secrete different cytokines that have autocrine and 
paracrine functions to engage other leucocytes including macrophages, mast 
cells, eosinophils, neutrophils, natural killer (NK) cells, and B cells. In addition, 
they can express different profiles of cell-surface molecules that determine their 
effector cell capacity. These include adhesion molecules and chemokine 
receptors that determine their capacity to home to and within lymphoid or 
peripheral tissues where offending target antigens may reside (reviewed in 
Romagnani, 1994; Sutton et al., 2006; reviewed in Zhu and Paul, 2008; reviewed 
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in Locksley, 2009; reviewed in Zhu and Paul, 2010).  Not only do different human 
TH cells secrete different cytokines, they also show different responsiveness to 
cytokines and also play different roles in host immune protection. In addition, 
they can also promote different immunopathological reactions (reviewed in 
Romagnani, 1994; Sutton et al., 2006; reviewed in Zhu and Paul, 2008; reviewed 
in Locksley, 2009; reviewed in Zhu and Paul, 2010). The development of TH cell 
subsets involves a complex cytokine network. More than one cytokine is 
generally required for differentiation to a particular phenotype. Furthermore, 
cytokines which promote differentiation to one lineage may suppress the 
development of other lineages (reviewed in Zhu and Paul, 2010). There is 
growing evidence suggesting the existence of plasticity in CD4+ TH cell lineage 
differentiation (reviewed in Locksley, 2009). 
 
TH1 cells mediate immune responses against intracellular pathogens and are 
responsible for both humoral and cell-mediated immune responses. They 
typically secrete interferon-gamma (IFN-Ȗ,/-2 and tumor necrosis factor (TNF)-
ȕF\WRNLQHVZKLFKDUHXVXDOO\DVVRFLDWHGZLWKLQIODPPDWLRQ7KHGHYHORSPHQWRI
TH1 cells is favoured by the presence of IFN-Ȗ,)1-Į7*)-ȕDQG,/- 12 
 (reviewed in Romagnani, 1994; Stobie et al., 2000). IL-12 plays a crucial role in 
both the induction and sustenance of a primary TH1 response in vivo (Stobie et 
al., 2000), however, its absence does not automatically induce TH2 polarisation 
(Jankovic et al., 2002). Most DC populations are able to produce IL-12 in 
response to activation by various stimuli, such as infection with pathogens or 
exposure to their products. CD40 ligation is also considered to be a major 
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inducer of IL-12 production) (Cella, 1996; Stobie et al., 2000).  IFN-ȖDQG,/-4 are 
potent enhancers of the production of IL-12p70 (the bioactive form of IL-12) 
.DOLĔVNLet al., .DOLĔVNLet al., 2000) while IL-10 and other factors suppress 
IL-SURGXFWLRQE\'&V.DOLĔVNLet al., 1998; .DOLĔVNLet al., 2000; Ebner et al., 
2001). 
 
IL-12 is now understood to be a family of cytokines made up of IL-12, IL-23, IL-
27 and IL-35. Each member is a heterodimeric complex consisting of two 
subunits whose expression is regulated independently. The biologically active 
form of the original IL-12 family member, IL-12 (or IL-12p70) is a covalently 
linked heterodimer composed of a light chain (IL-12p35) and a heavy chain (IL-
12p40). On their own, the IL-12p70 subunits do not possess IL-12 bioactivity; 
however, studies have shown that homodimers and monomers of the p40 
subunit (IL-12p40) may act as IL-12p70 antagonists. The IL-12 receptor 
encompasses IL-5ȕDQG,/-5ȕERWKRIZKLFKKDYHKRPRORJ\WR
glycoprotein (gp) 130 (Langrish et al., 2005; reviewed in Hunter, 2005; Sutton et 
al., 2006; reviewed in Gabay and McInnes, 2009). 
 
  
The IL-23 heterodimer consists of the IL-12p40 component of IL-12 and the IL-
23p19 component, which is homologous to IL-12p35. The receptor for IL-23 is 
formed by the association of IL-5ȕDQG,/-23R. IL-27 is a heterodimeric 
cytokine consisting of Epstein-Barr virus-induced gene 3 (EBI3) and IL-27p28, 
which are related to IL-12p40 and IL-12p35, respectively. It binds a receptor 
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composed of gp130 and WSX1 (Langrish et al., 2005; reviewed in Hunter, 2005; 
Sutton et al., 2006). The last member of the IL-12 family, IL-35, is a heterodimer 
consisting of IL-12p35 and EBI3 (reviewed in Hunter, 2005; Sutton et al., 2006; 
reviewed in Gabay and McInnes, 2009).  
 
Through the induction of IFN gamma (IFN-ȖSURGXFWLRQIL-12 family members 
play critical roles in regulating the inflammatory response. Each member plays a 
role in mediating T cell-dependent immunity. IL-12 and IL-27 are involved in TH1 
differentiation which is essential for host defense and tumor suppression 
(Langrish et al., 2005). The functions of IL-35 are still to be elucidated; however, 
preliminary data from mouse studies suggest that it is primarily concerned with 
Treg effector function (reviewed in Gabay and McInnes, 2009). Although IL-12 (IL-
12p70) and IL-23 share a common IL-12p40 subunit, the two cytokines exert 
very different biological effects.  While IL-12 is essential for the differentiation of 
naive T cells into IFN-Ȗ±producing TH1 cells (and hence for antimicrobial 
responses and tumour suppression) as already highlighted, IL-23 promotes the 
differentiation, survival and expansion of TH17 CD4+ cells, a T cell population 
characterized by the production of IL-17, IL-17F, IL-21, IL-10, TNF, IL-6, IL-22 
and other cytokines (Langrish et al., 2005; Sutton et al., 2006). 
 
TH17 cells regulate both innate and adaptive immune responses. They are also 
known to play an inflammatory pathological role in organ-specific autoimmune 
diseases such as multiple sclerosis (MS) and rheumatoid arthritis (Langrish et 
al., 2005). Sutton et al. (2006) demonstrated that IL-ĮRU IL-ȕDFWVGLUHFWO\RQ 
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murine T cells in synergy with IL-23 to promote IL-17 secretion in the presence 
or absence of T cell receptor engagement. TNF-Į can also synergize with IL-23 
to induce IL-17, however, this is dependent on IL-1. Furthermore, in mice lacking 
the IL-1 type 1 receptor, IL-17 production and development of experimental 
autoimmune encephalomyelitis (EAE) is compromised, suggesting that IL-1 
signalling is crucial for TH17 cell differentiation (Sutton et al., 2006). It has since 
been shown that inter-regulation between TH17 cytokines and the novel IL-1 
family members, IL-1F6, IL-1F8 and IL-1F9 (IL-Į,/-ȕDQG,/-ȖLV
involved in driving cytokine expression in psoriatic tissues (Blumberg et al., 
2010; Carrier et al., 2011).  
 
IL-12 and IL-18 (also known as IL-1F4 and originally known as the interferon-
inducing factor) synergistically induce interferon-ȖSURGXFWLRQLQ7FHOOV,/-12 up-
regulates expression of the IL-18 receptor on interferon-Ȗ-producing T cells. 
Although IL-18 does not induce the development of TH1 cells, it is vital for the 
effective induction and activation of TH1 cells by IL-12 (reviewed in Okamura et 
al., 1998; Sabatté et al., 2007). Depending on the surrounding cytokines, IL-18 
can induce both TH1 and/or TH2 responses. In addition to enhancing IL-12-driven 
TH1 immune responses, IL-18 can also stimulate TH2 immune responses in the 
absence of IL-12 (reviewed in Nakanishi et al., 2001). 
 
In humans, TH2 cells provide optimum support for humoral immune responses 
through the production of cytokines which help B cells to proliferate and 
differentiate.  TH2 cells typically secrete IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-25, 
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amphiregulin and low to negligible amounts of IFN-ȖUHYLHZHGLQ=KXDQG3DXO
2008). IFN-ȖLVWKRXJKWWRKDYHDVHOHFWLYHLQKLELWRU\HIIHFWRQWKHSUROLIHUDWLYH
response of TH2 cells. The overriding factor in determining the likelihood for TH2 
polarization in cultured cells appears to be IL-4. Although both TH1 and TH2 cells 
proliferate in response to IL-2, TH2 cells are much more responsive to IL-4 than 
TH1 cells (reviewed in Romagnani, 1994).   
 
To assess whether stimulating MDDCs with IL-1F8 produced functionally mature 
DCs, immature day 5 MDDCs were cultured (sections 2.9.0-2.9.2) at 4 x 105 
cells/ml and stimulated for 48 hours with IL-1F8 (50ng/ml, 200ng/ml, 400 ng/ml, 
or 500ng/ml), IL-ȕQJPORUE. coli 0127:B8 LPS (500 ng/ml). Control cells 
were cultured in cytokine-free complete RPMI 1640 medium for the same period. 
At the end of the culture period, supernatants were collected from the wells and 
IL-12 p70 and IL-18 concentrations were measured in the supernatant of 
stimulated or unstimulated DCs by specific ELISA methods as previously 
described (sections 2.9.1-2.9.2). Results are shown in Figures 3.13 and 3.14. 
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Figure 3.13 IL-1F8 induces IL-12p70 production in day 5 human MDDCs in a 
dose-dependent manner. An ELISA was done to quantify IL-12p70 levels in the 
supernatant of immature day 5 MDDCs which had been stimulated for 48 hours 
with IL-1F8 (50ng/ml, 200ng/ml, 400 ng/ml, or 500ng/ml), IL-ȕQJPORUE. 
coli 0127:B8 LPS (500 ng/ml). Control cells were cultured in cytokine-free 
complete RPMI 1640 medium only.  IL-1F8 induced significant IL-12p70 
production (*p < 0.05 compared with unstimulated control) at levels higher than 
200ng/ml and reached a plateau at around 400ng/ml. On the other hand, IL-ȕ
significantly induced IL-12p70 production at a concentration as low as 10 ng/ml 
Data shows mean ± SD of IL-12p70 levels obtained from three independent 
experiments. Each analysis was performed in duplicate. 
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Figure 3.14 IL-1F8 stimulates IL-18 production in human MDDCs. Graph 
shows IL-18 ELISA levels present in supernatants following 48 hour-culture of 
day 5 human MDDCs with IL-ȕQJPO,/-1F8 (100 ng/ml) or without 
cytokines.  *p < 0.05 = Statistical increase in the concentration of IL-18 in the 
supernatants of MDDCs stimulated with IL-ȕRU,/-1F8, compared with 
unstimulated controls. Data shown are means ± SD obtained from at least three 
independent experiments performed in triplicate. 
 
 
 
 
 
 
 
 
188 
 IL-1F8 induced significant IL-12p70 production at levels higher than 200ng/ml 
and reached a plateau at around 400ng/ml. On the other hand, IL-ȕVLJQLILFDQWO\
induced IL-12p70 production at a much lower concentration; 10 ng/ml (Figure 
3.13). Data obtained from the IL-18 (IL-1F4) ELISA analyses shows that IL-1F8 
(100 ng/ml) stimulated a very significant increase (p < 0.05) in IL-18 production 
and this was comparable with the effect of IL-ȕDWWKHVDPHFRQFHQWUDWLRQ
(Figure 3.14).    
 
 
3.2.9 Activation of allogeneic T lymphocytes by IL-1F8-matured MDDCs 
 
T-lymphocyte recognition and responsiveness to determinants expressed on 
genetically non-identical antigen-presenting cells can be studied in vitro by 
means of the allogeneic primary mixed lymphocyte reaction (MLR). Reactivity 
during a MLR indicates the T-cell proliferative response to differences in donor 
and recipient major histocompatibility complex (MHC) antigen expression 
(Bluman et al., 1996). 
 
Upon maturation with an appropriate stimulus, myeloid DCs upregulate surface 
markers (such as CD40, CD80, CD86) and migration markers such as CCR7, 
and can efficiently prime naive T cells (reviewed in Banchereau et al., 2000). 
Dendritic cells are the principal activators of naive T cells in vivo (Palucka and 
Banchereau, 1999). Having established that IL-1F8 can induce maturation of 
MDDCs, as evidenced by phenotypic changes (CD1a, CD83 and HLA-DR)  
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(Figure 3.10), the ability of IL-1F8-matured MDDCs to induce T cell proliferation 
in vitro was studied using an allogeneic MLR. 
 
3.2.9.1 IL-1F8-stimulated MDDCs activate T cell Proliferation  
 
1.44 x 106 day-5-MDDCs per well were plated on 12-well cell culture plates and 
cultured for 48 hours in complete RPMI 1640 culture medium supplemented with 
one of the following: IL-1F8 (100ng/ml or 500ng/ml), IL-ȕQJPORU
100ng/ml), or Escherichia coli 0127:B8 LPS (10ng/ml or 100ng/ml). Control 
samples were left unstimulated and cultured in complete RPMI 1640 medium 
only. All cultures were performed in duplicate. At the end of the culture period 
cells were harvested and viability and maturation were assessed as previously 
described (Chapter 2) prior to further culture with CD3+ T cells. Prior to 
assessing the effect of mature MDDCs on T cell populations, the surface 
expression of CD40 and CD80 on IL-1F8-matured MDDCs was measured by 
FACS analyses using antibodies listed in Table 2.2 (Chapter 2, section 2.6.1.2) 
to further confirm the ability of IL-1F8 to induce MDDC maturity and the FACS 
results are shown below (Figures 3.15 and 3.16).  
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 Figure 3.15 IL-1F8-stimulated-MDDCs upregulate CD40 expression. 
Immature (day 5) MDDCs were cultured with IL-1F8 (100 ng/ml or 500ng/ml) or 
with positive control (E. coli LPS-100 ng/ml) for 48 h prior to co-culture with 
allogeneic CD3+ T lymphocytes and the level of CD40 on the MDDC surface 
was determined by flow cytometry. Results show that IL-1F8-matured MDDCs 
upregulate CD40 expression in a comparable manner to LPS, an established 
inducer of MDDC maturation. Data are representative of three independent 
experiments. 
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Figure 3.16 IL-1F8-stimulated-MDDCs upregulate CD80 expression. 
Immature (day 5) MDDCs were cultured with IL-1F8 (100 ng/mL) for 48 h prior to 
co-culture with allogeneic CD3+ T lymphocytes and the level of CD80 on the 
surface was determined by flow cytometry. Data are representative of three 
independent experiments. 
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Results showed that IL-1F8 increased CD40 (Figure 3.15) and CD80 (Figure 
3.16) expression above the level expressed by isotype controls. After confirming 
MDDC maturation, the WST-1 cell proliferation assay (Roche Diagnostics Ltd., 
West Sussex, UK) was performed to assess the effect of mature MDDCs on T 
cell proliferation. Briefly, mature MDDCs (or unstimulated controls) were co-
cultured for 96 hours with allogeneic CD3+ T cells at a stimulator cell (MDDCs) 
to responder cell (CD3+ T cells) ratio of 1:10 per well as already described 
(Chapter 2, section 2.8.1). As a positive control, CD3+ T cells were also cultured 
in medium containing Concanavalin A (Con A) (75 µg/ml) and as a negative 
control CD3+ T cells were cultured for the same period in medium containing no 
additional supplements. All cultures were performed in triplicate and repeated on 
three separate occasions.   
 
After 96 hours, supernatants from the co-cultures were harvested and frozen for 
cytokine analysis as previously described (Chapter 2, sections 2.8.1 and 2.9.0). 
The WST-1 cell proliferation assay was then used to measure T cell proliferation 
in the co-cultures as previously described (Chapter 2, section 2.8.1). Briefly, the 
measured absorbance of each co-culture (measured at 450nm against a 
background/blank control) directly correlated to the number of viable cells in 
each well. The mean absorbance of each co-culture was divided by the mean 
absorbance of the unstimulated negative control and expressed as a proliferation 
ratio. The results obtained are summarised in the graph below (Figure 3.17).  
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Figure 3.17 IL-1F8-stimulated MDDCs induce T cell Proliferation. CD3+ 
lymphocytes were cultured for 96 h either alone (unstimulated control cells), in 
the presence of Concanavalin A (Con A) or with allogeneic MDDCs that had 
been matured for 48 hours with IL-1F8 (100 or 500 ng/mL), IL-ȕor 100 
ng/ml) or E. coli 0127:B8 LPS (10 or 100 ng/ml). T cell proliferation was 
determined using the Roche Cell Proliferation Assay (Cell Proliferation Reagent 
WST-1) and is shown relative to the unstimulated CD3+ T cells. Results show 
that IL-1F8-stimulated MDDCs activate T cell proliferation in a comparable way 
to IL-ȕ- or LPS-stimulated MDDCs. Data shown are means ± SD obtained from 
three independent experiments. Each experiment was performed in triplicate. 
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Results showed that MDDCs that had been matured with 100 ng/mL IL-1F8 
induced a two-fold expansion of the CD3+ T-cell population; however, this was 
below that observed for Con A-stimulated (positive control) cells (Figure 3.17). 
On the other hand, MDDCs that had been matured using 500 ng/mL IL-1F8 
induced >4-fold expansion of the T-lymphocyte population. This increase in T 
cell proliferation was greater than that measured in Con A-stimulated cultures 
and was comparable to that in IL-ȕ- or LPS-stimulated cultures. Taken together, 
these results show that IL-1F8-stimulated MDDCs activate T cell proliferation in 
a comparable way to IL-ȕ- or LPS-stimulated MDDCs. 
 
3.2.9.2 Induction of interferon gamma (IFN-ȖSURGXFWLRQE\0''&&'7
cell cultures 
 
Supernatants from the MDDC/T cell and Con A/T cell cultures described in 
section 3.2.9.1 were harvested to measure IFN-ȖDQG,/-10 concentration. IFN-Ȗ
ELISA was performed using the BD OptEIA Human IFN-Ȗ(/,6$.LW,,%'
%LRVFLHQFHV2[IRUG8.DVSHUPDQXIDFWXUHU¶VLQVWUXFWLRQVDVSUHYLRXVO\
described (Chapter 2, section 2.9.0). The graph below (Figure 3.18) shows IFN-Ȗ
levels in the different co-cultures.  
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Figure 3.18 IL-1F8-matured MDDCs induce proliferation of allogeneic TH1 
lymphocytes. CD3+ T lymphocytes were cultured for 96 h alone (unstimulated 
cells), with Con A, or with allogeneic MDDCs that had been matured for 48 hours 
with IL-ȕRUQJP/RUZLWK,/-1F8 (100 or 500 ng/mL) prior to 
determining  IFN-ȖFRQFHQWUDWLRQLQWKHVXSHUQDWDQWVE\(/,6$p < 0.05 = 
Statistical increase in the concentration of IFN-ȖLQWKHVXSHUQDWDQWVRI7
lymphocytes co-cultured with Con A or with MDDCs matured with IL-ȕRU,/-
1F8, compared with unstimulated controls. Data shown are means ± SD 
obtained from three independent experiments performed in triplicate 
 
 
 
196 
0
10
20
30
40
50
60
70
80
90
100
Un
st
im
u
la
te
d 
CD
3+
 
T 
ce
lls
Co
nc
a
n
av
a
lin
 
A
M
D
D
C+
 
IL
-
1F
8 
10
0n
g/
m
l
M
D
D
C+
 
IL
-
1F
8 
50
0n
g/
m
l
M
D
D
C+
 
IL
-
1ȕ

n
g/
m
l 
M
D
D
C+
 
IL
-
1ȕ

ng
/m
l 
IF
N
-
Ȗ c
o
n
ce
n
tr
at
io
n 
(P
g/m
l) 
CD3+ T cell treatment 
 ? 
 ?  ? 
Results (Figure 3.18) showed that compared with unstimulated CD3+ T cells, 
MDDCs matured with IL-ȕQJP/LQGXFHGVLJQLILFDQWp < 0.05) IFN-Ȗ
production when cultured with CD3+ T cells. On the other hand,  maturation of 
MDDCs with 100 ng/mL IL-1F8 did not stimulate significant IFN-ȖSURGXFWLRQLQ
allogeneic MDDC/T cell cultures, however, a significant increase (p < 0.05) in 
IFN-ȖSURGXFWLRQZDVPHDVXUHGLQVXSHUQDWDQWVLQZKLFK0''&VKDGEHHQ
matured using 500 ng/mL IL-1F8 prior to co-culture with T lymphocytes. The 
effect, on IFN-ȖSURGXFWLRQLQPL[HG0''&7FHOOFXOWXUHVRIQJPO,/-1F8 
was comparable to that induced by 100 ng/ml IL-ȕDQGKLJKHUWKDQWKDWGXHWR
Con A (75 µg/ml). 
 
3.2.9.3 IL-10 production by MDDC/ CD3+ T cell co-cultures 
 
IL-10 levels in supernatants from the MDDC/T cell and Con A/T cell cultures 
GHVFULEHGLQVHFWLRQZHUHPHDVXUHGXVLQJWKH%'2SW(,$ 
Human IL-10 ELISA Kit II (BD Biosciences, Oxford, UK) according to the 
PDQXIDFWXUHU¶VLQVWUXFWLRQVDVSUHYLRXVO\ described (Chapter 2, section 2.9.5). 
Results are summarised in the graph below (Figure 3.19).  
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Figure 3.19 IL-10 levels in supernatant of MDDC/T cell co-cultures. CD3+ T 
lymphocytes were cultured for 96 h alone (unstimulated control cells), with Con A 
(75 µg/ml), or with allogeneic MDDCs that had been matured for 48 hours with 
IL-ȕRUQJP/,/-1F8 (100 or 500 ng/mL) or E. coli 0127:B8 LPS (10 
ng/ml) prior to determining  IL-10 concentration in the supernatants by ELISA. *p 
< 0.05 = Statistical increase in the concentration of IL-10 in the supernatants of T 
lymphocytes co-cultured with Con A or with MDDCs matured with IL-ȕ,/-1F8 
or LPS, compared with unstimulated controls. Data shown are means ± SD 
obtained from three independent experiments. Each analysis was performed in 
triplicate. 
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Although IL-10 concentration in MDDC/T lymphocyte cultures was generally 
much lower than IFN-ȖFRQFHQWUDWLRQVLPLODUWUHQGVZHUHREVHUYHGLQWKDW
maturation of MDDCs with 100 ng/mL IL-1F8 did not stimulate significant IL-10 
production in allogeneic MDDC/T cell cultures where as a significant increase (p 
< 0.05) in IL-10 production was measured in supernatants in which MDDCs had 
been matured using 500 ng/mL IL-1F8 prior to co-culture with T lymphocytes 
(Figure 3.19). Furthermore, the effect of 500 ng/ml IL-1F8 on IL-10 production by 
the MDDC/T cell cultures was also comparable to that induced by 100 ng/ml IL-
ȕDQGKLJKHUWKDQWKDWLQGXFHGE\DZHOO-established inducer of T cell 
proliferation, Con A. On the other hand, a much lower concentration of E. coli 
0127:B8 LPS (10 ng/ml) induced the highest IL-10 production relative to the 
negative control in MDDC/T cell cultures.   
 
3.3 IL-1Rrp2 expression by blood DC Subsets 
 
Peripheral blood DCs comprise a heterogeneous population of cells that is 
divided into two main subsets, myeloid DCs (mDCs) and plasmacytoid DCs 
(pDCs), with distinct and complementary roles in the induction of immune 
responses. Myeloid DCs are further sub-divided into Type 1 myeloid DCs 
(mDC1) and Type 2 myeloid DCs (mDC2) (Dzionek et al., 2000). The diversity of 
DC subsets and lineages is thought to be responsible for the diverse functions of 
DCs in immune regulation. Different DC subsets are thought to recognize and 
respond to different pathogens and to differ in terms of cytokine production 
profile and capacity to direct TH Cell differentiation (reviewed in Liu, 2001). An 
 
199 
imbalance in DC subset levels is thought to play a role in diseases such as 
primary Sjögren's syndrome (Vogelsang et al., 2010). 
 
3.3.1 Human plasmacytoid DCs (pDCs) but not myeloid DCs (mDCs) 
constitutively express IL-1Rrp2 
 
Having established that human MDDCs expressed both IL-1Rrp2 mRNA and IL-
1Rrp2 protein, the next step was to investigate whether human peripheral blood 
DC subsets express IL-1Rrp2. Human buffy coat products were purchased from 
Sheffield National Blood Services and mDC1, mDC2 and pDCs were isolated 
using magnetic microbead kits purchased from Miltenyi Biotec Ltd (Surrey, UK) 
as previously described. Quantitative RT-PCR for IL-1Rrp2 mRNA was 
performed on the DC peripheral blood subsets and results obtained are shown in 
the graph below (Figure 3.20).  
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Figure 3.20 Human plasmacytoid DCs (pDCs) but not myeloid DCs (mDCs) 
constitutively express IL-1Rrp2. Quantitative RT-PCR was used to determine 
the level of IL-1Rrp2 mRNA expression in promonocytic THP-1 cells, mDC1, 
mDC2, MDDCs and pDCs isolated from human blood as compared with levels in 
calibrator HT29 cells. Data shown are means ± SD of at least three independent 
experiments. Each analysis was performed in triplicate. 
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Our results (Figure 3.20) showed that neither mDC1 nor mDC2 cells expressed 
IL-1Rrp2 mRNA at levels above those measured for non-expressing cells 
(promonocytic THP-1 cells) or the calibrator (HT 29 cells). On the other hand, 
pDCs expressed IL-1Rrp2 mRNA at levels comparable to those observed in 
MDDCs which had been generated using 50ng/ml GM-CSF and 10ng/ml IL-4. 
 
3.3.2 Relative expression of IL-1Rrp2 mRNA in human pDCs stimulated 
with IL-1F8 or IL-ȕ 
 
Quantitative RT-PCR was performed to investigate whether IL-1Rrp2 mRNA 
expression is regulated in pDCs stimulated with rhIL-1F8, rhIL-ȕE. coli 
0127:B8 LPS or imiquimod. Plasmacytoid DCs isolated from peripheral blood 
using the Diamond Plasmacytoid Dendritic Cell Isolation Kit (Miltenyi Biotec Ltd., 
Bisley, UK) as previously described (Chapter 2, section 2.3.6.4) were plated at a 
density of 4 x 104 cells/well on 6 well plates and cultured for 24 hours in 
complete medium supplemented with IL-1F8 (100ng/ml), IL-ȕQJPOE. 
coli 0127:B8 LPS (100ng/ml) or imiquimod (50µg/ml). Negative control cells were 
left unstimulated and were cultured for 24 hours in cytokine-free medium. Cells 
were harvested and processed for qRT-PCR to assess IL-1Rrp2 mRNA 
expression as previously described (Chapter 2, section 2.7.0) and the results are 
shown below.  
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Figure 3.21 Regulation of IL-1Rrp2 mRNA expression in human pDCs 
stimulated with IL-1F8. Figure shows that qRT-PCR IL-1Rrp2 mRNA 
expression is significantly down-regulated (*p < 0.05 relative to unstimulated 
pDCs) in pDCs stimulated with 100ng/ml IL-1F8 or 50µg/ml imiquimod (positive 
control). There is no significant down-regulation of IL-1Rrp2 expression 
(compared with unstimulated controls) in pDCs stimulated with either IL-ȕ
(100ng/ml) or E. coli 0127:B8 LPS (100ng/ml). Results shown are means ± SD 
of three independent experiments. Each analysis was performed in triplicate. 
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Unstimulated pDCs (cultured in complete RPMI 1640 medium only) showed 
higher IL-1Rrp2 mRNA levels than stimulated pDCs, suggesting a down-
regulation of IL-1Rrp2 in stimulated pDCs (Figure 3.21). Stimulating pDCs with 
either IL-1F8 (100ng/ml) or imiquimod (50µg/ml) resulted in a significant down-
regulation in IL-1Rrp2 mRNA levels compared with unstimulated controls. 
Although stimulating pDCs with either IL-ȕQJPORUQJPOE. coli 
0127:B8 LPS resulted in a down-regulation of IL-1Rrp2 mRNA synthesis, this 
was not statistically significant. 
 
3.3.3 Measurement of IFN-ĮSURGXFWLRQLQKXPDQS'&VVWLPXODWHGZLWK,/-
1F8 or IL-ȕ 
 
Plasmacytoid DCs (pDCs) are the principal IFN -producing cells in the blood and 
are capable of producing vast amounts of IFN-ĮLQUHVSRQVHWRYDULRXVVWLPXOi 
(Cella et al., 1999; Siegal et al., 1999; Kadowaki et al., 2000; Foster et al., 2000; 
Gibson et al., 2002). Imiquimod, a Toll-like Receptor 7 (TLR7) agonist and 
immune response modifier, induces INF-ĮVHFUHWLRQLQKXPDQS'&V*LEVRQet 
al., 2002). IFN-Įhas immunoregulatory activities and may be important in linking 
innate and adaptive immunity (reviewed in Brassard et al., 2002). It inhibits viral 
replication and can also act to stimulate other immune competent cells 
(McKenna, Beignon and Bhardwaj, 2005; Colonna, Trinchieri and Liu, 2004). 
 
To assess whether or not pDCs used in experiments were fully functional, their 
ability to secrete IFN-ĮLQUHVSRQVHWRYDULRXVVWLPXOLZDVH[DPLQHG 
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Plasmacytoid DCs isolated from peripheral blood using the Diamond 
Plasmacytoid Dendritic Cell Isolation Kit (Miltenyi Biotec Ltd., Bisley, UK) as 
previously described (Chapter 2, section 2.3.6.4) were plated at a density of 1.16 
x 105 cells/well on 6 well plates and cultured for 48 hours in complete RPMI 1640 
medium supplemented with IL-1F8 (100 ng/mL), IL-ȕQJP/RULPLTXLPRG
(50 µg/mL; positive control). Unstimulated pDCs were cultured for the same 
period without stimulants and were used as negative controls. At the end of the 
culture period, supernatants were collected from the wells and the IFN-Į
concentration was measured in the supernatant of stimulated or unstimulated 
pDCs using a sandwich ELISA immunoassay (VeriKineTM Human IFN-ĮELISA 
Kit, supplied by R & D Systems, Abington, UK) performed according to the 
manufacturers' instructions (Chapter 2, section 2.9.3). The results are shown in 
the graph below (Figure 3.22). 
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Figure 3.22 IL-1F8-stimulated plasmacytoid DCs (pDCs) induce IFN-Į
synthesis. Graph shows ELISA analysis of IFN-ĮFRQFHQWrations in the culture 
supernatants of pDCs stimulated with IL-1F8 (100 ng/mL), IL-ȕQJP/
imiquimod (50 µg/mL) or unstimulated controls. *p < 0.05 = Statistical increase in 
the concentration of IFN-ĮLQWKHVXSHUQDWDQWVRIS'&VVWLPXODWHGZLWK,/-ȕRU
imiquimod, compared with unstimulated controls. Data shown are means ± SD 
obtained from five independent experiments performed in triplicate. 
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Results (Figure 3.22) show that isolated pDCs used in the study were fully 
functional as they produced significant IFN-ĮOHYHOVLQUHVSRQVHWRLPLTXLPRG
compared to unstimulated cells. IL-ȕQJPOLQGXFHGVHFUHWLRQRI,)1-Į
levels that were comparable to those induced by imiquimod. On the other hand, 
IL-1F8 (100ng/ml) induced IFN-ĮVHFUHWLRQEXWWKHlevel of IFN-ĮZDVQRW
significantly higher than that in the supernatant isolated from unstimulated 
controls. 
    
 
3.3.4 IL-1F8-stimulated pDCs are weak inducers of T cell proliferation   
 
To assess the effect of IL-1F8-matured pDCs on T cell proliferation, pDCs 
isolated from peripheral blood using the Diamond Plasmacytoid Dendritic Cell 
Isolation Kit as previously described were stimulated for 24 hours with one of the 
following: IL-1F8 (500 ng/mL), E. coli 0127:B8 LPS (100 ng/ml) or imiquimod (50 
µg/ml) as described previously (Chapter 2, section 2.8.2). The WST-1 cell 
proliferation assay was then used to measure T cell proliferation induced by the 
stimulated pDCs. Briefly, mature pDCs (or unstimulated controls) were co-
cultured for 48 hours with allogeneic CD3+ T cells at a stimulator cell (pDCs) to 
responder cell (CD3+ T cells) ratio of 1:10 per well as already described 
(Chapter 2, section 2.8.2). As a positive control, CD3+ T cells were also cultured 
in medium containing Concanavalin A (Con A) (75 µg/ml) and as a negative 
control CD3+ T cells were cultured for the same period in medium containing no 
additional supplements. All cultures were performed in triplicate and repeated on 
three separate occasions.   
207 
After 48 hours, T cell proliferation in the co-cultures was assessed using the 
WST-1 cell proliferation assay as previously described (Chapter 2, section 
2.8.2). Briefly, the measured absorbance of each co-culture (measured at 450nm 
against a background/blank control) directly correlated to the number of viable 
cells in each well. The mean absorbance of each co-culture was divided by the 
mean absorbance of the unstimulated negative control and expressed as a 
proliferation ratio. The results obtained are summarised in the graph below 
(Figure 3.23). 
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Figure 3.23 IL-1F8-matured pDCs are weak inducers of T cell proliferation.  
pDCs were stimulated for 24 hours with IL-1F8 (500 ng/mL), E. coli 0127:B8 LPS 
(100 ng/mL) or imiquimod (50 µg/mL) and then cultured for 48 hours with CD3+ 
T cells. Graph shows that pDCs matured with IL-1F8, LPS or imiquimod did not 
induce significant cell proliferation above the negative control (unstimulated T 
cells). Data shown are means ± SD obtained from five independent experiments 
performed in triplicate. 
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Results obtained showed that IL-1F8-matured pDCs do not induce significant T 
cell proliferation relative to unstimulated CD3+ T cells.  Plasmacytoid DCs 
matured with IL-1F8, LPS or imiquimod did not induce significant cell 
proliferation above the negative control (unstimulated T cells) (Figure 3.23).    
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3.4 Discussion 
 
 
Results presented in this chapter show for the first time that within the human 
myelomonocytic lineage, constitutive expression of IL-1Rrp2 is unique to DCs, 
however, IL-1Rrp2 expression differs between monocyte-derived and blood 
isolated DC subsets (Mutamba et al., 2012). RT-PCR results show that 
monocyte derived DCs (MDDCs) express IL-1Rrp2 mRNA. Flow cytometry and 
fluorescent microscopy results further confirm that MDDCs express IL-1Rrp2 
protein on the cell surface. THP-1 cells (a promonocytic cell line) (Tsuchiya et 
al., 1980) or peripheral blood monocytes (PBMs) did not express IL-1Rrp2 
mRNA. Magne et al. (2006) also did not observe IL-1Rrp2 expression in THP-1 
cell lines, while work by Towne et al. (2004) has suggested that only Colo205, 
SW48, HT29, HBT75, HaCAT and NCI/ADR-RES cell lines express IL-1Rrp2. 
  
Our results from qRT-PCR analyses also showed that IL-1Rrp2 was not 
expressed by peripheral blood monocytes, isolated from PBMC using standard 
density gradient techniques (Mutamba et al., 2012). On the other hand, Debets 
et al. (2001) observed IL-1Rrp2 (then known as IL-1R6) mRNA expression in 
monocytes isolated from Phytohaemagglutinin (PHA)-activated peripheral blood 
mononuclear cells (PBMC). Since Debets et al. were working with activated 
PBMC; it is possible that the IL-1Rrp2 expression that they attributed to 
monocytes was actually due to immature pre-DCs which were differentiating 
from the activated monocytes. The fact that they did not observe IL-1Rrp2 
expression in unstimulated PBMC (Debets et al., 2001) further supports this 
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point. PHA is known to induce T cell proliferation in the presence of monocytes 
(Ceuppens et al., 1988) and in turn, activated T cells induce differentiation of 
monocytes to DCs (Wirths et al., 2002). 
 
In our study, monocyte-derived macrophages (MDMs) only expressed IL-1Rrp2 
mRNA on addition of IL-4 to the culture media. However, IL-1Rrp2 expression in 
these IL-4-stimulated MDM cultures was associated with a simultaneous 
increase in the numbers of MDDCs. IL-4 is known to convert macrophages to 
DCs (Sallusto and Lanzavecchia, 1994). IL-4 also caused a dose-dependent 
increase in IL-1Rrp2 expression in MDDC cultures but this was also associated 
with increased MDDC differentiation, evidenced by characteristic dendritic 
morphology and detachment from plastic culture flasks. However, the effect of 
IL-4 on IL-1Rrp2 expression by individual MDDCs was not investigated. There is 
also a possibility that IL-4 may be a trigger for the expression of IL-1Rrp2 by 
MDDCs.  Previous studies have shown the importance of IL-4 in DC biology. For 
example, IL-4 is known to be the main driving force behind MDDC differentiation 
(Roy et al., 2004) and is also known to induce expression of DC specific 
intercellular adhesion molecule grabbing non-integrin (DC-SIGN) (Relloso et al., 
2002; Li et al., 2006).  
 
The finding, in the present study, that IL-1F8 significantly increased IL-1Rrp2 
mRNA expression above unstimulated controls, is consistent with previous 
findings regarding the relationship between IL-1 cytokines and their receptors. 
For example, IL-ȕDFODVVLFDO,/-1 member, stimulates upregulation of the  
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synthesis of IL-1R1 (Zhang et al., 2007; Docagne et al., 2005). Furthermore, IL- 
1F6, one of the novel IL-1 family members, has been shown to upregulate IL-
1Rrp2 expression in mouse keratinocytes and in human psoriatic skin lesions 
(Blumberg et al., 2007). A correlation between IL-1Rrp2 expression and cellular 
responsiveness to IL-1F8 has also been reported by other researchers (Towne 
et al., 2004; Magne et al., 2006). Regulation of receptor expression must be 
important in host defence responses to disease and injury. Upregulation of IL-
1Rrp2 expression on cells is likely to make the cells more sensitive and more 
responsive to the corresponding novel IL-1 cytokines thereby further enhancing 
any subsequent effects. However, this kind of response may not always be 
beneficial to the host.       
 
Human peripheral blood is thought to contain two major DC populations, CD11c+ 
myeloid DC (mDC) and CD123+ plasmacytoid DC (pDC) (Robinson et al., 1999). 
Both populations are immature precursor DC derived from bone marrow stem 
cells that are on migration to their target sites. Myeloid DCs are further 
subdivided into CD1c+ myeloid DCs (type 1 myeloid DCs or mDC1) and CD141+ 
myeloid DCs (type 2 myeloid DCs or mDC2) (Dzionek et al., 2000). Myeloid DC 
preferentially home to non-lymphoid tissues, where they specialise in uptake of 
invading pathogens. They rapidly secrete proinflammatory cytokines following 
engagement of Toll-like receptor 2 (TLR2) and TLR4 (Liu, 2001). On the other 
hand, pDC are preferentially located in the T cell areas of lymphoid tissues and 
express TLR-7 and TLR-9. They produce large amounts of interferon (IFN)-Į
following TLR ligation. Myeloid DCs are thought to preferentially evoke T cell 
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responses against invading pathogens while pDCs are the principal IFN 
producing cells in the blood in response to viral infections (Gibson et al., 2002) 
and are thought to serve as a link to innate immunity and to help in the 
maintenance of tolerance against self-antigens (Liu, 2001; Shortman and Liu, 
2002; Palucka and Banchereau, 2002; Penna et al., 2002; Liu, 2005). 
 
Dendritic cells generated in vitro from peripheral blood monocytes (MDDCs), are 
the best-studied human DCs as they are much more readily available than DCs 
isolated ex vivo.  The current study adds to previous reported differences 
between mDCs and MDDCs as we show that IL-1Rrp2 was not expressed by 
either mDC1 or mDC2 subsets while immature MDDCs showed significant IL-
1Rrp2 expression. Unlike mDC1 cells, mDC2 cells lack expression of CD1a and 
do not produce IL-12 (Chang et al., 2000). In this respect, MDDCs are more 
closely related to mDC1 (Herbst et al., 1998; Grassi et al., 1998). Other 
researchers have reported phenotypic and functional differences between the 
MDDCs and mDCs. Horlock et al. (2007) reported that immature MDDCs have a 
more mature phenotype than unstimulated mDCs with significantly greater 
expression of CD11c, CD83 and increased expression of HLA-DR. However, in 
their study, mDCs were not separated into mDC1 and mDC2 populations. In 
their study, the immature MDDCs also had greater phagocytic capacity and 
induced greater T-cell proliferation than unstimulated mDCs, although the 
phenotypic and functional disparity between mDCs and MDDCs was balanced 
by MDDC maturation. 
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As previously mentioned, mature DCs are the most potent antigen-presenting 
cells (APCs), and the only ones capable of activating naive T cells and of 
initiating adaptive immune responses (reviewed in Steinman and Hemmi, 2006; 
reviewed in Adema, 2009). Not only are mature DCs able to present antigen, 
activate naïve T cells and initiate adaptive immune responses, but they can also 
selectively determine the type of immune response induced by lymphocytes via 
the dynamic expression of various signalling molecules (reviewed in Banchereau 
and Steinman, 1998; reviewed in Banchereau et al., 2000). 
 
We investigated (Mutamba et al., 2012) the effect of IL-1F8 and IL-1F9 on 
maturation of MDDCs using increased HLA-DR (Verhasselt et al., 1997) and 
CD83 (Zhou and Tedder, 1995) and decreased CD1a (Romani et al., 1996) 
expression as maturation markers. Consistent with previous findings, our results 
showed that IL-ȕDQG,)1-ȖVWLPXODWHG0''&PDWXUDWLRQ*XRet al., 2003; 
Wesa and Galy, 2002) but in addition we showed that IL-1F8 and IL-1F9 also 
have a potent effect on MDDC maturation.  
 
Further markers of MDDC maturation were examined using IL-1F8 as a model 
novel IL-1 cytokine. In vivo, after receiving a maturation signal, DCs migrate to 
the T-lymphocyte areas of lymphoid tissue and acquire a phenotype which 
relates to their stimulatory properties. Among other factors, mature DCs 
upregulate expression of co-stimulatory molecules such as CD40, CD80 and 
CD86 (reviewed in Shortman and Liu, 2002; reviewed in Steinman and Hemmi, 
2006), which provide co-stimulatory signals that are essential for T cell activation  
215 
and survival (reviewed in Banchereau and Steinman, 1998; reviewed in 
Steinman and Hemmi, 2006). In the present study, IL-1F8 (100 ng/ml) induced 
CD40 and CD80 expression, suggesting that IL-1F8-matured DCs are capable of 
activating T lymphocytes, thus pointing to a potential role for novel IL-1 cytokines 
in DC-mediated induction of T cell (adaptive) immune responses.   
 
IL-1F8, however, proved to be less potent than the classical IL-1, IL-ȕLQPDQ\
aspects. Although IL-1F8 and IL-ȕKDGHTXLSRWHQWHIIHFWVRQ,/-18 production 
by MDDCs, IL-1F8 had to be used at a concentration (400 or 500 ng/ml) that 
was at least 40 times that of IL-ȕQJPOWRLQGXFH,/-12 p70 levels similar to 
those induced by IL-ȕ)XUWKHUPRUHZKLOH0''&VPDWXUHGXVLQJQJPO,/-
1F8 induced a two-fold increase in T-cell proliferation, this level was doubled by 
MDDCs, which had been matured with 500ng/ml IL-1F8.  
 
Previous studies have also found IL-1F8 to be less potent than IL-ȕ7RZQHet 
al. (2004) reported that IL-1F6, IL-F8, and IL-1F9 activate the pathway leading to 
NF-kB in multiple cell types transfected with IL-1Rrp2 but much higher doses of 
IL-1F6, IL-1F8, and IL-1F9 are necessary to achieve significant activation of the 
pathway leading to NF-kB than was the case for IL-ȕ7KH\REVHUYHGWKDW,/-
1F8 significantly activated the pathway leading to NF-kB at concentrations above 
100ng/ml; reaching a plateau at around 1 µg/ml. On the other hand, IL-ȕ
significantly activated the pathway leading to NF-kB at a concentration as low as 
0.02ng/ml (Towne et al., 2004). Magne et al. (2006) observed that primary 
human synovial fibroblasts (hSFs) and human articular chondrocytes (hACs)  
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express IL-1Rrp2 mRNA and produce inflammatory cytokines (IL-6 and IL-8) in 
response to IL-1F8, however, the concentration of recombinant IL-1F8 required 
to stimulate hSFs and hACs was also higher than that of IL-ȕ6LJQLILFDQW
stimulatory effects were observed at IL-1F8 concentrations from 500±5,000 
ng/ml, compared with 0.1-10ng/ml for IL-ȕ0DJQHet al., 2006).  
 
It was previously proposed that IL-1F8 and other new members of the IL-1 
cytokine family only exert significant biological effects at such high 
concentrations because the recombinant IL-1 cytokines used in studies probably 
lack the post-translational modifications which might be vital for their biological 
activity (Towne et al., 2004; Magne et al., 2006). These speculations were 
recently confirmed by a study which showed that truncation of IL-1F6, IL-1F8, IL-
1F9 and IL-1F5 (recently renamed IL-Į,/-ȕ,/-36ȖDQG,/-36Ra, 
respectively) enhances their potency (Towne et al., 2011). In this recent study, it 
was shown that removal, from these IL-1 cytokines, of N-terminal amino acids at 
specific points increased their specific activity 1000-10000 times (Towne et al., 
2011). Whereas previously other researchers (Towne et al., 2004; Magne et al., 
2006) had failed to demonstrate the ability of IL-1F5 to antagonise IL-1F9 
(Debets et al., 2001), the recent work by Towne et al. (2011) helped resolve this 
controversy by showing that IL-1F5 is indeed an IL-1F9 antagonist but that 
antagonist activity requires removal of the N-terminal methionine which is 
present in the primary translation product. Furthermore, they extended previous 
findings by showing that truncated IL-F5 is also an antagonist for IL-1F6 and IL-
1F8 in a similar manner to the way IL-1Ra inhibits IL-ĮDQG,/-ȕ7RZQHet al., 
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2011). Although these findings suggest that post-translational modification might 
be vital for the biological activity of the novel IL-1 cytokines, this is yet to be 
confirmed in vivo.  It can be hypothesised that had truncated IL-1F8 been used 
in our study, its potency might have been more comparable to that of IL-ȕ, as a 
recent study in which truncated IL-1F6, IL-F8 and IL-1F9 were used suggests 
(Vigne et al., 2011).   
 
Having established that human MDDCs express IL-1Rrp2, mature in response to 
IL-1F8 and subsequently acquire the ability to induce T cell proliferation, the next 
step was to determine the T helper (TH) cell phenotype within the proliferating 
CD3+ T-cell population. Results from the present study show that IL-1F8-
matured MDDCs were functionally mature as they were able to secrete IL-12p70 
and IL-18 (Mutamba et al., 2012). As previously discussed, these two cytokines 
synergistically induce interferon-ȖSURGXFWLRQZKLFKLQWXUQHQKDQFHVWKH
production of IL-12p70 and thus favours the development of TH1 cells (reviewed 
in Okamura et al., .DOLĔVNLet al., .DOLĔVNLet al., 2000; Sabatté et al., 
2007). That IL-1F8-matured MDDCs stimulate differentiation of TH1 phenotypes 
was further evidenced by a much greater concentration of IFN-ȖFRPSDUHGZLWK
IL-10 in the supernatant of allogeneic MDDC/CD3+ cultures (Mutamba et al., 
2012). IL-10 generally contains and suppresses inflammatory responses and 
hence down-modulates effector adaptive immune responses so as to minimize 
tissue damage in response to microbial challenges.  It is known to suppress the 
differentiation and effector functions of TH1 cells through down-regulation or 
complete inhibition of IL-12 expression (reviewed in Maynard and Weaver, 
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2008). The present study, therefore, shows that IL-1F8 interaction with IL-1Rrp2 
induces TH1 polarization and hence production of proinflammatory cytokines in 
human MDDCs.  However, a significant effect on TH1 cytokine production was 
only observed when MDDCs were matured using an IL-1F8 concentration that 
was five times that of IL-ȕ, suggesting that the IL-1F8 used in this study was 
less potent than IL-ȕ. Alternatively, the result may also suggest that the IL-1F8 
receptor (IL-1Rrp2) may not be as strongly expressed as the IL-ȕUHFHSWRU,/-
1R1) on human MDDCs. 
 
IL-12 levels secreted by human MDDCs in the current study were generally 
lower than those observed in other studies (Ebner et al., 2001; Nakahara et al., 
2005). This discrepancy might be due to differences in the maturation stage of 
MDDCs used in the studies, differences in the numbers of MDDCs used, 
differences in analytical methodologies, differences in duration of stimulation and 
differences in maturation stimuli. IL-12 production is influenced by the 
environmental conditions at the site of induction of DC maturation (reviewed in 
Kalinski et al., 1999; Ebner et al., 2001; Nakahara et al., 2005).  
 
Some common features between pDCs and MDDCs (for example, IL-1Rrp2 
expression) were observed in the present study. IL-1Rrp2 was expressed by 
pDCs at levels comparable to IL-1Rrp2 expression measured in MDDCs 
generated from peripheral blood monocytes. This is a very interesting result 
because MDDCs are considered to be more similar to myeloid DCs (mDCs) than 
pDCs; for example, MDDCs and mDCs express the same TLRs (reviewed in 
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Iwasaki and Medzhitov, 2004). Furthermore, neither mDCs nor MDDCs are 
recognized as primary type I interferon producers whereas pDCs constitutively 
express large amounts of type I interferons (Grouard et al., 1997; Siegal et al., 
1999). It has been suggested that the difference between mDCs and pDCs is 
such that they even originate from different haematopoietic lineages, with mDCs 
arising from myeloid precursors in the bone marrow and pDCs arising from 
lymphoid precursors (Galy et al., 1995). More recently, this has been questioned 
since it has been found that pDCs or mDCs can be generated from either pDC or 
mDC precursors (Ishikawa et al., 2007; Zuniga et al., 2004), suggesting that 
there may not be a strict lineage specific development of mDCs or pDCs. On the 
other hand, human pDCs express pre T-FHOOUHFHSWRUĮP51$5HVet al., 1999) 
and murine pDCs have IgH gene D-J gene rearrangements, (Corcoran et al., 
2003) neither of which are found in mDCs nor MDDCs. Two possible models for 
the generation of functionally distinct (DC) subtypes have been proposed; these 
are the functional plasticity model and the specialized lineage model. The 
functional plasticity model proposes that all DCs belong to a single 
haematopoietic lineage and that the different subtypes of DCs arise due to local 
environmental influences on a relatively mature buW³SODVWLF´HQG-product cell. 
The specialised lineage model, on the other hand, proposes that the different DC 
subtypes are the products of entirely separate developmental lineages (reviewed 
in Shortman and Liu, 2002). In reality, both mDCs and pDCs show functional 
plasticity, thus, the origin and developmental pathways of DC subtypes is an 
area that still needs clarification.       
 
220 
Not only do human MDDCs and pDCs constitutively express IL-1Rrp2 and 
respond to IL-1F8, they both regulate IL-1Rrp2 expression in response to IL- 
1F8. It was interesting to note the differences in the way MDDCs and pDCs 
responded to IL-1F8 with regards to IL-1Rrp2 expression. MDDCs up-regulated 
IL-1Rrp2 expression in response to IL-1F8, on the other hand, pDCs responded 
to IL-1F8 by down-regulating IL-1Rrp2 expression. This difference in terms of 
response to stimulation suggests that different sets of DCs perform different 
functions as previously suggested by others (reviewed in Shortman and Liu, 
2002).  
 
Berglof et al. (2003) investigated the expression of IL-1Rrp2 and the effect of IL-
1F9 on known IL-1 signaling pathways in the different cell types of the mouse 
brain in culture. They observed that LPS strongly reduced expression of IL-
1Rrp2 mRNA in both mixed glia and microglia, suggesting that during 
inflammatory situations, possible IL-1F9 actions might be suppressed by 
decreased expression of IL-1Rrp2 mRNA (Berglof et al., 2003), however, in our 
study, MDDCs responded to both LPS and IL-1F8 stimulation by up-regulating 
IL-1Rrp2 expression, suggesting that novel IL-1 cytokines have different effects 
on different cells.  
 
While the finding that pDCs down-regulate IL-1Rrp2 expression in response to 
stimulation with IL-1F8 was an unexpected finding since MDDCs had shown IL-
1Rrp2 up-regulation in response to IL-1F8, it is easy to see why this could be an 
appropriate or desirable response in certain diseases. For example, it is now 
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known that pDCs are activated in psoriasis and that pDCs initiate psoriasis 
through interferon-ĮSURGXFWLRQ1HVWOHet al., 2005). The contribution of IL-1Rrp2 
and its ligands to the cytokine network in psoriasis is beginning to be 
appreciated. Using a mouse model of human psoriasis, Blumberg et al. (2010) 
found that TNF-Į,/-17A, and IL-23, inflammatory cytokines thought to 
contribute to the development of psoriasis, were upregulated in the mouse skin. 
They also observed that these cytokines were induced by and could induce IL-
1F6 and related IL-1 family cytokines. Inhibition of TNF-ĮRU,/-23 inhibited the 
increased epidermal thickness, inflammation, and cytokine production. Blockade 
of IL-1Rrp2 (which they called IL-1RL2) also resolved the inflammatory changes 
in human psoriatic lesional skin transplanted onto immunodeficient mice. 
Therefore, this latter study may suggest that employing strategies which reduce 
or block IL-1Rrp2 expression could be beneficial in the treatment of psoriasis. 
The down-regulation of IL-1Rrp2 expression in pDCs observed in the present 
study may suggest that in an effort to limit the potentially harmful inflammatory 
effects of IL-1F8, pDCs respond by down-regulating the expression of the IL-1F8 
receptor. 
 
Another area in which IL-1F8-matured MDDCs and pDCs responded differently 
in the present study was with regards to their interaction with CD3+ T cells. 
While IL-1F8-stimulated MDDCs strongly and significantly induced T cell 
proliferation, IL-1F8-stimulated pDCs were very weak inducers of T cell 
proliferation. The ability of pDC to present antigen to naïve T cells is still 
somewhat controversial. In a previous study, although CpG-activated pDC  
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induced higher proliferation of T cells than pDC activated by influenza virus, this 
proliferation was observed to be considerably weaker compared with T cells 
stimulated by mDC (Iparraguirre et al., 2007). Whether or not direct antigen 
presentation is the main function of pDCs during immune responses is yet to be 
determined, however, pDCs are the major type I IFN-producing cells in response 
to virus infection (Siegal et al., 1999). The in vitro and in vivo use of model 
ligands for the two main TLRs expressed by pDC, TLR7 and TLR9 has facilitated 
understanding of the interaction between pDC and pathogens (or pathogen 
components). Imiquimod, an imidazoquinoline and synthetic TLR7agonist, is a 
stronger inducer of IFN-ĮSURGXFWLRQLQS'&V*LEVRQet al., 2002; Iparraguirre et 
al., 2007) and was therefore used as a positive control marker/indicator of pDC 
maturation/stimulation in the present study. Although pDCs express IL-1Rrp2 
and mature in response to IL-1F8 with subsequent secretion of IFN-ĮUHVXOWV
suggest that IL-1F8 is not as potent as IL-ȕLQVWLPXODWLQJ,)1-ĮSURGXFWLRQLQ
pDCs.  
 
Although the in vivo significance of the maturation of human DC subsets by 
novel IL-1 cytokines (acting via the IL-1Rrp2 receptor) is yet to be demonstrated, 
a lot can be gleaned from previous studies.  As already mentioned, a role for IL-
1Rrp2 ligands (IL-1F5, IL-1F6, IL-1F8- and IL-1F9) in the induction of 
proinflammatory cytokines (Debets et al, 2001; Towne et al., 2004; Magne et al., 
2006, Blumberg et al., 2010)  and in the pathogenesis of psoriasis (Debets et al., 
2001; Blumberg et al., 2007; Blumberg et al., 2010) has already been suggested.   
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Results presented in this chapter extend current understanding regarding the 
interaction between myelomonocytic cells and IL-1F8/IL-1F9 via the IL-1Rrp2 
receptor. In view of previous studies and results from the current study, there is a 
possibility that IL-1Rrp2 and its ligands act differently on different cells. The 
effect of the newer IL-1 cytokine family members on Langerhans cells or 
epidermal DCs in the skin, which are phenotypically similar to MDDCs, is not 
known (Galy et al., 1995; Ishikawa et al., 2007). One study has shown that 
Langerhans cells act to dampen skin inflammation (Kaplan et al., 2005) and 
another study has shown that Langerhans cell recruitment is increased in the 
skin of psoriatic patients successfully treated with propylthiouracil, which has 
anti-inflammatory properties (Elias et al., 2003). 
 
The potential of IL-1 cytokines for immunomodulatory therapies has previously 
been reviewed (reviewed in Dumont, 2006). Added to that, the recent finding that 
IL-1Rrp2 (IL-1RL2) and its ligands contribute to the cytokine network in human 
psoriasis (Blumberg et al., 2010) raises interesting questions about the potential 
of therapeutic strategies targeting IL-1Rrp2. If IL-1F8 and IL-1F9 function as 
maturation signals for other cells similar to MDDCs, such as Langerhans cells, 
then it is possible that IL-1F8 and IL-1F9 may have potential in Langerhans cell 
activation and immune modulation in vivo.  
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CHAPTER 4: IL-1RRP2 EXPRESSION IN VARIOUS HUMAN 
CELLS  
 
4.1 Introduction 
At the commencement of the current study, the function of IL-1Rrp2 was only 
starting to be clarified. It had just been identified as being part of the receptor 
complex through which IL-1F6, IL-1F8 and IL-1F9 signal. It had also been shown 
to mediate inflammatory responses triggered by these newer members of the IL-
1 cytokine family (Towne et al., 2004; Magne et al., 2006). IL-1Rrp2 expression 
had been reported in rat meninges, choroid plexus and cerebral cortex 
(Lovenberg et al., 1996).  In humans, high IL-1Rrp2 expression had been 
observed in skin while lower levels were found in prostate, ovary, thyroid, uterus, 
liver, kidney, lung, and trachea. Extremely low levels were found in human testis, 
heart, spleen, and small intestine. IL-1Rrp2 expression was also observed in 
some human cell lines (Towne et al., 2004). Recent studies are suggesting the 
therapeutic potential of targeting IL-1Rrp2 in chronic inflammatory conditions 
such as psoriasis, which are mediated by IL-1Rrp2 and its ligands (Blumberg et 
al., 2010). The present study has extended previous findings, not only by 
showing differential IL-1Rrp2 expression in human myelomonocytic cells, but 
also by showing differential biological response of these cells to IL-1Rrp2 ligands 
(Chapter 3; quoted in Mutamba et al., 2012).  
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After showing that human MDDCs and pDCs express IL-1Rrp2 and respond to 
IL-1F8 and IL-1F9 (Chapter 3, partially quoted in Mutamba et al., 2012) the next 
step was to investigate IL-1Rrp2 expression in other human cells and cell lines 
so as to identify other potential targets for the novel IL-1 ligands. Cells in which 
IL-1Rrp2 expression had not yet been extensively studied were chosen. The 
specific aim of the work described in this chapter was to investigate IL-1Rrp2 
expression in human immature blood CD209+/CD14+ Langerhans cells, human 
lymphocytes, granulocytes, human lamina propria cells and NCI/ADR-RES cells 
(OVCAR-8 ovarian adenocarcinoma cell line previously thought to be a breast 
cancer cell line) (Towne et al., 2004; Liscovitch and Ravid, 2007).    
 
Phenotypically, MDDCs share some characteristics with Langerhans cells and it 
has been hypothesised that these cells may be the blood-borne precursors of 
these skin DCs (Geissmann et al., 1998; Grassi et al., 1998; Herbst et al., 1998). 
Langerhans cells (LCs), first described by Paul Langerhans in 1868, are DCs 
found in an immature state mainly within epidermal and mucosal stratified 
squamous epithelia and constituting approximately 2-4% of all epidermal cells 
(reviewed in Stingl and Shevach, 1991). They are the first antigen presenting 
cells that come into contact with pathogens at the skin surface (reviewed in 
Banchereau and Steinman, 1998). After encountering antigen, LCs migrate from 
the skin to T cell areas in the regional lymph node where they present processed 
antigen to T cells (reviewed in Banchereau and Steinman, 1998).  
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Previously, LCs were thought to initiate adaptive immune responses but this 
view is currently being debated based on more recent in vivo studies using LC-
deficient mice which suggest that LCs actually dampen skin inflammation 
(Kaplan et al., 2005; reviewed in Romani et al., 2006). 
  
Based on the findings presented in Chapter 3 of this thesis (also reported in 
Mutamba et al., 2012), it was hypothesised that maturation of MDDCs by novel 
IL-1 cytokines ex vivo may mirror the effect of these cytokines on immature 
Langerhans cells in vivo. Such a scenario could have important effects during 
human disease considering that over-expression of IL-1F6 in murine basal 
keratinocytes with co-existing IL-1F5 deficiency was found to increase skin 
inflammation in a human psoriasis mouse model (Blumberg et al., 2007). Since 
Langerhans cells have been shown to dampen skin inflammation (Kaplan et al., 
2005) and to be recruited into the skin of psoriatic patients successfully treated 
with propylthiouracil (an antithyroid thioureylene drug with immunomodulatory 
effects) (Elias et al., 2003), there is a chance that the production of IL-1F6/IL-
1F8/IL-1F9 during skin pathology may induce maturation of skin DCs which 
would in turn down-regulate the inflammatory response. As such, ascertaining 
whether immature human Langerhans cells express IL-1Rrp2 and whether they 
are matured by novel IL-1 cytokines was considered an important step in the 
present study. 
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Having investigated IL-1Rrp2 expression in human MDDCs and human blood 
DCs and having demonstrated the ability of IL-1Rrp2 ligands to induce 
inflammatory TH1 subsets (Chapter 3, Mutamba et al., 2012), and also, in view of 
published literature suggesting a role for IL-1Rrp2 and its ligands in 
inflammation-mediated diseases (Blumberg et al., 2007; Blumberg et al., 2010), 
attention was turned to studying IL-1Rrp2 expression in other human immune 
cells. Human lymphocytes and granulocytic neutrophils were considered to be of 
interest because of their role in immune responses, including inflammation. The 
inter-dependent relationship that exists between DCs and other immune cells 
has been highlighted in preceding chapters of this thesis (Chapters 1 and 3).  
 
A common feature of the innate immune response to an immunological 
challenge is the localized production of proinflammatory cytokines (such as TNF-
Į,)1-ĮȕDQG,/-ȕOHDGLQJWRWKHLQIOX[DQGDFWLYDWLRQRIQHXtrophils and 
macrophages at the site of infection, resulting in inflammation, thus, neutrophils 
play a vital role in the innate arm of the immune response that rapidly develops 
at sites of injury and infection (Nathan, 2006). Although primarily recognized for 
the destruction of invading pathogens, neutrophils can also shape immune 
responses (Nathan, 2006). Neutrophils deliver activation signals and antigenic 
molecules to DCs, and in turn, activated DCs mature and migrate to secondary 
lymphoid organs, where they initiate activation of naive T lymphocytes and elicit 
antigen-specific responses (Megiovanni et al. 2006).  
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Using human live blood neutrophils and immature monocyte-derived DCs, 
Megiovanni et al. (2006) demonstrated that co-culture of immature MDDCs with 
live neutrophils led to DC maturation as evidenced by up-regulation of CD40, 
CD86, and HLA-DR on DCs and that neutrophil-DC cell contact was essential for 
CD86 and HLA-DR up-regulation. They also reported that DCs acquired Candida 
albicans-derived antigens from neutrophils via a cell-contact-dependent 
mechanism (Megiovanni et al. 2006), suggesting that cross-talk between DCs 
and neutrophils could be more intimate than previously appreciated (Megiovanni 
et al. 2006). Furthermore, in different models and animal species, it has been 
shown that the classical IL-1, IL-ȕFDXVHVERWKGRVH-and time-dependent 
neutrophil migration (Faccioli et al., 1990; Perretti et al., 1993) through the 
release of neutrophil chemotactic mediators (Simbirtsev et al., 2001; Oliveira et 
al., 2008).  
 
In inflammatory diseases like Rheumatoid Arthritis (RA), neutrophils play a huge 
part in the inflammation and tissue destruction associated with the diseases 
(Jonsson, Allen and Peng, 2005). In a more recent study, a mouse model was 
used to show that IL-1F11 (IL-33) orchestrates neutrophil migration in arthritis 
(Verri et al., 2010). We therefore speculated that IL-1Rrp2 ligands might also 
induce neutrophil migration in a similar manner to the other IL-1 family members, 
IL-ȕDQG,/-1F11, thereby enhancing inflammatory processes. Thus, the 
decision to investigate IL-1Rrp2 expression in human granulocytic neutrophils 
was based on the mentioned published reports showing the involvement of other  
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IL-1 family members (IL-Į,/-ȕDQG,/-1F11) in neutrophil migration 
culminating in inflammation (Faccioli et al., 1990; Perretti et al., 1993; Simbirtsev 
et al., 2001; Jonsson, Allen and Peng, 2005; Oliveira et al., 2008) and also 
because there is cross-talk between neutrophils and DCs (Megiovanni et al. 
2006).  
 
Interest in IL-1Rrp2 expression in intestinal lamina propria (LP) cells was based 
on reports that IL-1Rrp2 ligands were highly expressed in tissues containing 
epithelial cells (stomach, skin, lung and oesophagus) (Debets et al., 2001; 
Towne et al., 2004) and also because of reports (based on in vitro analysis of 
human gut inflammatory cells and experimental colitis models) suggesting a role 
for IL-18 (IL-)LQWKHSDWKRJHQHVLVRI&URKQ¶VGLVHDVHDPDMRUIRUPRI
inflammatory bowel disease (IBD)) ( Maerten et al., 2004). Furthermore, IL-Į
and IL-ȕDUHNQRZQWRPHGLDWHLQIODmmation in inflammatory bowel diseases 
OLNH&URKQ¶VGLVHDVHDQGXOFHUDWLYHFROLWLV<RXQJPDQet al., 1993; Ludwiczek et 
al., 2004). We speculated that in a similar way, novel IL-1 cytokines, acting via 
IL-1Rrp2-expressing cells in intestinal LP, induce inflammatory T cell responses 
in the gut. In addition, studies involving both mouse models of ulcerative colitis 
(UC) (one of the major types of IBD) as well as patients with UC suggest that 
DCs play a role in the pathogenesis of IBD (reviewed in Rutella and Locatelli, 
2011). Because our study had found IL-1Rrp2 expression in some human DC 
subsets (MDDCs and pDCs), we speculated that human ileal LP might contain 
IL-1Rrp2-expressing DCs.  
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The gastrointestinal tract is constantly exposed to a diverse array of commensal 
bacterial as well as food and potentially pathogenic microorganisms. The 
intestinal immune system has the ability to maintain tolerance to harmless food 
antigens and commensal microorganisms on one hand while mounting 
appropriate protective immune responses to harmful pathogens (and avoiding 
the development of destructive inflammatory responses) on the other hand. 
When this balance is upset, chronic inflammatory disorders, such as IBD occur 
in humans (reviewed in Rutella and Locatelli, 2011). In &URKQ¶VGLVHDVHIRU
example, an imbalance of immunoregulatory factors and/or cells is thought to 
contribute to uncontrolled mucosal T cell activation and inflammation (Maerten et 
al., 2004).    
 
The gastric mucosa is lined by a monolayer of columnar epithelial cells which are 
separated from the lamina propria by a basement membrane. The deepest 
layers of the gastric mucosa comprise of the muscularis mucosae (consisting of 
a layer of smooth muscle cells) and the submucosa which lies below it. The 
submucosa consists almost exclusively of connective tissue (Castro and 
Arntzen, 1993; Wu et al., 1999). Immune responses to antigen in the intestinal 
lumen are initiated at three sites; the lamina proSULD/33H\HU¶VSDWFKHV33
in gut-associated lymphoid tissue (GALT) and mesenteric lymph nodes (MLN), 
all of which are rich in intestinal mononuclear phagocytic cells (Mahida et al., 
1997; Neiss et al., 2005). The normal lamina propria consists of connective 
tissue matrix within which lie many different cell types, T and B lymphocytes, 
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plasma cells, macrophages, myofibroblasts, and cells that make up blood and 
lymphatic vessels. The intestinal LP, gut-associated lymphoid tissue (GALT) and 
epithelium are abundant in T cells; in fact, there are more T cells in these sites 
than in the rest of the body (reviewed in Maynard and Weaver, 2009). There is 
interaction between the epithelial monolayer and cellular components of the 
lamina propria (Wu et al., 1999). This was first shown using an in vitro model 
whereby normal human mucosal samples whose surface epithelium had been 
denuded were maintained in culture (Yahida et al., 1997). That study 
demonstrated that there was considerable movement of mononuclear cells 
(mostly T cells, macrophages and eosinophils) into and out of the intestinal LP, 
via basement membrane pores (Yahida et al., 1997).  
 
In a follow up study using intestinal mucosal samples from patients with active 
IBD, McAlindon et al. (1998) observed that in mucosal samples that had lost 
their epithelium, the basement membrane was either destroyed or contained 
numerous large pores through which polymorphonuclear cells (PMCs), 
lymphocytes, eosinophils and macrophages migrated into the lumen (McAlindon 
et al., (1998). Further phenotypic and functional characterisation of the 
emigrating cells showed that emigrating lymphocytes were predominantly  
 
CD45RO+ and CD69+ T cells (activated T cells) while emigrating macrophages 
expressed cyclooxygenase (COX) 1 and 2 enzymes. Furthermore, in addition to 
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PMCs and eosinophils, myofibroblasts expressing COX 1 and 2 enzymes and 
prostaglandin E2, were also observed emigrating (Wu et al., 1999).    
 
It is now known that during inflammation, polymorphonuclear cells, lymphocytes, 
and monocytes are recruited into the lamina propria from the systemic circulation 
(reviewed in Maynard and Weaver, 2009). Lamina propria T cells receive signals 
from epithelial cells, stromal cells, and the matrix itself via integrin receptors, and 
are closely associated with dendritic cells and macrophages (reviewed in 
Maynard and Weaver, 2009). CD4+ T cells predominate in the lamina propria 
and CD8+ T cells in the gut epithelium. A number of studies involving humans 
have shown that the CD4+ T cells in normal gut lamina propria have the 
phenotype of activated effector T cells (Wu et al., 1999; reviewed in Maynard 
and Weaver, 2009).  
 
Cells with antigen-presenting function within the intestine and associated 
lymphoid tissue include macrophages (the most abundant) and DCs (including 
conventional CD11c-expressing DCs and plasmacytoid DCs) (Varol et al., 2009; 
reviewed in Rutella and Locatelli, 2011). In addition to their established role as 
efficient antigen-presenting cells (APCs), human LP DCs (CD11b+ CD14+ 
CX3CR1+ DCs, CD103+ CX3CR1í DCs and CD1c+ DCs) (Varol et al., 2009; 
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Dillon et al., 2010) as well as DCs in the draining MLN and PP, have been 
shown to be instrumental in the maintenance of immune homeostasis and 
tolerance in the gut (reviewed in Coombes and Powrie, 2008; reviewed in Rutella 
and Locatelli, 2011). Interest in LP DCs was first aroused when it was shown 
that in mice and humans, LP DCs penetrate epithelial tight junctions (by 
projecting dendrites through the epithelial cell layer) to directly sense and sample 
antigen in the gut lumen (Rescigno et al., 2001; Niess et al., 2005).  
 
Mouse and human studies suggest that tolerogenic DCs act by promoting the 
differentiation and expansion of intestinal FoxP3+ regulatory T cells (FoxP3+ 
Tregs) which then efficiently modulate gut inflammation. On the other hand, 
migrating DC subsets which are recruited to the gut in response to pathogenic 
insults are thought to initiate immune responses (reviewed in Rutella and 
Locatelli, 2011). The unique ability of DCs to sense the local environment and to 
shape the ensuing immune response accordingly is thought to be the reason 
behind the functional diversity and plasticity seen in gut DCs (reviewed in 
Coombes and Powrie, 2008).  
 
Based on reports that IL-1Rrp2 ligands were highly expressed in tissues 
containing epithelial cells (Debets et al., 2001; Towne et al., 2004) and that IL-
1Rrp2 was expressed in very low amounts in human small intestine (Towne et 
al., 2004), as well as on studies showing migration of cells in and out of human 
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intestinal LP (Mahida et al., 1997; McAlindon et al., 1998; Wu et al., 1999), and 
after demonstrating IL-1Rrp2 expression in human MDDCs and pDCs (Chapter 3 
of this thesis; Mutamba et al., 2012), we speculated that human LP contains IL-
1Rrp2-expressing cells which can move in and out of the LP (based on Mahida 
et al., 1997), making it a target for potentially inflammatory novel IL-1 cytokines.   
 
The present study also assessed IL-1Rrp2 expression in the OVCAR-8 ovarian 
adenocarcinoma cell line; NCI/ADR-RES. When Towne et al. (2004) looked for a 
cell line which naturally expressed IL-1Rrp2; they observed that out of all cell 
lines tested, NCI/ADR-RES cells, which they called a breast cancer cell line, 
showed the highest IL-1Rrp2 expression, suggesting that this cell line could be 
useful in studies involving IL-1Rrp2 ligands. NCI/ADR-RES cells, previously 
known as MCF-7/AdrR cells, are widely used as a multidrug-resistant model in 
cancer research (Liscovitch and Ravid, 2007). They were previously thought to 
be a breast cancer cell line (MCF-7); however, single-nucleotide polymorphism 
(SNP) and karyotypic analyses have since revealed that NCI/ADR-RES cells are 
derived from OVCAR-8 ovarian adenocarcinoma cells (Liscovitch and Ravid, 
2007; Ke et al., 2011). In view of reports suggesting that NCI/ADR-RES cells are 
definitely not breast cancer cells (Liscovitch and Ravid, 2007; Ke et al., 2011) 
and the reported high expression of IL-1Rrp2 in these cells (Towne et al., 2004), 
we decided to investigate IL-1Rrp2 expression in NCI/ADR-RES cells to 
ascertain if we could replicate previous findings by Towne et al. (2004).     
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4.2. Results 
4.2.1 Flow cytometry results showing that IL-1Rrp2 is not expressed by 
CD209+/CD14+ (immature blood) Langerhans cells  
CD209+(DC-SIGN+)/CD14+ blood cells were freshly isolated from PBMC using 
MACS beads (Miltenyi Biotec Ltd., Surrey, UK) as already described (Chapter 2, 
section 2.3.6.5). The population of cells was then stained for IL-1Rrp2 
expression prior to FACS analysis as previously described (Chapter 2, section 
2.6.1.1). Results showed that neither CD209+/CD14+ (immature blood 
Langerhans cells) (Figure 4.1) nor CD209-/CD14+ cells (monocytes used as a 
negative control) (Figure 4.2) expressed IL-1Rrp2 above that measured for 
isotype controls.  
 
 
 
 
 
 
 
 
 
      236 
 Figure 4.1 Immature blood CD209+/CD14+ Langerhans cells do not express 
IL-1Rrp2. Peripheral blood CD209+(DC-SIGN+)/CD14+ cells were stained for 
IL-1Rrp2 expression using an appropriate monoclonal antibody and isotype 
control prior to FACS analysis. Results show that CD209+/CD14+ cells 
(immature blood Langerhans cells) did not express IL-1Rrp2 above that 
measured for the isotype control. 
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 Figure 4.2 Immature blood CD209-/CD14+ cells do not express IL-1Rrp2. 
Peripheral blood CD209-/CD14+ cells were stained for IL-1Rrp2 expression using 
an appropriate monoclonal antibody and isotype control prior to FACS analysis. 
Results show that CD209-/CD14+ - cells did not express IL-1Rrp2 above that 
measured for the isotype control. 
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4.2.1.1 Quantitative RT-PCR results showing that CD209+/CD14+ (immature 
blood) Langerhans cells do not express IL-1Rrp2 mRNA 
To further investigate lack of surface expression of IL-1Rrp2 by CD209+/CD14+ 
blood cells, qRT-PCR was used to measure IL-1Rrp2 mRNA expression in 
human peripheral blood CD14+/CD209+ cells, THP-1 promonocytes (negative 
control), HT29 cells (positive control/calibrator), MDDCs stimulated with IL-1F8 
(500ng/ml) for 48 hours and MDDCs stimulated with IL-ȕQJPO5HVXOWV
again showed that IL-1Rrp2 was not expressed by immature blood Langerhans 
cells (CD14+/CD209+) (Figure 4.3). 
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Figure 4.3 Quantitative RT-PCR results showing that immature human blood 
Langerhans cells (CD14+/CD209+ cells) do not express IL-1Rrp2 mRNA. qRT-
PCR was used to measure IL-1Rrp2 mRNA expression in peripheral blood 
CD14+/CD209+ cells, THP-1 promonocytes (negative control), HT29 cells 
(positive control/calibrator), MDDCs stimulated with IL-1F8 (500ng/ml) for 48 
hours and MDDCs stimulated with IL-ȕQJ/ml) for 48 hours. Results show 
that MDDC stimulated with IL-ȕRU,/-1F8 express IL-1Rrp2 mRNA but 
immature peripheral blood Langerhans cells (CD14+/CD209+) and THP-1 cells 
do not. 
 
         
240 
4.2.2 Human peripheral blood lymphocytes and CD3+ T cells express IL-
1Rrp2 mRNA  
Total lymphocytes were isolated from PBMCs by density gradient centrifugation 
using sterile- filtered ACCUSPIN Histopaque®-1077 centrifuge tubes as per 
PDQXIDFWXUHU¶VLQVWUXFWLRQV6LJPD-Aldrich, Poole, UK) as previously described 
(Chapter 2, section 2.3.4.2). In separate experiments, human CD3+ T cells were 
isolated from PBMC by positive selection using CD3+ microbeads (human) 
IROORZHGE\PDJQHWLFVHSDUDWLRQRQDQ$XWR0DFV6HSDUDWRUFROXPQDFFRUGLQJ
WRWKHVXSSOLHU¶VLQVWUXFWLRQV0Lltenyi Biotec Ltd., Surrey, UK). Analysis of purity 
was performed by flow cytometry with appropriate fluorochrome-labeled 
antibodies (Abd Serotec, Oxford, UK) (Chapter 2, section 2.3.6.6.) Total RNA 
was extracted from both human peripheral blood lymphocytes and CD3+ T cells 
DQGȝJRIWRWDO51$IURPHDFKVDPSOHZDVUHYHUVH-transcribed into cDNA 
using random hexamer primers prior to performing qRT-PCR for IL-1Rrp2 gene 
as previously described (Chapter 2, section 2.7.0). GAPDH was used as the 
reference gene. HT 29 cells and THP-1 cells were used as positive and negative 
controls respectively. As Figure 4.4 shows, qRT-PCR analysis indicated that IL-
1Rrp2 mRNA was expressed by human lymphocytes (non-adherent fraction of 
PBMCs) and by CD3+ T cells. 
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 Figure 4.4 Quantitative RT-PCR results showing that lymphocytes (non-
adherent PBMC fraction) and CD3+ T cells express IL-1Rrp2 mRNA. Non-
adherent lymphocytes were isolated from blood using ACCUSPIN 
Histopaque®-1077. In separate experiments, CD3+ T cells were positively 
selected from PBMCs using CD3 magnetic beads on DQ$XWR0DFV6HSDUDWRU
column.  Isolated cells were subsequently assessed for IL-1Rrp2 mRNA 
expression relative to GAPDH. HT29 cells were used as a positive 
control/calibrator and THP-1 cells were used as a negative control. Results 
shown are means ± SD obtained from three independent experiments. Each 
analysis was performed in triplicate.  
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4.2.2.1 Immunofluoresence analysis of IL-1Rrp2 protein expression by 
human peripheral blood lymphocytes 
After showing that human total blood lymphocyte populations express IL-1Rrp2 
mRNA, fluorescence microscopy was used to further study IL-1Rrp2 protein 
expression by these cells. Briefly, non-adherent lymphocytes, isolated from 
PBMCs, were resuspended in PBS at a concentration of 1 x 105 cells/ml prior to 
being fixed with 4% v/v paraformaldehyde (PFA) in PBS as previously described 
(Chapter 2, sections 2.3.4.2 and 2.6.2). Cytospin preparations were made and 
cells were then stained with a primary IL-1Rrp2 antibody (M145, Amgen 
Corporation, Seattle, WA) followed by staining with an appropriate FITC-
conjugated, secondary/detection antibody and DAPI nuclear stain. Isotype 
control cells were incubated with secondary antibody only. Unstained cells were 
also included as controls. Slides were then analysed using a Leica fluorescence 
microscope (Leica Microsystems, UK) as previously described (Chapter 2, 
section 2.6.2). Results are shown in Figure 4.5. 
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Figure 4.5 Human peripheral blood lymphocytes express IL-1Rrp2 on their 
cell membrane. Lymphocytes were incubated with an IL-1Rrp2 monoclonal 
antibody ((M145, Amgen Corporation, Seattle, WA) followed by staining with a 
FITC-conjugated secondary antibody and DAPI nuclear stain (images A-C). The 
negative control sample (images D-F) was incubated with secondary antibody 
and DAPI only but not with the primary IL-1Rrp2 mAb. C and F are the overlay 
images for the test and negative control samples respectively. Images are 
representative of three independent experiments with similar results. (Scale bar 
represents 20µm) 
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Compared with the negative control (Figure 4.5, images D-F), results confirm 
that human lymphocytes (Figure 4.5, images A-C) express IL-1Rrp2 protein on 
the cell surface. The blue images (Figure 4.5, A and D) show nuclear staining 
with DAPI while Figure 4.5, images B and E show presence/absence of IL-1Rrp2 
protein (green-staining due to the fluorescein isothiocyanate (FITC)-labelled 
secondary antibody binding to the IL-1Rrp2 monoclonal antibody (mAb) which is 
in turn bound to IL-1Rrp2 in the cells). Figure 4.5, images C and F are the 
overlay images showing co-localisation (or lack of) of IL-1Rrp2 and DAPI. IL-
1Rrp2 (FITC) staining was not observed when the primary antibody was omitted 
(negative control cells; Figure 4.5, images E and F). 
 
4.2.3 qRT-PCR analysis of blood granulocyte showing lack of expression 
of IL-1Rrp2 mRNA 
Granulocytes were isolated from PBMCs as already described (Chapter 2, 
section 2.3.5). Contaminating RBCs were lysed and removed before 
granulocytes were assessed for viability and purity of isolation as already 
described (Chapter 2). Total RNA was extracted from the granulocytes and 
reverse-transcribed into cDNA and quantitative RT-PCR for IL-1Rrp2 gene was 
performed on a LightCycler® 480 analyser as previously described (Chapter 2, 
section 2.7.0). GAPDH was used as the reference gene. HT 29 cells and THP-1 
cells were used as positive and negative controls respectively. Results are 
shown in the graph below (Figure 4.6). 
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 Figure 4.6 Quantitative RT-PCR results showing that human granulocytes 
do not express IL-1Rrp2 mRNA. Granulocytes were isolated from PBMC using 
Histopaque®-1077 density gradient centrifugation. Isolated cells were 
subsequently assessed for IL-1Rrp2 mRNA expression relative to GAPDH. HT29 
cells were used as a positive control/calibrator and THP-1 cells were used as a 
negative control. Results shown are means ± SD obtained from three 
independent experiments. Each analysis was performed in triplicate. 
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As the graph in Figure 4.6 shows, granulocytes do not express IL-1Rrp2 mRNA. 
The graph shows mean ± SD of data from three independent experiments. Each 
analysis was performed in triplicate. 
 
4.2.3.1 Immunofluoresence analysis of IL-1Rrp2 protein expression by 
human peripheral blood granulocytes 
Fluorescence microscopy was used to further investigate IL-1Rrp2 expression in 
human granulocytes. Granulocytes were isolated from PBMCs as already 
described (Chapter 2, section 2.3.5). Briefly, after removing any contaminating 
RBCs as already described (Chapter 2, section 2.3.5), granulocytes were 
assessed for viability and purity using previously described methods (Chapter 2) 
prior to being resuspended in PBS at a concentration of 1 x 105 cells/ml. 
Cytospin preparations were made from the cell suspensions as previously 
described (Chapter 2, section 2.6.2) and cells were stained for fluorescence 
microscopy using a monoclonal primary antibody specific for IL-1Rrp2 (M145, 
Amgen Corporation, Seattle, WA) followed by staining with a secondary 
detection antibody (FITC-conjugated Goat anti-mouse IgG). Cells were 
counterstained with DAPI nuclear stain prior to being analysed using a Leica 
fluorescence microscope (Leica Microsystems, UK) as described in Chapter 2, 
Section 2.6.2. The images are shown below (Figure 4.7). Images are 
representative of at least three independent experiments. 
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Figure 4.7 Immunofluorescence images showing that human peripheral 
blood granulocytes do not express IL-1Rrp2 on their cell membrane. 
Granulocytes were incubated with an IL-1Rrp2 monoclonal antibody (M145) 
followed by staining with a FITC-conjugated secondary antibody and DAPI 
nuclear stain (A-C). The negative control sample (D-F) was incubated with 
secondary antibody and DAPI only but not with the primary IL-1Rrp2 mAb. C and 
F are the overlay images for the test and negative control samples respectively. 
Images are representative of three independent experiments with similar results. 
Scale bar represents 20µm.   
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Fluorescence microscopy images (Figure 4.7) showed no significant difference 
between test images (Figure 4.7, A-C) and negative control images (Figure 4.7, 
D-F). The blue-staining images (Figure 4.7, A and D) show nuclear staining with 
DAPI while B and E show presence/absence of IL-1Rrp2 protein (green-staining 
due to the fluorescein isothiocyanate (FITC)-labelled secondary antibody binding 
to the IL-1Rrp2 monoclonal antibody (mAb) which is in turn bound to IL-1Rrp2 in 
the cells). Figure 4.7, C and F are the overlay images showing no co-localisation  
of IL-1Rrp2 and DAPI due to weak IL-1Rrp2/FITC immunoreactivity. IL-1Rrp2 
(FITC) immunoreactivity was not observed when the primary antibody was 
omitted (negative control cells; Figure 4.7, E and F). The faint green staining 
shows non-specific binding. 
 
4.2.4 Human lamina propria cells express IL-1Rrp2 mRNA (qRT-PCR) 
Lamina propria cells were isolated from histologically normal human ileal 
mucosal samples as described in Chapter 2 (section 2.2.4). To stabilize RNA 
prior to total RNA extraction, the isolated lamina propria cells were immediately 
pelleted and suspended in RNAlater RNA Stabilization Reagent according to the 
PDQXIDFWXUHU¶VUHFRPPHQGDWLRQV4,$*(1&UDZOH\8.7RWDO51$ZDV
extracted from 1x106 cells, reverse-transcribed into cDNA and amplified in a 
typical real time PCR reaction as described previously (Chapter 2, section 2.7.0). 
A relative quantification analysis using GAPDH as the reference gene was 
performed on a LightCycler® 480 analyser as previously described (Chapter 2, 
 
249  
section 2.7.0). HT 29 cells and THP-1 cells were used as positive and negative 
controls respectively. Each analysis was performed in triplicate on samples from 
three different patients. Results are shown in the graph below (Figure 4.8). 
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 Figure 4.8 Quantitative RT-PCR results showing that human ileal lamina 
propria (LP) cells express IL-1Rrp2 mRNA. LP cells were isolated from 
histologically normal human ileal mucosal samples. Isolated cells were 
subsequently assessed for IL-1Rrp2 mRNA expression relative to GAPDH. HT29 
cells were used as a positive control/calibrator and THP-1 cells were used as a 
negative control. Results show that compared with the negative control (THP-1 
cells), human ileal lamina propria cells express IL-1Rrp2 mRNA. The level of IL-
1Rrp2 mRNA expression in human ileal lamina propria cells is nearly twice that 
of the positive control (HT-29 cells). Results shown are means ± SD obtained 
from three different patients. Each analysis was performed in triplicate. 
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Results show that compared with the negative control (THP-1 cells), human ileal 
lamina propria cells express IL-1Rrp2 mRNA. The level of IL-1Rrp2 mRNA 
expression in human ileal lamina propria cells is nearly twice that of the positive 
control (HT-29 cells) (Figure 4.8). 
 
4.2.5 qRT-PCR analysis showing IL-1Rrp2 mRNA expression in NCI/ADR-
RES cells 
NCI/ADR-RES cells, a kind gift from Professor Susan Watson (Division of Pre-
Clinical Oncology, University of Nottingham), were maintained in culture as 
previously described (Chapter 2, section 2.2.2). Total RNA was extracted from 
1x106 cells using the RNeasy Mini Kit and qRT-PCR for IL-1Rrp2 gene relative to 
GAPDH was performed as previously described (Chapter 2, section 2.7.0). HT 
29 cells and THP-1 cells were used as positive and negative controls 
respectively. Each analysis was performed in triplicate and the experiment was 
repeated on three separate occasions. Results are shown below (Figure 4.9).    
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 Figure 4.9 Quantitative RT-PCR results showing that NCI/ADR-RES cells 
express IL-1Rrp2 mRNA. NCI/ADR-RES cells were assessed for IL-1Rrp2 
mRNA expression relative to GAPDH (reference gene). HT29 cells were used as 
a positive control/calibrator and THP-1 cells were used as a negative control. 
Results show that compared with the negative control (THP-1 cells), NCI/ADR-
RES cells express IL-1Rrp2 mRNA. The level of IL-1Rrp2 mRNA expression in 
NCI/ADR-RES cells is more than seven times that of the positive control (HT-29 
cells). Results shown are means ± SD obtained from three independent 
experiments. Each analysis was performed in triplicate. 
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Results (Figure 4.9) show that compared with the negative control (THP-1 cells), 
NCI/ADR-RES cells strongly express IL-1Rrp2 mRNA. The level of IL-1Rrp2 
mRNA expression in NCI/ADR-RES cells is more than seven times that of the 
positive control (HT-29 cells) (Figure).  
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4.3 Discussion 
After showing that IL-1F8-stimulated human MDDCs have the ability to activate 
CD3+ T lymphocytes, induce their proliferation and stimulate TH1 responses in 
vitro and that the only other DCs we found to express IL-1Rrp2 were pDCs 
(Chapter 3, partially quoted in Mutamba et al., 2012) which may be lymphoid in 
origin (Galy et al., 1995), the next step was to investigate IL-1Rrp2 expression in 
other human cells and cell lines in an effort to identify other potential targets for 
the novel IL-1 cytokines. As already stated in the introduction (section 4.1), cells 
in which IL-1Rrp2 expression had not yet been extensively studied were chosen 
for reasons that have already been stated (section 4.1). The aim of the work 
described in this chapter was to investigate IL-1Rrp2 expression in human 
immature peripheral blood CD209+/CD14+ Langerhans cells, human 
lymphocytes, granulocytes, human lamina propria cells and NCI/ADR-RES cells. 
 
The role of MDDC in vivo is controversial; it is not known whether monocytes 
stimulated with IL-4 and GM-CSF in vivo serve as a DC pool, replenishing 
activated DCs during infection. However, MDDCs generated in vitro by culture 
with IL-4 and GM-CSF have phenotypic characteristics similar to Langerhans 
cells (Geissmann et al., 1998; Grassi et al., 1998; Herbst et al., 1998), lacking 
CD14 expression and gaining CD209 (DC-SIGN) expression (Relloso et al., 
2002). CD209 has important functions in vivo since it initiates T cell contact via 
ICAM (Geijtenbeek et al., 2000a) and also functions during DC trafficking from 
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blood to peripheral tissues (Geijtenbeek et al., 2000b) and is now known as a 
pathogen recognition receptor for some microbial pathogens, particularly viruses 
(Collin et al., 2011). 
 
Although the conversion of monocytes to DCs is associated with an epigenetic 
switch from CD14 to CD209 (Bullwinkel et al., 2011), a rare sub-population of 
CD14+/CD16+ blood monocytes also co-express CD209 (Merino et al., 2011).  
CD209 has also previously been shown to be expressed by immature pDCs 
(which do not express CD14) (Masten et al., 2006) and macrophages in 
peripheral tissue (Geijtenbeek et al., 2000b; Soilleux et al., 2002). It is also 
expressed in high concentration by intradermal DCs (Turville et al., 2002) and by 
macrophage-like intradermal APCs (Angel et al., 2007) which may differentiate 
into Langerhans cells (Larregina et al., 2001).  
 
In the current study, CD14+/CD209+ cells were isolated from blood and results 
show that these cells, in contrast to MDDC, do not express IL-1Rrp2. Whether 
this CD209+/CD14+ population represents a rare monocyte population or is 
indeed blood-borne precursors of dermal DCs, as previously reported (Larregina 
et al., 2001; Turville et al., 2002; Angel et al., 2007) is a matter that still needs 
elucidation, however, results presented in this chapter clearly show that this 
population is not comparable to MDDC with regards to IL-1Rrp2 expression and, 
hence, activation via IL-1F6, IL-1F8 or IL-1F9.  As such, this study suggests that 
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MDDCs are functionally different from blood borne immature skin DCs (or 
CD209+/CD14+ blood monocytes). 
  
In the current study, IL-1Rrp2 expression was observed in total lymphocytes and 
in CD3+ T lymphocytes. This suggests that IL-1Rrp2 ligands may exert direct 
stimulatory effects on lymphocytes, although time did not allow further studies 
regarding this possibility in this thesis.  Using a mouse model, one study found 
that by acting directly on CD4+ T cells, IL-ȕHQKDQFHVDQWLJHQ-driven expansion 
and differentiation in vivo and in vitro (Ben-Sasson et al., 2009). Results 
observed in the present study show that human T cells express IL-1Rrp2, 
suggesting that they could be a direct target for IL-1Rrp2 ligands such as IL-1F8. 
 
In previous initial studies involving the newer IL-1 family members, Debets et al., 
(2001) demonstrated that IL-1F9 activates NF-ț%Ln IL-1Rrp2-transfected Jurkat 
T cells (a T lymphocyte cell line). Towne et al., (2004) extended this finding by 
showing that IL-1F6 and IL-1F8, in addition to IL-1F9, activate the pathway 
leading to NF-ț%LQDQ,/-1Rrp2/IL-1RAcP-dependent manner in Jurkat cells as 
well as in multiple other human and mouse cell lines. However, when Magne et 
al., (2006) investigated endogenous IL-1Rrp2 expression in human cell lines 
they did not observe constitutive IL-1Rrp2 expression in Jurkat cell lines, which 
explains why previous researchers had to transfect (Debets et al., 2001). 
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Although Jurkat T cells are a T cell leukaemia cell line (Gillis and Watson, 1980), 
there are a number of reasons why they may have failed to show constitutive IL-
1Rrp2 expression in Magne et al. ¶VVWXG\HYHQWKRXJKWRWDOO\PSKRF\WHV
and CD3+ T lymphocytes in the present study showed IL-1Rrp2 expression. 
Being a tumour cell line, Jurkat T cells probably have aberrant expression or 
totally lack expression of the IL-1Rrp2 protein. It is not unusual for tumour cells 
to lack expression of some surface molecules (reviewed in Yokota, 2000). A 
number of studies have found that Jurkat T cells either do not express certain 
molecules that are normally found on T cells or they show reduced expression 
levels. One study found that Jurkat cells lack surface expression of Fas/CD95; a 
type-I membrane glycoprotein which induces apoptotic cell death (Monleón et al., 
2002). Another study which used Jurkat cells to investigate glucocorticoid 
resistance in lymphoid malignancies found that deficient Glucocorticoid Receptor 
(GR) expression in Jurkat cells was due to a mutated GR allele (Riml et al., 
2004). In view of these previous findings, it can be hypothesised that Jurkat T 
cells either lack the IL-1Rrp2 protein or they have a mutated version; hence the 
reported absence of constitutive IL-1Rrp2 expression (Magne et al., 2006). 
Further studies are needed to confirm this hypothesis.  
 
The ability of IL-1F8-stimulated MDDCs to activate CD3+ T cells and to induce 
their proliferation has already been demonstrated in the current study. It has 
already been shown that IL-1F8-matured MDDCs secrete cytokines which  
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induce TH1 polarization leading to secretion of inflammatory cytokines (Chapter 
3, partially quoted in Mutamba et al., 2012). If indeed human CD3+ T cells 
express IL-1Rrp2 as results presented in this chapter suggest, it can be 
extrapolated that IL-1 cytokines which signal via IL-1Rrp2 can also stimulate T 
lymphocytes directly. Further studies are needed to investigate the effect of such 
direct stimulation and also to establish IL-1Rrp2 expression in all human T cell 
subsets as well as human B cells and B cell subsets. 
 
The present study also investigated IL-1Rrp2 expression in human granulocytes. 
Granulocytes are polymorphonuclear cells (PMCs) characterized by the 
presence of differently staining granules in their cytoplasm when viewed under 
light microscopy. They can be divided into three subtypes; neutrophils, 
eosinophils, and basophils. Eosinophils make up about 3% of total circulating 
white blood cells and basophils constitute less than 1%. Collectively, 
granulocytes phagocytose pathogens, secrete toxic granules or histamines, 
contribute to inflammatory responses and regulate innate immune responses. 
Neutrophils are the most abundant type of phagocyte and make up 50% to 60% 
of the total circulating white blood cell population. They also form the major 
proportion of granulocytes in mammalian peripheral blood (Hoffbrand et al., 
2001). 
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Recruitment of neutrophils to sites of inflammation is promoted by adhesion 
molecules and chemokines expressed on endothelium following its activation by 
IL-ȕDQGWXPRXUQHFURVLVIDFWRU71)-Į)XULHDQG0F+XJK3UHYLRXV
studies have shown that IL-ĮȕFDQDOVRDIIHFWKXPDQQHXWURSKLOVGLUHFWO\
through interaction with IL-1 receptors which are present on human neutrophils 
(Rhyne et al., 1988; Parker et al., 1989). Other studies have shown that human 
neutrophils can regulate their expression of IL-1R2 in response to IL-ȕRURWKHU
stimulants both in vivo and in vitro. Increased expression of the IL-1R2 receptor 
was observed on blood neutrophils of humans with the sepsis syndrome 
(Fasano et al., 1991). 
 
In another study, when human neutrophils obtained from healthy donors were 
incubated with various doses of IL-ȕ,/-ȕVSHFLILFDOO\GRZQ-modulated IL-1 
binding to neutrophils by reducing IL-1R2 expression. On the other hand, when 
IL-ȕZDVLQWUDYHQRXVO\DGPLQLVWHUHGLQWRKHDOWK\GRQRUVIROORZHGE\
assessment of peripheral blood neutrophils, up-regulation of IL-1R2 expression 
and up-modulation of IL-ȕELQGLQJWRQHXWURSKLOVZDVREVHUYHG6KLHKet al., 
1993). This difference between in vitro and in vivo effects of IL-ȕRQKXPDQ
neutrophils could be because there may be an indirect effect in vivo owing to the 
involvement of other biological molecules induced by IL-ȕ,WZDVUHFHQWO\
shown that human neutrophils also express IL-1R1 and respond to in-vitro IL-
ĮȕVWLPXODWLRQE\XS-regulation of chemokines, both at gene and protein levels, 
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and the effect is blocked by pretreatment with IL-1Ra (IL-1F3) (Paulsson et al., 
2012). During initial stages of the inflammatory reaction, neutrophils are the 
dominant mediating cells. Reports that neutrophils respond to in-vitro IL-Įȕ
stimulation by up-regulation of chemokines show that neutrophils are important 
modulators of the proinflammatory environment (Nathan, 2006; Megiovanni et al. 
2006). It remains to be established whether neutrophils respond to stimulation by 
the newer IL-1 family members. 
 
To date, the expression of IL-1Rrp2 (or its ligands) by human neutrophils has not 
been extensively studied. The present study sought to address this by studying 
IL-1Rrp2 expression in human granulocytes since neutrophils make up more 
than 95% of the total granulocyte population in normal patients (Hoffbrand et al., 
2001). Both quantitative RT-PCR and fluorescence microscopy methods did not 
detect IL-1Rrp2 expression in human granulocytes in this study. This suggests 
that IL-1Rrp2 ligands do not have a direct effect on human neutrophils. Another 
possibility is that neutrophils normally express IL-1Rrp2 at levels that are below 
the detection level of the methods used in this study. This is certainly the case 
with regards to IL-1R1/R2 expression on resting (unstimulated) neutrophils 
where the number of IL-1R has been estimated previously as 500±900 receptors 
per cell (Rhyne et al., 1988; Parker et al., 1989). Low numbers of receptors (less 
than 2000 molecules of target antigen per cell) may be difficult to detect by 
conventional qRT-PCR or immunofluorescence techniques (Zola et al., 1990). 
Since low receptor expression may still be biologically significant, further work 
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needs to be done to establish whether stimulated neutrophilic granulocytes 
express IL-1Rrp2. 
 
The present study found IL-1Rrp2 expression in lamina propria (LP) cells 
isolated from histologically normal human small intestine (ileum) mucosa 
following removal of the epithelium. This finding is consistent with the report by 
Towne et al. (2004) which shows that IL-1Rrp2 is expressed in very low amounts 
in the human small intestine, however, in their study; Towne et al. (2004) used 
whole tissue extract rather than LP cells.   
 
Results described in this chapter, which show that LP cells express IL-1Rrp2, 
therefore add a new dimension to studies which investigate IL-1Rrp2 expression 
in humans. Furthermore, these results indicate that lamina propria mononuclear 
cells (and not epithelial cells) may be the source of the IL-1Rrp2 expression 
found in the small intestine (Towne et al., 2004). However, although 
histologically normal human small intestine mucosae were used as a source of 
the LP cells used in our study, the patients from whom the samples were 
obtained were resected for cancer or IBD and these underlying conditions could 
have had an effect on IL-1Rrp2 expression. 
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Using an in vitro model in which normal human intestinal mucosal samples from 
which the surface epithelium had been removed were kept in culture, Yahida et 
al., (1997) demonstrated the migration of large numbers of cells (mostly T cells; 
63.4-73.6% and macrophages; 9.2-11.8%) out of the lamina propria of the 
normal human small and large intestine via basement membrane pores following 
loss of the surface epithelium. They speculated that this in vitro model reflected 
the in vivo host defence mechanism following loss of surface epithelial cells as a 
result of injury. 
 
The intestinal mucosa is a battlefield between the immune system, pathogens, 
and dietary and environmental antigens. It is now known that more T cells are 
found in the gut-associated lymphoid tissue (GALT), intestinal lamina propria and 
epithelium than in the rest of the body (reviewed in Maynard and Weaver, 2009). 
T cells in the lamina propria receive signals from epithelial cells, stromal cells, 
and the matrix itself via integrin receptors (reviewed in Maynard and Weaver, 
2009).They are also closely associated with dendritic cells and macrophages. 
Many studies in humans have shown that the CD4+ cells in normal gut lamina 
propria have the phenotype of activated effector T cells, probably in response to 
diet, or intestinal microorganisms (reviewed in Maynard and Weaver, 2009). 
 
IL-1Rrp2 ligands have been implicated in the pathogenesis of cytokine-mediated, 
inflammatory diseases such as psoriasis (Blumberg et al., 2007; Blumberg et al., 
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2010). An imbalance between pro- and anti-inflammatory cytokines produced 
within the intestinal mucosa is also thought to be behind the initiation and 
SHUSHWXDWLRQRILQIODPPDWLRQLQLQWHVWLQDOGLVHDVHVVXFKDV&URKQ¶VGLVHDVH
(Colpaert et al., 2002). The finding that lamina propria cells express IL-1Rrp2 is 
interesting since it suggests that proinflammatory IL-1Rrp2 ligands (IL-1F6, IL-
1F8 or IL-1F9) may act on these cells. Results in this thesis, therefore, may 
indicate that treatment strategies which target IL-1Rrp2, or its ligands, may have 
future therapeutic value in conditions such as IBD, although much greater 
investigation regarding the biology of IL-1Rrp2 in lamina propria cells needs to 
be performed. 
 
Further studies are needed to identify the IL-1Rrp2-expressing cells within the 
lamina propria cell population; time constraints hindered this pursuit in the 
present study. However, based on published reports and findings from the 
current research project, the most likely source would have been T cells and/or 
DCs. In the previously mentioned in vitro model which showed migration of cells 
into and out of the lamina propria, T cells were the most abundant emigrating 
population (Mahida et al., 1997). Although migration of macrophages and 
eosinophils was also observed in that study, the possibility of either of these two 
cell populations being the IL-1Rrp2-expressing cells in the lamina propria cells 
used in the current study can be ruled out since IL-1Rrp2 expression was not 
observed in macrophages (Chapter 3, Mutamba et al., 2012) or granulocytic 
eosinophils in the current study. 
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Speculation that T cells and/or DCs were the IL-1Rrp2-expressing LP cells in the 
current study is based on the observation that CD3+ T cells (Chapter 4), MDDCs 
and pDCS (Chapter 3) showed strong IL-1Rrp2 expression in the present study. 
Furthermore, it is now known that human intestinal LP contains an abundance of 
DC subtypes (including pDCs) and T cells which play a vital role in intestinal 
immune defence and gut tolerance but can also play a role in the pathogenesis 
of chronic inflammatory disorders such as IBD  (Wu et al., 1999; Rescigno et al., 
2001; Maerten et al., 2004; Neiss et al., 2005; Sun et al., 2007; reviewed in 
Coombes and Powrie, 2008; reviewed in Maynard and Weaver, 2009; Varol et 
al., 2009; Dillon et al., 2010). Clearly, further work is needed to take the current 
findings forward. 
 
The present study confirmed that NCI/ADR-RES cells show very strong IL-1Rrp2 
mRNA expression.  Towne et al., (2004) reported that out of all the human cell 
lines that they tested, NCI/ADR-RES cells showed the highest level of IL-1Rrp2 
expression. In the current study, NCI/ADR-RES cells showed the highest 
constitutive IL-1Rrp2 mRNA expression out of all primary cells and cell lines we 
tested. The significance of this finding needs to be investigated further. However, 
identifying a cell line which strongly expresses IL-1Rrp2 constitutively is 
invaluable given the attention that IL-1Rrp2 and its ligands are currently getting. 
NCI/ADR-RES could prove to be just as useful in research involving the newer 
IL-1 family members as they have been in cancer research. 
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CHAPTER 5: GENERAL DISCUSSION AND CONCLUSION 
 
IL-1Rrp2 and the signal-transducing sub-unit, IL-1RAcP, form the receptor 
complex through which the newer IL-1 family members, IL-1F6, IL-1F8 and IL-
1F9 signal (Debets et al., 2001; Towne et al., 2004). Highest expression of IL-
1Rrp2 ligands has been reported in skin and epithelial tissue of internal organs 
that are exposed to pathogens, possibly suggesting that these ligands play a role 
in inflammatory immune responses in these organs (Kumar et al., 2000; Debets 
et al., 2001; Towne et al., 2004). It has been shown that like other IL-1 family 
members (e.g. IL-ĮDQG,/-ȕ,/-1F6, IL-1F8 and IL-1F9 stimulate signalling 
pathways which rHVXOWLQDFWLYDWLRQRI1)ț%DQG0$3.V7RZQHet al., 2004) 
and that IL-1F5 acts as an antagonist for these ligands in a similar manner to the 
way IL-1Ra antagonises IL-ȕDFWLYLW\'HEHWVet al., 2001; Blumberg et al., 
2007; Towne et al., 2011).  
 
Classical IL-1 family members, such as IL-ĮDQG,/-ȕDUHLPSRUWDQWQRWRQO\LQ
the initiation of protective immunity but also in the development of inflammatory 
pathology (reviewed in Dinarello, 1984; 1993; 1996; 1997; 2000; 2002). The role 
of IL-1F6, IL-1F8 and IL-1F9 in activating responses that augment immunity and 
promote inflammation is becoming elucidated, thanks to recent studies 
(Blumberg et al., 2007; Blumberg et al., 2010; Johnston et al., 2011; Carrier et 
al., 2011). However, to date, very little has been reported regarding the role of 
novel IL-1 cytokines in human immune cells which are known to be activated by 
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and/or produce classical members of the IL-1 family.  
 
The overall objective of the work presented in this thesis was to investigate the 
expression and biological response of the IL-1Rrp2 receptor in various human 
immune cells. Interest in this receptor is growing, not only because it is the 
receptor through which potentially inflammatory cytokines (IL-1F6, IL-1F8 and IL-
1F9) signal and hence its expression profile points to the cells/tissues which are 
potential targets for its ligands, but also because of its potential role as a 
therapeutic target in certain inflammatory diseases. Recently, IL-1Rrp2 blockade 
was observed to resolve the inflammatory changes in human psoriatic lesional 
skin that had been transplanted onto immunodeficient mice (Blumberg et al., 
2010). Furthermore, IL-1F5, which antagonises the inflammatory effect of IL-1F6 
(and of IL-1F8 and IL-1F9) in vitro (Debets et al., 2001; Towne et al., 2011) and 
in vivo (Blumberg et al., 2007) also signals via IL-1Rrp2 and may possibly be 
used therapeutically as an anti-inflammatory in future. 
 
A number of previously unreported findings are presented in this thesis. 
Expression of IL-1Rrp2 in human immune cells had not been extensively studied 
previously. The current thesis reports the first extensive study of IL-1Rrp2 
expression in human myeloid and non-myeloid immune cells. It is the first study 
focusing on investigating IL-1Rrp2 expression in human DC subsets, monocytes, 
macrophages, lymphocytes and granulocytes in addition to other cells and cell 
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lines. The current study reports for the first time that within the myelomonocytic 
lineage, IL-1Rrp2 expression is unique to DCs. MDDCs and pDCs showed 
constitutive IL-1Rrp2 expression while mDC1, mDC2, monocytes and 
macrophages did not. By showing differences in IL-1Rrp2 expression, not only 
between MDDCs and peripheral blood DCs, but indeed among peripheral blood 
DC subsets, this study also provides further evidence of the complexity of DC 
biology, plasticity and crosstalk (reviewed in Liu et al., 2001; Liu, 2001).  
 
A number of reports have highlighted the differences between myeloid DCs and 
pDCs and even suggested that they originate from different haematopoietic 
lineages (Galy et al., 1995; Liu et al., 2001; reviewed in Shortman and Liu, 
2002). The idea that pDCs are of lymphoid origin was initially supported by 
findings that genes originally found to be expressed only in developing T and B 
cells, such as pre-TCR-ĮȜDQG6SL-B, are also expressed in pDCs, but not in 
myeloid cells (Res et al., 1999; Bendriss-Vermare et al., 2001. Furthermore, the 
inhibition of Id2/Id3 expression was shown to prevent the development of pDCs, 
but not that of myeloid DCs, hence suggesting a lymphoid origin for pDCs (Spits 
et al., 2000).  However, other studies have proposed a myeloid origin for pDCs 
based on the finding that in humans, IL-3Rhigh pDCs were derived from CD34+ M-
CSFR+ progenitors (Olweus et al., 1997) and also because mice deficient in 
interferon (IFN) consensus sequence-binding protein (ICSBP), a critical 
transcription factor in myeloid cell differentiation, display loss of pDCs (Schiavoni 
et al., 2002), suggesting that ICSBP may also be essential in pDC development. 
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Another proposal is the view that pDCs can originate from both lymphoid 
progenitors and myeloid progenitors based on mouse studies showing that both 
lymphoid and myeloid progenitors have the potential to generate pDCs (Zuniga 
et al., 2004; Yang et al., 2005; Karsunky et al., 2005; Ishikawa et al., 2007), 
bringing into question the view that there is a distinct and separate lineage 
specific development for mDCs and pDCs as previously proposed (Galy et al., 
1995; Liu et al., 2001; reviewed in Shortman and Liu, 2002). Nevertheless, it is 
not yet clear whether there is a phenotypic or indeed functional difference 
between pDCs of myeloid origin and those of lymphoid origin.  
 
The current study provides an interesting dimension by showing some common 
features between pDCs and MDDCs, as well as differences. As an example, 
both MDDCs and pDCs constitutively express IL-1Rrp2. Furthermore, they both 
regulate IL-1Rrp2 expression in response to stimulation with IL-1F8 and IL-ȕ
suggesting that IL-1Rrp2 and its ligands may have a role in mediating immune 
processes involving these cells.  However, there is a difference in the way they 
respond to stimulation. While MDDCs respond to stimulation by up-regulating IL-
1Rrp2 expression, pDCS respond by down-regulating IL-1Rrp2 expression, 
suggesting functional differences between these two DC types. The phenotypic 
and functional differences between mDCs and pDCs have already been 
highlighted (Chapter 1 and Chapter 3 of this thesis). Myeloid DCs and pDCs 
show differences not only in terms of phenotypic markers but also with regards 
to cytokine secretion pattern, chemokine receptor expression and pathogen 
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recognition receptor (PRR) expression, suggesting differences in functional 
properties among these DC subsets (Sallusto and Lanzavecchia, 2002; reviewed 
in Banchereau et al., 2003). 
 
The differences between MDDCs and pDCs in terms of regulation of IL-1Rrp2 
expression as observed in this study suggests that regulation of IL-1Rrp2 
expression varies depending on cell/ tissue type, nature of immunological 
challenge, concentration of stimulant and duration of stimulation. Clearly, DC 
biology is more intricate than previously appreciated. The functional plasticity 
model for DC origin and development proposes that DCs arise from a single 
haematopoietic lineage and that local environmental influences determine 
subtype development (reviewed in Shortman and Liu, 2002), thus, whether or 
not myeloid DCs and pDCs are different activation states of a single lineage is 
yet to be revealed.  
 
Another interesting finding from the current study is the observation that in a 
similar manner to IL-ȕ,/-1F2) and IFN-Ȗ,/-1Rrp2 ligands (IL-1F8 and IL-1F9) 
induce maturation of human MDDCs as measured by increased expression of 
HLA-DR and CD83 and decreased expression of CD1a. Further evidence that 
IL-1Rrp2 ligands induce MDDC maturation is shown by upregulation of 
accessory/co-stimulatory molecules (CD40 and CD80) which are critical for T 
cell activation. In vivo, DCs are the principal activators of naive T cells (Palucka 
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and Banchereau, 1999). Following maturation with an appropriate stimulus, 
myeloid DCs upregulate surface markers (such as CD40, CD80, CD86) and 
migration markers such as CCR7, and can efficiently prime naive T cells 
(reviewed in Banchereau et al., 2000). Co-administration of costimulatory 
molecules (CD40, CD80 and CD86) with a protective antigen target has been 
shown to enhance immune responses in vaccination studies using bovine (Maue 
et al., 2004) and murine models (Blackstock, 2003). Thus, the ability of IL-1Rrp2 
ligands used in this study to induce upregulation of CD40 and CD80 in MDDCs 
suggests that these cytokines could play an important role in augmenting 
vaccine-induced protection.  
 
This study also showed that stimulation of MDDCs by IL-1Rrp2 ligands 
(represented by IL-1F8) leads to the production of cytokines (IL-12p70 and IL-
18) by MDDCs, which favour
 
TH1 polarization, as evidenced by increased IFN-Ȗ
concentrations in allogeneic MDDC/T-cell co-cultures (quoted in Mutamba et al., 
2012). In view of the crucial role that DCs play in bridging innate and adaptive 
immunity, this finding, coupled with the observation that CD3+ T cells express IL-
1Rrp2, provides new evidence that IL-1Rrp2 and its ligands play an important 
role in innate and adaptive immunity in humans. Of particular importance is the 
observation that IL-1F8 stimulation in MDDCS induces TH1 polarization and 
hence inflammatory cytokine production. This provides further evidence of the 
potential role of IL-1Rrp2 and its ligands in inflammatory responses and 
suggests that they may also have a role as therapeutic targets. 
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The finding that CD3+ T cells express IL-1Rrp2, suggesting that IL-1Rrp2 ligands 
can stimulate them directly, is interesting in that it may suggest a role for IL-
1Rrp2 ligands in antigen-presenting-cell-independent T cell-mediated adaptive 
immune responses. Further studies will help clarify whether IL-1Rrp2 ligands 
behave like IL-ȕLQWHUPVRIEHLQJDEOHWRGLUHFWO\DFWRQ7FHOOVUHVXOWLQJLQ
enhancement of antigen-driven expansion and differentiation as observed in 
mouse models (Ben-Sasson et al., 2009). However, results from the current 
study which show that human CD3+ T cells express IL-1Rrp2 (suggesting that 
they can respond to stimulation by IL-1Rrp2 ligands) suggest that this could be 
the case. Our results are also consistent with a recent published report which 
shows that  mouse DCs and CD4+ T lymphocytes express IL-1Rrp2 (which they 
referred to as IL-36R) and that both cell types respond to IL-1Rrp2 ligands 
(Vigne et al. 2011).   
 
The current study also showed that MDDCs are functionally distinct from blood 
borne immature skin DCs (or CD209+/CD14+ blood monocytes). In line with 
reports that IL-1Rrp2 ligands are present in skin DCs (Langerhans cells) (Dunn 
et al., 2001; Debets et al., 2001; Johnston et al., 2011) and also in view of 
emerging data showing a role for IL-1Rrp2 ligands in skin disorders such as 
psoriasis (Blumberg et al., 2007; Blumberg et al., 2010) plus findings from the 
current study which showed IL-1Rrp2 expression in human MDDCs, it was 
speculated that immature peripheral blood CD209+/CD14+ Langerhans cells 
would express IL-1Rrp2 and be matured by novel IL-1 cytokines. However,  
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under the experimental conditions used in this study, immature peripheral blood 
CD209+/CD14+ Langerhans cells proved to be functionally different from 
MDDCs with regards to IL-1Rrp2 expression, raising questions about previously 
suggested similarities between MDDCs and skin Langerhans cells (Geissmann 
et al., 1998; Grassi et al., 1998; Herbst et al., 1998). Alternatively, it could well be 
that the CD209+/CD14+ population considered to be immature Langerhans cells 
in the current study is actually a rare monocyte population and not blood-borne 
precursors of dermal DCs, as previously reported (Larregina et al., 2001; Turville 
et al., 2002; Angel et al., 2007). In addition, although MDDCs have served as a 
convenient in vitro model for DCs for a long time, their existence in vivo is 
questionable considering that there are differences in the levels of expression of 
CD14, CD1a, and DC-SIGN between in vitro derived MDDC and in vivo dermal 
DCs (which MDDCs are thought to resemble) (Turville et al., 2002). There is a 
possibility that either MDDCs are just a unique in vitro DC phenotype which does 
not exist in vivo or alternatively, they exist in vivo as a completely separate DC 
population that is used to replenish exhausted peripheral DCs during infection 
(reviewed in Donaghy, Wilkinson and Cunningham, 2006). Further work would 
shed more light. 
 
Classical IL-1 family members, IL-ĮDQG,/-ȕDVZHOODV,/-F11 (a newer IL-1 
family member), play a huge role in neutrophil migration which results in 
inflammation in diseases like RA (Faccioli et al., 1990; Perretti et al., 1993; 
Simbirtsev et al., 2001; Jonsson, Allen and Peng, 2005; Oliveira et al., 2008). 
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Furthermore, it is now appreciated that neutrophils can indirectly shape immune 
responses, for example, by delivering activation signals and antigenic molecules 
to DCs, resulting in the activation and maturation of DCs and subsequent 
activation of naive T lymphocytes and induction of antigen-specific responses 
(Megiovanni et al. 2006). In our study, granulocytic neutrophils did not express 
IL-1Rrp2, suggesting that IL-1Rrp2 ligands do not act on these cells, and hence 
IL-1Rrp2 ligands cannot cause neutrophil migration.  
 
When Towne et al. (2004) searched for a cell line that naturally expressed IL-
1Rrp2 and which could respond to IL-1F6, IL-1F8 and IL-1F9 without the need 
for further transfection, they only found IL-1Rrp2 expression in the following 
transformed cell lines: Colo205, SW48, HT29, HBT75, HaCAT and NCI/ADR-
RES. The current study has confirmed that HT29 and NCI/ADR-RES cells 
express IL-1Rrp2 (Towne et al., 2004) while THP-1 cells do not (Magne et al., 
2006). The current study also went a step further to test the functional status of 
THP-1 cells since they were going to be used as negative controls in qRT-PCR 
experiments investigating IL-1Rrp2 expression in our study (Appendix 1). The 
ability of THP-1 cells to induce TNF-ĮH[SUHVVLRQLQUHVSRQVHWR/36LVHYLGHQFH
that they were functional. On the other hand, their inability to respond to IL-1F8 
further confirms lack of IL-1Rrp2 expression as previously reported (Magne et 
al., 2006) and as shown in the current study. 
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IL-1Rrp2 expression in NCI/ADR-RES (OVCAR-8) cells was also investigated in 
the present study. NCI/ADR-RES cells are a human ovarian cancer cell line but 
were previously thought to be a breast cancer cell line (Towne et al., 2004; 
(Liscovitch and Ravid, 2007; Ke et al., 2011). They are widely used as a 
multidrug-resistant model in cancer research (Liscovitch and Ravid, 2007). In 
their study, Towne et al., reported that NCI/ADR-RES cells showed the highest 
IL-1Rrp2 expression among all cell lines tested, however, they referred to these 
cells as a breast cancer cell line. Realising that this cell line could be useful in 
studies involving IL-1Rrp2 ligands (based on reports that they highly expressed 
IL-1Rrp2) (Towne et al., 2004), we set out to re-investigate IL-1Rrp2 in 
NCI/ADR-RES cells. Consistent with previous findings (Towne et al., 2004) the 
present study found highest IL-1Rrp2 expression in NCI/ADR-RES cells, not just 
among the cell lines studied, but among all cells studied, suggesting that these 
cells could be useful in studying the biology of IL-1Rrp2 and its ligands . 
Furthermore, the finding is consistent with their new identity as human ovarian 
cancer cells since IL-1Rrp2 expression was reported in human ovaries (Towne 
et al., 2004).  Further studies would help establish the full significance of this 
finding.  
 
The finding that human ileal lamina propria cells express IL-1Rrp2 mRNA is 
interesting as it suggests that IL-1Rrp2 ligands may play a part in inflammatory 
responses in the intestine. Classical IL-1 family members, IL-ĮDQG,/-ȕDUH
NH\PHGLDWRUVRILQIODPPDWLRQLQLQIODPPDWRU\ERZHOGLVHDVHVOLNH&URKQ¶V 
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disease and ulcerative colitis (Youngman et al., 1993; Ludwiczek et al., 2004). It 
has been shown that in both of these diseases, the inflammatory IL-1 cytokines 
are generated by lamina propria cells and not by epithelial cells (Youngman et 
al., 1993). Other studies have shown that IL-18 (IL-1F4) is expressed in the 
affected inWHVWLQDOWLVVXHVRISDWLHQWVZLWK&URKQ¶VGLVHDVHDQGWKDWWKHF\WRNLQH
is found in both intestinal epithelial cells as well as in lamina propria 
mononuclear cells (reviewed in Dinarello, 2002). Further studies using animal 
models would help clarify the role of IL-1Rrp2 ligands in intestinal inflammation. 
 
Evidence from the present study suggests that IL-1Rrp2 ligands are functionally 
similar to IL-ȕDOEHLWZLWKORZHUOHYHOVRISRWHQF\ZKLFKRWKHUUHVHDUFKHUVKDYH
also previously noted (Towne et al., 2004; Magne et al., 2006). A very recent 
study (Towne et al., 2011) provided possible reasons for the lower levels of 
potency of IL-1Rrp2 ligands (compared with IL-ȕZKLFKZHDQGRWKHUV7RZQH
et al., 2004; Magne et al., 2006) noted. Previously, it had been speculated that, 
in a similar manner to the classical IL-1 cytokines (IL-ȕDQG,/-18), IL-1Rrp2 
ligands might require proteolytic cleavage in order to become fully active (Towne 
et al., 2004; Magne et al., 2006). Indeed, Towne et al. (2011) showed that 
truncation (removal of specific N-terminal amino acid(s) at a specific site) of IL-
1F5, IL-F6, IL-1F8 and IL-1F9 (which they called IL-36Ra, IL-Į,/-ȕDQG,/-
ȖUHVSHFWLYHO\GUDPDWLFDOO\HQKDQFHVWKHLUDFWLYLW\VXJJHVWLQJWKDWSRVW-
translational processing is required for full activity. We hypothesise that if 
truncated IL-1Rrp2 ligands had been used in our study, increased effects 
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(probably matching IL-ȕHIIHFWVZRXOGKDYHEHHQREVHUYHG,IWKDWLVWUXHWKHQ
there is a real possibility that IL-1Rrp2 ligands have similar or even higher 
biological activity to the other highly inflammatory IL-1 cytokines like IL-ȕDV
suggested by a recent study which showed that truncated IL-1F6, IL-1F8 and IL-
1F9 (all used at 100 ng/ml) were more potent than IL-ȕQJPODWLQGXFLQJ
maturation of murine bone marrow derived DCs and subsequent inflammatory 
cytokine production (Vigne et al., 2011). Further studies are needed to 
characterize the in vivo effects of these IL-1Rrp2 ligands and to identify the 
proteases that are responsible for their processing in vivo.     
 
In conclusion, by investigating IL-1Rrp2 expression and its regulation, findings 
from the current study will help shed more light into the interaction between IL-
1Rrp2 ligands and human immune and non-immune cells. By showing human 
dendritic cell IL-1Rrp2 expression and biological response, evidence from this 
study suggests that IL-1Rrp2 ligands may play a role in innate and adaptive 
immune responses.  Classical IL-1 family members and receptors are 
established therapeutic targets for inflammatory diseases such as rheumatoid 
arthritis (RA) (Fleischmann, 2002; Cohen et al., 2003). Recent data (Blumberg et 
al., 2007; Blumberg et al., 2010) and results from the present study suggest that 
IL-1Rrp2 and its ligands participate in inflammatory responses and could, 
therefore, be potential therapeutic targets for inflammatory diseases. 
Alternatively, these inflammatory IL-1Rrp2 ligands could also make good 
candidates as adjuvants. Although a great deal has been learnt about IL-1Rrp2 
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expression and biological response in human cells from the in vitro models used 
in this study, full understanding will only come from in vivo studies in the 
presence of disease. 
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CHAPTER 6: SCOPE FOR FURTHER RESEARCH 
 
The work outlined in this thesis could be expanded by investigating the 
production and release of IL-1F6, IL-1F8 and IL-1F9 by human DC subsets and 
T cells,  investigating the possibility of autocrine stimulation by IL-1Rrp2 ligands 
in human DCs subsets and T cells, investigating IL-1Rrp2 expression and 
biological response in human CD4+ T cells and CD8+ T cells, identifying the 
particular mononuclear cells expressing IL-1Rrp2 in lamina propria cells, 
assessing the in vivo effects of IL-1Rrp2 and its ligands by studying different 
disease models (e.g. colitis), studying in vivo expression of IL-1Rrp2 among 
human DC subsets and T cells, investigating whether a soluble form of IL-1Rrp2 
which could serve as a decoy receptor exists, studying the in vivo effects of IL-
1F6, IL-1F8 and IL-1F9, studying the effects of IL-1Rrp2 and IL-1Rrp2-ligand 
blockade in disease models and studying the effect of IL-1Rrp2 gene knock-out. 
        
 
 
 
 
 
 
 
 
 
279 
CHAPTER 7: BIBLIOGRAPHY 
ABBAS, A.K., MURPHY, K.M., SHER, A., 1996. Functional diversity of helper T 
lymphocytes. Nature, 383, 787 ± 793. 
ADEMA, G.J., 2009. Dendritic cells from bench to bedside and back. 
Immunology Letters, 122 (2), 128-130. 
AGARWAL, S., PIESCO, N.P., JOHNS, L.P., RICCELLI, A.E., 1995. Differential 
expression of IL-1 beta, TNF-alpha, IL-6, and IL-8 in human monocytes in 
response to lipopolysaccharides from different microbes. Journal of Dental 
Research, 74 (4), 1057-1065. 
AIZAWA, Y., AKITA, K., TANIAI, M., TORIGOE, K., MORI, T., NISHIDA, Y., 
USHIO, S., NUKADA, Y., TANIMOTO, T., IKEGAMI, H., IKEDA, M., 
KURIMOTO, M., 1999. Cloning and expression of interleukin-18 binding protein. 
FEBS Letters, 445 (2-3), 338-342. 
AKSENTIJEVICH, I., MASTERS, S.L., FERGUSON, P.J., DANCEY, P., 
FRENKEL, J., VAN ROYEN-KERKHOFF, A., LAXER, R., TEDGÅRD, U., 
COWEN, E.W., PHAM, T.H., BOOTY, M., ESTES, J.D., SANDLER, N.G., 
PLASS, N., STONE, D.L., TURNER, M.L., HILL, S., BUTMAN, J.A., 
SCHNEIDER, R., BABYN, P., EL-SHANTI, H.I., et al., 2009. An 
Autoinflammatory Disease with Deficiency of the Interleukin-1±Receptor 
Antagonist. New England Journal of Medicine, 360 (23), 2426-2437. 
 
280 
ALI, S., NGUYEN, D.Q., FALK, W., MARTIN, M.U., 2010. Caspase 3 inactivates 
biologically active full length interleukin-33 as a classical cytokine but does not 
prohibit nuclear translocation. Biochemical and Biophysical Research 
Communications, 391 (3), 1512-1516. 
ALTEN, R., GRAM, H., JOOSTEN, L.A., VAN DEN BERG, W.B., SIEPER, J., 
WASSENBERG, S., BURMESTER, G., VAN RIEL, P., DIAZ-LORENTE, M., 
BRUIN, G.J., WOODWORTH, T.G., RORDORF, C., BATARD, Y., WRIGHT, 
A.M., JUNG, T., 2008. The human anti-IL-1 beta monoclonal antibody ACZ885 is 
effective in joint inflammation models in mice and in a proof-of-concept study in 
patients with rheumatoid arthritis. Arthritis Research & Therapy, 10 (3), R67. 
ANDRE, R., LEROUET, D., KIMBER, I., PINTEAUX, E., ROTHWELL, N.J., 
2005. Regulation of expression of the novel IL-1 receptor family members in the 
mouse brain. Journal of Neurochemistry, 95, 324-330. 
 
ANGEL, C. E., LALA, A., CHEN, C.J., EDGAR, S.,G., OSTROVSKY, L.L., 
DUNBAR, P.R., 2007. CD14+ antigen-presenting cells in human dermis are less 
mature than their CD1a+ counterparts. International Immunology, 19, 1271±
1279. 
 
ANGUS, D.C., LINDE-ZWIRBLE, W.T., LIDICKER, J., CLERMONT, G., 
CARCILLO, J., PINSKY, M.R., 2001. Epidemiology of severe sepsis in the 
United States: analysis of incidence, outcome, and associated costs of care. 
Critical Care Medicine, 29, 1303-1310 
281 
AREND, W.P., MALYAK, M., GUTHRIDGE, C.J., GABAY, C., 1998.  Interleukin-
1 receptor antagonist: role in biology. Annual Review of Immunology, 16, 27-55. 
 
AREND, W.P., GUTHRIDGE, C.J., 2000. Biological role of interleukin 1 receptor 
antagonist isoforms. Annals of the Rheumatic Diseases, 59 (Suppl 1), i60±i64.   
 
AREND, W.P., 2002. The balance between IL-1 and IL-1Ra in disease. Cytokine 
and Growth Factor Reviews, 13, 323-340. 
 
AREND, W.P., PALMER, G., GABAY, C., 2008. IL-1, IL-18, and IL-33 families of 
cytokines. Immunological Reviews, 223, 20-38. 
       
ARTHRITIS CARE, 2007. Arthritis Care Fact Sheet: The Impact of Arthritis 
(statistics), Reviewed July 2007 [online]. Available at: <URL: 
http://www.arthritiscare.org.uk/PublicationsandResources/Listedbytype/Factshee
ts/main_content/GEN01_impactofarthritis_jul07.pdf> [Accessed 4 March 2009].  
 
ASAKURA, E.T., HANAMURA, A., UMEMURA, K., YADA, K., YAMAUCHI, T., 
TANABE, T., 1996. Effects of macrophage colony-stimulating factor (M-CSF) on 
lipopolysaccharide (LPS)-induced mediator production from monocytes in vitro. 
Immunobiology, 195, 300-313.  
 
AUWERX, J., 1991. The human leukemia cell line, THP-1: a multifaceted model 
for the study of monocyte-macrophage differentiation. Experientia, 47 (1), 22-31. 
282 
BAEKKEVOLD, E.S., ROUSSIGNÉ, M., YAMANAKA, T., JOHANSEN, F.E., 
JAHNSEN, F.L., AMALRIC, F., BRANDTZAEG, P., ERARD, M., HARALDSEN, 
G., GIRARD, J.P., 2003. Molecular characterization of NF-HEV, a nuclear factor 
preferentially expressed in human high endothelial venules. American Journal of 
Pathology, 163 (1), 69-79. 
BAGBY, G.C. Jr., 1989. Interleukin-1 and hematopoiesis. Blood Reviews, 3 (3), 
152±161.  
BANCHEREAU,  J., STEINMAN, R.M., 1998. Dendritic cells and the control of 
immunity. Nature, 392 (6673), 245-252. 
BANCHEREAU,  J., BRIERE, F., CAUX, C., DAVOUST, J., LEBECQUE, S., LIU, 
Y.J., PULENDRAN, B., PALUCKA, K., 2000. Immunobiology of dendritic cells. 
Annual Review of Immunology, 18, 767-811. 
 
BANCHEREAU J., PACZESNY, S., BLANCO, P., BENNETT, L., PASCUAL, V., 
FAY, J., PALUCKA, A.K., 2003. Dendritic cells: controllers of the immune system 
and a new promise for immunotherapy. Annals of the New York Academy of 
Sciences, 987í 
 
BANDA, N.K.., GUTHRIDGE, C., SHEPPARD, D., CAIRNS, K.S., MUGGLI, M., 
BECH-OTSCHIR, D., DUBIEL, W., AREND, W.P., 2005. Intracellular IL-1 
receptor antagonist type I inhibits IL-1-induced cytokine production in 
keratinocytes through binding to the third component of the COP9 signalosome. 
Journal of Immunology, 174, 3608±3616. 
283 
BARGETZI, M.J., LANTZ, M., SMITH, C.G., TORTI, F.M., OLSSON, I., 
EISENBERG, S.P., STARNES, H.F., 1993. Interleukin-1 beta induces 
interleukin-1 receptor antagonist and tumor necrosis factor binding protein in 
humans. Cancer Research, 53 (17), 4010-4013. 
 
BARKER, B.R., TAXMAN, D.J., TING, J.P., 2011. Cross-regulation between the 
IL-ȕ,/-18 processing inflammasome and other inflammatory cytokines. Current 
Opinion in Immunology,  23, 591±597 (2011). 
 
BARKSBY, H.E., LEA, S.R., PRESHAW, P.M., TAYLOR, J.J., 2007. The 
expanding family of interleukin-1 cytokines and their role in destructive 
inflammatory disorders. Clinical and Experimental Immunology, 149, 217-225. 
 
BARNES, P.J., KARIN, M., 1997. Nuclear factor-kappaB: a pivotal transcription 
factor in chronic inflammatory diseases. The New England Journal of Medicine, 
336 (15), 1066-1071. 
       
BARTON, J.L., HERBST, R., BOSISIO, D., HIGGINS, L., NICKLIN, M.J., 2000. 
A tissue specific IL-1 receptor antagonist homolog from the IL-1 cluster lacks IL-
1, IL-1ra, IL-18 and IL-18 antagonist activities. European Journal of Immunology, 
30, 3299-3308. 
 
BAZAN, J.F., TIMANS, J.C., KASTELEIN, R.A., 1996. A newly defined 
interleukin-1? Nature, 379 (6566), 591. 
284 
BEN-SASSON, S.Z., HU-LI, J., QUIEL, J., CAUCHETAUX, S., RATNER, M., 
SHAPIRA, I., DINARELLO, C.A., PAUL, W.E., 2009. IL-1 acts directly on CD4 T 
cells to enhance their antigen-driven expansion and differentiation. Proceedings 
of the National Academy of Sciences, 106 (17), 7119-7124. 
 
BENDELE, A., McABEE, T., SENNELLO, G., FRAZIER, J., CHLIPALA, E., 
MCCABE, D., 1999. Efficacy of sustained blood levels of interleukin-1 receptor 
antagonist in animal models of arthritis: Comparison of efficacy in animal models 
with human clinical data. Arthritis & Rheumatism, 42 (3), 498-506 
 
BENDRISS-VERMARE, N., BARTHÉLÉMY, C., DURAND, I., BRUAND, C., 
DEZUTTER-DAMBUYANT, C., MOULIAN, N., BERRIH-AKNIN, S., CAUX, C., 
TRINCHIERI, G., BRIÈRE F., 2001. Human thymus contains IFN-alpha-
producing CD11c(-), myeloid CD11c(+), and mature interdigitating dendritic cells. 
Journal of Clinical Investigation, 107 (7), 835-844. 
 
BENSEN, J.T., DAWSON, P.A., MYCHALECKYJ, J.C., BOWDEN, D.W., 2001. 
Identification of a novel human cytokine gene in the interleukin gene cluster on 
chromosome 2q12-14.  Journal of Interferon and Cytokine Research, 21, 899-
904. 
 
BERGLOF, E., ANDRE, R., RENSHAW, B.R., ALLAN, S.M., LAWRENCE, C.B., 
ROTHWELL, N.J., PINTEAUX, E., 2003. IL-1Rrp2 expression and IL-1F9 (IL-
1H1) actions in brain cells. Journal of Neuroimmunology, 139, 36-43.  
285 
BISTRIAN, B.R., SCHWARTZ, J., ISTFAN, N.W., 1992. Cytokines, muscle 
proteolysis, and the catabolic response to infection and inflammation. 
Proceedings of the Society for Experimental Biology and Medicine, 200 (2), 220-
223. 
 
BLACKSTOCK, R., 2003. Roles for CD40, B7 and major histocompatibility 
complex in induction of enhanced immunity by cryptococcal polysaccharide-
pulsed antigen-presenting cells. Immunology, 108 (2), 158-166. 
 
BLUMAN, E.M., SCHNIER, G.S., AVALOS, B.R., STROUT, M.P., SULTAN, H., 
JACOBSON, F.W., WILLIAMS, D.E., CARSON, W.E., CALIGIURI, M.A., 1996. 
The c-kit ligand potentiates the allogeneic mixed lymphocyte reaction. Blood, 88 
(10), 3887-3893. 
  
BLUMBERG, H., DINH, H., TRUEBOLD, E.S., PRETORIUS, J., KUGLER, D., 
WENG, N., KANALY, S.T., TOWNE, J.E., WILLIS, C.R., KUECHLE, M.K., SIMS, 
J.E., PESCHON, J.J., 2007. Opposing activities of two novel members of the IL-
1 ligand family regulate skin inflammation. Journal of Experimental Medicine, 
204(11), 2603-2614. 
 
BLUMBERG, H., DINH, H., DEAN. C. JR, TRUEBLOOD, E.S., BAILEY, K., 
SHOWS, D., BHAGAVATHULA, N., ASLAM, M.N., VARANI, J., TOWNE, J.E., 
SIMS, J.E., 2010. IL-1RL2 and Its Ligands Contribute to the Cytokine Network in 
Psoriasis. The Journal of Immunology, 18 (7), 4354-4362. 
       286   
BORN, T.L., SMITH, D.E., GARKA, K.E., RENSHAW, B.R., BERTLES, J.S., 
SIMS, J.E., 2000. Identification and characterization of two members of a novel 
class of the IL-1R family: delineation of a new class of IL-1R-related proteins 
based on signalling. Journal of Biological Chemistry, 275 (39), 29946-29954. 
 
BOYUM, A. (1968). Isolation of mononuclear cells and granulocytes from human 
blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes 
by combining centrifugation and sedimentation at 1 g. Scandinavian Journal of 
Clinical & Laboratory Investigation. Supplement 97, 77-89. 
 
BRADDOCK, M., QUINN, A., 2004. Targeting IL-1 in inflammatory disease: new 
opportunities for therapeutic intervention. Nature Reviews Drug Discovery, 3, 
330-339. 
 
BRASSARD, D.L., GRACE, M.J., BORDENS, R.W., 2002. Interferon-alpha as 
an immunotherapeutic protein. Journal of Leukocyte Biology, 71 (4), 565-581. 
 
BRIGL, M., BRENNER, M.B., 2004.  CD1: Antigen Presentation and T Cell 
Function. Annual Review of Immunology, 22, 817-890.  
 
 
 
 
287 
BRISSONI, B., AGOSTINI, L., KROPF, M., MARTINON, F., SWOBODA, V., 
LIPPENS, S., EVERETT, H., AEBI, N., JANSSENS, S., MEYLAN, E., 
FELBERBAUM-CORTI, M., HIRLING, H., GRUENBERG, J., TSCHOPP, J., 
BURNS, K., 2006. Intracellular trafficking of interleukin-1 receptor I requires 
Tollip. Current Biology, 16 (22), 2265-2270. 
 
BROOK, M., TCHEN, C.R., SANTALUCIA, T., MCILRATH, J., ARTHUR, J.S., 
SAKLATVALA, J., CLARK, A.R., 2006. Posttranslational Regulation of 
Tristetraprolin Subcellular Localization and Protein Stability by p38 Mitogen-
Activated Protein Kinase and Extracellular Signal-Regulated Kinase Pathways. 
Molecular and Cellular Biology, 26 (6), 2408-2418. 
 
BRUNO, L., RES, P., DESSING, M., CELLA, M., SPITS, H., 1997. Identification 
of a committed T cell precursor population in adult human peripheral blood. 
Journal of Experimental Medicine, 185, 875.  
 
BUFLER, P., AZAM, T., GAMBONI-ROBERTSON, F., REZNIKOV, L.L., 
KUMAR, S., DINARELLO, C.A., KIM, S.H., 2002. A complex of the IL-1 
homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. 
Proceedings of the National Academy of Sciences, 99, 13723-13728. 
 
 
 
288 
 
BUFLER, P., GAMBONI-ROBERTSON, F., AZAM, T., KIM, S.H., DINARELLO, 
C.A., 2004. Interleukin-1 homologues IL-1F7b and IL-18 contain functional 
mRNA instability elements within the coding region responsive to 
lipopolysaccharide. Biochemical Journal, 381, 503-510. 
 
BULLWINKEL, J., LÜDEMANN, A., DEBARRY, J., SINGH, P.B., 2011. 
Epigenotype switching at the CD14 and CD209 genes during differentiation of 
human monocytes to dendritic cells. Epigenetics, 6, 45-51. 
 
BURNS, K., CLATWORTHY, J., MARTIN, L., MARTINON, F., PLUMPTON, C., 
MASCHERA, B., LEWIS, A., RAY, K., TSCHOPP, J., VOLPE, F., 2000. Tollip, a 
new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. Nature 
Cell Biology, 2 (6), 346-351. 
 
BURNS, K., JANSSENS, S., BRISSONI, B., OLIVOS, N., BEYAERT, R., 
TSCHOPP, J., 2003. Inhibition of Interleukin 1 Receptor/Toll-like Receptor 
Signaling through the Alternatively Spliced, Short Form of MyD88 Is Due to Its 
Failure to Recruit IRAK-4. The Journal of Experimental Medicine, 197 (2), 263±
268. 
 
BURNS, K., MARTINON, F., TSCHOPP, J., 2003. New insights into the 
mechanism of IL-ȕPDWXUDWLRQCurrent Opinion in Immunology, 15, 26-30. 
 
289 
BUSFIELD, S.J., COMRACK, C.A., YU, G., CHICKERING, T.W., SMUTKO, J.S., 
ZHOU, H., LEIBY, K.R., HOLMGREN, L..M, GEARING, D.P., PAN, Y., 2000. 
Identification and gene organization of three novel members of the IL-1 family on 
human chromosome 2. Genomics, 66, 213-216. 
 
CANNON, J.G., TOMPKINS, R.G., GELFAND, J.A., MICHIE, H.R., STANFORD, 
G.G., VAN DER MEER, J.W., ENDRES, S., LONNEMANN, G., CORSETTI, J., 
CHERNOW, B., et al., 1990. Circulating interleukin-1 and tumor necrosis factor 
in septic shock and experimental endotoxin fever. Journal of Infectious Diseases, 
161(1), 79±84. 
 
CARRIE, A., JUN, L., BIENVENU, T., VINET, M.C., MCDONELL, N., 
COUVERT, P., ZEMNI, R., CARDONA, A., VAN BUGGENHOUT, G., FRINTS, 
S., HAMEL, B., MORAINE, C., ROPERS, H.H., STROM, T., HOWELL, G.R., 
WHITTAKER, A., ROSS, M.T., KAHN, A., FRYNS, J.P., BELDJORD, C., 
MARYNEN, P., CHELLY, J., 1999. A new member of the IL-1 receptor family 
highly expressed in hippocampus and involved in X-linked mental retardation. 
Nature Genetics, 23, 25-31. 
 
CARRIER, Y., MA, H.L., RAMON, H.E., NAPIERATA, L., SMALL, C., O'TOOLE, 
M., YOUNG, D.A., FOUSER, L.A., NICKERSON-NUTTER, C., COLLINS, M., 
DUNUSSI-JOANNOPOULOS, K., MEDLEY, Q.G., 2011. Inter-regulation of Th17 
cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis 
pathogenesis. Journal of Investigative Dermatology, 131 (12), 2428-2437. 
         290    
CARRIERE, V., ROUSSEL, L., ORTEGA, N., LACORRE, D.A., AMERICH, L., 
AGUILAR, L., BOUCHE, G., GIRARD, J.P., 2007. IL-33, the IL-1-like cytokine 
ligand for ST receptor, is a chromatin-associated nuclear factor in vivo. 
Proceedings of the National Academy of Sciences, 104, 282-287. 
 
CASEY, L.C., BALK, R.A., BONE, R.C., 1993. Plasma cytokines and endotoxin 
levels correlate with survival in patients with the sepsis syndrome. Annals of 
Internal Medicine, 119, 771-778. 
 
CASTRO, G.A., ARNTZEN, C.J., 1993. Immunophysiology of the gut: a research 
frontier for integrative studies of the common mucosal immune system. 
American Journal of Physiology, 65 (4 Pt 1), G599-G610. 
 
CAUX, C., DEZUTTER-DAMBUYANT, C., SCHMITT, D., BANCHEREAU, J., 
1992. GM-CSF and TNF-alpha cooperate in the generation of dendritic 
Langerhans cells. Nature, 360 (6401), 258-261. 
 
CELLA, M., SCHEIDEGGER, D., PALMER-LEHMANN, K., LANE, P., 
LANZAVECCHIA, A., ALBER, G., 1996. Ligation of CD40 on dendritic cells 
triggers production of high levels of interleukin-12 and enhances T cell 
stimulatory capacity: T-T help via APC activation. The Journal of Experimental 
Medicine, 184 (2), 747-752. 
 
291 
CELLA, M., SALLUSTO, F., LANZAVECCHIA, A., 1997.  Origin, maturation and 
antigen presenting function of dendritic cells. Current Opinion in Immunology, 9 
(1), 10-16. 
 
CELLA, M., JARROSSAY, D., FACCHETTI, F., ALEBARDI, O., NAKAJIMA, H., 
LANZAVECCHIA, A., COLONNA, M., 1999. Plasmacytoid monocytes migrate to 
inflamed lymph nodes and produce large amounts of type I interferon. Nature 
Medicine, 5 (8), 919-923. 
 
CEUPPENS, J.L., BAROJA, M.L., LORRE, K., VAN DAMME, J., BILLIAU, A., 
1988. Human T cell activation with phytohemagglutinin. The function of IL-6 as 
an accessory signal. Journal of Immunology, 141 (11), 3868-3874. 
 
CHACKERIAN A.A., OLDHAM E.R., MURPHY E.E., SCHMITZ J., et al., 2007. 
IL-1 Receptor Accessory Protein and ST2 Comprise the IL-33 Receptor 
Complex. The Journal of Immunology, 179, 2551-2555. 
 
CHANG, C.C., WRIGHT, A., PUNNONEN, J., 2000. Monocyte-derived CD1a+ 
and CD1a- dendritic cell subsets differ in their cytokine production profiles, 
susceptibilities to transfection, and capacities to direct Th cell differentiation. 
Journal of Immunology, 165 (7), 3584-3591. 
 
 
292 
CHEN, M., WANG, H., CHEN, W., MENG, G., 2011. Regulation of adaptive 
immunity by the NLRP3 inflammasome. International Immunopharmacology, 11 
(5), 549-554. 
 
CHEVALIER, X., GIRAUDEAU, B., CONROZIER, T., MARLIERE, J., KIEFER, 
P., GOUPILLE, P., 2005. Safety study of intraarticular injection of interleukin 1 
receptor antagonist in patients with painful knee osteoarthritis: a multicenter 
study. The Journal of Rheumatology, 32, 1317±1323. 
 
CHURCH, L.D., SAVIC, S., MCDERMOTT, M.F., 2008. Long term management 
of patients with cryopyrin-associated periodic syndromes (CAPS): focus on 
rilonacept (IL-1 Trap). Biologicals, 2, 733±742. 
 
COHEN, S.B., RUBBERT, A., 2003. Bringing the clinical experience with 
anakinra to the patient. Rheumatology, 42, II36-II40 
 
COLLIN, M., BIGLEY, V., HANIFFA, M., HAMBLETON, S., 2011. Human 
dendritic cell deficiency: the missing ID? Nature Reviews Immunology, 11, 575-
583. 
 
COLONNA, M, TRINCHIERI, G, LIU, Y.J., 2004. Plasmacytoid dendritic cells in 
immunity. Nature Immunology, 5 (12), 1219-1226. 
 
293 
COLPAERT, S., VANSTRAELEN, K., LIU, Z., PENNINCKX, F., GEBOES, K., 
RUTGEERTS, P., CEUPPENS, J., 2002. Decreased lamina propria effector cell 
responsiveness to interleukin-10 in ileal Crohn's disease. Clinical Immunology, 
102 (1), 68-76. 
 
COLOTTA, F., RE, F., MUZIO, M., BERTINI, R., POLENTARUTTI, N., SIRONI, 
M., GIRI, J.G., DOWER, S.K., SIMS, J.E., MANTOVANI, A., 1993. Interleukin-1 
type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science, 261 
(5120), 472-475. 
 
COLOTTA, F., DOWER, S.K., SIMS, J.E., MANTOVANI, A., 1994. The type II 
'decoy' receptor: a novel regulatory pathway for interleukin 1. Immunology 
Today, 15 (12), 562-566. 
 
COOMBES, J.L., POWRIE, F., 2008. Dendritic cells in intestinal immune 
regulation. Nature Reviews Immunology, 8 (6), 435-446. 
 
COONEY, R.N., MAISH III, G.O. 3RD., GILPIN, T., SHUMATE, M.L., LANG, C.H., 
VARY, T.C., 1999a. Mechanism of IL-1-induced inhibition of protein synthesis in 
skeletal muscle. Shock, 11, 235-241.   
       
COONEY, R.N., SHUMATE, M., 2006. The Inhibitory Effects of Interleukin-1 on 
Growth Hormone Action During Catabolic Illness. Vitamins and Hormones, 74C, 
317-340.     294 
COOPER, N.J., 2000. Economic burden of rheumatoid arthritis: a systematic 
review. Rheumatology, 39, 28-33. 
 
CORCORAN, L., FERRERO, I., VREMEC, D., LUCAS, K., WAITHMAN, J., 
O'KEEFFE, M., WU, L., WILSON, A., SHORTMAN, K., 2003. The lymphoid past 
of mouse plasmacytoid cells and thymic dendritic cells. Journal of Immunology, 
170 (10), 4926-4932. 
 
COSTELLOE, C., WATSON, M., MURPHY, A., MCQUILLAN, K., LOSCHER, C., 
ARMSTRONG, M.E., GARLANDA, C., MANTOVANI, A., O'NEILL, L.A., MILLS, 
K.H., LYNCH, M.A., 2008. IL-1F5 mediates anti-inflammatory activity in the brain 
through induction of IL-4 following interaction with SIGIRR/TIR8. Journal of 
Neurochemistry, 105 (5), 1960-1969.   
 
DEBETS, R., TIMANS, J.C., HOMEY, B., ZURAWSKI, S., SANA, T.R., LO, S., 
WAGNER, J., EDWARDS, G., CLIFFORD, T., MENON, S., BAZAN, J.F., 
KASTELEIN, R.A., 2001. Two novel IL-1 family members, IL-1 delta and IL-1 
epsilon, function as an antagonist and agonist of NF-kappa B activation through 
the orphan IL-1 receptor-related protein 2. Journal of Immunology, 167, 1440-
1446. 
 
DEDRICK, R.L., CONLON, P.J., 1995. Prolonged expression of 
lipopolysaccharide (LPS)-induced inflammatory genes in whole blood requires 
continual exposure to LPS. Infection and Immunity, 63, (4), 1362±1368. 
295 
DEL PUENTE, A., KNOWLER, W.C., PETTITT, D.J., BENNETT, P.H., 1989. 
High incidence and prevalence of rheumatoid arthritis in Pima Indians. American 
Journal of Epidemiology, 129 (6), 1170-1178. 
 
DE VERTEUIL, R., IMAMURA, M., ZHU, S., GLAZENER, C., FRASER, C., 
MUNRO, N., HUTCHISON, J., GRANT, A., COYLE, D., COYLE, K., VALE, L., 
2008. Systematic review of the clinical effectiveness and cost-effectiveness and 
economic modelling of minimal incision total hip replacement approaches in the 
management of arthritic disease of the hip. Health Technology Assessment, 12 
(26), 1-244  
 
DIDIERLAURENT, A., BRISSONI, B., VELIN, D., AEBI, N., TARDIVEL, A., 
KÄSLIN, E., SIRARD, J.C., ANGELOV, G., TSCHOPP, J., BURNS, K., 2006. 
Tollip regulates proinflammatory responses to interleukin-1 and 
lipopolysaccharide. Molecular and Cellular Biology, 26 (3), 735-742. 
 
DILLON, S.M., ROGERS, L.M., HOWE, R., HOSTETLER, L.A., BUHRMAN, J., 
MCCARTER, M.D., WILSON, C.C., 2010. Human intestinal lamina propria 
CD1c+ dendritic cells display an activated phenotype at steady state and 
produce IL-23 in response to TLR7/8 stimulation. Journal of Immunology, 184 
(12), 6612-6621. 
 
DINARELLO, C.A., 1984. Interleukin-1 and the pathogenesis of the acute phase 
response. New England Journal of Medicine, 311(22), 1413-1418. 
296 
DINARELLO, C.A., 1991. Interleukin-1 and interleukin-1 antagonism. Blood, 77, 
1627-1652.  
 
DINARELLO, C.A., WOLFF, S.M., 1993. The Role of Interleukin-1 in Disease. 
New England Journal of Medicine, 328 (2), 106-113. 
 
DINARELLO, C.A., 1996. Biologic basis for interleukin-1 in disease. Blood, 87, 
2095-2147. 
 
DINARELLO, C.A., 1997. Interleukin-1. Cytokine and Growth Factor Reviews, 8, 
253-265. 
 
DINARELLO, C.A., 1998. Interleukin-1 beta, interleukin-18, and the interleukin-1 
beta converting enzyme. Annals of the New York Academy of Sciences, 856, 1-
11. 
 
DINARELLO, C.A., 2000. Proinflammatory cytokines. Chest, 118, 503-508. 
 
DINARELLO, C.A., 2002. The IL-1 family and inflammatory diseases. Clinical 
and Experimental Rheumatology, 20(5), Supplement 27, S10-S13. 
 
DINARELLO, C.A., 2003. Setting the cytokine trap for autoimmunity. Nature 
Medicine, 9, 20 ± 22. 
297 
DINARELLO, C.A., 2003. Anti-cytokine therapeutics and infections. Vaccine, 21 
(Suppl 2), S24-34  
 
DINARELLO, C.A., FANTUZZI, G., 2003. Interleukin-18 and host defense 
against infection. Journal of Infectious Diseases, 187 (Supplement 2), 370-384. 
 
DINARELLO, C.A., 2003. Interleukin-1 Family [IL-1F1, F2]. In: THOMSON, A.W. 
and LOTZE, M.T. (Eds.) The Cytokine Handbook. 4th Ed. London: Academic 
Press. P643-668   
 
DINARELLO, C.A., 2005. Blocking IL-1 in systemic inflammation. Journal of 
Experimental Medicine, 201, 1355-1359. 
 
DINARELLO, C.A., 2005. The many worlds of reducing interleukin-1. Arthritis 
and Rheumatism, 52, 1960-1967. 
 
DINARELLO, C.A., 2005. An IL-1 family member requires caspase-1 processing 
and signals through the ST2 receptor. Immunity, 2005, 23, 461-462. 
 
DINARELLO, C.A., 2009. Immunological and inflammatory functions of the 
interleukin̻ 1 family. Annual Review of Immunology, 27, 519±550 (2009). 
 
DINARELLO, C.A., 2011. Interleukin-1 in the pathogenesis and treatment of 
inflammatory diseases. Blood, 117 (14), 3720-3732. 
298 
DINARELLO, C., AREND, W., SIMS, J., SMITH, D., et al., 2010. IL-1 family 
nomenclature. Nature Immunology, 11 (11), 973.   
 
DINARELLO, C.A., SIMON, A., VAN DER MEER, J.W., 2012. Treating 
inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nature 
Reviews Drug Discovery, 11 (8), 633-652. 
 
DOCAGNE, F., CAMPBELL, S.J., BRISTOW, A.F., POOLE, S., VIGUES, S., 
GUAZA, C., PERRY, V.H., ANTHONY, D.C., 2005. Differential regulation of type 
I and type II interleukin-1 receptors in focal brain inflammation. European Journal 
of Neuroscience, 21 (5), 1205-1214. 
 
DONAGHY, H., WILKINSON, J., CUNNINGHAM, A.L., 2006. HIV interactions 
with dendritic cells: has our focus been too narrow? Journal of Leukocyte 
Biology, 80 (5), 1001-1012. 
 
DRIPPS, D.J., BRANDHUBER, B.J., THOMPSON, R.C., EISENBERG, S.P., 
1991. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor 
but does not initiate IL-1 signal transduction. The Journal of Biological 
Chemistry, 266 (16), 10331-10336. 
  
DUMONT, F.J., 2006. The interleukin-1 families of cytokines and receptors: 
therapeutic potential for immunomodulation and the treatment of inflammatory 
disorders. Expert Opinion on Therapeutic Patents, 16(7), 879-912. 
299 
'811(6,06-(1,&./,10-2¶1(,///$$QQRWDWLQJJHQHV
with potential roles in the immune system: six new members of the IL-1 family. 
Trends in Immunology, 22, 533-536. 
 
'811$2¶1(,///$7KHLQWHUOHXNLQ-1 receptor/Toll-like receptor 
superfamily: signal transduction during inflammation and host defense. 6FLHQFH¶V 
STKE: Signal Transduction Knowledge Environment, 171, re3. 
 
DUNN, E.F., GAY, N.J., BRISTOW, A.F., GEARING, D.P., O'NEILL, L.A., PEI, 
X.Y., 2003. High-Resolution Structure of Murine Interleukin 1 Homologue IL-1F5 
Reveals Unique Loop Conformations for Receptor Binding Specificity. 
Biochemistry, 42, 10938-10944. 
 
DZIONEK, A., FUCHS, A., SCHMIDT, P., CREMER, S., ZYSK, M., MILTENYI, 
S., BUCK, D.W., SCHMITZ, J., 2000. BDCA-2, BDCA-3, and BDCA-4: Three 
Markers for Distinct Subsets of Dendritic Cells in Human Peripheral Blood. The 
Journal of Immunology, 165, 6037-6046. 
 
EASTGATE, J.A., SYMONS, J.A., WOOD, N.C., GRINLINTON, F.M., DI 
GIOVINE, F.S., DUFF, G.W., 1988. Correlation of plasma interleukin 1 levels 
with disease activity in rheumatoid arthritis. Lancet, 2(8613), 706±709 
 
 
300 
 
EBNER, S., RATZINGER, G., KRÖSBACHER, B., SCHMUTH, M., WEISS, A., 
REIDER, D., KROCZEK, R.A., HEROLD, M., HEUFLER, C., FRITSCH, P., 
ROMANI, N., 2001. Production of IL-12 by human monocyte-derived dendritic 
cells is optimal when the stimulus is given at the onset of maturation, and is 
further enhanced by IL-4. Journal of Immunology, 166 (1), 633-641. 
 
EISENBERG, S.P., EVANS, R.J., AREND, W.P., VERDERBER, E., BREWER, 
M.T., HANNUM, C.H., THOMPSON, R.C., 1990.  Primary structure and 
functional expression from complementary DNA of a human interleukin-1 
receptor antagonist. Nature, 343, 341 ± 346 
 
ELIAS, A.N., NANDA, V.S., BARR, R.J., 2003. CD1a expression in psoriatic skin 
following treatment with propylthiouracil, an antithyroid thioureylene. BMC 
Dermatology, 3, 3. 
 
EL-OMAR, E.M., CARRINGTON, M., CHOW, W.H., MCCOLL, K.E., BREAM, 
J.H., YOUNG, H.A., HERRERA, J., LISSOWSKA, J., YUAN, C.C., ROTHMAN, 
N., LANYON, G., MARTIN, M., FRAUMENI, J.F. JR., RABKIN, C.S., 2000. 
Interleukin-1 polymorphisms associated with increased risk of gastric cancer. 
Nature, 404 (6776), 398-402. 
 
 
 
301 
 
ESSNER, R., RHOADES, W.H., McBRIDE, D.L., MORTON, D.L., ECONOMOU, 
J.S., 1990. Differential effects of granulocyte-macrophage colony-stimulating 
factor and macrophage colony-stimulating factor on tumor necrosis factor and 
interleukin-1 production in human monocytes. Journal of Clinical & Laboratory 
Immunology, 32, 161-166. 
 
FACCIOLI, L.H., SOUZA, G.E., CUNHA, F.Q., POOLE, S., FERREIRA, S.H., 
1990. Recombinant interleukin-1 and tumor necrosis factor induce neutrophil 
migration "in vivo" by indirect mechanisms. Agents and Actions, 30 (3-4), 344-
349. 
 
FASANO, M.B., COUSART, S., NEAL, S., MCCALL, C.E., 1991. Increased 
expression of the interleukin 1 receptor on blood neutrophils of humans with the 
sepsis syndrome. Journal of Clinical Investigation, 88 (5), 1452-1459. 
     
FERGUSON, P.J., EL-SHANTI, H.I., 2007. Autoinflammatory bone disorders. 
Current Opinion in Rheumatology, 19 (5), 492-498. 
 
FISCHER, E., MARANO, M.A., BARBER, A.E., HUDSON, A., LEE, K., ROCK, 
C.S., HAWES, A.S., THOMPSON, R.C., HAYES, T.J., ANDERSON, T.D., et al., 
1991. Comparison between effects of interleukin-1  administration and sublethal 
endotoxemia in primates. American Journal of Physiology, 261, R442±R452. 
 
302 
 
FISHER, C.J.J., SLOTMAN, G.J., OPAL, S., et al., November 7, 1991. 
Interleukin-1 receptor antagonist reduces mortality in patients with sepsis 
syndrome. Abstract. Presented at the Annual Meeting of the American College of 
Chest Physicians, San Fransisco. 
 
FLEISCHMANN, R.M., 2002. Safety of anakinra, a recombinant interleukin-1 
receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and 
comparison to anti-TNF-ĮDJHQWVClinical & Experimental Rheumatology, 20 (5 
Suppl 27), S35-S41.  
 
FLEISCHMANN, R., STERN, R., IQBAL, I., 2004. Anakinra: an inhibitor of IL-1 
for the treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy, 4 
(8), 1333-1344. 
 
FOSTER, G.R., GERMAIN, C., JONES, M., LECHLER, R.I., LOMBARDI, G., 
2000. Human T cells elicit IFN-alpha secretion from dendritic cells following cell 
to cell interactions. European Journal of Immunology, 30 (11), 3228-35. 
 
FOSTER, N., ANDREADOU, K., JAMIESON, L., PRESHAW, P.M., TAYLOR, 
J.J., 2007. VIP Inhibits P. gingivalis LPS-induced IL-18 and IL-18BPa in 
Monocytes. Journal of Dental Research, 86, 883-887 
 
FRANCHI, L., MUÑOZ-PLANILLO, R., NÚÑEZ, G., 2012. Sensing and reacting 
to microbes through the inflammasomes. Nature Immunology, 13 (4), 325-332. 
303 
FURIE, M.B., MCHUGH, D.D., 1989. Migration of neutrophils across endothelial 
monolayers is stimulated by treatment of the monolayers with interleukin-1 or 
tumor necrosis factor-alpha. Journal of Immunology, 143 (10), 3309-3317. 
       
FURST, D.E., 2004. Anakinra: review of recombinant human interleukin-1 
receptor antagonist in the treatment of rheumatoid arthritis. Clinical 
Therapeutics, 26, 1960-1975. 
 
GABRIEL, S.E., 2001. The epidemiology of rheumatoid arthritis. Rheumatic 
Diseases Clinics of North America, 27 (2), 269-281. 
 
GALDIERO, M., D'ISANTO, M., VITIELLO, M., FINAMORE, E., PELUSO, L., 
GALDIERO, M., 2001. Porins from Salmonella enterica serovar Typhimurium 
induce TNF-alpha, IL-6 and IL-8 release by CD14-independent and 
CD11a/CD18-dependent mechanisms. Microbiology, 147 (Pt 10), 2697-2704. 
 
GALY, A., TRAVIS, M., CEN, D., CHEN, B., 1995. Human T, B, natural killer, 
and dendritic cells arise from a common bone marrow progenitor cell subset. 
Immunity, 3 (4), 459-473. 
 
GARAT, C., AREND, W.P., 2003. Intracellular IL-1Ra type 1 inhibits IL-1-induced 
IL-6 and IL-8 production in Caco-2 intestinal epithelial cells through inhibition of 
p38 mitogen-activated protein kinase and NF-kappaB pathways. Cytokine, 23 (1-
2), 31-40. 
304 
GEGNER, J.A., ULEVITCH, R.J., TOBIAS, P.S., 1995. Lipopolysaccharide 
(LPS) signal transduction and clearance. Dual roles for LPS binding protein and 
membrane CD14. Journal of Biological Chemistry, 270 (10), 5320-5325. 
 
GEIJTENBEEK, T.B., TORENSMA, R., VAN VLIET, S.J., VAN DUIJNHOVEN, 
G.C., ADEMA, G.J., VAN KOOYK, Y., FIGDOR, C.G., 2000. Identification of DC-
SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary 
immune responses. Cell, 100 (5), 575-585. 
 
GEIJTENBEEK, T.B., KROOSHOOP, D.J., BLEIJS, D.A., VAN VLIET, S.J., VAN 
DUIJNHOVEN, G.C., GRABOVSKY, V., ALON, R., FIGDOR, C.G., VAN 
KOOYK, Y., 2000. DC-SIGN-ICAM-2 interaction mediates dendritic cell 
trafficking. Nature Immunology, 1 (4), 353-357. 
 
GEISSMANN, F., PROST, C., MONNET, J.P., DY, M., BROUSSE, N., 
HERMINE, O., 1998. Transforming growth factor beta1, in the presence of 
granulocyte/macrophage colony-stimulating factor and interleukin 4, induces 
differentiation of human peripheral blood monocytes into dendritic Langerhans 
cells. Journal of Experimental Medicine, 187 (6), 961-966. 
 
 
 
 
305 
GIBSON, S.J., LINDH, J.M., RITER, T.R., GLEASON, R.M., ROGERS, L.M., 
FULLER, A.E., OESTERICH, J.L., GORDEN, K.B., QIU, X., MCKANE, S.W., 
NOELLE, R.J., MILLER, R.L., KEDL, R.M., FITZGERALD-BOCARSLY, P., 
TOMAI, M.A., VASILAKOS, J.P., 2002. Plasmacytoid dendritic cells produce 
cytokines and mature in response to the TLR7 agonists, imiquimod and 
resiquimod. Cellular Immunology, 218 (1-2), 74-86. 
 
GILLIS, S., WATSON, J., 1980. Biochemical and biological characterization of 
lymphocyte regulatory molecules. V. Identification of an interleukin 2-producing 
human leukemia T cell line. Journal of Experimental Medicine, 152 (6), 1709-
1719. 
 
GOLDBACH-MANSKY, R., 2012. Immunology in clinic review series; focus on 
autoinflammatory diseases: update on monogenic autoinflammatory diseases: 
the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1. 
Clinical and Experimental Immunology, 167 (3), 391-404. 
 
GRABBE, S., KÄMPGEN, E., SCHULER, G., 2000. Dendritic cells: multi-lineal 
and multi-functional. Immunology Today, 21, 431-433. 
 
GRACIE, J.A., FORSEY, R.J., CHAN, W.L., GILMOUR, A., LEUNG, B.P., 
GREER, M.R., KENNEDY, K., CARTER, R., WEI, X.Q., XU, D., FIELD, M., 
FOULIS, A., LIEW, F.Y., MCINNES, I.B., 1999. A proinflammatory role for IL-18 
in rheumatoid arthritis. Journal of Clinical Investigations, 104, 1393-1401. 
306 
GRACIE, J.A., ROBERTSON, S.E., McINNES, I.B., 2003. Journal of Leukocyte 
Biology, 73, 213-224. 
 
GRASSI, F., DEZUTTER-DAMBUYANT, C., MCILROY, D., JACQUET, C., 
YONEDA, K., IMAMURA, S., BOUMSELL, L., SCHMITT, D., AUTRAN, B., 
DEBRÉ, P., HOSMALIN, A., 1998. Monocyte-derived dendritic cells have a 
phenotype comparable to that of dermal dendritic cells and display ultrastructural 
granules distinct from Birbeck granules. Journal of Leukocyte Biology, 64 (4), 
484-493. 
 
GRAVES, D.T., COCHRAN, D., 2003. The contribution of interleukin-1 and 
tumor necrosis factor to periodontal tissue destruction. Journal of 
Periodontology, 74, 391-401. 
 
GROVES, R.W., SHERMAN L., MIZUTANI, H., DOWER, S.K., KUPPER, T.S., 
1994. Detection of interleukin-1 receptors in human epidermis. Induction of the 
type II receptor after organ culture and in psoriasis. The American Journal of 
Pathology, 145 (5), 1048-1056. 
 
GROVES, R.W., GIRI, J., SIMS, J., DOWER, S.K., KUPPER, T.S., 1995. 
Inducible expression of type 2 IL-1 receptors by cultured human keratinocytes. 
Implications for IL-1-mediated processes in epidermis. The Journal of 
Immunology, 154 (8), 4065-4072. 
307 
GROUARD, G., RISSOAN, M.C., FILGUEIRA, L., DURAND, I., BANCHEREAU, 
J., LIU, Y.J., 1997. The enigmatic plasmacytoid T cells develop into dendritic 
cells with interleukin (IL)-3 and CD40-ligand. Journal of Experimental Medicine, 
185 (6), 1101-1111. 
 
GUO, Z., ZHANG, M., AN, H., CHEN, W., LIU, S., GUO, J., YU, Y., CAO, X., 
2003. Fas ligation induces IL-ȕ-dependent maturation and IL-ȕ-independent 
survival of dendritic cells: different roles of ERK and NF-ț%VLJQDOLQJSDWKZD\V
Blood, 102, 4441-4447. 
 
HANNIGAN, B.M., PALLISTER, C.J., (Ed.), 2000. Biomedical Sciences 
Explained-Immunology. London: Arnold Publishers, pp. 22-23. 
 
HANNUM, C.H., WILCOX, C.J., AREND, W.P., JOSLIN, F.G., DRIPPS, D.J., 
HEIMDAL, P.L., ARMES, L.G., SOMMER, A., EISENBERG, S.P., THOMPSON, 
R.C., 1990.  Interleukin-1 receptor antagonist activity of a human interleukin-1 
inhibitor. Nature, 343 336±340. 
 
HARMAN, B.C., MILLER, J.P., NIKBAKHT, N., GERSTEIN, R., ALLMAN, D., 
2006. Mouse plasmacytoid dendritic cells derive exclusively from estrogen-
resistant myeloid progenitors. Blood, 108 (3), 878-885. 
 
308 
HARRINGTON, L.E., HATTON, R.D., MANGAN, P.R., TURNER, H., MURPHY, 
T.L., MURPHY, K.M., WEAVER, C.T., 2005. Interleukin 17-producing CD4+ 
effector T cells develop via a lineage distinct from the T helper type 1 and 2 
lineages. Nature Immunology, 6 (11), 1123-1132. 
 
HARRISON, D.A., WELCH, C.A., EDDLESTON, J.M., 2006. The epidemiology 
of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: 
secondary analysis of a high quality clinical database, the ICNARC Case Mix 
Programme Database. Critical Care, 10(2), R42. 
 
HARVEY, J., LOTZE, M., STEVENS, M.B., LAMBERT, G., JACOBSON, D., 
1981. Rheumatoid arthritis in a Chippewa Band. I. Pilot screening study of 
disease prevalence. Arthritis and Rheumatism, 24 (5), 717-721. 
HAZUDA, D.J., LEE J.C., YOUNG P.R., 1988. The kinetics of interleukin 1 
secretion from activated monocytes. Differences between interleukin 1 alpha and 
interleukin 1 beta. The Journal of Biological Chemistry, 263 (17), 8473-8479. 
 
HERBST, B., KÖHLER, G., MACKENSEN, A., VEELKEN, H., LINDEMANN, A., 
1998. GM-CSF promotes differentiation of a precursor cell of monocytes and 
Langerhans-type dendritic cells from CD34+ haemopoietic progenitor cells. 
British Journal of Haematology, 101 (2), 231-241. 
 
309 
HOFFBRAND, A.V., PETTIT, J.E., MOSS, P.A.H., 2001. Essential Haematology. 
4th Edition. Oxford: Wiley-Blackwell, pp. 331. 
 
HOFFMAN, H.M., MUELLER, J.L., BROIDE, D.H., WANDERER, A.A., 
KOLODNER, R.D., 2001. Mutation of a new gene encoding a putative pyrin-like 
protein causes familial cold autoinflammatory syndrome and Muckle-Wells 
syndrome. Nature Genetics, 29 (3), 301-305. 
 
HOFFMAN, H.M., THRONE, M.L., AMAR, N.J., SEBAI, M., KIVITZ, A.J., 
KAVANAUGH, A., WEINSTEIN, S.P., BELOMESTNOV, P., YANCOPOULOS, 
G.D., STAHL, N., MELLIS, S.J., 2008. Efficacy and safety of rilonacept 
(interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: 
results from two sequential placebo-controlled studies. Arthritis and 
Rheumatism, 58 (8), 2443-2452. 
 
HOFFMAN, H.M., 2009. Management of Cryopyrin-associated Periodic 
Syndromes. European Musculoskeletal Review, 9, 56-59. 
 
HORLOCK, C., SHAKIB, F., MAHDAVI, J., JONES, N.S., SEWELL, H.F., 
GHAEMMAGHAMI, A.M., 2007. Analysis of proteomic profiles and functional 
properties of human peripheral blood myeloid dendritic cells, monocyte-derived 
dendritic cells and the dendritic cell-like KG-1 cells reveals distinct 
characteristics. Genome Biology, 8 (3), R30. 
310 
HUNTER, C.A., 2005. New IL-12-family members: IL-23 and IL-27, cytokines 
with divergent functions. Nature Reviews Immunology, 5 (7), 521-531. 
 
IPARRAGUIRRE, A., TOBIAS, J.W., HENSLEY, S.E., MASEK, K.S., 
CAVANAGH, L.L., RENDL, M., HUNTER, C.A., ERTL, H.C., VON ANDRIAN, 
U.H., WENINGER, W., 2008. Two distinct activation states of plasmacytoid 
dendritic cells induced by influenza virus and CpG 1826 oligonucleotide. Journal 
of Leukocyte Biology, 83 (3), 610-620. 
 
ISHIKAWA, F., NIIRO, H., IINO, T., YOSHIDA, S., SAITO, N., ONOHARA, S., 
MIYAMOTO, T., MINAGAWA, H., FUJII, S., SHULTZ, L.D., HARADA, M., 
AKASHI, K., 2007. The developmental program of human dendritic cells is 
operated independently of conventional myeloid and lymphoid pathways. Blood, 
110 (10), 3591-3660. 
 
IWAHANA, H., YANAGISAWA, K., ITO-KOSAKA, A., KUROIWA, K., TAGO, K., 
KOMATSU, N., KATASHIMA, R., ITAKURA, M., TOMINAGA, S., 1999. Different 
promoter usage and multiple transcription initiation sites of the interleukin-1 
receptor-related human ST2 gene in UT-7 and TM12 cells. European Journal of 
Biochemistry, 264 (2), 397-406. 
 
IWASAKI, A., MEDZHITOV, R., 2004. Toll-like receptor control of the adaptive 
immune responses. Nature Immunology, 5 (10), 987-95. 
311 
JANKOVIC, D., KULLBERG, M.C., HIENY, S., CASPAR, P., COLLAZO, C.M., 
SHER, A., 2002. In the absence of IL-12, CD4(+) T cell responses to intracellular 
pathogens fail to default to a Th2 pattern and are host protective in an IL-10(-/-) 
setting. Immunity, 16 (3), 429-439. 
 
JOHNSTON A., XING X., GUZMAN A.M., RIBLETT M., LOYD, C.M., WARD, 
N.L., WOHN, C., PRENS, E.P., WANG, F., MAIER, L.E., KANG, S., 
VOORHEES, J.J., ELDER, J.T., GUDJONSSON, J.E., 2011. IL-1F5, -F6, -F8, 
and -F9: a novel IL-1 family signaling system that is active in psoriasis and 
promotes keratinocyte antimicrobial peptide expression. The Journal of 
Immunology, 186 (4), 2613-2622. 
JONSSON, H., ALLEN, P., PENG, S.L., 2005. Inflammatory arthritis requires 
Foxo3a to prevent Fas ligand-induced neutrophil apoptosis. Nature Medicine, 11 
(6), 666-671. 
JUNG, N., HELLMANN, M., HOHEISEL, R., LEHMANN, C., HAASE, I., 
PERNIOK, A., HALLEK, M., RUBBERT, A., 2010. An open-label pilot study of 
the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to 
or intolerant of methotrexate (MTX). Clinical Rheumatology, 29 (10), 1169-1173. 
 
KACZOROWSKI, D.J., MOLLEN, K.P., EDMONDS, R., BILLIAR, T.R., 2008. 
Early events in the recognition of danger signals after tissue injury. Journal of 
Leukocyte Biology, 83, 546-552. 
312 
KADOWAKI, N., ANTONENKO, S., LAU, J.Y., LIU, Y.J., 2000. Natural Interferon 
Įȕ±Producing Cells Link Innate and Adaptive Immunity. The Journal of 
Experimental Medicine, 192 (2), 7269-7276. 
 
KAHLENBERG, J.M., LUNDBERG, K.C., KERTESY, S.B., QU, Y., DUBYAK, 
G.R., 2005. Potentiation of caspase-1 activation by the P2X7 receptor is 
dependent on TLR signals and requires NF-kB-driven protein synthesis. Journal 
of Immunology, 175, 7611-7622. 
 
.$/,ē6.,36&+8,7(0$.(5-++,/.(16&0.$36(1%(5*0/
1998. Prostaglandin E2 induces the final maturation of IL-12-deficient 
CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final 
dendritic cell maturation and are resistant to further modulation. Journal of 
Immunology, 161 (6), 2804-2809. 
 
.$/,ē6.,36&+8,7(0$.(5-++,/.(16&0:,(5(1*$($
KAPSENBERG, M.L., 1999. Final maturation of dendritic cells is associated with 
impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: 
decreased ability of mature dendritic cells to produce IL-12 during the interaction 
with Th cells. Journal of Immunology, 162 (6), 3231-3236. 
 
 
 
313 
 
.$/,ē6.,360,76++6&+8,7(0$.(5-+9,(,5$3/9$1(,-.
M., DE JONG, E.C., WIERENGA, E.A., KAPSENBERG, M.L., 2000. IL-4 is a 
mediator of IL-12p70 induction by human Th2 cells: reversal of polarized Th2 
phenotype by dendritic cells. Journal of Immunology, 165 (4), 1877-1881. 
 
KAPLAN, D.H., JENISON, M.C., SAELAND, S., SHLOMCHIK, W.D., 
SHLOMCHIK, M.J., 2005. Epidermal langerhans cell-deficient mice develop 
enhanced contact hypersensitivity. Immunity, 23 (6), 611-620. 
 
KARSUNKY, H., MERAD, M., MENDE, I., MANZ, M.G., ENGLEMAN, E.G., 
WEISSMAN, I.L., 2005. Developmental origin of interferon-alpha-producing 
dendritic cells from hematopoietic precursors. Experimental Haematology, 33 
(2), 173-181. 
 
KE, W., YU, P., WANG, J., WANG, R., GUO, C., ZHOU, L., LI, C., LI, K., 2011. 
MCF-7/ADR cells (re-designated NCI/ADR-RES) are not derived from MCF-7 
breast cancer cells: a loss for breast cancer multidrug-resistant research. 
Medical Oncology, 28 (Suppl 1), S135-S141. 
 
KIM, S.H., EISENSTEIN, M., REZNIKOV, L., FANTUZZI, G., NOVICK, D., 
RUBINSTEIN, M., DINARELLO, C.A., 2000. Structural requirements of six 
naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. 
Proceedings of the National Academy of Sciences, 97 (3), 1190-1195. 
314 
 
KLEMENZ, R., HOFFMAN, S., WERENSKIOLD, A.K., 1989. Serum- and 
oncoprotein-mediated induction of a gene with sequence similarity to the gene 
encoding carcinoembryonic antigen. Proceedings of the National Academy of 
Sciences of the United States of America, 86 (15), 5708-12. 
 
KNOUFF, C., AUWERX, J., 2004. Peroxisome proliferator-activated receptor-
gamma calls for activation in moderation: lessons from genetics and 
pharmacology. Endocrine Reviews, 25 (6), 899-918. 
 
KOBAYASHI, K., HERNANDEZ, L.D., GALÁN, J.E., JANEWAY, C.A. JR, 
MEDZHITOV, R., FLAVELL, R.A., 2002. IRAK-M is a negative regulator of Toll-
like receptor signaling. Cell, 110 (2), 191-202. 
 
KOBAYASHI, Y., APPELLA, E., YAMADA, M., COPELAND, T.D., OPPENHEIM, 
J.J., MATSUSHIMA, K., 1988. Phosphorylation of intracellular precursors of 
human IL-1. Journal of Immunology, 140 (7), 2279-2287. 
 
KOCH, F., STANZL, U., JENNEWEIN, P., JANKE, K., HEUFLER, C., 
KÄMPGEN, E., ROMANI, N., SCHULER, G., 1996. High level IL-12 production 
by murine dendritic cells: upregulation via MHC class II and CD40 molecules and 
downregulation by IL-4 and IL-10. Journal of Experimental Medicine, 184, 741-
746. 
 
315 
KOCH, A.E., KUNKEL, S.L., CHENSUE, S.W., HAINES, G.K., STRIETER, R.M., 
1992. Expression of interleukin-1 and interleukin-1 receptor antagonist by human 
rheumatoid synovial tissue macrophages. Clinical Immunology and 
Immunopathology, 65 (1), 23-29. 
 
KOENDERS, M.I., DEVESA, I., MARIJNISSEN, R.J., ABDOLLAHI-ROODSAZ, 
S., BOOTS, A.M., WALGREEN, B., DI PADOVA, F.E., NICKLIN, M.J., 
JOOSTEN, L.A., VAN DEN BERG, W.B., 2008. Interleukin-1 drives pathogenic 
Th17 cells during spontaneous arthritis in interleukin-1 receptor antagonist-
deficient mice. Arthritis and Rheumatism, 58 (11), 3461-3470. 
 
KUBOTA, T., KOIKE, R., 2010. Cryopyrin-associated periodic syndromes: 
background and therapeutics. Modern Rheumatology, 20 (3), 213-221. 
       
KUMAR, S., McDONNELL, P.C., LEHR, R., TIERNEY, L., TZIMAS, M.N., 
GRISWOLD, D.E., CAPPER, E.A., TAL-SINGER, R., WELLS, G.I., DOYLE, 
M.L., YOUNG, P.R., 2000. Identification and initial characterization of four novel 
members of the interleukin-1 family. Journal of Biological Chemistry, 275, 10308-
10314.  
 
 
 
 
 
316 
KUMAR, S., HANNING, C.R., BRIGHAM-BURKE, M.R., RIEMAN, D.J., LEHR, 
R., KHANDEKAR, S., KIRKPATRICK, R.B., SCOTT, G.F., LEE, J.C., LYNCH, 
F.J., GAO, W., GAMBOTTO, A., LOTZE, M.T., 2002. Interleukin-1F7B (IL-
1H4/IL-F7) is processed by caspase-1 and mature Il-1F7B binds to the IL-18 
receptor but does not induce IFN-gamma production. Cytokine, 18, 61-71. 
 
KURT-JONES, E. A., BELLER, D. I., MIZEL, S. B.,  UNANUE, E. R., 1985.  
Identification of a membrane̻ associated interleukin 1 in macrophages. 
Proceedings of the National Academy of Sciences USA, 82, 1204±1208. 
 
LACKMAN, R.L., CRESSWELL, P., 2006. Exposure of the promonocytic cell line 
THP-1 to Escherichia coli induces IFN-gamma-inducible lysosomal thiol 
reductase expression by inflammatory cytokines. Journal of Immunology, 177 
(7), 4833-4840.     
 
LANDER, E.S., LINTON, L.M., BIREEN, B., NUSBAUM, C., ZODY, M.C., 
BALDWIN, J., DEVON, K., DEWAR, K., DOYLE, M., et al., 2001. Initial 
sequencing and analysis of the human genome. Nature, 409 (6822), 860-921. 
 
LANG, D., KNOP, J., WESCHE, H., RAFFETSEDER, U., KURRLE, R., 
BORASCHI, D., MARTIN, M.U., 1998. The Type II IL-1 Receptor Interacts with 
the IL-1 Receptor Accessory Protein: A Novel Mechanism of Regulation of IL-1 
Responsiveness. The Journal of Immunology, 161, 6871-6877. 
317 
LANGDAHL, B.L., LØKKE, E., CARSTENS, M., STENKJAER, L.L., ERIKSEN, 
E.F., 2000. Osteoporotic fractures are associated with an 86-base pair repeat 
polymorphism in the interleukin-1--receptor antagonist gene but not with 
polymorphisms in the interleukin-1beta gene. Journal of Bone and Mineral 
Research, 15 (3), 402-414. 
 
LANGRISH, C.L., CHEN, Y., BLUMENSCHEIN, W.M., MATTSON, J., BASHAM, 
B., SEDGWICK, J.D., MCCLANAHAN, T., KASTELEIN, R.A., CUA, D.J., 2005. 
IL-23 drives a pathogenic T cell population that induces autoimmune 
inflammation. Journal of Experimental Medicine, 201 (2), 233-240. 
 
LARREGINA, A.T., MORELLI, A.E., SPENCER, L.A., LOGAR, A.J.,  WATKINS, 
S.C., ANGUS, W., THOMSON, A.W., FALO, L.D., 2001. Dermal-resident CD14+ 
cells differentiate into Langerhans cells. Nature Immunology, 2, 1151-1158. 
 
LEE, J.K., KIM, S.H., LEWIS, E.C., AZAM, T., REZNIKOV, L.L., DINARELLO, 
C.A., 2004. Differences in signalling pathways by IL-ȕDQG,/-18. Proceedings 
of the National Academy of Sciences, 101, 8815-8820. 
 
LENNARD, A., GORMAN, P., CARRIER, M., GRIFFITHS, S., SCOTNEY, H., 
SHEER, D., SOLARI, R., 1992. Cloning and chromosome mapping of the human 
interleukin-1 receptor antagonist gene. Cytokine, 4 (2), 83-89. 
318 
LEUCHT, C., BALLY-CUIF, L., 2002. The Universal ProbeLibrary - a Versatile 
Tool for Quantitative Expression Analysis in the Zebrafish. Biochemica, 2, 16-18 
 
LI, J., FENG, Z.H., LI, G.Y., MOU, D.L., NIE, Q.H., 2006. Expression of dendritic 
cell-specific intercellular adhesion molecule 3 grabbing nonintegrin on dendritic 
cells generated from human peripheral blood monocytes. World Journal of 
Gastroenterology, 12 (3), 453-456. 
  
LI, X., QIN, J., 2005. Modulation of Toll-interleukin 1 receptor mediated 
signalling. Journal of Molecular Medicine, 83, 258-266. 
 
LIN, H., HO, A.S., HALEY-VICENTE, D., ZHANG, J., BERNAL-FUSSELL, J., 
PACE, A.M., HANSEN, D., SCHWEIGHOFER, K., MIZE, N.K., FORD, J.E., 
2001. Cloning and characterization of IL-1HY2, a novel interleukin-1 family 
member. Journal of Biological Chemistry, 276, 20597-20602. 
     
LIPSCOMB, M.F., MASTEN, B.J., 2002. Dendritic Cells: Immune Regulators in 
Health and Disease. Physiological Reviews, 82, (1), 97-130. 
LISCOVITCH, M., RAVID, D., 2007. A case study in misidentification of cancer 
cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from 
OVCAR-8 human ovarian carcinoma cells. Cancer Letters, 245 (1-2), 350-352. 
 
 
319 
LIU, Y.J., KANZLER, H., SOUMELIS, V., GILLIET, M., 2001. Dendritic cell 
lineage, plasticity and cross-regulation. Nature Immunology, 2 (7), 585-589. 
 
LIU, Y.J., 2001. Dendritic cell subsets and lineages, and their functions in innate 
and adaptive immunity. Cell, 106 (3), 259-262. 
 
LIU, Y.J., 2005. "IPC: professional type 1 interferon-producing cells and 
plasmacytoid dendritic cell precursors". Annual Review of Immunology, 23, 275±
306. 
LIVAK, K. J., SCHMITTGEN, T. D., 2001. Analysis of Relative Gene Expression 
Data Using Real-Time Quantitative PCR and the 2-¨¨&7 Method. Methods, 25, 
402±408. 
 
LOCKSLEY, R.M., 2009. Nine lives: plasticity among T helper cell subsets. 
Journal of Experimental Medicine, 206 (8), 1643-1646. 
 
LUDWICZEK, O., VANNIER, E., BORGGRAEFE, I., KASER, A., SIEGMUND, 
B., DINARELLO, C.A., TILG, H., 2004. Imbalance between interleukin-1 agonists 
and antagonists: relationship to severity of inflammatory bowel disease. Clinical 
and Experimental Immunology, 138 (2), 323-329. 
 
320 
LUTZ, M.B., SCHULER, G., 2002. Immature, semi-mature and fully mature 
dendritic cells: which signals induce tolerance or immunity? Trends in 
Immunology,  
23 (9), 445-449. 
LUTZ, M.B., SCHNARE, M., MENGES, M., RÖSSNER, S., RÖLLINGHOFF, M., 
SCHULER, G., GESSNER, A., 2002. Differential Functions of IL-4 Receptor 
Types I and II for Dendritic Cell Maturation and IL-12 Production and Their 
Dependency on GM-CSF. The Journal of Immunology, 169, 3574-3580. 
MACATONIA, S.E., HSIEH, C.S., MURPHY, K.M., O'GARRA, A., 1993. 
Dendritic cells and macrophages are required for Th1 development of CD4+ T 
cells from ß TCR transgenic mice: IL-12 substitution for macrophages to 
stimulate IFN-ȖSURGXFWLRQLV,)1-Ȗ-dependent. International Immunology, 5, (9), 
1119-1128. 
MACATONIA, S.E., HOSKEN, N.A., LITTON, M., 1995. Dendritic cells produce 
IL-12 and direct the development of Th1 cells from naive CD4+ T cells. The 
Journal of Immunology, 154 (10), 5071-5079. 
MAERTEN, P., SHEN, C., COLPAERT, S., LIU, Z., BULLENS, D.A., VAN 
ASSCHE, G., PENNINCKX, F., GEBOES, K., VANHAM, G., RUTGEERTS, P., 
CEUPPENS, J.L., 2004. Involvement of interleukin 18 in Crohn's disease: 
evidence from in vitro analysis of human gut inflammatory cells and from 
experimental colitis models. Clinical and Experimental Immunology, 135 (2), 
310-317. 
321 
MAERTEN, P., SHEN, C., COLPAERT, S., LIU, Z., BULLENS, D.A., VAN 
ASSCHE, G., PENNINCKX, F., GEBOES, K., VANHAM, G., RUTGEERTS, P., 
CEUPPENS, J.L., 2004. Involvement of interleukin 18 in Crohn's disease: 
evidence from in vitro analysis of human gut inflammatory cells and from 
experimental colitis models. Clinical and Experimental Immunology, 135 (2), 
310-317. 
MAGNE, D., PALMER, G., BARTON, J.L., MÉZIN, F., TALABOT-AYER, D., 
BAS, S., DUFFY, T., NOGER, M., GUERNE, P.A., NICKLIN, M.J., GABAY, C., 
2006. The IL-1 family member IL-1F8 stimulates production of inflammatory 
mediators by synovial fibroblasts and articular chondrocytes. Arthritis Research 
& Therapy, 8, R80. 
 
MAIER, J.A.M., STATUTO, M., RAGNOTTI, G., (1994). Endogenous interleukin 
1 alpha must be transported to the nucleus to exert its activity in human 
endothelial cells. Molecular and Cellular Biology. 14 (3), 1845±1851. 
 
MARRAKCHI, S., GUIGUE, P., RENSHAW, B.R., PUEL, A., PEI, X.Y., 
FRAITAG, S., ZRIBI, J., BAL, E., CLUZEAU, C., CHRABIEH, M., TOWNE, J.E., 
DOUANGPANYA, J., PONS, C., MANSOUR, S., SERRE, V., MAKNI, H., 
MAHFOUDH, N., FAKHFAKH, F., BODEMER, C., FEINGOLD, J., HADJ-RABIA, 
S., FAVRE, M., GENIN, E., SAHBATOU, M., MUNNICH, A., CASANOVA, J.L., 
SIMS, J.E., TURKI, H., BACHELEZ, H., SMAHI, A., 2011. Interleukin-36-
receptor antagonist deficiency and generalized pustular psoriasis. New England 
Journal of Medicine, 365 (7), 620-628 
322 
MARTIN, G.S., MANNINO, D.M., EATON, S, MOSS, M., 2003. The 
epidemiology of sepsis in the United States from 1979 through 2000. New 
England Journal of Medicine, 348 (16), 1546-1554. 
 
MARTIN U., SCHOLLER J., GURGEL J., RENSHAW B., RENSHAW, B., SIMS, 
J.E., GABEL, C.A., 2009. Externalization of the leaderless cytokine IL-1F6 
occurs in response to lipopolysaccharide/ATP activation of transduced bone 
marrow macrophages. Journal of Immunology, 183 (6), 4021-4030. 
 
MARTINON, F., BURNS, K., TSCHOPP, J., 2002. The inflammasome: a 
molecular platform triggering activation of inflammatory caspases and 
processing of proIL-beta. Molecular Cell, 10 (2), 417-426. 
 
MAROOF, A., PENNY, M., KINGSTON, R., MURRAY, C., ISLAM, S., 
BEDFORD, P.A., KNIGHT, S.C., 2005.  Interleukin-4 can induce interleukin-4 
production in dendritic cells. Immunology, 117, 271-279. 
 
MASTEN, B.J., OLSON, G.K., TARLETON, C.A., RUND, C., SCHUYLER, M., 
MEHRAN, R., ARCHIBEQUE, T., LIPSCOMB, M.F., 2006. Characterization of 
Myeloid and Plasmacytoid Dendritic Cells in Human Lung. Journal of 
Immunology, 177, 7784-7793. 
 
 
323 
MAUE, A.C., WATERS, W.R., PALMER, M.V., WHIPPLE, D.L., MINION, F.C., 
BROWN, W.C., ESTES, D.M., 2004. CD80 and CD86, but not CD154, augment 
DNA vaccine-induced protection in experimental bovine tuberculosis. Vaccine, 
23 (6), 769-779. 
 
MAYNARD, C.L., WEAVER, C.T., 2008. Diversity in the contribution of 
interleukin-10 to T-cell-mediated immune regulation. Immunological Reviews, 
226, 219-233. 
 
MAYNARD, C.L., WEAVER, C.T., 2009. Intestinal effector T cells in health and 
disease. Immunity, 31 (3), 389-400. 
 
MCALINDON, M.E., GRAY, T., GALVIN, A., SEWELL, H.F., PODOLSKY, D.K., 
MAHIDA, Y.R., 1998. Differential lamina propria cell migration via basement 
membrane pores of inflammatory bowel disease mucosa. Gastroenterology, 115 
(4), 841-848.     
 
McCARTHY, D.M., SAN MIGUEL, J. F., FREAKE, H. C., GREEN, P.M., ZOLA, 
H., CATOVSKY, D., GOLDMAN, J.M., 1983. 1,25-dihydroxyvitamin D3 inhibits 
proliferation of human promyelocytic leukaemia (HL60) cells and induces 
monocyte-macrophage differentiation in HL60 and normal human bone marrow 
cells. Leukemia Research, 7 (1), 51-55. 
 
         
324 
McCORMICK, A., FLEMING, D., CHARLTON, J., 1995. Morbidity Statistics from 
General Practice: 4th National Study, 1991-1992. Series MB5, No. 3. London: 
HMSO: pp 1-366 
 
MCKENNA, K., BEIGNON, A.S., BHARDWAJ, N., 2005. Plasmacytoid dendritic 
cells: linking innate and adaptive immunity. Journal of Virology, 79 (1), 17-27. 
 
MCMAHAN, C.J., SLACK, J.L., MOSLEY, B., COSMAN, D., LUPTON, S.D., 
BRUNTON, L.L., GRUBIN, C.E., WIGNALL, J.M., JENKINS, N.A., BRANNAN, 
C.I., et al., 1991. A novel IL-1 receptor, cloned from B cells by mammalian 
expression, is expressed in many cell types. EMBO, 10 (10), 2821-2832. 
 
MEGIOVANNI, A.M., SANCHEZ, F., ROBLEDO-SARMIENTO, M., MOREL C, 
GLUCKMAN, J.C., BOUDALY, S., 2006. Polymorphonuclear neutrophils deliver 
activation signals and antigenic molecules to dendritic cells: a new link between 
leukocytes upstream of T lymphocytes. Journal of Leukocyte Biology, 79 (5), 
977-988. 
 
MELLMAN, I., TURLEY, S.J., STEINMAN, R.M., 1998. Antigen processing for 
amateurs and professionals. Trends in cell biology, 8 (6), 231±237. 
 
 
325 
MERINO, A., BUENDIA, P., MARTIN-MALO, A., ALJAMA, P., RAMIREZ, R., 
CARRACEDO, J., 2011. Senescent CD14+CD16+ monocytes exhibit 
proinflammatory and proatherosclerotic activity. Journal of Immunology, 186, 
1809-1815. 
 
MILLER, A.M., LIEW, F.Y. (2011). The IL-33/ST2 pathway ² A new therapeutic 
target in cardiovascular disease. Pharmacology & Therapeutics, 131 (2), 179-
186. 
 
MILTENYI BIOTEC, 1999. MACS® Technology²Gold standard in cell 
separation  [online]. Available at: 
URL:http://www.miltenyibiotec.com/download/flyer_en/680/MACS_Technology_
Flyer.pdf> [Accessed 27 October 2008]. 
 
MILTENYI BIOTEC, 2006. CD141 (BDCA-3) MicroBead Kit (human) [online]. 
Available at: 
<URL:http://www.miltenyibiotec.com/en/PG_298_49_CD141_BDCA_3_MicroBe
ad_Kit.aspx> [Accessed 15 October 2008]. 
 
MILTENYI BIOTEC, 2006b. AutR0$&66HSDUDWRU)O\HU [online]. Available at: 
<URL:http://www.miltenyibiotec.com/download/flyer_en/737/autoMACS_Flyer.pd
f> [Accessed 15 October 2008]. 
 
 
326 
MILTENYI BIOTEC, 2006c. CD141 (BDCA-3) MicroBead Kit (human) [online]. 
Available at: <URL: 
http://www.miltenyibiotec.com/download/datasheets_en/156/DS130-090-
512.pdf> [Accessed 15 October 2008]. 
 
  MILTENYI BIOTEC, 2007. CD303 (BDCA-2) MicroBead Kit (human) [online]. 
Available at: <URL: 
http://www.miltenyibiotec.com/download/datasheets_en/153/DS130-090-
509.pdf> [Accessed 15 October 2008]. 
       
  MILTENYI BIOTEC, 2007b. CD14 MicroBeads (human) [online]. Available at: 
<URL: http://www.miltenyibiotec.com/download/datasheets_en/56/DS130-050-
201.pdf> [Accessed 15 October 2008]. 
 
 MILTENYI BIOTEC, 2008. CD1c (BDCA-1)+ Dendritic Cell Isolation Kit  [online]. 
Available at: <URL: 
http://www.miltenyibiotec.com/download/datasheets_en/150/DS130-090-
506.pdf> [Accessed 15 October 2008].   
 
MISHELL, B.B., SHIIGI, S. M., (Eds.), 1980. Selected Methods in Cellular 
Immunology. New York: W.H. Freeman and Company, pp. 16-19, 331±333.  
   
MITCH, W.E., 2000. Mechanisms accelerating muscle atrophy in catabolic 
diseases. Transactions of the American Clinical and Climatological Association, 
III, 258-270    327 
 MOLL, H., SCHARNER, A., KÄMPGEN, E., 2002. Increased Interleukin 4 (IL-4) 
Receptor Expression and IL-4-Induced Decrease in IL-12 Production by 
Langerhans Cells Infected with Leishmania major. Infection and Immunity, 70 (3) 
1627-1630.   
 
MOLLER, B., PAULUKAT, J., NOLD, M., BEHRENS, M., KUKOC-ZIVOJNOV, 
N., KALTWASSER, J.P., PFEILSCHIFTER, J., MÜHL, H., 2003. Interferon-Ȗ
induces expression of interleukin-18 binding protein in fibroblast-like 
synoviocytes. Rheumatology, 42, 442-445. 
 
MOLLER, B., VILLIGER, P.M., 2006. Inhibition of IL-1, IL-6, and TNF-alpha in 
immune-mediated inflammatory diseases. Springer Seminars in 
Immunopathology, 27, 391-408. 
 
MONLEÓN, I., ITURRALDE, M., MARTÍNEZ-LORENZO, M.J., MONTEAGUDO, 
L., LASIERRA, P., LARRAD, L., PIÑEIRO, A., NAVAL, J., ALAVA, M.A., ANEL, 
A., 2002. Lack of Fas/CD95 surface expression in highly proliferative leukemic 
cell lines correlates with loss of CtBP/BARS and redirection of the protein toward 
giant lysosomal structures. Cell Growth & Differentiation, 13 (7), 315-324. 
 
MORRISON, D. C., ULEVITCH, R. J., 1978. The effects of bacterial endotoxins 
on host mediation systems. A review. The American Journal of Pathology, 93 
(2), 526±617.  
328 
MOSMANN, T.R., COFFMAN, R.L., 1989. TH1 and TH2 cells: different patterns 
of lymphokine secretion lead to different functional properties. Annual Review of 
Immunology, 7, 145-173. 
 
MUHL, H., PFEILSCHIFTER, J., 2004. Interleukin-18 bioactivity: a novel target 
for immunopharmacological anti-inflammatory intervention. European Journal of 
Pharmacology, 500, 63-71. 
 
MUHR P., ZEITVOGEL J., HEITLAND I., WERFEL T., WITTMANN M., (2011). 
Expression of interleukin (IL)-1 family members upon stimulation with IL-17 
differs in keratinocytes derived from patients with psoriasis and healthy donors. 
British Journal of Dermatology, 165 (1), 189-193. 
 
MULERO, J.J., PACE, A.M., NELKEN, S.T., LOEB, D.B., CORREA, T.R., 
DRMANAC, R., FORD, J.E., 1999. IL1HY1: A novel interleukin-1 receptor 
antagonist gene. Biochemical and Biophysical Research Communications, 263 
(3), 702-706 
 
MUTAMBA, S., ALLISON, A., MAHIDA, Y., BARROW, P., FOSTER, N., 2012. 
Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs and 
facilitates DC maturation by IL-1F8 and IL-1F9. European Journal of 
Immunology, 42 (3), 607-617. 
  
 
329 
MUZIO, M., POLENTARUTTI, N., FACCHETTI, F., PERI, G., DONI, A., SIRONI, 
M., TRANSIDICO, P., SALMONA, M., INTRONA, M., MANTOVANI, A., 1999. 
Characterization of type II intracellular IL-1 receptor antagonist (IL-1ra3): a depot 
IL-1ra. European Journal of Immunology, 29 (3), 781-788. 
 
NAKAHARA, T., URABE, K., FUKAGAWA, S., UCHI, H., INABA, K., FURUE, M., 
MOROI, Y., 2005. Engagement of human monocyte-derived dendritic cells into 
interleukin (IL)-12 producers by IL-1beta + interferon (IFN)-gamma. Clinical & 
Experimental Immunology, 139, 476-482. 
 
NAKANISHI, K., YOSHIMOTO, T., TSUTSUI, H., OKAMURA, H., 2001. 
Interleukin-18 regulates both Th1 and Th2 responses. Annual Review of 
Immunology, 19, 423-474. 
 
NATHAN, C., 2006. Neutrophils and immunity: challenges and opportunities. 
Nature Reviews Immunology, 6 (3), 173-182. 
 
NESTLE, F.O., CONRAD, C., TUN-KYI, A., HOMEY, B., GOMBERT, M., 
BOYMAN, O., BURG, G., LIU, Y.J., GILLIET, M., 2005. Plasmacytoid 
predendritic cells initiate psoriasis through interferon-alpha production. Journal of 
Experimental Medicine, 202 (1), 135-143. 
 
330 
NEUMANN, D., KOLLEWE, C., MARTIN, M.U., BORASCHI, D., 2000. The 
Membrane Form of the Type II IL-1 Receptor Accounts for Inhibitory Function. 
The Journal of Immunology, 165, 3350-3357. 
NICKLIN, M.J., WEITH, A., DUFF, G.W., 1994. A physical map of the region 
encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-
1 receptor antagonist genes. Genomics, 19 (2), 382-384. 
 
NICKLIN, M.J., BARTON, J.L., NGUYEN, M., FITZGERALD, M.G., DUFF, G.W., 
KORNMAN, K., 2002. A sequence-based map of the nine genes of the human 
interleukin-1 cluster. Genomics, 79, 718-725. 
 
NIESS, J.H., BRAND, S., GU, X., LANDSMAN, L., JUNG, S., MCCORMICK, 
B.A., VYAS, J.M., BOES, M., PLOEGH, H.L., FOX, J.G., LITTMAN, D.R., 
REINECKER, H.C., 2005. CX3CR1-mediated dendritic cell access to the 
intestinal lumen and bacterial clearance. Science, 307 (5707), 254-258. 
  
NIKI, Y., YAMADA, H., SEKI, S., KIKUCHI, T., TAKAISHI, H., TOYAMA, Y., 
FUJIKAWA, K., TADA, N., 2001. Macrophage- and neutrophil-dominant arthritis 
in human IL-1 alpha transgenic mice. Journal of Clinical Investigations, 107, 
1127-1135.  
 
NOLAN, K.F., GREAVES, D.R., WALDMANN, H., 1998. The Human Interleukin 
18 Gene Il18 Maps to 11q22.2-q22.3, Closely Linked to the DRD2 Gene Locus 
and Distinct from Mapped IDDM Loci. Genomics, 51, 161-163.  
331 
NOVICK, D., KIM, S.H., FANTUZZI, G., REZNIKOV, L.L., DINARELLO, C.A., 
RUBINSTEIN, M., 1999. Interleukin-18 binding protein: a novel modulator of the 
Th1 cytokine response. Immunity, 10, 127-136. 
 
2¶'2+(57<803(1*6*(=(/7(5:-SWIGGARD, W.J., BETJES, 
M., BHARDWAJ, N., STEINMAN, R.M., 1994. Human blood contains two 
subsets of dendritic cells, one immunologically mature and the other immature. 
Immunology, 82, 487.  
 
OKAMURA, H., KASHIWAMURA, S., TSUTSUI, H., YOSHIMOTO, T., 
NAKANISHI, K., 1998. Regulation of interferon-gamma production by IL-12 and 
IL-18. Current Opinion in Immunology, 10 (3), 259-264. 
 
OKUSAWA, S., GELFAND, J.A., IKEJIMA, T., CONNOLLY, R.J., DINARELLO, 
C.A., 1988. Interleukin 1 induces a shock-like state in rabbits. Synergism with 
tumor necrosis factor and the effect of cyclooxygenase inhibition. Journal of 
Clinical Investigations, 81 (4), 1162. 
 
OLIVEIRA, S.H., CANETTI, C., RIBEIRO, R.A., CUNHA, F.Q., 2008. Neutrophil 
migration induced by IL-1beta depends upon LTB4 released by macrophages 
and upon TNF-alpha and IL-1beta released by mast cells. Inflammation, 31 (1), 
36-46. 
 
 
332 
OLWEUS, J., BITMANSOUR, A., WARNKE, R., THOMPSON, P.A., 
CARBALLIDO, J., PICKER, L.J., LUND-JOHANSEN, F., 1997. Dendritic cell 
ontogeny: a human dendritic cell lineage of myeloid origin. Proceedings of the 
National Academy of Sciences, 94 (23), 12551-12556. 
 
ONDA, H., KASUYA, H., TAKAKURA, K., HORI, T., IMAIZUMI, T., TAKEUCHI, 
T., INOUE, I., TAKEDA, J., 1999. Identification of Genes Differentially Expressed 
in Canine Vasospastic Cerebral Arteries After Subarachnoid Hemorrhage. 
Journal of Cerebral Blood Flow & Metabolism, 19, 1279±1288. 
 
PALMER, G., TALABOT-AYER, D., SZALAY-QUINODOZ, I., MARET, M., 
AREND, W.P., GABAY, C., 2003. Mice transgenic for intracellular interleukin-1 
receptor antagonist type 1 are protected from collagen-induced arthritis. 
European Journal of Immunology, 33, 434-440. 
 
PALMER, G., GABAY, C., 2011. Interleukin-33 biology with potential insights into 
human diseases. Nature Reviews Rheumatology, 7 (6), 321-329. 
 
PALUCKA, K., BANCHEREAU, J., 1999. Dendritic Cells: A Link Between Innate 
and Adaptive Immunity. Journal of Clinical Immunology, 19 (1), 12-25. 
 
PALUCKA, K., BANCHEREAU, J., 2002. How dendritic cells and microbes 
interact to elicit or subvert protective immune responses. Current Opinion in 
Immunology, 14 (4), 420-431. 
333 
PAN, G., RISSER, P., MAO, W., BALDWIN, D.T., ZHONG, A.W., FILVAROFF, 
E., YANSURA, D., LEWIS, L., EIGENBROT, C., HENZEL, W.J., VANDLEN, R., 
2001. IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp. 
Cytokine, 13, 1-7. 
 
PARKER, K.P., BENJAMIN, W.R., KAFFKA, K.L., KILIAN, P.L., 1989. Presence 
of IL-1 receptors on human and murine neutrophils. Relevance to IL-1-mediated 
effects in inflammation. Journal of Immunology, 142 (2), 537-542. 
 
PARNET, P., GARKA, K. E., BONNERT, T.P., DOWER, S.K., SIMS, J.E., 1996. 
IL-1Rrp is a Novel Receptor-like Molecule Similar to the Type I Interleukin-1 
Receptor and Its Homologues T1/ST2 and IL-1R AcP. Journal of Biological 
Chemistry, 271 (8), 3967-3970. 
 
PAULSSON JM, MOSHFEGH A, DADFAR E, HELD C, JACOBSON SH, 
LUNDAHL J., 2012. In-vivo extravasation induces the expression of interleukin 1 
receptor type 1 in human neutrophils. Clinical and Experimental Immunology, 
168 (1), 105-112. 
 
PAULUKAT, J., BOSMANN, M., NOLD, M., GARKISCH, S., KÄMPFER, H., 
FRANK, S., RAEDLE, J., ZEUZEM, S., PFEILSCHIFTER, J., MÜHL, H., 2001. 
Expression and release of IL-18 binding protein in response to IFN-ȖJournal of 
Immunology, 167, 7038-7043. 
 
334 
PENNA, G., VULCANO, M., RONCARI, A., FACCHETTI, F., SOZZANI, S., 
ADORINI, L., 2002. Cutting Edge: Differential Chemokine Production by Myeloid 
and Plasmacytoid Dendritic Cells. The Journal of Immunology, 169, 6673-6676.  
 
PERKINS, N.D., 2007. Integrating cell-signalling pathways with NF-kappaB and 
IKK function. Nature Reviews Molecular Cell Biology, 8 (1), 49-62. 
 
PERRETTI, M., APPLETON, I., PARENTE, L., FLOWER, R.J., 1993. 
Pharmacology of interleukin-1-induced neutrophil migration. Agents and Actions. 
38, C64-C65. 
 
PFAFFL, M.W., 2001. A new mathematical model for relative quantification in 
real-time RT±PCR. Nucleic Acids Research, 2001, 29 (9), e45, 2001-2007. 
 
PFAFFL, M.W., HORGAN, G.W., DEMPFLE, L., 2002. Relative expression 
software tool (REST©) for group-wise comparison and statistical analysis of 
relative expression results in real-time PCR. Nucleic Acids Research, 30 (9), 
e36, 1-10. 
 
PFAFFL, M.W., 2004. Quantification strategies in real-time PCR. In: Bustin, S.A., 
(Ed.), A-Z of quantitative PCR. La Jolla, CA: International University Line, pp. 87-
120.  
       
 
335 
PICKL, W.F., MAJDIC, O., KOHL, P., STÖCKL, J., RIEDL, E., SCHEINECKER, 
C., BELLO-FERNANDEZ, C., KNAPP, W., 1996. Molecular and Functional 
Characteristics of Dendritic Cells Generated from Highly Purified CD14+ 
Peripheral Blood Monocytes. The Journal of Immunology, 157, 3850-3859. 
 
PULENDRAN, B., SMITH, J.L., CASPARY, G., BRASEL, K., PETTIT, D., 
MARASKOVSKY, E., MALISZEWSKI, C.R., 1999. Distinct dendritic cell subsets 
differentially regulate the class of immune response in vivo. Proceedings of the 
National Academy of Sciences, 96 (3), 1036-1041. 
 
QIAGEN, 2006. RNeasy® Mini Handbook. 4th ed. Crawley: QIAGEN, pp. 1-83. 
 
QIAN, Y., COMMANE, M., NINOMIYA-TSUJI, J., MATSUMOTO, K., LI, X., 
2001. IRAK-mediated translocation of TRAF6 and TAB2 in the interleukin-1-
induced activation of NFkappa B. The Journal of Biological Chemistry, 276 (45), 
41661-41667. 
 
RAUSCHMAYR, T., GROVES, R.W., KUPPER, T.S., 1997. Keratinocyte 
expression of the type 2 interleukin 1 receptor mediates local and specific 
inhibition of interleukin 1-mediated inflammation. Proceedings of the National 
Academy of Sciences, 94 (11), 5814-5819. 
 
 
33
RE, F., SIRONI, M., MUZIO, M., MATTEUCCI, C., INTRONA, M., ORLANDO, 
S., PENTON-ROL, G., DOWER, S.K., SIMS, J.E., COLOTTA, F., MANTOVANI, 
A., 1996. Inhibition of interleukin-1 responsiveness by type II receptor gene 
WUDQVIHUDVXUIDFHµUHFHSWRU¶ZLWKDQWL-interleukin-1 function. Journal of 
experimental Medicine, 183, 1842-1850. 
 
REINER, A.P., WURFEL, M.M., LANGE, L.A., CARLSON, C.S., NORD, A.S., 
CARTY, C.L., RIEDER, M.J., DESMARAIS, C., JENNY, N.S., IRIBARREN, C., 
WALSTON, J.D., WILLIAMS, O.D., NICKERSON, D.A., JARVIK, G.P., 2008. 
Polymorphisms of the IL1-receptor antagonist gene (IL1RN) are associated with 
multiple markers of systemic inflammation. Arteriosclerosis, Thrombosis, and 
Vascular Biology, 28 (7), 1407-1412. 
 
REINHERZ, E.L., SCHLOSSMAN, S.F., 1980. The differentiation and function of 
human T lymphocytes. Cell, 19 (4), 821-827. 
 
REIS E SOUSA, C., SHER, A., KAYE, P., 1999. The role of dendritic cells in the 
induction and regulation of immunity to microbial infection. Current Opinion in 
Immunology, 11, 392-399. 
 
REIS E SOUSA, C., 2004. Activation of dendritic cells: translating innate into 
adaptive immunity. Current Opinion in Immunology, 16 (1), 21-25. 
 
 
337 
REIS E SOUSA, C., 2006. Dendritic cells in a mature age. Nature Reviews 
Immunology, 6 (6), 476-483.    
 
RELLOSO, M., PUIG-KRÖGER, A., PELLO, O.M., RODRÍGUEZ-FERNÁNDEZ, 
J.L., DE LA ROSA, G., LONGO, N., NAVARRO, J., MUÑOZ-FERNÁNDEZ, 
M.A., SÁNCHEZ-MATEOS, P., CORBÍ, A.L., 2002. DC-SIGN (CD209) 
expression is IL-4 dependent and is negatively regulated by IFN, TGF-beta, and 
anti-inflammatory agents. Journal of Immunology, 168 (6), 2634-2643. 
 
RES, P.C., COUWENBERG, F., VYTH-DREESE, F.A., SPITS, H., 1999. 
([SUHVVLRQRIS7ĮP51$LQDFRPPLWWHGGHQGULWLFFHOOSUHFXUVRULQWKHKXPDQ
thymus. Blood, 94 (8), 2647-2657. 
 
RHYNE, J.A., MIZEL, S.B., TAYLOR, R.G., CHEDID, M., MCCALL, C.E., 1988. 
Characterization of the human interleukin 1 receptor on human 
polymorphonuclear leukocytes. Clinical Immunology and Immunopathology, 48 
(3), 354-361. 
 
RIML, S., SCHMIDT, S., AUSSERLECHNER, M.J., GELEY, S., KOFLER, R., 
2004. Glucocorticoid receptor heterozygosity combined with lack of receptor 
auto-induction causes glucocorticoid resistance in Jurkat acute lymphoblastic 
leukemia cells. Cell Death and Differentiation, 11 Suppl 1, S65-S72. 
 
338 
RISSOAN, M.C., SOUMELIS, V., KADOWAKI, N., GROUARD, G., BRIERE, F., 
DE WAAL MALEFYT, R., LIU, Y.J., 1999. Reciprocal Control of T Helper Cell 
and Dendritic Cell Differentiation. Science 283, 1183-1186. 
 
ROBINSON, S.P., PATTERSON, S., ENGLISH, N., DAVIES, D., KNIGHT, S.C., 
REID, C.D., 1999. Human peripheral blood contains two distinct lineages of 
dendritic cells. European Journal of Immunology, 29 (9), 2769-2778. 
 
ROBINSON, S.R., PATTERSON, S., ENGLISH, N., DAVIES, D., KNIGHT, S.C., 
REID, C.D., 1999. Human peripheral blood contains two distinct lineages of 
dendritic cells. European Journal of Immunology, 29 (9), 2769 ± 2778. 
 
ROCHE APPLIED SCIENCE, 2006. The E-Method: a highly accurate technique 
for gene-expression analysis. Nature Methods, 3, i ± ii. 
 
ROCHE DIAGNOSTICS LTD., 2007. Universal ProbeLibrary Assay Design 
Center [online]. Available at: <URL: https://www.roche-applied-
science.com/sis/rtpcr/upl/acenter.jsp?id=030000> [Accessed 9 June 2008]. 
 
ROCHE APPLIED SCIENCE, 2008. LightCycler® 480 Software Release 1.5.0., 
Version 1.5.0.39 
       
ROCHE DIAGNOSTICS LTD, 2008. LightCycler® ,QVWUXPHQW2SHUDWRU¶V
Manual Version 3.0, February 2008.  
339 
ROMAGNANI, S., 1994. Lymphokine production by human T cells in disease 
states. Annual Review of Immunology, 12, 227-257. 
 
ROMANI, N., GRUNER, S., BRANG, D., KÄMPGEN, E., LENZ, A., 
TROCKENBACHER, B., KONWALINKA, G., FRITSCH, P.O., STEINMAN, R.M., 
SCHULER, G., 1994. Proliferating dendritic cell progenitors in human blood. 
Journal of Experimental Medicine, 180 (1), 83-93. 
 
ROMANI, N., REIDER D, HEUER M, EBNER, S., KÄMPGEN, E., EIBL, B., 
NIEDERWIESER, D., SCHULER, G., 1996. Generation of mature dendritic cells 
from human blood. An improved method with special regard to clinical 
applicability. Journal of Immunological Methods. 196 (2), 137-151. 
 
ROMANI, N., EBNER, S., TRIPP, C.H., FLACHER, V., KOCH, F., STOITZNER, 
P., 2006. Epidermal Langerhans cells--changing views on their function in vivo. 
Immunology Letters, 106 (2), 119-125. 
 
ROUBENOFF, R., ROUBENOFF, R.A., CANNON, J.G., KEHAYIAS, J.J., 
ZHUANG, H., DAWSON-HUGHES, B., DINARELLO, C.A., ROSENBERG, I.H., 
1994. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying 
reduced body cell mass in chronic inflammation. Journal of Clinical 
Investigations, 93 (6), 2379-2386. 
 
340 
ROUSSEL, L., ERARD, M., CAYROL, C., GIRARD, J.P., 2008. Molecular 
mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-
H2B acidic pocket. EMBO reports, 9 (10), 1006±1012. 
 
ROY, K.C., BANDYOPADHYAY, G., RAKSHIT, S., RAY, M., 
BANDYOPADHYAY, S., 2004. IL-4 alone without the involvement of GM-CSF 
transforms human peripheral blood monocytes to a CD1a(dim), CD83(+) myeloid 
dendritic cell subset. Journal of Cell Science, 117 (16), 3435-3445. 
 
RUTELLA, S., LOCATELLI, F., 2011. Intestinal dendritic cells in the 
pathogenesis of inflammatory bowel disease. World Journal of Gastroenterology, 
17 (33), 3761-3775. 
 
SABATTÉ, J., MAGGINI, J., NAHMOD, K., AMARAL, M.M., MARTÍNEZ, D., 
SALAMONE, G., CEBALLOS, A., GIORDANO, M., VERMEULEN, M., 
GEFFNER. J., 2007. Interplay of pathogens, cytokines and other stress signals 
in the regulation of dendritic cell function. Cytokine & Growth Factor Reviews, 18 
(1-2), 5-17. 
 
SAIJO, S., ASANO, M., HORAI, R. YAMAMOTO, H., IWAKURA, Y., 2002. 
Suppression of autoimmune arthritis in interleukin-1-deficient mice in which T cell 
activation is impaired due to low levels of CD40 ligand and OX40 expression on 
T cells. Arthritis & Rheumatism, 46, 533-544. 
341 
SALLUSTO, F., LANZAVECCHIA, A., 1994. Efficient presentation of soluble 
antigen by cultured human dendritic cells is maintained by 
granulocyte/macrophage colony-stimulating factor plus interleukin 4 and 
downregulated by tumor necrosis factor alpha. The Journal of Experimental 
Medicine, 179, 1109±1118. 
 
SALLUSTO, F., LANZAVECCHIA, A., 2002. The instructive role of dendritic cells 
on T-cell responses. Arthritis Research, 4 (Suppl 3), S127±132. 
       
SANA, T.R., DEBETS, R., TIMANS, J.C., BAZAN, J.F., KASTELEIN, R.A., 2000. 
Computational identification, cloning, and characterization of IL-1R9, a novel 
interleukin-1 receptor-like gene encoded over an unusually large interval of 
human chromosome Xq22.2-q22.3. Genomics, 69 (2), 252-262.  
 
SANADA, S., HAKUNO, D., HIGGINS, L.J., SCHREITER, E.R., MCKENZIE, 
A.N., LEE, R.T., 2007. IL-33 and ST2 comprise a critical biomechanically 
induced and cardioprotective signaling system. The Journal of Clinical 
Investigation, 117 (6), 1538-1549. 
 
 
 
 
342 
SCHIAVONI, G., MATTEI, F., SESTILI, P., BORGHI, P., VENDITTI, M., 
MORSE, H.C. 3RD., BELARDELLI, F., GABRIELE, L., 2002. ICSBP is essential 
for the development of mouse type I interferon-producing cells and for the 
generation and activation of CD8alpha(+) dendritic cells. Journal of Experimental 
Medicine, 196 (11), 1415-1425. 
 
SCHMITZ, J., OWYANG, A., OLDHAM, E., SONG, Y., MURPHY, E., 
MCCLANAHAN, T.K., ZURAWSKI, G., MOSHREFI, M., QIN, J., LI, X., 
GORMAN, D.M., BAZAN, J.F., KASTELEIN, R.A., 2005. IL-33, an interleukin-1-
like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T 
helper type 2-associated cytokines. Immunity, 23, 479-490. 
 
SCHRODER, K., TSCHOPP, J., 2010. The inflammasomes. Cell 140, 821±832. 
 
SCHWENDE, H., FITZKE, E., AMBS, P., DIETER, P., 1996. Differences in the 
state of differentiation of THP-1 cells induced by phorbol ester and 1,25-
dihydroxyvitamin D3. Journal of Leukocyte Biology, 59, (4), 555-561.  
 
SEKI, K., SANADA, S., KUDINOVA, A.Y., STEINHAUSER, M.L., HANDA, V., 
GANNON, J., LEE, R.T., 2009. Interleukin-33 prevents apoptosis and improves 
survival after experimental myocardial infarction through ST2 signaling. 
Circulation: Heart Failure, 2 (6): 684-691. 
 
343 
SHARMA S., KULK N., NOLD M.F., GRÄF R., KIM S.H., REINHARDT D., 
DINARELLO C.A., BUFLER P., 2008. The IL-1 Family Member 7b Translocates 
to the Nucleus. The Journal of Immunology, 180, 5477 -5482. 
 
SHIEH, J.H., GORDON, M., JAKUBOWSKI, A., PETERSON, R.H., 
GABRILOVE, J.L., MOORE, M.A., 1993. Interleukin-1 modulation of cytokine 
receptors on human neutrophils: in vitro and in vivo studies. Blood, 81 (7), 1745-
1754. 
 
SHORTMAN, K., LIU, Y.J., 2002. Mouse and human dendritic cell subtypes. 
Nature Reviews Immunology, 2, 151-161 
 
SIEGAL, F.P., KADOWAKI, N., SHODELL, M., FITZGERALD-BOCARSLY, P.A., 
SHAH, K., HO, S., ANTONENKO, S., LIU, Y.J., 1999. The nature of the principal 
type 1 interferon-producing cells in human blood. Science, 284 (5421), 1835-
1837. 
 
SILMAN, A.J., PEARSON, J.E., 2002. Epidemiology and genetics of rheumatoid 
arthritis. Arthritis Research, 4 (Suppl 3), S265-272. 
 
 
 
 
344 
 
SIMBIRTSEV, A., VARIOUCHINA, E., KONUSOVA, V., KOTOV, A., 
KETLINSKY, S., SALAMATOV, A., BISENKOV, L., 2001. Local administration of 
interleukin-1beta for the treatment of lung abscesses induces neutrophil 
activation and changes in proinflammation cytokine production. European 
Cytokine Network, 12 (3), 420-429. 
 
SIMÓN, C., VALBUENA, D., KRÜSSEL, J., BERNAL, A., MURPHY, C.R., 
SHAW, T., PELLICER, A., POLAN, M.L., 1998. Interleukin-1 receptor antagonist 
prevents embryonic implantation by a direct effect on the endometrial epithelium. 
Fertility and sterility, 70 (5), 896-906. 
 
SIMS, J.E., NICKLIN, M.J., BAZAN, J.F., BARTON, J.L., BUSFIELD, S.J., 
FORD, J.E., KASTELEIN, R.A., KUMAR, S., LIN, H., MULERO, J.J., PAN, J., 
PAN, Y., SMITH, D.E., YOUNG, P.R., 2001. A new nomenclature for IL-1 family 
genes. Trends in Immunology, 22, 536-537. 
 
SIMS, J.E., 2002. IL-1 and IL-18 receptors and their extended family. Current 
opinion in Immunology, 14, 117-122. 
 
SIMS, J.E., SMITH, D.E., 2010. The IL-1 family: regulators of immunity. Nature 
Reviews Immunology, 10, 89-102. 
 
 
 
345 
SMITH, D.E., RENSHAW, B.R., KETCHEM, R.R., KUBIN, M., GARKA, K.E., 
SIMS, J.E., 2000. Four new members expand the interleukin-1 superfamily. 
Journal of Biological Chemistry, 275, 1169-1175. 
 
SMITH, D.E., 2011. The biological paths of IL-1 family members IL-18 and IL-33. 
Journal of Leukocyte Biology, 89 (3), 383-392.   
 
SMITH, J.W. 2nd, URBA, W.J., CURTI, B.D., ELWOOD, L.J., STEIS, R.G., 
JANIK, J.E., SHARFMAN, W.H., MILLER, L.L., FENTON, R.G., CONLON, K.C., 
et al., 1992. The toxic and hematologic effects of interleukin-1 alpha 
administered in a phase I trial to patients with advanced malignancies. Journal of 
Clinical Oncology, 10, 1141-1152. 
 
SMITH, J.W., LONGO, D., ALFORD, W.G., JANIK, J.E., SHARFMAN, W.H., 
GAUSE, B.L., CURTI, B.D., CREEKMORE, S.P., HOLMLUND, J.T., FENTON, 
R.G., et al., 1993. The effects of treatment with interleukin-ĮRQSODWHOHW
recovery after high-dose carboplatin. New England Journal of Medicine, 328, 
756-761. 
 
SMITHGALL, M.D., COMEAU, M.R., YOON, B.R., KAUFMAN, D., ARMITAGE, 
R., SMITH, D.E., 2008. IL-33 amplifies both Th1- and Th2-type responses 
through its activity on human basophils, allergen-reactive Th2 cells, iNKT and 
NK cells. International Immunology, 20 (8), 1019-1030. 
346 
SOILLEUX, E.J., MORRIS, L.S., LESLIE, G., CHEHIMI, J., LUO, Q., 
LEVRONEY, E., TROWSDALE, J., 2002. Constitutive and induced expression of 
DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. 
Journal of Leukocyte Biology, 71, 445-457. 
 
SONG, M., PHELPS, D.S., 2000. Comparison of SP-A and LPS effects 
on the THP-1 monocytic cell line. American Journal of Physiology- Lung Cellular 
and Molecular Physiology, 279, L110-L117. 
 
SPITS, H., COUWENBERG, F., BAKKER, A.Q., WEIJER, K., 
UITTENBOGAART, C.H., 2000. Id2 and Id3 inhibit development of CD34(+) 
stem cells into predendritic cell (pre-DC)2 but not into pre-DC1. Evidence for a 
lymphoid origin of pre-DC2. Journal of Experimental Medicine, 192 (12), 1775-
1784. 
 
STEINMAN, R.M., HEMMI, H., 2006. Dendritic cells: translating innate to 
adaptive immunity. Current Topics in Microbiology and Immunology, 311, 17-58. 
 
 
STINGL, G., SHEVACH, E.M., 1991. Langerhans cells as antigen-presenting 
cells. In: Schuler, G. (Ed.). Epidermal Langerhans Cells, Boca Raton: CRC 
Press, pp. 159±190. 
 
 
347 
STOBIE, L., GURUNATHAN, S., PRUSSIN, C., SACKS, D.L., GLAICHENHAUS, 
N., WU, C.Y., SEDER, R.A., 2000. The role of antigen and IL-12 in sustaining 
Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells 
sufficient to mediate protection to an infectious parasite challenge. Proceedings 
of the National Academy of Sciences, 97 (15), 8427-8432 
 
STROBL, H., SCHEINECKER, C.,  RIEDL, E., CSMARITS, B., BELLO-
FERNANDEZ, C., PICKL, W.F., MAJDIC, O., KNAPP, W., 1998. Identification of 
CD68+ lin- peripheral blood cells with dendritic precursor characteristics. Journal 
of  Immunology, 161, 740.  
  
SUBRAMANIAM, S., STANSBERG, C., CUNNINGHAM, C., 2004. The 
interleukin 1 receptor family. Developmental & Comparative Immunology, 28, 
415-428. 
 
SUN, C.M., HALL, J.A., BLANK, R.B., BOULADOUX, N., OUKKA, M., MORA, 
J.R., BELKAID, Y., 2007. Small intestine lamina propria dendritic cells promote 
de novo generation of Foxp3 T reg cells via retinoic acid. Journal of 
Experimental Medicine, 204 (8), 1775-1785. 
 
SYMMONS, D., TURNER, R., WEBB, P., ASTEN, P., BARRETT, E., LUNT, M., 
SCOTT, D., SILMAN, A., 2002. The prevalence of rheumatoid arthritis in the 
United Kingdom: new estimates for a new century. Rheumatology, 41, 793-800. 
 
348 
SYMONS, J.A., YOUNG, P.R., DUFF, G.W., 1995. Soluble type II interleukin 1 
(IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses 
affinity for IL-1 receptor antagonist. Proceedings of the National Academy of 
Sciences, 92 (5), 1714-1718. 
 
TAKAESU, G., KISHIDA, S., HIYAMA, A., YAMAGUCHI, K., SHIBUYA, H., IRIE, 
K., NINOMIYA-TSUJI, J., MATSUMOTO, K., 2000. TAB2, a novel adaptor 
protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the 
IL-1 signal transduction pathway. Molecular Cell, 5 (4), 649-658. 
 
TAKASHIBA, S., VAN DYKE, T.E., AMAR, S., MURAYAMA, Y., SOSKOLNE, 
A.W., SHAPIRA L., 1999. Differentiation of monocytes to macrophages primes 
cells for lipopolysaccharide stimulation via accumulation of cytoplasmic nuclear 
factor kappaB. Infection and Immunity, 67 (11), 5573-5578. 
 
TATAKIS, D.N., 1993. Interleukin-1 and bone metabolism: A review. Journal of 
Periodontology, 64, 416-431  
  
TAYLOR, S.L., RENSHAW, B.R., GARKA, K.E., SMITH, D.E., SIMS, J.E., 2002. 
Genomic organization of the interleukin-1 locus. Genomics, 79, 726-733. 
 
 
 
349 
TETE, S., TRIPODI, D., ROSATI, M., CONTI, F., MACCAURO, G., SAGGINI, A., 
CIANCHETTI, E., CARAFFA, A., ANTINOLFI, P., TONIATO, E., CASTELLANI, 
M.L., CONTI, P., THEOHARIDES, T.C., 2012. IL-37 (IL-1F7) the newest anti-
inflammatory cytokine which suppresses immune responses and inflammation. 
International Journal of Immunopathology and Pharmacology, 25 (1), 31-38. 
 
TOMINAGA, S., 1989. A putative protein of a growth specific cDNA from 
BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 
1 receptor. FEBS Letters, 258 (2), 301-304. 
 
TOMURA, M., ZHOU, X.Y., MARUO, S., AHN, H.J., HAMAOKA, T., OKAMURA, 
H., NAKANISHI, K., TANIMOTO, T., KURIMOTO, M., FUJIWARA, H., 1998. A 
critical role for IL-18 in the proliferation and activation of NK1.1+ CD3- cells. The 
Journal of Immunology, 160 (10), 4738-4746. 
 
TOWNE, J.E., GARKA, K.E., RENSHAW, B.R., VIRCA, G.D., SIMS, J.E., 2004. 
Interleukin (IL)-1F6, IL-1F8, IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to 
activate the pathway leading to NF-kappa B and MAPKs. Journal of Biological 
Chemistry, 279, 13677-13688. 
 
TOWNE, J.E., RENSHAW, B.R., DOUANGPANYA, J., LIPSKY, B.P., SHEN, M., 
GABEL, C.A., SIMS, J.E., 2011. Interleukin-36 (IL-36) ligands require processing 
for full agonist (IL-Į,/-ȕDQG,/-ȖRUDQWDJRQLVW,/-36Ra) activity. 
Journal of Biological Chemistry, 286 (49), 42594-42602. 
350 
TOWNSEND, M.J., FALLON, P.G., MATTHEWS, D.J., JOLIN, H.E., MCKENZIE, 
A.N., 2000. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in 
developing primary T helper cell type 2 responses. Journal of Experimental 
Medicine, 191, 1069-1076. 
 
TSUCHIYA, S., YAMABE, M., YAMAGUCHI, Y., KOBAYASHI, Y., KONNO, T., 
TADA, K., 1980. Establishment and characterization of a human acute 
monocytic leukemia cell line (THP-1). International Journal of Cancer, 26 (2), 
171-176. 
 
TSUCHIYA, S., KABAYASHI, Y., GOTO, Y., OKUMURA, H., NAKAE, S., 
KONNO, T., TADA, K., 1982. Induction of maturation in cultured human 
monocytic cells by a phorbol diester. Cancer Research, 42, 1530-1536. 
 
TURVILLE, S. G., CAMERON, P. U., HANDLEY, A., LIN, G., PÖHLMAN, S., 
DOMS, R. W., CUNNINGHAM, A. L., 2002. Diversity of receptors binding HIV on 
dendritic cell subsets. Nature Immunology, 3, 975-983. 
 
VAN ASSELDONK, E.J., STIENSTRA, R., KOENEN, T.B., VAN TITS, L.J., 
JOOSTEN, L.A., TACK, C.J., NETEA, M.G., 2010. The Effect of the Interleukin-1 
Cytokine Family Members IL-1F6 and IL-1F8 on Adipocyte Differentiation. 
Obesity, 18 (11), 2234±2236. 
 
 
 
351 
VAN DER MEER, J.W., BARZA, M., WOLFF, S.M., DINARELLO, C.A., 1988. A 
low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal 
gram-negative infection. Proceedings of the National Academy of Sciences, 
85(5), 1620±1623. 
 
VAN DE VEERDONK, F.L., STOECKMAN, A.K., WU, G., BOECKERMANN, 
A.N., AZAM, T., NETEA, M.G., JOOSTEN, L.A., VAN DER MEER, J.W., HAO, 
R., KALABOKIS, V., DINARELLO, C.A., 2012. IL-38 binds to the IL-36 receptor 
and has biological effects on immune cells similar to IL-36 receptor antagonist. 
Proceedings of the National Academy of Sciences, 109 (8), 3001-3005. 
 
VAROL, C., VALLON-EBERHARD, A., ELINAV, E., AYCHEK, T., SHAPIRA, Y., 
LUCHE, H., FEHLING, H.J., HARDT, W.D., SHAKHAR, G., JUNG, S., 2009. 
Intestinal lamina propria dendritic cell subsets have different origin and functions. 
Immunity, 31 (3), 502-512. 
 
VERBSKY, J.W., WHITE, A.J., 2004. Effective use of the recombinant interleukin 
1 receptor antagonist anakinra in therapy resistant systemic onset juvenile 
rheumatoid arthritis. Journal of Rheumatology, 31(10), 2071-2075. 
 
VERHASSELT, V., BUELENS, C., WILLEMS, F., DE GROOTE, D., HAEFFNER-
CAVAILLON, N., GOLDMAN, M., 1997. Bacterial lipopolysaccharide stimulates 
the production of cytokines and the expression of costimulatory molecules by  
 
352 
human peripheral blood dendritic cells: evidence for a soluble CD14-dependent 
pathway. Journal of Immunology, 158 (6), 2919-2925. 
 
VERRI, W.A. JR., SOUTO, F.O., VIEIRA, S.M., ALMEIDA, S.C., FUKADA, S.Y., 
XU, D., ALVES-FILHO, J.C., CUNHA, T.M., GUERRERO, A.T., MATTOS-
GUIMARAES, R.B., OLIVEIRA, F.R., TEIXEIRA, M.M., SILVA, J.S., MCINNES, 
I.B., FERREIRA, S.H., LOUZADA-JUNIOR, P., LIEW, F.Y., CUNHA, F.Q., 2010. 
IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-
TNF therapy. Annals of the Rheumatic Diseases, 69 (9), 1697-1703. 
 
VIGNE, S., PALMER, G., LAMACCHIA, C., MARTIN, P., TALABOT-AYER, D., 
RODRIGUEZ, E., RONCHI, F., SALLUSTO, F., DINH, H., SIMS, J.E., GABAY, 
C., 2011. IL-36R ligands are potent regulators of dendritic and T cells. Blood, 
118 (22), 5813-5823. 
 
VOGELSANG, P., BRUN, J.G., OIJORDSBAKKEN, G., SKARSTEIN, K., 
JONSSON, R., APPEL, S., 2010. Levels of plasmacytoid dendritic cells and 
type-2 myeloid dendritic cells are reduced in peripheral blood of patients with 
primary Sjogren's syndrome. Annals of the Rheumatic Diseases, 69 (6), 1235-
1238. 
 
WANG, P., MEINHARDT, B., ANDRE, R., RENSHAW, B.R., KIMBER, I., 
ROTHWELL, N.J., PINTEAUX, E., 2005. The interleukin-1-related cytokine IL- 
 
353 
1F8 is expressed in glial cells, but fails to induce IL-1beta signalling responses. 
Cytokine, 29, 245-250. 
 
WATSON, J.M., LOFQUIST, A.K., RINEHART, C.A., OLSEN, J.C., MAKAROV, 
S.S., KAUFMAN, D.G., HASKILL, J.S., 1995. The intracellular IL-1 receptor 
antagonist alters IL-1-inducible gene expression without blocking exogenous 
signaling by IL-1 beta. The Journal of Immunology, 155 (9), 4467-4475. 
 
WEI, X.Q., LEUNG, B.P., ARTHUR, H.M., MCINNES, I.B., LIEW, F.Y., 2001. 
Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-
18. Journal of Immunology, 166, 517-521. 
 
WEINBERG, E.O., SHIMPO, M., DE KEULENAER, G.W., MACGILLIVRAY, C., 
TOMINAGA, S., SOLOMON, S.D., ROULEAU, J.L., LEE, R.T., 2002. Expression 
and regulation of ST2, an interleukin-1 receptor family member, in 
cardiomyocytes and myocardial infarction. Circulation, 106 (23), 2961-2966. 
 
WEN, H., TING, J.P., O'NEILL, L.A., 2012. A role for the NLRP3 inflammasome 
in metabolic diseases--did Warburg miss inflammation? Nature Immunology, 13 
(4), 352-357. 
 
WESA, A., GALY, A., 2002. Increased production of pro-inflammatory cytokines 
and enhanced T cell responses after activation of human dendritic cells with IL-1  
354 
and CD40 ligand. BMC Immunology, 3, 14. 
 
WHEELER, A.P., BERNARD, G.R., 1999. Treating patients with severe sepsis. 
New England Journal of Medicine, 340, 207-214. 
 
WILLIAM, K.J., 2005. Krause's Essential Human Histology for Medical Students, 
Boca Raton, Florida: Universal-Publishers, pp. 75 
 
WIRTHS, S., REICHERT, J., GRÜNEBACH, F., BROSSART, P., 2002. 
Activated CD8+ T lymphocytes induce differentiation of monocytes to dendritic 
cells and restore the stimulatory capacity of interleukin 10-treated antigen-
presenting cells. Cancer Research, 62 (17), 5065-5068. 
 
WITKIN, S.S., GERBER, S., LEDGER, W.J., 2002. Influence of interleukin-1 
receptor antagonist gene polymorphism on disease. Clinical Infectious Diseases, 
34 (2), 204-209. 
 
WU, K.C., JACKSON, L.M., GALVIN, A.M., GRAY, T., HAWKEY, C.J., MAHIDA, 
Y.R., 1999. Phenotypic and functional characterisation of myofibroblasts, 
macrophages, and lymphocytes migrating out of the human gastric lamina 
propria following the loss of epithelial cells. Gut, 44 (3), 323-330. 
 
355 
WYKES, M., POMBO, A., JENKINS, C., MACPHERSON, G.G., 1998. Dendritic 
cells interact directly with naive B lymphocytes to transfer antigen and initiate 
class switching in a primary T-dependent response. Journal of Immunology, 161 
(3), 1313-1319. 
 
YANG, G.X., LIAN, Z.X., KIKUCHI, K., MORITOKI, Y., ANSARI, A.A., LIU, Y.J., 
IKEHARA, S., GERSHWIN, M.E., 2005. Plasmacytoid dendritic cells of different 
origins have distinct characteristics and function: studies of lymphoid progenitors 
versus myeloid progenitors. Journal of Immunology, 175 (11), 7281-7287. 
 
YOKOTA J., 2000. Tumor progression and metastasis. Carcinogenesis, 21 (3), 
497-503. 
 
YOUNGMAN, K.R., SIMON, P.L., WEST, G.A., COMINELLI, F., 
RACHMILEWITZ, D., KLEIN, J.S., FIOCCHI, C., 1993. Localization of intestinal 
interleukin 1 activity and protein and gene expression to lamina propria cells. 
Gastroenterology, 104 (3), 749-758. 
 
ZHANG, X.J., WANG, X., XIONG, L.Z., FAN, J., DUAN, X.L., WANG, B.R.,2007. 
Up-regulation of IL-1 receptor type I and tyrosine hydroxylase in the rat carotid 
body following intraperitoneal injection of IL-1beta. Histochemistry and Cell 
Biology, 128 (6), 533-540. 
356 
ZHANG, Y., LIU, C., PENG, H., ZHANG, J., FENG, Q., 2012. IL1 Receptor 
Antagonist Gene IL1-RN Variable Number of Tandem Repeats Polymorphism 
and Cancer Risk: A Literature Review and Meta-Analysis. PLoS One, 7 (9), 
e46017. 
 
ZHOU, L.J., TEDDER, T.F., 1995. Human blood dendritic cells selectively 
express CD83, a member of the immunoglobulin superfamily. Journal of 
Immunology, 154 (8), 3821-3835. 
 
ZHOU, X., KRUEGER, J.G., KAO, M.C., LEE, E., DU, F., MENTER, A., WONG, 
W.H., BOWCOCK, A.M., 2003. Novel mechanisms of T-cell and dendritic cell 
activation revealed by profiling of psoriasis on the 63,100-element 
oligonucleotide array. Physiological Genomics, 13, 69-78. 
 
ZHOU, T., ZHANG, Y., SUN, G., ZHANG, Y., ZHANG, D., ZHAO, Y., CHEN, N., 
2006. Anti-P-selectin lectin-EGF domain monoclonal antibody inhibits the 
maturation of human immature dendritic cells. Experimental and Molecular 
Pathology, 80 (2), 171-176. 
 
ZHU, J., PAUL, W.E., 2008. CD4 T cells: fates, functions, and faults. Blood, 112 
(5), 1557-1569. 
 
357 
ZHU, J., PAUL, W.E., 2010. Peripheral CD4+ T-cell differentiation regulated by 
networks of cytokines and transcription factors. Immunological Reviews, 238 (1), 
247-262. 
 
ZOLA, H., NEOH, S.H., MANTZIORIS, B.X., WEBSTER, J., LOUGHNAN, M.S., 
1990. Detection by immunofluorescence of surface molecules present in low 
copy numbers. High sensitivity staining and calibration of flow cytometer. Journal 
of Immunological Methods, 135 (1-2), 247-255. 
 
ZUNIGA, E.I., McGAVERN, D.B., PRUNEDA-PAZ, J.L., TENG, C., OLDSTONE, 
M.B., 2004. Bone marrow plasmacytoid dendritic cells can differentiate into 
myeloid dendritic cells upon virus infection. Nature Immunology, 5, 1227 ± 1234. 
 
 
 
 
 
 
 
 
 
 
 
 
 
358 
APPENDIX 1: INVESTIGATION OF THE FUNCTIONAL STATUS 
OF IL-1RRP2-NEGATIVE THP-1 CELLS 
 
Introduction 
Based on published reports which stated that THP-1 cells did not express IL-
1Rrp2 (Magne et al, 2006) and on results from our own preliminary experiments,  
THP-1 cells were used as a negative control in all qRT-PCR experiments 
investigating IL-1Rrp2 mRNA expression (Chapters 3 and 4). However, prior to 
using THP-1 cells as negative controls for IL-1Rrp2 expression in qRT-PCR 
studies presented in this thesis, their functional status was tested using an 
established system; measuring TNF-ĮP51$H[SUHVVLRQE\7+3-1 cells in 
response to bacterial (E. coli 0127:B8 LPS) stimulation (Essner et al, 1990; 
Agarwal et al., 1995; Asakura et al., 1996; Dedrick and Conlon, 1995; Jones et 
al., 2003; Foster et al., 2005; Lackman and Cresswell, 2006).  
 
THP-1 is a human monocytic cell line originally derived from the peripheral blood 
of a 1 year old boy with acute monocytic leukaemia by Tsuchiya and co-workers 
(1980). This cell line expresses Fc and C3b receptors but lacks surface or 
cytoplasmic immunoglobulins. THP-1 cells also lack Epstein-Barr virus-
associated nuclear antigen. Furthermore, they show alpha-naphthyl butyrate 
esterase activities which can be inhibited by sodium fluoride. They also produce  
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lysozyme and are able to phagocytose latex particles and sensitized sheep red 
blood cells. In addition, they can restore T lymphocyte response to Concavalin A 
(a lectin protein which is also a lymphocyte mitogen) (Tsuchiya et al., 1980).  
 
THP-1 cells are widely used as a substitute for human blood 
monocyte/macrophage models because they easily divide and can be 
maintained in cell culture for long periods (Auwerx, 1991). In the original culture, 
THP-1 cells maintained monocytic characteristics for over 14 months (Tsuchiya 
et al., 1980). THP-1 cells can be easily stimulated to differentiate along the 
monocytic pathway into human monocyte-derived macrophages (MDMs) by 
treating them with phorbol esters (Tsuchiya et al., 1982) or with 1,25-
dihydroxyvitamin D3 (McCarthy et al., 1983; Schwende et al., 1996). 
Differentiation of THP-1 cells into mature THP-1 monocytes is accompanied by 
increased expression of CD14 (which is an LPS receptor) by the cells (Foster et 
al., 2005). Vitamin D3 (1,25-dihydroxyvitamin D3) induces CD14 expression on 
THP-1 cells which in turn facilitates interaction of LPS with CD14 culminating in 
induction of cytokine expression. The binding of LPS to CD14 is facilitated by an 
LPS-binding protein (LBP) which is present in plasma (Gegner et al., 1995; 
Galdiero et al., 2001).  
 
THP-1 cells can be further differentiated into immature human monocyte-derived 
dendritic cells (MDDCs) by culturing them with granulocyte-macrophage colony 
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stimulating factor (GM-CSF) plus interleukin-4 (IL-4) (Sallusto and Lanzavecchia, 
1994; Berges et al., 2005). In this study, the response of THP-1 cells to LPS and 
IL-1F8 stimulation was used to confirm their functional status (Essner et al, 1990; 
Agarwal et al., 1995; Asakura et al., 1996; Dedrick and Conlon, 1995; Jones et 
al., 2003; Foster et al., 2005; Lackman and Cresswell, 2006). 
 
Materials and Methods 
THP-1 cells, obtained and cultured as previously stated (Chapter 2, Section 
2.2.1), were plated at a density of 9 x105 cells per well on 24 well plates. Cells 
were stimulated for 6 RUKRXUVZLWKFHOOFXOWXUHWHVWHGȖ-irradiated E. coli 
0127:B8 LPS (100ng/ml) (Sigma-Aldrich, Poole, UK) or recombinant human IL-
1F8 (100 ng/ml) (Amgen Corporation, Seattle, WA, USA) in RPMI 1640 
supplemented with FCS (10% v/v) and L-Glutamine (2mM). Control samples 
were left unstimulated and were cultured in cytokine-free, RPMI 1640 medium 
only.  Cells were kept in a humidified incubator at 37oC and 5% CO2 for the 
specified incubation times. At the end of the incubation period, cells were 
harvested and preserved in RNAlater Stabilization reagent (Qiagen, Crawley, 
UK) prior to total RNA extraction using the RNeasy Mini Kit (Qiagen, Crawley, 
8.DFFRUGLQJWRWKHPDQXIDFWXUHU¶VUHFRPPHQGDWLRQVȝJRIWRWDO51$ZDV
reverse-transcribed into cDNA using random hexamer primers according to the 
PDQXIDFWXUHU¶VUHFRPPHQGDWLRQV7UDQVFULSWRU)LUVW6WUDQGF'1$6\QWKHVLV.LW
(Roche, West Sussex, UK). After primer optimization, gene-specific primers and  
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probes for TNF-ĮDQGWKHKRXVH-keeping gene (GAPDH), template cDNAs were 
amplified in a typical PCR reaction on a LightCycler® 480 Real-Time PCR 
analyser (Roche, West Sussex, UK) and ratios of TNF-Į*$3'+JHQH
expression levels in each sample were automatically generated from crossing 
point values.  
  
Results 
TNF-ĮP51$H[SUHVVLRQLQ7+3-1 cells stimulated with E. coli 0127:B8 LPS 
or recombinant IL-1F8  
THP-1 cells, obtained and cultured as already stated (Chapter 2, Section 2.2.1), 
were plated at a density of 9 x105 cells per well on 24 well plates. Cells were 
sWLPXODWHGIRURUKRXUVZLWKFHOOFXOWXUHWHVWHGȖ-irradiated E. coli 0127:B8 
LPS (100ng/ml) (Sigma-Aldrich, Poole, UK) or recombinant IL-1F8 (100 ng/ml). 
Control samples were left unstimulated and were cultured in cytokine-free, RPMI 
1640 medium only.  Cells were kept in a humidified incubator at 37oC and 5% 
CO2 for the specified incubation times. At the end of the incubation period, RNA 
was extracted from the cells and qRT-PCR for TNF-ĮJHQHH[SUHVVLRQ
performed as previously stated (Chapter 2). GAPDH was used as the reference 
gene. Peripheral blood monocytes stimulated with LPS for 24 hours were used 
as the positive control. Unstimulated THP-1 cells were used as a negative 
control.  Results are shown in the graph below (Figure A.1)  
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Figure A.1 TNF-ĮP51$H[SUHVVLRQLQ/36-stimulated THP-1 cells. Graph 
shows TNF-ĮP51$H[SUHVVLRQUHVXOWVPHDVXUHGE\T57-PCR relative to 
GAPDH) following culture of THP-1 cells with E. coli 0127:B8 LPS (100ng/ml), 
IL-1F8 (100ng/ml) or without stimulant (negative control) for 6 or 24 hours. 
Results show that unstimulated THP-1 cells (cultured in RPMI 1640 only) or 
THP-1 cells stimulated with IL-1F8 do not express TNF-ĮP51$2QWKHRWKHU
hand, E. coli 0127:B8 LPS stimulates TNF-ĮP5NA expression in THP-1 cells. 
Peak Levels of TNF-ĮP51$H[SUHVVLRQDUHUHDFKHGZLWKLQWKHILUVWKRXUVRI
encounter with LPS and are halved by 24 hours post-exposure. Data shown are 
mean± SD of at least three independent experiments. All analyses were 
performed in triplicate. 
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Results (Figure A.1) show that unstimulated THP-1 cells and THP-1 cells 
stimulated with IL-1F8 do not show TNF-ĮP51$H[SUHVVLRQ2QWKHRWKHUKDQG
THP-1 cells stimulated with E. coli 0127:B8 LPS show TNF-ĮP51$H[SUHVVLRQ. 
Peak Levels of TNF-ĮP51$H[SUHVVLRQDUHUHDFKHGZLWKLQWKHILUVWKRXUVRI
encounter with LPS and are halved by 24 hours post-exposure (Figure). 
 
Discussion 
 
The purpose of this experiment was to use a well-established method to confirm 
the functional status of THP-1 cells used as negative controls for IL-1Rrp2 
expression. Human monocytes are known to secrete TNF-ĮIROORZLQJVWLPXODWLRQ
with bacterial LPS (Henricson et al., 1990; Agarwal et al., 1995; Dedrick and 
Conlon, 1995). As a monocytic cell line, functional THP-1 cells should respond in 
the same way. In this experiment, THP-1 cells were used as a substitute for 
human blood monocytes or macrophages. Results show that LPS-stimulated 
THP-1 samples express TNF-ĮP51$7KLVILQGLQJLVFRQVLVWHQWZLWKSublished 
literature pertaining to expression of TNF-ĮP51$E\KXPDQPRQRF\WHVLQ
response to LPS (Henricson et al., 1990; Agarwal et al., 1995; Dedrick and 
Conlon, 1995) and confirms that the THP-1 cells used in the present study were 
functional. The current experiment also showed that LPS-induced TNF-ĮP51$
expression levels are time-dependant. TNF-ĮP51$H[SUHVVLRQLQ7+3-1 
samples stimulated with LPS for 6 hours was nearly twice as high as TNF-Į
mRNA expression in samples stimulated with LPS for 24 hours.   
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A number of other researchers have also observed a similar time-dependant 
trend in TNF-ĮP51$H[SUHVVLRQE\DFWLYDWHG7+3-1 cells (Baqui et al., 1998; 
Jones et al., 2003; Foster et al., 2005; Lackman and Cresswell, 2006). When 
Agarwal et al. (1995) activated healthy human monocytes with 100ng/ml LPS 
from E. coli strain B:0111 prior to measuring mRNA expression for TNF-Į,/-ȕ
IL-6 and IL-8, they observed that E. coli LPS induced mRNA for   TNF-Į,/-ȕ
and IL-8 within 30 minutes of monocyte activation. For IL-6, mRNA expression 
following LPS-activation occurred nearly an hour later. Generally, expression of 
mRNA for all cytokines continued to increase for an additional 2.5 hours. After 3 
hours, expression of mRNA continued to increase for only IL-6 and IL-8 but not 
for TNF-ĮRU,/-ȕ$JDUZDOet al., 1995).   
 
The time-dependant trend in TNF-ĮH[SUHVVLRQE\7+3-1 cells observed in the 
current and previous studies ties in perfectly with the biological role of TNF-Įin 
vivo. Just like IL-ȕ71)-ĮLVDSURLQIODPPDWRU\F\WRNLQHZLWKDEURDGUDQJHRI
effects on host immune responses. Some of the effects of TNF-ĮDUHLQGXFWLRQRI
fever, activation of neutrophils, T cells and macrophages, anti-tumour activities, 
weight loss, lipolysis, loss of muscle, loss of visceral protein, anorexia, chronic 
nausea, weakness, suppression of lipoprotein lipase and induction of other 
mediators such as IL-1 cytokines (reviewed in Dinarello, 1993; 1996; 2000). As 
is the case with IL-1 cytokines, TNF-ĮV\QWKHVLVDQGELRORJLFDODFWLYLW\LV
normally tightly regulated. Administration of LPS in vivo is known to rapidly 
increase circulating levels of TNF-Į8QGHUQRUPDOFLUFXPVWDQFHVOHYHOVRI71)-
ĮWDLORIIDVLQ-built regulatory mechanisms kick in. Suppression of TNF-Į 
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expression is accomplished through a number of strategies, including synthesis 
of potent anti-inflammatory cytokines such as IL-4, IL-10, and IL-13 (reviewed in 
Dinarello, 1993; 1996; 2000; Bruera, 1997). 
       
The purpose of this study was to confirm that THP-1 cells which were used as 
negative controls in experiments investigating IL-1Rrp2 expression (Chapters 3, 
4, and 5) were functional. The ability of E.coli LPS to induce TNF-ĮH[SUHVVLRQLQ
monocytes is an established finding. Results from the current experiment confirm 
that THP-1 cells used in this study were functional as they showed TNF-ĮP51$
expression in response to stimulation with E. coli 0127:B8 LPS. By showing 
time-dependent TNF-ĮP51$H[SUHVVLRQLWDOVRVXFFHVVIXOO\ reflected the in 
vivo scenario whereby TNF-ĮP51$SURGXFWLRQLVUDSLGO\VZLWFKHGRQDQGRII
following encounter of monocytes/macrophages with pathogen (Dinarello, 2000; 
Taffet et al., 1989; Beutler and Cerami, 1989; Yu et al., 1990; Henricson et al., 
1990; Zhong et al, 1993; Agarwal et al., 1995; Dedrick and Conlon, 1995). 
 
Under the conditions used in the current experiment, THP-1 cells stimulated with 
IL-1F8 (used at a concentration of 100ng/ml) showed similar TNF-ĮH[SUHVVLRQ
levels to unstimulated negative controls (Figure A.1) suggesting that IL-1F8 does 
not induce TNF-ĮH[SUHVVLRQLQ7+3-1 cells. The failure of IL-1F8 to induce TNF-
ĮH[SUHVVLRQLQPRQRF\WLF7+3-1 cells in the present experiment is an interesting 
finding. In previous studies, IL-1F6, IL-1F8 and IL-1F9 stimulated production of 
TNF-ĮDQGRWKHUF\WRNLQHVLQ-XUNDWFHOOV'HEHWVet al., 2001; Towne et al., 
2004) and epithelial cells (Towne et al., 2004). The present study has shown that  
 
366 
IL-1F8 does not have a similar effect on THP-1 cells. THP-1 cells used in this 
study were clearly functionally viable as they were responsive to LPS. Failure of 
IL-1F8 to induce TNF-ĮLQWKH7+3-1 cells suggests that these cells either lack 
the IL-1F8 receptor (IL-1Rrp2) or they express it at very low levels. Throughout 
the preliminary and current research project, THP-1 cells consistently showed 
lack of IL-1Rrp2 expression and were used as negative controls in all studies 
investigating IL-1Rrp2 expression. Absence of IL-1Rrp2 expression in THP-1 
cells has also been reported previously (Magne et al., 2006). In a way, by 
showing that THP-1 cells are unresponsive to IL-1F8, the current study confirms 
that THP-1 cells do not express the IL-1Rrp2 receptor and is consistent with our 
report that human promonocytes do not express IL-1Rrp2. Considering that 
THP-1 cells served as a negative control in all qRT-PCR experiments 
investigating IL-1Rrp2 expression in the current research project (Chapters 3 
and 4), establishing their functional status was an invaluable venture.   
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